var title_f29_55_30576="Urinary IgG fragment immunofix";
var content_f29_55_30576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urinary immunoglobulin fragment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 162px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACiAVIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKDnBxgn3rKm1u2jbTP3kSrfTtbxmVmjLOFZtqgryfkbg44BNAGrRUMdzDIIWicSLMu5HjG5SpGQcjjBHQ96eJEJIVg2CQcc4I9aAH0VVa72zBCoGFLFc5fGQAQoByDzz249eHyTFXVh5X2YIzSSNJgr6YGMEdcnIxjv2AJ6KZHKkhYIc7Tg/WnBlLFQwLAZIB/wA+hoAWimxuJAxUMMEr8ykdPr296UnGD296AFoopFYHOOxwaAFopoYFtuRu6kZ6UpYLjJAz60ALRRQeooAKKQnHWjIzgnk9qAFooooAKKa7hdvDHc23gZx9fakDMZWBC7MDB3c55yCMemO/f8wB9FFFABRRRQAUUU2WRIlDSuqKWCgscDJIAH1JIH40AOopkciyO4RkYIdrbWyQ3ofTjH505CSoLDae4zmgBaKitZJJbaKSeEwSsoLRFgxQ+mRwfwqWgAooooAKKKKACiiigAooooAKKKKACiiigArkU1OwudCEtpf30cs12JUR2dJzIJctCFdSR9xlKY4G7kfeHQ6xYpqdhLY3EayWtyrRTAuVOwqRxt5znHQqR1ByOeWnkuY7nUb2C4WOG2uAl5biJWkuikXKKwckZDq68qVKYPDEgAj1G1TTrjSYLIWdlaW0ouVhAVZLW1VNriKJQAFDsgYncqqcgbsGt+4ks2mvHt5ktHRkuLyYQ4aaMJkFW6EYAG4buAy8HkYljZTSXC39vayXzaZbpBZPczZefgFpY5wcOJFYBtwGXQbuACIpL+ayeBLTTkb7JCE0+4u9RjiS4umYpJaybQdkvAxgMhJ4xtxQBej1fT9Rk0PUrgrbJPcsunzNcxgXSOreXtwwyHUrIE5YhRlcg40or53uPljNu6Svb29s8gVblfkJkwFLDb8wA7c56gjIsf7PvDewWbTCeCEKYLy2ZYo/Pw0QCOABjAG0EYxgjkGkaGxbxlBHcy6U2q21ukzzJsjnSR/kJReW2NkKVZm+/GB0yQDorTUg9yllcJi/WIPMsQZo0bAyAxAJHPBIGcHuCBG91cxWN7qXlE/ud0NpMREQVDH5mLFRuyOcDA69Kz7OJr/VLmaCe5tFUoV8jGWRXDskqup2sW81fl52HqDtNbkc8F091bKHYwkJKHRgPmUNwSMNwR0yO3UYoAlEqmWRCGBQBiSpC856HoenOOnFV7i7sn0w3cjxz2JjEwdF81XXggrjO7PBGM57VPcmUwyLatELjblfMBKg9iQOcVQi0xJdHhtL2CGNjsaYWTNCgdSGypBDAZUe9AF0EveKY1hZEVldt3zox2kLjHQjJOSOi8HPGRpuuwXL6nGsXlXNveG2KiOQ7jlVWQ5RSVOQCwyowRuODi7BawzzTSPItwjcqNigDcDk5HUFSo5z90VhanDFqMs1/bTiS2urSa1bUba8CG1VcsjRq25C+4tl+MFEJBAGADTttUt4JmS/tBYXbCDecBld5XZVRXH3jlcnjgMD64g8U6p9j8N3eoAxWrQGRI0vzsikky0UYcjPyO7Jz6MD7Ve2wfaIkfUCt23lKuZELSBS7DCkYywWTJAzgHGMccL8QrW4v7PU7fWLaHU4Yra8kjt7gJbWrMY90SLM7jEiJEzFirAM5OUC/KAVNZ+NOi6dPNpuo6J4j/tFJfK+z2VqZC6gHdKkgIVkDJKuQc/um44rs38XW6xRTGApA00cbtNMkbQpIVEckik5UMSQB1zgEA7tviGtwx6VHezaedREumnSPsv9pRm2Csl2kK+a5XzCFBlQSthGDSbVfaSvq8ZSLU5tPRVWW7tnn02z8mXy9kbIwZzJja4My4RcBec5wNoB0Z1mQQwq6JFPcF3gZxhGiUbtzZIK5XjHUE5xgGsm68Ry6pb3tlpkQa5N6dMMtlexPJF+7UzSrwwV4ixBVwOUH95QY/sEWqWn2rUNNl22nnRx2kiLIskyxiPztoiODhZEUj5SrE7TuAFq3RzqjR2VrpbxmGS4mti6r5V9lHRiBGHDOsjFmIyNqELycgGlrGpz6Vp0kyWV3ei3hZ3+zw7nYoMlVjyCSwBC4yM8fW0+qwRTzRXCSwmMnBZc+YAE+ZACSRmQL06gj0yn2uGA3DSXrTPEGLwxgSOu35ioRF3E7WXjBONvGTy3UrSa63i3mlgkkjCrMqITEAwLAZ53MDxnIBUH6gEgurkalLE9srWnyLHJG5Z9xDF96kAKoATBBJJboMDNewngbxFqtvFPA0qJDJLELlmkViGGTGRhFIVcEHDENwCDmSGQ3MyLDON1pcFJ0GSRmIkIx3dcOhJ5Ht3E9hcRXFulx5flyuib1I+ZcgEKT3xu/U0ASyoZoZLcySI5TBkjBUjORlT0z/LipJHWONnkYKigsxPQAd6aXcS7WQlScArzjjOT/L/9dVL2SYi0ngmdY0uAs0ccPmGVTlNp7qAzKxYdAh7ZoAtmTE4j2Pypbfj5RyOM+vP6VJQSFBJOAOpNAORkdKAKE0Nt/a1u7QBrhlZhLvAKhRjpnJHznoCBk9M827mMzW8sSSyQs6lRJHjchI6jIIyPcGow0cs5ZC7SQN5bAMQASFPI6Hgg9/anwRvEHDytLlywLAZAJzjjsOg9sdepAGyRxTSKDI+9HEm1JWXkDHIB5HPQ8d8U60toLO1htrSJIbeFAkcaDCqoGAAPSo7ObzYo3Mc8bSguVlHKH+6cZH5HBxkE9adLCzzoyu6AYJIc9jwNpBGDlsnr09iACnFJff8ACSXERiP9m/ZY3WQnpLvcED/gO0nn06Z5sWSXUTyxTlHt02iGQuWkfj5i4wADnpjP4U6/tre6jiW7QuqTJKmM8OrAqePcD29asMWyu0Agn5snGBj9e1AC0UUUAFFFFABRRRQAUUUUAFFcp8U9V1PQfAWs6xok9tFeafbtcj7RAZUcICSuAy4z6549DXH/APC0L/SdG06O907+2tVGgHxHqMlti0igteSNoYtubgrjPO3PGcAA9borw/U/ihqOo6vqzWup23hvQ9H0+yvJ55tNkv5ZXuovNX5EIxGo4Zh37jPHsWg3Z1DQtOvGlimNxbRzGWFGRH3KDuVW+YA5yAefWgCe8VpI1jSRI97AHcDkjuFwQQ2M4PbriuAvjZXGka7erGr2E0Bn+z+bJEs0KQqoScqjFAwLEEZLKwODjjttas/tsNsoSUvHcxSq8U3lGPawJO4ckYyCv8QYqeCTXI7ZJYb95YjZtNAbaFrdVUAeaRbt5pLJnaygZQlSH5PyggEdxp0+jaRBp819e/ZQzCGdLH7VNsVHJzsBVW2gHJBDhcBQzYM9vJcSeKRcKNQW3m3IZlYCKFeWRJkZs+YXZdhUfcKjIzhtCK7t7+OyuH32lp5hllZLh43EyyAojYIJVvm4OVYHHIIzmNf21vqOlnS9NCi9vJIgEh8uZWL5ebYWGVUF8uQQRKCuVYLIAbOn3ltJE8Wn3TXjwXR09ZJVEv75fmdmZecqBg7iOUx1Iy/QdMjEBhkniukt3kSXzBvl8/zA5ck/dPCsFxxlSDgAnEv7mSXxDY2d1p91JeX0k1tdx2U5mtxAqctMxC7BseIquQQ0rEBuS+r4cmvYdLnZ0tDeFpbiW1iGPJZiGVHK5O4qSSdrZJyCeCwBoeG3nTSbOK9RWu0h23MsUvmqZUwjDcQHY5HUqOnPNX7e6Ml5dW7osbQlSv7xSXRhw+0cqNwdeeu01ywsBcySwWumMbB7MbLkXs1tdXDb8OeArK4GT5hOW3jkAsam0S2a5g0XXdXijTxBLF5a5neECORi/ksBgSMqeqDLISAnYA2dXhsofKv7m1a4nhIjiKKWcF5EwB7bgnJ4GMnAzVDWtS+zRz2UsuopOzK4ltYQ8ojZ1XfEqo24IzKGyOFyx4xm7eRSSLLdaf8AavtVvI0ggaQxR3LiNlCMWBwh3A5UdVB5wQc20RrjxdeXbWn2e5hiS1kuAImjkhLSlAsnl7y4ON0RYBSwIznLAF7T/se7UbiKwFpN5u+aSNPL+0bBtVi+F3fKgXnoBj7uCcyW208XtldQWcqz6nKFdzKgCbomf7pbZKMKykJvI3EjjJE7ah/Y2kW7XHnXshb7PbxCN4nkAAG1vMY7n+ViCTls8ZySaR1F7ryry20g3WqWtoby10+SVYGVXGECgkp5m0spcHA3Fc4YmgCa80+3sdUN0i6yTqT/AGKWCFy6RZLBbjjLRYXKhkI4Zdw+UFMnx7rw0221M6tG0OhRTpHOtvA7z3EQjV5mI2kGLa2GKg7RGwLAsfLsX6zWlzpVx4gvIrFXtJhcyW7TsyTMPnKy/wAMSglhvIVAmSp2ho6vjG6v7WEQ6Sl1LGmmSRAQWrJebPkEkkMmMF0DRuIxtLFGADH/AFYB5TqmpSWUWqvdwS6wq2VlJ9qWzJl1TTZ5f30TJ+6DeUssaKAAwLqSEz8nqGnLcf8ACPt5tzqGoTXXnWMULma3Z4FkK8h9jGZF3Esu1pFjJHbb5N4zjsv7bttUutK1d7OO6t5rq7SC4S7tZ47SFj9nto2Cwl0jgw8hBH7wENsAT03Q7FLzw5pum6kU/wCJfb2zmQ3kh3COFjHPOr7HgIZCcYLZ2kjKkIAdtbX6Ws0cH2uRFmuZLW3huIsebJ5fmBYmxyihJDkg8A/3azrfWo7jU7aa+1D7NPDGlxLZW9zE6RI0GXWbB5VSVYSHbnKBeCdzdQ1DyrSz1W0spr5bqdGCQ27M5j27TNhwoQ7SyljjKkc9K0LmBdHeW9maSWwjimmuZZwjkIGaRVAC7zt3sEGcBdwxnBIBINOu/NYxLpcEc1uv2m7+zETTyH7+U4CDAyCzPy2CBt+bVe5CwStGru6OV2ujLk5HT5ckcjkAiuUneXU9FeNor60s0t3/ALQt5NNZZrl2IOY9jYLHa+VAcN5oz0KnfMLzafaWeLmxjmt/LZI+ZYThePNBIBAyM85PIPHIBXh3WfiSZFMsjzW7zPGkoPmlfLVXZSoCN95RhgCF5zj5b89yi2hdHaIwBZWRioYR5PLBiMAgNycYx6jFU5LmSY2UWl3VvcyW84jn8+Qq7Bco5+XALDk8gjK4wM7lsWqtPI19DEwjulRTFcBo2VQWy205wSpX5SqngBuRgAFy6eaKzZ4l8yZQDtxnd6+n9KLq4S2WMy+afMkWNfLiZyCxwM7QcD1J4Hc0QiNY3t4Y2hjhAjUKm1QNoxt7YHT8Kq3UHzWVvLcTfZxgEDeHd0KupaRSMD5G3A8PnB4yCAMtIrPSUtbWa+Ml5JClusl3ODLcbBjcRxubnJIAyT9K0YY1hhjjjRERFChUGFUDsB2FRW9zDczSrGrkwkDe0ZCtuUMCjEYYYPUE85FVfD08l1pcdxLbXFsZmaVYrly0iqx3AMDyp5+7/CMDjoAC5JOFnSFVJkYbwCCBtBAJzjGRuHHf86eS3mqBnZtOeO/GP61m60WmjEX2eSa2V8zbJGikBUB12HKjGcZO4DjHOTjTc8bQwViDj60AKqqgwqhR6AYqO1gFvCI1eR+WYtI5ZiSSTyfcngcAcAAACoHW5Fva+WVedWUSO6gAr/GcDpkA4x3x2zU8EKwArGW8vJIUktgkknknpzwOgAwOKAJH3FfkIByOSM8d6WoriRIkWSWYQoGAJYgAknAGT6kj8cVJg7iQ3HHFAC0UUUAFFFFABRRRQAUUUUAZXifw/pvijR5tK1uGSewm/wBZEk8kO8ehZGU49s4NeeeNPgzY63Z6fZaPerpVpa2clhudJ7icwu24oJTOpKjJwrh1HGAMV6xRQBxWpfC/wnqltZRalprTva2aWAmW4lheWBQAEkMbLvXjo2R7V19law2NnBaWkYitoI1iijXoqqMAD6AVNRQBT1O6tYEigvJQn2tmhjXnMh2M5UY5zsRz+Brg9FW1024NjFe2FrayL59rFDGN8kDbikwUZWRjLJkkLjc6DG45fsvEdp9pt7VvPWJYZwzJJ/q5gysnlt3w2/Axzu28MMq3IX8Fvarvay021lihXS4QbZhEsEw+S1YIGU5KpgYwhkUDdnEgBJZ6pbR6zf6hKsQ1aytpLN5lkeK3uRGsbqMEkIuZCRkOULkBiGHmWPD9rLBOL2+sl875V8kXa3r2EoUJtSRwG3FHLMBnO5u/+szrprvUVjjEamxnZ0NlcXnlvtWUPJM7KCAAAqsDkMHPJ/5aW49Ds9ZnuriGOS50O/tY7iKC6uCImmR9ynaV8xEYKr4DFWyxKgsxcAqaXY6qdV1C9utI06bxJJFumZmbyIrdpH8qF3UnzJkjLgsIvuso3Y5fYsr6OzuNUuLh1t7xrBJH3wrvd4lYyYRAXcJvQECR8ZABHV2R2l82pz3n2RdNhu4be4uTcSCSYsjENDIQxjCBT/Cx7kBsmksr94ba+ul0nUUubeWS2tkvrUb5JNuV2yRbysOBtDMOSeSSeQC7oMYm0NYYL3UGuI47eSe3uZVkuYJBGr+WxLEK5+UkFiOc9GzV/Tr24n+1TNHdrM8gaOxu/KUoiqgby2TIYfNnJYjccZA6U/DNrfMbmXVYbJ7yG5+SeEfLIPLC7gSC2dpwSSTkFc4AJvWUdxbWo8y00976BWEUNr8gjjPRQTzhigzwB9duSALqFvNqNuqrcJayv5csKywJI8JVgW4JI3YO3P8ADnPNU7FZdN1O3tGlv72C4kdIWuI2ItFjQ8bwmTnOA8jZYdyfvWfDWowaot/PaXtjdxR3TwD7Jci4Ee05Ku3UP82Sn8OQBxzRLPaXOoWrNeTWlwLpoIoZ4xH57IrlljEi5YFSW3R9QnXAIoAQAQ6lqcdtcG4up1S4SCa48xYioCAqh5UZUHAOC2TkEk1i6Fcva6VrEd1qMGnalYwhZRMI2trPKlkkKpsXBB3MuQe2QNpO0Zbc31rcSRrGHlKKs8IVlnAKbt/94ruUY4I4Bx1oNo85dfLe58+6mmuDdiOKM2wJzGChBEjrkKCwPG4k5ABAMCxg1S78CanBIrm1dbl7aOa0VXuxI7ssD28zHCnOzaXXcrDGztH8R9ONz4Gu1vDNbtc3Fnvu4pfJuLRA0Y+0sQNu+MguQoA2qQCvWtltXsdc06J7DX2gFwiX1q6w7sIS/lMQyj5G2fd4J2kBjnJp+MNTurPS5r5Be3GqaVax3MVppzFzLLIHhP7k4eRQW3ANkHA5B5oA8Z1y7XU7fU4dTdbK21XV4vt95fLHHc2twvJgiicbZREWjJlZgWglMYD7Mr6n4WezvNC8NvY6dJpyWqwMSY/OF3awQEI/nkDMWJUZWPzN8y7VO4DybxZb2NpFY2ul6ZqstrNqX2jydJ/027P7iPdcWk75mgaGW3CtG2NwA5VSK9ovLG71SW9j+030Tq1wi3d3C4CM1ooHlbAo8g7g5DP99SowV+UA0EkuUttNsNWu45dXlsZRcRrEwjmZjGJGil2nAGWKoQWYY4+U4SC+b/hH5be38rVbm2SKyixMsN1LE0aeYzK6KqS/LIRHjaSgBK/MFS72+Iba5h0jxReWkiWyLbtEqq0cvzfM25fn/wBUwK9v3nQ7StbVo5LrUnk1n93bQ3MWIb6bZbL5YSQ3EMnlZWRGclct84Vs42/IAXodOvzrF1qO+zW4Ba1sDcqyTxw/xozBj5iySQq6nAKqzY5GK6KK1nt3C277YTCECu25YSowu0YBbOecnsK5K/tFW+l1DTrrUNV1K3vftXk6fPArxoysnlyBmCvEVTADZcMCVIIG3fsHlsor25vDcRiJWRbR3VkCxlj5iE8ncGGcsegGFIIoAqaB4hl1Dw1fa61teJGJJzFZXaJbyxiM7CjFiFB3IxyTgBsZOM1tb0/tPclkzuP3TXKlDsBG7B53DovQd17DIyrS/kvbzTJ0/eWdx5myXzyQyspZWAjUqeAACzLj5up6um1C307VNQZLhpEjga8uLeO2LNxgEoUTLthcbclugxyMAGjY3cX2e2MR86K4ldYpIZGuFx8zBmfHAwuOeASFBPFLJfWVlqFrpv8Aq7m7Es0MaRnDBSpkYkDA5kHUjJbvUrT3BsopYbYPK7R5iZ9m1CwDEkjqqknGOSMe9JcSXMkVwkNsQ6kqnmyhEk4HOV3MBye2cr9MgEVtPemMpe2xSVAGMluwZH5Hyjd8wJ6cj8as2drHaR7IlXJwXfaqs7AAZO0AZwAPwFVjPYaXJa2rTLHJcHy4VkkLO5A6DJJOB/nmkgu49VsLvy4pCgeWDCzKDJtJUlWRuOQR1BBByARQBbyXuJI3hfywqsJGKlGOTwBnORgE5AHIwTziQopbcRlh0z2+lQCYxi2jupYUuJcKFX+JwCWC56jANMu38hJriRFj2ggyp8zBAPTaSTk8Lg/0oALeC6Kf6XMpkO0sYsquQ2eB1GRgHkj265muIpHG6GXy5QpVSQWXkjquRnp+pot5HfeGjkVVICu+P3g2g5x1HJIwQOlLNCspjZgN8bb0bAJU9DjPTIJH0NADI5GuJGwJ4BBKVO5QBKNvbOfl+bqMHK+nWMW90NXa4N4xsmgEYtPLXCyBiTJv+9kggY6fKDxzmCOykH9qRvPcrBcEsrhyXQlcEocnAHGBgYIPXNWrcyK6IBJJE6tJ5shAIJbIXbgHoT9NvNAFmiiigAooooAKKKKACiiigAooooAKKKKAKGstCloJblA6RuHABbeSAcBdvJJ6bR1BI5zg8rYT2cWiXlw0V8JI5ZA7NE6BpWUSMQqc4PCKwLZ4wX3MW6LxQrHToyHEcQmQSv5ojMak7d4J4yhIfB4O36VyM7W09zdC+ub831jEjieVJYVVjtjPnGNwhZzFG4AVCoYMAOaALWm3Nsmo3JFtK+nGO1jigZAYrTdG4LAEnauwnLDaDu28nOIHiZ00jULgyi+tbSVkaRZJTIikCQC3X5pS8Y3AFiwwuAeQZ7+6tjA99rstx5dlNFLDe+UsasSqoIxkAKwkcffxhmbBUKQtaOK40/QLbSL3UoZvEccReFo4i/nNuKrc+WQN8qgElAdox0UYwAad3ME0aG7trOa5lSJwLa4eNWWN2DLvDuvCqNwViDtUg4bpUjWbTYNLtL+SQyJqSW8dxqdyxa/IRt0gWNsZ2CQhHG35VbjaMaMc2nWunyL5CIdOsxEBFCFQIyDbCEJGDgoBG23OV46YSHQ9L1DRdMElpctBbvHdxsbl2lt54hjkq2Sw+ZTgnPKkEcUAT2WiwNZLZ6qGv/tMlxcGdpNyRPJuVkjOQ6grJIFAzgBhkcZZo0UV3bvLaJHePZNINPuruYuTIoeIgHG4IAApbksdx54Zr0C3F7JC5CZidpU+122XictjC4IC4jLqDkkh8njIa7aRJ9uupGtnFwpEX2mREBlT74VSvJVS5ABxyD16kAwrS1bT11Cwije0uZXguftzK1ws8jfKVy5LO6iHHPRPL567Y7uz12G0u5tMmgF3JIgSWfdJuQ+WrzvHtX96qK22Ndqk9c543tSvWtLdJreznuS1xFCVjU5UO4UuR12ruySB2OcDJFq6j86Jo/n+YdVkKYxyOQQR+FAHPve3w1C0S1tJoo7i1nuGtpiiHzQ8e0GQOSuQzZUKwxzlSArLq1r/AGlpF1b2to805kVmtpXlghZ/MO7L4BdDhsjlWUD5SG5v208WoDUVZgHgJt5IVAZovlDcgr1YMpxypG3Ge+BJBY6NqN9dw6reyXAt7crZOrzBId4G1EUB2ZiMZJbaWB2/MdwBGLbWE0uwmW0tjqglMd3JG5lFuqs7l44z8u9wdu0cqZB8zhMmbxDEZvD09haWAkuWjbyrW9doI57pl85MOoPzBwW3Iw2sOueRs6gs8Gn2ENjAwiRlS4DMZJIYQhzjDbmY4C8EnLbvmxgt1S6trnw/q62Lfb1gSWCaC2lbzdwX54wUO9ZMHjHOSCKBpXdji7zw1LHFp9rpjLbQSaebLVJLeQ+WkkMYEbvkqWj+V43A2u4kTkCMFNW5EujeB4NK0uyhMlnbiJLaW6eSNbdMqkpkCl/uxhhtBbPABPNc3Y+P5db1O80toJbeJEijVEdcwjlZXkkY84+UAD72cDn5q7X+2LVbHULSO3N3HaQrALGAoDcIVbaYSzAHcAV2lhgo3sTEJxmrxOjFYOrhJKNVWbV/vI5PtkM9sLVPPeO5Ml7fTubYRxgZBZQMSERMUGe4UsOMrlxadbaVe6Ib61GsQ6jeMIrlWDvG7wKxkdVQCRWaIksfunYQAoAj20aGygu5JS8syXDC4hgjlnBE0qgbgisxZUx/ug5IVejdctV1m+tordtPnl0u7huxaToxZdoddwwV2v8ANlSQy/KDj5gVs5jN3PFqNvbxXAjaO+2RxXEzoI7qRGkfYW2+fEI3kCKARuGP4cx0PE02lX2i6te3ardXlhPJal7NBI3kyXGwxs0qPhTgrIEDcK4UE4Wuh1m41C6vo47BbNNMtpI3lknT5pQVPEPUcF42D8AMmPmySukouF1CBY4bicwwPE087hFJ+UhsAYYsRyQONpwBnkAraVqtyptl1axOkrMzQwQSyCaRmDNtLOhKLlApwSTubaDwC1axaHUrqe80sv8AYWiWWC5sZARPyX74XkluCCCGzkZAE2itYy3GoDQrSCJGmnhuLhY9hWdXLMGHDNl5JGznHJIPzA0/QopdN1C7sFtkFoXDxyRq8aIPLjGzDscksJG+T5QOvzZLAFy0u0iuotOuBDbO8Ze0hM+6WSNAgckf7LOo4LdQTjNNnh8rUrq8s5fMvGg8pLWSdkjdlDMo7hc7+WClumcgAVpb3D7TESpOAwI6Y6n8fr1HvirbXiXtyGszbXFohljeeOYMY5kfY0e0DsQ4POQVxj0AM6Mam/iy1ee0tksV0+QNMpJcTF4zsBxymO5wSV6ekHhTUo9VlvWtZ2jMVz5k1qwJaMPErKjZ4UnIfCkj5gc4ar9hBY6M1tZonkzXE0zqsSttkkcmWWTbltoLFuW4BIUH5hmxYactlaxrGyvdiFI3uXXc8pVcAuSdzdT1OeTzQAt1bG8uLdipj+yT7wXXPmDYR8uG45b+IHlTx0YVJLlLnSlFxL/ryqQSK3kNKx5BQMcg8Hg5zj0q7pwlW0jhuJZrmQBhJcNGItzA4OF4IHXHXgdT1LbSwtY5Tcokjys7uHnZmZdx5C7uVHGABgAUAS28pl8zy5FkVX27gQenDDg9dwYHpg544pEghj1GSWOBVlmTMsqkAttwF3DvwTg+2KZYR77K3Z2eRmRWaV/ldiOQThV75JGAOenNW43WSNXTJVgGGRjg0Ac1p+pXttHqXmabqd2BeOsH+kW7mZTnd5eWXaqEMNrc8cZ7a3h6yOnaLZ2WQUto1hjPzZKLwud3OcAZz3qWwhnCrcXrYu3jCyRxys0Sck4UHAOM43bQWAGQOgsiVTM0Q3blUMflOOc9+meOlAD6KKKACiiigAooooAKKKKACiiigAooooAztbaPybeJryW1lnmWKIxH53Yg5UDBz8oY9OApbjGRyWqudP1LRoGe6ktSryFbgsRcrEm8EH5VimVmZgu35gnbZmPo/Fm1LO1nkv5LKCG5RpWSQx70IKFC3YHd17YyCpAdcWz0/UU0kx+RYCKGeSZQVUGBFO2KNFB2h1RVJLPgMMDaMBAA0e7gEuuW143nz2KxxywTTuZG43RyMGAUmRtwDoP4AvBUojJH05tXhvNQi05rjSYjJdSXQBe03/cMYdsxIxT746+XjGQSuRLqlx/bvh/XtW1CS20B4pIXhkbMeTh7We4DKohZgCOgYO0aclsLq+G477RreFZ/Pv4Yh/Z8u6PdOm2VtskzbmMjOsiMzZCg73OA2AAR6FK2kXeq317q5+z20bQtaywvCG8tEYSySS/NJKFYAyjCspUYyvGpeLb6NdHXHmazskgNxqCykiJ2KookLEbmkVYwoB6gjPIXFHX7aUz69anTNUubOaBZllt9QVJHkOFZIS0q+VhUBz8qg7jkliKybWG18STaZpupMkML6fEEhm1I3ZuYHi3rJERJxMkkZ/fMrblQlG5baAdD4XvojqFzptgrxpp6CW/I02SGO4uZwJSY2ZshxlmdTuP71QTkGrXhy/fXLD7Rb6naNPBfSR3Rsj5sTbCV8ols4IXZnaeGB5IznCa1g1WWeG8kS8gXVUFgJo4YZ45QFMkkEiEZICzuTgSf6wdABXbxRyxGFIlgWAFvMAUqc54Kjp1zmgCnbPcT6WVa2jtroSENDBMQoxJ2copORyfl7kZPWofE160GmSFd0BIys8g/dI+4CNXA+YqzEAhRnGc4qLSUOrWU9xqizRu9xNFAWie0uIoRKAE3AhsFkByCAy7Tz3ytPltfD0OjvBNcQafMq2zWgsliSS5nmUecw2CRGLb85AU78nGM0AakWrQaVK9pOL58TIZp5yWjikuJPljWRsBwC2AFztG3OARUmq609rbOYIzOzrcgXUCiSG3aIMQJcHIORjAB+YEccVT1JLhL2xF/qUNtYxPNczwzLlZ12sVRZNy48vG4gggr7AkRw6Q9naHR7m6fU0udMkhcXSlo3VCQBs2MnImCsTksFX5W5IADxDBeXejXgfUILfMEbjbG7yYABl3rGwLHbnbsIwT34Bo63q8VyNTVZtPjso7o2EsV/M0fn3RWMqElVz5eULKFKbi+0gYILVNKtHtbPw/o80EUupW0FqzRWrNELZVRYpHtRMo/dpuTdhtxDEEZIVuI8b2mvXugS6Ro2maU+mGO9uHS6id7iXc8qAQeYwLyCRnl3h1KiRQM/L5gNNp3R0tnonhr7Xp15prW0MOtxJPpsk0QhNu8YXyygJDFj5mSpGGK4Yg4Ddbc3qHwpfXc9veCyChDDDZsskqg7WYRffIbnjqQBtzkE+Owanqq+Ir2SWa2uWhs7yS4nX7Td2Mh8+1W3tlKs8m9iAzRgcrMGw+/Lel6deXaWUh1TVgbq0MyKLt3s47px5KsrE5+T7QSiuqfdKgBg26SYwUdka1sRVrtOrJu3c6fVGsbiO5W0jivb62kJNrBceWxlMartkwf7kqZ3A4VlOPu1g6jqltqs1rpWpaRefZdWiEYkZUmjdnjy8G6KQ+WQAr5ztbY20k4zjtdS3V9cX+iG0uljt4oZ4haNLcIcH55mBZnzGzbOHypDAtu2yYN1r2q6brKRXjy3Rh1tIUCXpjjMk6vGtukaqSyIRnZL5akmNt235moxNKbxzo8dr4VW4ghuJI1nIn03UWRFltoCxVGk2efCwEkZZjsDgK2W5HbH+0NS1NPs+pT2ghuhNJCBGSiKoBiI2nerhyxIbKMFxkAivm7X0lstau4dBvJmS+063kF5pF4lg8E2VZnf5Sod3ulXyYZAh8xC+C4ce/aJNbi91XxDHqss1lGxhUTFwq4VUkLrsHlnzYyGIBC7Gzj5lAB0Gm6ik9lLKBJ5cCecJgMRTIwLAq2AD7jGQRznqY7RLfWFF3HGxmjiZYJrq1IA8xBuwGw23gZAI5GO3FOwmmsNGa41G5ubi4e3WcReYHnl8tcuVWMBWycf6tBkEfLk4pW1CwbxfZWT5i1AoZEMU7HzRtYupAGGRdyn5sYLggDjIBq317exaEbvTrNdRvBB5qWwcQGY7chVLZCknA+Y4GeTxTNImlM5tL6We4vIQztOIzHEwZyQgxgOUG1Scds8EkVRubbTrbQdRuJLI6dbR2kiyw/8e/lKyBpCJIskcbQWQnBTg5FWl0uz0nRns7aBmM6+XLNg75XKBTLK64YsQo3P1469KANedGmgKxTPCxxiRACR9Mgj9KrrqVr9nSd5PJhcoqvMPLDM7bEUFsZJbAA77l9RWHp2qLG+s332KGV7YSrdJZxFrrdCT5aMv33Z4yrIMDhhjIYGltba1uvDFtpcsL64lzbB3GrFJPMB5BnwpXnHGFIyvtQBvzvIyQmCSOJjINwkQuSufmUYYYPvyB6GpUjiWR5ERA8mCzqBlsdMnvVLU5bexiiuGiQ+VIMYQEqXO3I/u5Lct2BJPGTVG61UQXEVrA8I8mXFwqyJvhiyMMUGfkwQCeCMgkAZIANKS1NxZLC13NuGFaeIqrsAwyMgcZxg7cHrjacYtRusiBo3V19VORWPbW66Roj6Zpc0IextAIY/LyUGGCEqvY7cYVeqnA7DRimll0xJ4Iy07wh0juCYssVyA/y5Xnr8uR6dqAFjX7FZwxZnuNgSLcx3u3IXcx7+pP1qx6c1TtWV5pHiuHlSR1lA3oy7CgA245CEgn1Jz2qzJ5m6Pyym3d8+4HOMHp75x+GaAH0UUUAFFFFABRRRQAUVg+HfFui+IPCsHiTT71Bo0wdluZx5KgK5Rid2MfMpHNXo9c0mWxS9i1OxezdiizrcIYywBJAbOM4B/KgDQorJbxFpH2eWWDUbS58u2a82QTI7tEvV1API7Z6ZqDwv4r0fxNpEGo6ZeRGOS3S5aJ5FEkKMu4eYoJ28etAG7RXKab8QPDeo6lrVrBqdsI9JFubi7eZBbnzgxTbJuwT8hB6c10tndW99ax3NlPFcW0gyksTh0YeoI4NAFTXLFNSt4bWaISwNMrvkfcKAuj53AgrIqEFeQQOnUcLG2oa9oOq3FrpV1a3d8uZUtrsQNcxK2CQrcJIyho1chWZVXcY8AJ3+r7WsnjdJWWYiEmLG5N527ufTP8A9Y1z0EV9JeT6jpr2zbZlj8qe2YSMql0YCUtwGGxlwuBgnB35ABn3EMjIIpLi5v7nSZCwhASBL1zGgTOUCMyq67Qvy7sZwQCrLOxXwn4dVNUmY6ZBeTyPNPPuWG3cOwSUklpFQEIcsxJRTwudtTw0onsfMgMuqaXHBPG/2qHM+7zWLgszAFmYICBsRTHkYB409CRrCBfMu7SezuLidUQP5JgmMk0shIJyzDLZAPHlblABIUAcmhNZpqPl391Z2cTnUFuVZXeOZiS5jM++OKPYNoVQAA75IJ4v26XtuNOuDqm2zhtpGuZLi0UNcRhfkLsuAjKcsSAqEMwCjgrj61psltZ6YLSWP7VE63EMsjPneiJGsYCBVZZI/M3B2A6kDjKdBpcs9xBLO9rf/bI7YRCWdRGs52hspFv+XlsHO08YJ4BABDBp5uNImgluBNN5QuIlWJBPbyMrfOpIUbi+4qzKOd2fabSpZraymh1CGXT7Wzhjhhu7qSIu428sSGIBHyg5AywJ5BFXrEANNdO115rRxxuJSyx5Vd2VU8DO8gkAdMH7oxiaNDq9xqF3eJrEJVBJaCzZhcR/JLhJmK7SshCy7lHGWUf8s+QDW1jT47iW2nnhN1DGQskBSNg4JADtvwMJlm45xnGc7TmvDPbW1lLcXsMF/JfxrJdSRlftS78BFVHOAyHC5JAPO3PTVjv7W9hjt5WQS3QlWOKdP9Z5bbWO3PI6HryOabHezro876kYbS7iidncHemFH+tUBs7e+Mgjp70AP1WKK7It/ssVy7YilEirhYH+/ncDlWC7cAHJx0wSOZi8MJZ6ql1BqcBha8/d206q6iFYVVoIwMbcNEG2gEDaeCQCtpNEudL0jw5DNe6vfXdpLGlxdwMpklZ2BkeQvlvJLDlF6AjAAUFenu5jBGz5QKFbls/e7dO3XNAHI2OnzxSOFvEtfE11DBLqCWgke1jlKbPMRSDgEQ7V3HA2hipJIbzb4vaPp2o6pDc6JaWw1ASPpf2O6gtYgw89JppIY7iMh5HeRY1Y8M06spwcyen28Vhp2oCeG4aa+1W7ZpJ4j56rMhWNkWNegAVkL4+XBLnJOfKNVg03WvEesald2t79ph1Py7HTZbKC9iguQEEiqEYgM4iMjKSCGUNggjzQDntH0DUtO1DVk0SbUNOnkurhrCWwj86xklUlEWeV922VZTKjRtIQ2Sqlg2J/TbdL9ZLga9caNcPYW8ObW6kaeb5lMspkjG99xZgirucKpyN/STzHwppGna1LZN4ie/a+1vULiTRodXEkqT/ZmXzobmIcRrJK00gXDBDk7iRiT0SLW9Sm0WW4u5oT4lWWdTax6RcT/ZZ4tzwxB4BvZVG5cniRXYDPzKwA/wAUQaVaaClxquo2sdtcxJIbq6hFvHZJPDLulVQCs0rt5vyuxIEhGG3ESck99cPbpf6ReW+n/YoH1aGPxPa+dNIWnuV8+QH94vlRpA0bjJVJTu3Bue8ubPZp2qz2sEs+sJYXEFrdS6aWeC7VZ2LpHIu5kJkIXarBxxliTuqTNoa6vaubHTtNudbW2jv9QvNJCy6gkrBfsxDbdrzlD8mGKrG7MAShoA4HxFpENh4g8RW2oastnp5uYNXgspYWnmaKzj/0jADKEbhDhlEZURsjHBdfUvA6C+CXv2rWJNRkVIr+WeNrVAUVS0kUDKFWKZt53LyxckZK5TwjRHeP/hCdat9Qu7PXtQ1G2ttR3ag6yxtEZY3kkTdLuD74o2MiAp5ahgPNzXtvgK9SfwhnxDfaafPMd1D9miuYbWJBKqoqLKFZCsoKqmQThSBztAB0fhyKK0vtPjkuITfSWtxKqROIo52Lx+YQi7gQhCAMWZgGwc5zWpdXGnaLpup3zC9uIRzPEGluTkIBtSMk4yMcKBuJzyW5wITqf9lqb6OWO9e3kmi0ee+DiUoWLKz7Xdg6yKGX5wmwBcjJa2rC28XzRXVvb2Fk9nbIsyymOSZ0lAjRArf6tWkKkdzIqkbTlwDoNW0uPU4nimuL2KN4zGwtrmSA4JByGQhgwIHII4JHQ1T+zwaHBO/mLDDIyAzsWdlSOMAtK7sSx2oQW69M55NJLqz6W0x1q5skTdPOCgddlugJHXO9wBlgMd8A45t6zqUOkWd1fXEjSIkLyrApQM2xGYhM4ySB3OOO3NAGPrOnX/8AaN5d6ZLHbXbGIpILXAnXBBhkdSxwWVf3m3KKx29Ti7YTNZWMd5e2c6392Rvty0ck6ktnywy4Dqm526khc/SrUTRrqUqSX7vNkXJt2lUeSpTYFAABKEqzfMT83tgDN0S/vBdPpmqXfn3Nv5RNzawDZKX8w7W+ZipwgY8IBvXBINAGhq1qrm2MyLLY2+6eRXRpG3LgqQQ2ePmONrZOMYxzWiey1B557i2g2yR7fMV/M82Jm/dujL2YAHjnIUc4Um0Z3tr2xtrnUbJbq5R/3TKVad1CnMSmTIAGSQN3UHIxzVvjd2vk2dlqVtHOZllUXCBmaDeqtH94c/MAr4OOMhj94AsO1reXt/ZATxXjQhXPzgbMttIIIHVm6HPUHpWZo8j6d4R07SBcRnVbazitWaWJpY1dYSQ8u1jtjYI3zM+CeNxYgGzrDTarZ3Vh9j2mREV4ZZGSRo2B37XThGGOGDH5h/Dw1WJ45ZNOuZLG3hbUpLMpbTXcRIf5cqs2ACBuPK5HGcd8AHP+Fm0uw0gzWmmy2AF1Fp5FsUYXal8RyqwZiYyJvMyTuC5znHPT2QjsRp1iJr+YpbmNXmR5N4TaC0shXG//AHiC2WIBwcU9Lv57rVZrVngijt40EqLFtZrg4d9rbyNoDAEYyC33jWlZ3sd7JIbV1eOGR4ZgwKukikDGCOmOc9wVIyCDQBbooooAKKKKACiiigDwzwz8PfiDpPwpbwU0/heOKCNjb3SSyys7m5EpV1eHao2s4DAEghSB3EWj/BvVotOt7PUf7Gkth4qh1yW2M0k6G3WEoyEvGN7knuACO46V7xRQB4ZoHwa1DSJtFmtxosEtqusJdPBuVpVuhi3GQg3BBwQfu9s1nWXwT1+fQLiyvbnRNLnj8Pf2LC+mtI32lzIrmSdii8HZjADH5ic9j9CUUAeDzfCzxbK+vXMC+F9OfUZ9NYWVo7+T5VukqyIHMOYi29SHVSeCOM5r0D4O+Er7wV4Rk0rU5LV5Tez3CC2kd0VHfcq5YA5H0ruKKAMvxJOLbSzKYJ5tskZAhALKdww2MEnB7AMT2BNcpqv2pddnv7WWVbnT2YS28k5ijv4dr+UFIOAVkkVS+M8MpVvlNdjrJ0/7Iq6qbUQPIkS/aQpVnc7VXDcEkttA6nOK5eQQz3N0mqXYlSZPNhsZ4hkATFXn8uQB9qlouAdoCqeC3IBX8Q6dqVr4bhj0WJZJrWRUs4J4A6T5YKscsalAqAhW3KRgJnaQCDUiu1iMd7o+pQT6YUuiNRu7guqTxko0KgEAIBHK7NwpZVwSCNpPrEM9zKV1fTri9gjmt0tnik84SxyYWSRdwIjUOMgrhvMRtxG3NvR5tN+0WqWdokVnf27SWs0NpmB0EgMZdgvlqxypXJ+bI9BkA05LVdWl0m5EsrwOrNHLaXbiCdZQxZso3zKyAFd3A3DBzghmkHzfEF8I7K7lW2jDxX4cQxXb/N8m3I37Vdf3gBQliOCgAq3FtaXOs62IdbnP2q2Sw+wrJLF9nk2sYzGyuuwsAx4xn5SpGfmoaFDo0dpcXwmW1OmWrWTyLZ+SuJgHeMqS24mQqwH3juXl94ZgDTutet9Lu9Q897+4WcobSSZEdJJgm4xQICrOQAJAMfMSQrE/Kuv4YaSLSLWXUp7oXc4VHW/ljM2/nCsI/wB2GxjIQAZB69azP+JdZ6hHf3gnsoJNsEkdzKggVy6MpOC37zzHRFBb5dpC4z81zStRs9Q2o1xZrrHyS3UFpN54jZJTE2FYBsbkkTfsX7p5G3gAhudUuNN8N3F7NPLcfYU+13F3eWrWw8sSOZdqhC2FRWAG0nbtO5y242UhewE95az284uGI0+B5Wt4EDRqVj+UMDukXO/buAc4z0MtvFDBoKR6ZJJ9kkct5k9xIrxq8hLEEgsNuSApwAAFyAKh8UaJY6p4dk03V3intZWEZN3HFKNznanEgwWDMu3OTkDr0IBpWsswNidQkhjvHtz5sMMhZN42liuQCVByNxA6j1rC1ZFivfDkun3dx/ZlzcOruk3mQuJVZ1LZbkM3CkFgCygLg5WHRZdO0u/ggu/ObxHDpcTTW0bMzi3MpG/YCVY79xYruI6ZOV3W4tAhtbtxaILWytzbLa21vdGG3XYz/L5SjCf6wZA4bCcDFAHN67bWGueIdJ8TXH2d9LsRLaxXRjVGsZvMaJ5PMyTncoADKFXB3cn5fOPF/hm6fWNX0S3+zzXNwyFopVDtb2ckRtvPVAI42eVg0jfvFCMgYKCSa9NvvEukQQWCaTdPqdz4kkSwFxKTNGrgOnmy26gbf9XIGCooLR4cooLJwni+wkgv9Njld9Kis9Tn825jdbdJZDaG3tpyjIFDkkImCIyI3BYjiMA5Tw5bahpd/wCILqSC8v8ATHtpbaLUNJj8y0Wa3Zi84+1SgSOpjD5O4l0PlnGTXr1hFqaWlkl800pjjWX7AP31/wABjAjXPnD5+GLFjg7nwwXOPMvA15fJqfg29l8LS2N9dWkun3VtuFiI1tpRmZYnkIcIZiMHZIoSQr8v3fSdW1LSToUzakNV0NLeWTS9NvboSwJLJK42Oqb921ZETa8gCgAFSATgAzruXSNDuPEN3HvvtY1G9Gny/ZJJRcxMSgdg0kykALJGf3RVVJAU88V737BpPim/n8Xa1jU0gJlu7SC4zHHCENuyKWZDKpZ3ICNxOUJIbD9BrqXVzqeiyX1ncZsLi3BuTLDG7K8e555GWMtHtaMgoCqPwCcHbXM6zdWF5fx6dr93ey68kluZrW+jZW+yzyhHhmWERxXMAYttfJAZ1XBOVcA8j1m3Oh6/omnaWli99PLJotxpn9ox3SwSXyLG1zbMMHc4WTc0oOwsq7duwn2/wxpNlZaH4e0pbi9t00+5S0S50zYv+kqGxFIA8mEAcsytlS6Zy24b/LJobX+1dJlkhubq0j1CxsNMM+iw2Ul5vEzwM+DtlESKIwwSPDMNy4Vlb2DRtf8AA/h3RNEsNNZbdIHa3tI9slzMkyrho1EW8u/zDcoPIfIyGBIBY0K8t9b0iDUogEkia4h0xRqzyfaCPuJIyEAnPOxstGUO0kcjYtYZNBimv1bW9cRZVtYYpWjllt037HKEAMy8AkuWc7ck8VneINT0zUfDsD63LfaPY6myu995v2F7d02FCGfa6l9oCgZfBxgc7bWnX2kXcMsurXdnPbFlnlleDygbiEZZZSQAXRVjO1lDAoxAGwqgBPeaFdaV4fsNO0BbgJaXdvcPL55LSA3Ie4PzEsSVMhwcg7toHTHVRpOtw7POrxHlU8vBXpjnP17d6xLbxTojx6q8F/bFNP1BbC7YswEc7FF2EkctmRQMZGTjOc4m0iS4j1fV4r2aGebzN0AW08iQw4yF3lyJQpfbuAXByCO5AJYZku9Eee3SW+cJJEpmTyXk52sDkDbyOeB0zjpWdbwwy6altqE80txp99F+8uLPCpKWUosXyLuQbwocZIHDMSGrRguhfXQWS21K1kFksrrINiL5h+6WBKmVdhztJ256/MM2dJitILKFbGPybZslEKFM55Jweck5Pvkn3oAq6hLFJcw30UP22OyEzfugJCsgBUhBu/1nDL0z8zDIyQaxOof8JZfqbNH0x7KNFZ0GZZgZDjdz8m04wRwecfNlrF7pkGoFmtmiKHKk7i0YdZCWUopG7cdwcE9VGQccJqdvK0MFha6m9pctAyxEKPnIABPI6gHt064OKAMK2e5uLJphqlzpepXpkhHnQofs88gQpHKpyGdAMLtIVgT1LBjZ1yWyl0nUL+C+hSQJcWSzXEnmRxMXWNk3pIuzLovHmKQf7pHGjboRfGysTbNDbFfNjmjO5ASu0LzzwrfMc5OMHgiqviESiwm03STFFNGYbmeaW3E6pH5hZiYxy7sI2Axzls9qAFswNYuJ/wCztdlmt7TUGjuozCFeICJT9nR1ClQGKOSdxOWUn0t6LpOoWGo3lzdazNewXZ8xraWMbIJOB+5P3lTA5Vi3OCCvINOyslv9diu2tIglhJMQ11smmjnbgNGysdg8tmBBOcMgwNpy/wAPzWQtYBol3PLHqMsl+klzI9xujLgsUy2VRgflx8oyOOcEA6SiiigAooooAKKKKACiiigAooooAKKKKAMrxJCZ9P8ALNuJrcljOwwZIkEbHdGpVgz7towccEnOQAeKsoH023F1e6c8N1OftTw2to0jHKs9xH5eXZSWUv8AIeXKgFi2X7bxBEZbeD99eIBLho7RlDTBkZdpyOg3buCCNgOeCDyl/rsek6leRTwPeXCxzMlvFGHE8gAKlQiGRd3nCM53KvAPLKZADK1S4ePUIY7mQ2El5BG6kxo1zAVnRltGSLG/asgCjc6/e3Bt43v0uwvtZ1K41mw1TS7r7VHbyxqGneKIweYh8jkYVnVcqMgbjlSeZJ5rhNL+z29tNdLBpVw9tM0Fq0komkjXaQh3NIo87dvILHnLHJ8y/rFmVvbayktY7i1nhDC3uL4xxlS6iZZ4wjKVwVYPzucbDt3EuAcjqeipqOh/ZX1jUdPurCKIwrY3jvG0suxZJwkbmUlhKwC+Yxw5IBLBn6C2vU1me8h0ie80+xt7OAw6jIC9rIsEiv5kKMwLjacFvmXI5yNpkrXs7X1/40gtXiVri3jgf7XK9s0eyLE0e4KWIVJN4kBwGkTjB3Ns6StnBpbaRY6pZ6oIbSK/tpZn8yR4DGVSZihAcM6MSUChlJ4JYkgBFpc93baYsRtb7Sr2V7rWLu+h2iYqoEYit3UhQX2uDwB5Zb5mcsbcM1p/wjtzq3iDyYZFgeC5vLSSYyQ7sLKEYqJIVDKDgY27QxxjNXRfXE0+tRGGVZIrhLWFbpCsMuY0fMZH3gd7Ansyle2aampIYI0QKl3PdmymjjuHuBBtVnO4p9xzEue2GZck8ZAMfXbbRL22vPCvie3WTQzHGI2LFo4Y0CbVllzujYsMgtjd2ZjkDZtLi8j07RJruSO0Ky+RcLcXS5kBDJGCQGDSM/lfKG4LEBmxhqyeVoN5pNmbDUDYIXQX8l7LcOkryBI0l3EvIH8xmyxYIQM4+UjNgsjaa1q8up6Olot5deZaTzagslt54xFE8a4DwzSCRt2xT9w/MSckAu6rqNxcaey2t6LuXUCDarpMsYkghfaomDscMAdzbipXc6jBA5ztRtLy40ITRWV7qN2JIJx50dv5qzxmNVOxkADMpbczcIeV4w1Xrfw02i6dothpTzm0022SCFGm8pppACoM8ka5xgliACGcgkDHzMgsZ7LwwItHRZnvWFtNNJdSXLWoIZA3mZWWYIxA5kUgZIYYAoAk1lRc3um6np0lu9hpN5NJqAeSUqQEkD7NgId0didpBG4EcMoK+cfEDSre60/V7y50tIbqayhv72DUpEgh2EskFv8AagmRsmjWTbJtXkBjtGI++utLvbjw9Y3V1rEQ1fT5R5GoWdvLHDyVzvjMjGVCMhsvhskjawVlqQ+HbvxBpdtZaprIktY7O6ivvs1wZVneeMKjsxRUk2gykBl2jKHbwCADyLwPpmrRxJZS6Lba3Hf3zTTG7htI5rW+Z5IryBofN+TMUTyq0ZQMEVcHcSPXdPtLiSPU7zTtRncw3Pnafb2KWyhgiMrQMufmOflYSMMNGmCm3jFtvhD4YgttPto0im0/TRLFPPBJ5V0MSwzJGzxbMorIxO/c4yCGBJz0Oo+HPtni/StUEjz27yTXqJbxKVSXyYoYz5yqD5ezcxBbczLHtyExQBFqkWi6Q1xdN9mhv7iFg9zqcxZmChJHRjLhAfKUk85UJ0IWuf8AFdpYWOq2/mOVsotTaUQXwmvlN59mMiyWwGeYljKCNsRjJwFIAbrpfDmoRXtrEkourFzePdR3EhkWQSvGVUhwwLDDYLZ2qGjCkNuWh448K3eq2mo6THqos9Au5VvdSkuIiGSLdHvigmVgsY2xSFt6v/rOoB4APONR09m8R6WLzS9Z1CGATW12L944r22gZUZ5hOiqFD/aJlYbxvKYjJwS3UeDtLuNNiube0e5n1SDWI3utPmihjji82a2LvIYgA0iwr5iEuWw207sYLL74W2C6ZPqGo+L7+8htL03d1IzxIt5HAiRx2922VWXyzDjcxX7zg4J3DovD/h7WdA8QR2MviFLu0vTc38m2x8mVHNyJW2yDchVjKqbH+bbkqwwQADS8Vw/b9OZbj7Da6mW8mF7jbK0R8wkNEWyBIVCuq8E4AyNuVlaeK1lvbu3t7eWY4vY7SGQ2++Fwp86ZHAxIGVxnH93OMfLak0yaTXFeU26Qb47qZzBu82QAKqqx4Uhlzk5bDAAjFUFso3urSDT71NLn1A3N7JE1kY7mTBjHDZG0KfLDZDbxgAgYoA6KwsriPSfss+oPPN86x3SoodVJPln5twZlXaCxyGIJwM4GguQMHJx3PeoNPtxa2UMIjhi2rykIwgPU7R2Gc4qWJRHGI0LYXjLksfzPJoAzbWcma9iuo5VuCwJSPc22JnZIyHwOoQsQD8mfoS6zdNN0mwt/Nmu2EYhiZ5xJJOVjJ++xG9iFJyevU9zVmU3GJIh8g8kkXPB2v8A7v6/55y57OW10pdOEE2oRjTpIpFTZCLh1CgL8u1UZst02gZPTAwAVJ2kiudNjh0vUoMXLRIIkQxQRIuxT8kgxEzbG2nLEdVAXKXQ9uslxJfX7CMWiLK5uVWMEFwzgggo3YsAvUdSMLHqCHTLm0laW7ngmuXEkQkZ8eZwMKTnapPqQMnCgAbde/UvB5YYKJCEJ80xkAnkqRzu9OlADYADbSslqIZpNzPEzKCzdMkrnrgc+mPpVDVZbmwvI7yfVI4bB5oYBA8SgZYsgG8n7zO8eM4HygAEtWkhtywJaNpVQMWbG7Azgn9fzNWKAMjSpGjN7PLJMBPdZWK4ESGPCqGVSn3gNpOWJbqM4Axdt7SOK8uLtTmS4ChvTC5xjv0PTOO4AJOa+m6ZZ29sYoUd7bzGeOKdciEnIIXcMgct1zw2BhcCtFVCqFUAKBgAdBQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMmDlCYwC45UMSAT6HH/1/pWNLosssUkEkqNBLGImBMhwCoVuGZgTweoP3jnPO7cooA5E+ERb6VBpmnpaLaotvGTP5km1UyrlAxJBKcDLEEu5YNlg1m18M/ZLjWJYJmE2pziWa5Vykqr5XlKOhDFFC4LA5PJGeT0tFAGFpfh1NP0GfTIbqVfNiEX2gKryL+7CZ+cMGOQW+YEZPTHFJaaMdO8+102w0uOxFqkcB8sIQyhl2MiIB5YByMH+JhgDFb1FAGZo+mzae95517LdpLcSTQmXJeJXIYxk5wQGztwBhdq84yV0fThppuY447ZYpH8wGFPLx/CF29PlRUGc846CtKigChJo+nyakNQNsi3oZHMyEqzFFdV3Y+8AJHGDnr9Kv4oooArwCYz3XnwwJEXAiZHLNIu0ZLgqNp3bhgFuADnnALWzt7KxitLG2ggtoECQwRoEjQD7oAAwAMDoOKsUUAZMelLajTYbKO38i2lLuZF+YZjZSUwAAxLZJ46t61oQwtCY44mQWyRhAhUlsjod2emPbPvU1FAFaKzgtkkFlDDAz8/Im0FuxIGM0y2sRHBHE/lgIGCiGMRhQewxyO/TFXKKAIkgRbdICDJGqhf3jFycdMk8k8dTVCzh1S2t7h5ZkvLia4WRYZXCJbxnaGRXVMsBh2BYZJOCQORqUUAVp7aO7jkivbeGSDeCqN84bGDllIxkNn16A9ejpbdHu4Ljy4TLGGTzGTLhGwSqnsCVQn12j0FT0UAZ93a3EuoRXCMNluu6JDJhZHIcMGG046qQwJPUYAzunisrdPLPlRb45GlDKgXDtncePXcc/XnmrNFAEUVvFFNNNGgEsxBds5LYGB+Ht9fWorKwgs3leMSNLKzM0krmR8FmbbuYkhQWOF6AcACrVFABSLnaN2N2OcdM0tFAENxbx3BiMq5MTiRfZh/P/J6gU4x7pSzkOnBVSo+UjPOfxqSigCJreF5Hd4o2d08tmKjJX+6T3HJ496kIypBzg8cHFLRQA1FCIqKWIUYG4kn8SeTTqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates immunofixation of a single urine specimen with antisera to IgG and lambda light chain determinants. There are two lambda bands. A discrete IgG band corresponds to one of the lambda bands (red asterisk). The findings indicate a monoclonal lambda protein plus an IgG lambda fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30576=[""].join("\n");
var outline_f29_55_30576=null;
var title_f29_55_30577="NSCLC liver met PET";
var content_f29_55_30577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver metastasis-PET",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 76-year-old woman with a right upper lobe mass and this PET-CT of the liver showing multiple areas of hypermetabolic activity. Ultrasound guided needle aspirate of the liver revealed metastatic adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30577=[""].join("\n");
var outline_f29_55_30577=null;
var title_f29_55_30578="Rabies";
var content_f29_55_30578=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Rabies (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?29/55/30578/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30578/contributors\" id=\"au2082\">",
"       Alfred DeMaria, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?29/55/30578/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30578/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?29/55/30578/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30578/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?29/55/30578?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      RABIES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Rabies is a disease caused by a virus that, with very rare exceptions, is always fatal. It is spread through bites or scratches from infected, fur-bearing animals. The virus infects the brain, causing the animal to exhibit unusual, often aggressive, behavior. The rabies virus is present in the saliva of the infected animal and is spread when the saliva gets into a bite or scratch. The risk of getting rabies is greater if a person is bitten multiple times or if the bites are close to or on the head.",
"    </p>",
"    <p>",
"     In developing countries, 90 percent or more of rabies cases in humans are caused by dog bites. In the United States, rabies in dogs has been largely eliminated as a result of animal vaccination. Wild bats now pose the greatest risk of rabies.",
"    </p>",
"    <p>",
"     This article discusses strategies to prevent infection with rabies after being bitten or exposed to an infected animal. Animal bites are discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=see_link\">",
"      \"Patient information: Animal bites (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      POST-BITE RABIES PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Rabies infection can be prevented, even after a bite or a scratch from an infected animal occurs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Rabies vaccine and immune globulin",
"     </span>",
"     &nbsp;&mdash;&nbsp;A series of injections, including rabies vaccine and human rabies immune globulin (RIG) can prevent rabies, even if the virus enters the body. This preventive strategy is called post-exposure prophylaxis (PEP). RIG provides immediate antibody protection against rabies infection while the rabies vaccine provides protection within approximately two weeks.",
"    </p>",
"    <p>",
"     Side effects of rabies vaccine and RIG can include discomfort at the injection site (similar to a flu shot), low-grade fever, and muscle aches. If needed, rabies post-exposure prophylaxis is safe to give to children and pregnant women who need immunization.",
"    </p>",
"    <p>",
"     Wounds should be washed with soap and lots of water and may be rinsed with an antiseptic. This will reduce the risk of the rabies virus entering the body. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=see_link\">",
"      \"Rabies immune globulin and vaccine\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      When is rabies prophylaxis needed?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain information is needed to determine if post-exposure rabies prophylaxis is needed. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Whether the person was bitten and the location of the bite",
"      </li>",
"      <li>",
"       The type of animal involved (",
"       <a class=\"graphic graphic_table graphicRef65106 \" href=\"mobipreview.htm?27/29/28123\">",
"        table 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Whether the exposure was provoked or unprovoked (animals infected with rabies are more likely to attack, even when not provoked)",
"      </li>",
"      <li>",
"       Whether the animal was previously vaccinated against rabies",
"      </li>",
"      <li>",
"       The presence of rabies in that animal species in the region",
"      </li>",
"      <li>",
"       The availability of the animal for testing or observation",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Immediate treatment recommended",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person with a high risk exposure to an animal that is or may be infected with rabies should be given immediate post-exposure prophylaxis with rabies vaccine and RIG.",
"    </p>",
"    <p>",
"     Post-exposure prophylaxis may also be recommended immediately if a bite from a high-risk animal involves the head or neck. If the animal can be observed (see below) and is not infected with rabies, the regimen can be discontinued.",
"    </p>",
"    <p>",
"     If the animal is not available for observation or testing, most experts recommend post-bite rabies prophylaxis because of the risk of fatal illness caused by infection with the rabies virus.",
"    </p>",
"    <p>",
"     If post-exposure prophylaxis is needed, the rabies vaccine should be given as soon as possible (considered day zero for the immunization schedule). The rabies vaccine is given into a muscle, usually in the upper arm. The rabies vaccine is given again on the third, seventh, and fourteenth day after the exposure. A fifth dose of rabies vaccine was previously recommended, but experts now agree that this is not necessary.",
"    </p>",
"    <p>",
"     One dose of RIG is also given on day zero. As much of this as possible is injected into and around the wound(s). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20088?source=see_link\">",
"      \"When to use rabies prophylaxis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some persons have received rabies prophylaxis before exposure (eg, veterinarians). These persons only require two doses of rabies vaccine on days zero and three. No RIG is necessary for people who have previously received the rabies vaccine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Defer treatment during observation period",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the animal is a healthy pet, such as a dog, cat or ferret, and the animal is available for observation, rabies prophylaxis can be delayed while the animal is observed (in a secure facility, such as a veterinary clinic) for 10 days. If the animal develops signs of rabies, post-bite rabies vaccine and immune globulin should be started immediately (see",
"     <a class=\"local\" href=\"#H3\">",
"      'Rabies vaccine and immune globulin'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     If the animal remains healthy during the 10-day observation, the bite victim does not need vaccine or immune globulin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Indirect exposure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people receive post-exposure prophylaxis in circumstances of \"indirect exposure\". For example, if a pet dog gets into a fight with a rabid or potentially rabid wild animal, the owner will frequently comfort their pet immediately. If there is infectious saliva from the attacking animal on the pet and this saliva gets into a break in the owner's skin, other open wound, eye, nose, or mouth, there is a theoretical risk of rabies.",
"    </p>",
"    <p>",
"     However, there have never been any reports of a human case of rabies resulting from this type of exposure. For the virus to be infectious and for any risk to exist, the person must be exposed to wet saliva from the rabid animal.",
"    </p>",
"    <p>",
"     The need for post-exposure prophylaxis in cases of indirect exposure should be discussed with a public health official. In the United States, further information is available from the Centers for Disease Control and Prevention (",
"     <a class=\"external\" href=\"file://www.cdc.gov/rabies/\">",
"      www.cdc.gov/rabies/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      RABIES AND TRAVEL",
"     </span>",
"    </p>",
"    <p>",
"     Rabies is still quite common in many developing countries. When traveling to countries where rabies is more common, you should avoid touching all wild and domestic animals. If you are bitten or scratched, you should wash the area immediately and seek expert advice about the need for post-exposure prophylaxis.",
"    </p>",
"    <p>",
"     In developing countries, the availability and type of rabies vaccine and immune globulin varies considerably. If a person has a high risk exposure to rabies, he or she should consult with a reliable source of information for care.",
"    </p>",
"    <p>",
"     Pre-exposure rabies vaccination may be recommended if you are traveling to a developing country and might be living in conditions where exposure to rabid and potentially rabid animals is likely. The decision to have pre-exposure rabies vaccination should be discussed with a healthcare provider who is knowledgeable about travel medicine (eg, an infectious disease physician).",
"    </p>",
"    <p>",
"     It is important to know that having pre-exposure rabies vaccination does not eliminate the need for future vaccination if you are bitten. If you have had the rabies vaccine previously and are bitten or scratched by a rabid animal, you need two doses of rabies vaccine, on days zero and three; no rabies immune globulin is needed. (See",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"      \"Patient information: Vaccines for travel (The Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ADVICE REGARDING SPECIFIC ANIMALS AND RABIES",
"     </span>",
"    </p>",
"    <p>",
"     Contact with wild and unfamiliar domestic animals should always be avoided. Wild animals should not be kept as pets and should never be handled by people who are not properly trained and vaccinated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Domestic animals",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the United States, dogs, cats, or ferrets that have received rabies vaccination are unlikely to be infected with rabies. The number of rabies cases among domestic animals, such as dogs and cats, declined markedly in the United States in the 1930 and 40s due to rabies vaccination.",
"    </p>",
"    <p>",
"     While vaccinated animals present little risk, domestic animals must be up-to-date on rabies booster vaccination to assure their protection. Rabies booster vaccines are given every one to four years, depending upon the vaccine used.",
"    </p>",
"    <p>",
"     The likelihood of rabies in domestic animals is small and varies by region. In the United States, rabies is most often reported in dogs along the United States-Mexico border and in cats in areas of rabid raccoon activity. However, sporadic cases of rabies develop in domestic animals outside of these areas.",
"    </p>",
"    <p>",
"     Domestic animals that have been imported from areas of the world where rabies is more common have occasionally developed rabies after arrival; these animals can be a threat to humans and other animals.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Wild animals",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bites from wild animals are considered to carry a risk of rabies unless proven otherwise by testing. Post-exposure prophylaxis should be given immediately to anyone who is bitten or scratched unless the animal is caught and tested promptly. In the United States, raccoons, skunks, foxes, bats, and coyotes are the most commonly infected species.",
"    </p>",
"    <p>",
"     Among large rodents, rabies has been reported in woodchucks and beavers in areas where raccoon rabies is common. Small rodents, such as squirrels, chipmunks, rats, hamsters, gerbils, guinea pigs, mice, and lagomorphs, such as rabbits, are almost never found to be rabid, and there has",
"     <strong>",
"      never",
"     </strong>",
"     been a reported case of rabies transmission to a human from one of these animals. These animals are capable of developing rabies, although this is unlikely because small animals are usually killed or severely injured during an attack by a rabid animal.",
"    </p>",
"    <p>",
"     Pet rabbits and rodents that are caged outdoors are at risk of exposure to rabid wild animals. The pet could survive the exposure and could potentially develop rabies. Decisions about post-exposure prophylaxis for people bitten by such animals must be made depending upon the individual situation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Livestock",
"     </span>",
"     &nbsp;&mdash;&nbsp;Among all types of domestic livestock, rabies is most likely to occur in cows. Horses, goats and other livestock species are rarely affected. Anyone who is bitten by livestock should be managed individually, in consultation with local public health authorities.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Bats",
"     </span>",
"     &nbsp;&mdash;&nbsp;Among 40 reported cases of human rabies in the US between 1990 and 2006, 37 cases (93 percent) were caused by a bat strain of rabies.",
"    </p>",
"    <p>",
"     Anyone who is bitten or scratched by a bat should receive post-exposure prophylaxis, unless the bat can be collected and tests negative for rabies. However, under certain circumstances, bats can bite and transmit rabies without the victim being aware of the bite. As a result, the following precautions are recommended:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Post-exposure prophylaxis is recommended if a person has direct contact with a bat, unless the exposed individual is",
"       <strong>",
"        certain",
"       </strong>",
"       that there was no bite or scratch or the bat was tested and found not to be rabid.",
"      </li>",
"      <li>",
"       Bats should never be kept as pets and should not be picked up or handled by anyone, except those who are trained and have received rabies vaccination. If a bat is found in a home, avoid touching it. If possible, the bat should be allowed to escape outdoors. If it is not possible to allow the bat to escape, advice about safely capturing the bat is available at",
"       <a class=\"external\" href=\"file://www.cdc.gov/rabies/qanda/general.html\">",
"        www.cdc.gov/rabies/qanda/general.html#b3",
"       </a>",
"       . Contact your health department with questions about potential rabies exposures and about testing captured bats for rabies.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Post-exposure rabies prophylaxis, with both vaccine and rabies immune globulin, is recommended immediately if a biting or scratching animal is infected with rabies or suspected to be infected with rabies. Anyone who is bitten or scratched by a bat should always receive post-exposure prophylaxis, unless the bat can be collected and tested for rabies.",
"      </li>",
"      <li>",
"       If a biting or scratching dog, cat or ferret is healthy and available for observation, it should be observed for 10 days. If the animal remains healthy during the 10-day observation, then the bite victim was not exposed to rabies and does not need rabies vaccine or rabies immune globulin. If the animal develops signs of rabies during the 10 days, the exposed person should receive rabies vaccine and immune globulin immediately. There is no recommendation for a 10-day observation of other animals because of lack of data about virus in the saliva.",
"      </li>",
"      <li>",
"       Post-exposure prophylaxis may be needed immediately if a bite from a high risk animal involves the head or neck. If the animal is not rabid, as determined by either testing or observation, the regimen can be discontinued.",
"      </li>",
"      <li>",
"       If the animal is not available for observation, most healthcare providers recommend post-exposure rabies prophylaxis because of the risk of serious illness caused by rabies virus infection and the safety of the currently available rabies immune globulin and rabies vaccine.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H151\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H374970568\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/23/2418?source=see_link\">",
"      Patient information: Rabies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28161?source=see_link\">",
"      Patient information: Animal bites (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H374970585\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/15/22770?source=see_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/16/24839?source=see_link\">",
"      Approach to the patient with a suspected spider bite: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24248?source=see_link\">",
"      Bites of recluse spiders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29624?source=see_link\">",
"      Clinical manifestations and diagnosis of rabies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"      Immunizations for travel",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/0/13321?source=see_link\">",
"      Pasteurella infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=see_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28038?source=see_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20088?source=see_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31401?source=see_link\">",
"      Zoonoses from cats",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/24/29065?source=see_link\">",
"      Zoonoses from dogs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26986?source=see_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       World Health Organization",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.who.int/rabies/human/postexp/en/index.html\">",
"      www.who.int/rabies/human/postexp/en/index.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?29/55/30578/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 2, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?29/55/30578?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30578/abstract/1\">",
"      Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30578/abstract/2\">",
"      Moran GJ, Talan DA, Mower W, et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emergency ID Net Study Group. JAMA 2000; 284:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30578/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). First human death associated with raccoon rabies--Virginia, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30578/abstract/4\">",
"      Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med 2004; 351:2626.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f29_55_30578=[""].join("\n");
var outline_f29_55_30578=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           RABIES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           POST-BITE RABIES PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           RABIES AND TRAVEL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ADVICE REGARDING SPECIFIC ANIMALS AND RABIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/29/28123\" title=\"table 1\">",
"           Postexposure rabies PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f29_55_30579="Robotic laparoscopy ports";
var content_f29_55_30579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Port sites for robotic-assisted laparoscopy in gynecology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 567px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30579=[""].join("\n");
var outline_f29_55_30579=null;
var title_f29_55_30580="Breast density";
var content_f29_55_30580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Varying patterns of normal breast density",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 538px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIaAUEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzG68OeG7oSlrDyGkP7p7e4KbT6FWyPyFYd94BtC8n9n6sAVI/dTx5IB77l6/lXa3EShxHgMZBkbFG1T3phluLQlEaVAgwXHR/f3FAHmlz4H1qIKbeOG7VidpglBLD1wcH9Kw77TL6w/4/bO4t+cZljKj8zXt8Wt6hbwr5V26w5BCyMdrH29qsaw73sfnx+VDZzNiW2Uttjc9xjsaAPnyivbZ/COl3t3i7s7fhCo8pvLJbHfGMn6muX1LwDaBd1leTxOWxslQOqj3KnI/I0AedUVs3XhvU4GbbbPOqnG6IE5+gxn9KyHRo3KOpVgcFSMEUANooooAKKKKACiiigAooooAKKKKACiiut+GHgi88f+KBo9jcw2gWCS5muZgSkMaD7xx2yVH40AclRWn4m0a58O+ItS0e/A+1WNw9vIR0JUkZHseo9jWZQB9UfB/w34A8S/BvTrLxTp9pBeyGUPqMcSx3AJnk2kSgZ4GBhsjAHWvIPi/8Jda+HN8skub/AEG4bFtqUS/Ic8hXAzsbH4HsTggdp8OLmA/C+K1Z3aV1mwgO3H7x+c12mk+MZl0iTSNat01Dw/Oohntrgh1EZ5JXHQg4I75GRQB8sT2NzBGJJIWEf98cj8xVWvUvE+hjwtqjnSpnvPD87nyJud0Y/wCeb49PXvWVd6HZXqSOYfJmxkGLC/mvQ/higDgqK3b3wzewrutit0vpH94f8B/wzWLLG8UjJKjI68FWGCPwoAZRRRQAUUUUAFFFFABRRRQAUUVa0y0a/wBStLNGCNcTJEGPQFiBn9aAKtFeqeOfhBJ4Y0TW9Qh8Q2GoNos8VvfQCCaFlaQ4UIXULJ6naTgAmvK6ACiiigD6PuEiigLJF85UhicE/h9KpeSEfErl3I3RB8dPetW4ns42jaESNKcnmQHnvxUNoLG4kSWeN4WZsfeyVP8AhQBQmtovJie5Y7H4AxkbqhimMAeaONvMf924YjBHritiSWyQyqgZwjHcXfOPcCltbSSf99cMbWyX5mlxt3Dtj1NAGfJY3Maw4d/IlAYMSc9elNFrcLdSSuU2heCXCg/nU72+pa2Z3sC0iR/djyDsXtwaaNLKEefAQ5TEnzABT7igCmIoiULSNNIpJ2o3y/i1SRaNp2uu1pf6fCvmbvJmAJ2vjIDc5wemRimMoh4MAV8cjqP04qbTbuQ3iCVhgtggHGBz0oA4LWPAEQge4srj7Pgfcky6k/UDK/jmuJ1LR77TgGuoGER6SL8yn8R/WvbbRkJxiXapxwcAU+7toZQVZQyAc7ucigD5/or1TW/BNldw+dZx/ZZG+7tBAP1HT8sVwWr+H9Q0sF54S0P/AD0TkD6+n40AZFFFFABRRRQAUUUUAFehfDfx/a+CPD3iGCPRrfUdU1URwBrzcYEgBJdSFZWJYkdCPuivPaKAO0+LPi+18deKl1+CwNjd3FrCt8gOUe4VdrOncKQFwDzxzXF0UUAe1fDhoz4Ps1kVFysi7iu7d+8bP6GuhaKAxKYVScR5ySCxUgdfT8O1YHgEZ8D6cLhz5JWTaoYrk+a/U10ttfi2gCRqVXHCKvykeoHegDHvLbUvsW2UXCQk+YuDlDwOMdOv86wWuTEwhltWUE4G5QCv1zzXVX17eBd4lKgrz3JPHUY4qjcXV687SRoSxGC4j3E8fSgDFhu0MpUWhcA4BKsn8qs3WnW+pRRx3NjHLH6kksv0Ycj6Zp89zfyqomkcKpI+bp+VERkfehdVIOAS+Mn2oA4/VvA+DI2mTgFefJnI/Rv8R+Nchf2F1p83lXsDwv2DDg+4PQ/hXtbWd+VAi8p1xyCCQPxHFVL6xkeFhdWcbRMfmAKuCfcUAeK0V3mr+Cw6mXTg0TH/AJZtlkP0bqPxz+FcVd2s9nMYrqJ4pB2YUAQUUUUAFFFFABVzRrtbDV7G8dS6286TFR1IVgcfpVOigD3T4i/GnTfEug+IbK2sdbuH1hkKx6pdxy29htbO6BFQFT1HXv8AhXhdFFABRRRQB9F3Me6NUuFypbKNjBU+memKrwF3w8aNP5R2EDhsHp9a1ruyE9z581wJzj5FVjk8U+WBbBBNeStEQMxW6nl8evtQBUs7Wewj+0S2skjEny42IzJg9SPSoLi/1S5vRJdQTSE8ANFkKPpjoKImXVJ2ku53cs25WI+6PTHtVyCz8qeRLe7MTbs9CpFADI3upo5YmjMOOdyrt5/AVVuFch0Eo2HCsc9COlbEbllZft0kmw4YN3Ppz61BKbiKVQLYSGYr8uCQPY+9AEMdl50Ns1pOGljGJWbhQPr3p9utv9tYypbyOiNuaM4x8vr3/Ktm0FzaTBrtYfs7EEoQDgZ6gdq17bRNEvxcOA8U8iFcouA2SOxPpQBwM9hK0StHBx22uP5UzCwKqAusjYXaSDk/XtXaXnhm4jJNt5LxDgRFv8/zrlrnw8Vud4fDZwVLDGfxoAzhPOZQgVih4MZOCD6VYl0p7qVGWF2AHJHBU98npiun/wCEdmni8x54Hk2BQu4AcdST34rD1SCbTLl44o50t1PMiLjzR7gdB14oA4jWvA1rqNwwXFldOGKPEm5XbrhlHAz0yPXvXmmsaRe6TOYr2IrzgOOVJ+vr7da92tr+U3AKuNu4H0/Squp2tves8UiLIX4IkXIPsaAPAqK7bxN4JmtmM2lxu69Wtzyy/wC6f4h7dfrXFMpUkMCCOCDQAlFFFABRRRQAUUUUAezeCJVPgrSgiszp5oJIyAfMYit+KSXLM4cOfvPj5W4/z0rK+Hd2IfA9h5sxRVWUqBwP9Y3BPT/9VXQrXkrBrksn3j1Gfbp9aAJbhXijSTzli3ZOfvEfh1FILxWj+zy3U9wXG4EttU/lzUc0EaMHEqsyk7BnB/GltEBldpXhRgd0ZTDAfXtQBPMtq80ZlEkiKv3RJhgfT2rL3XE0ojCrEM8Kf4fxpJZJFlypQc7gw44PFVxPtHzqSxIOAc45oAmdlM2ZDM8q4AaMnH1qS0YxFiZJolbozcj8R3FWYgEP7yaGA7MAMc8+5HPNSBJbq3AIjLDPC52nHT/9dADLd42kxsQl+jR/J+JGdp/DFUNU0e2vLSWOaJblB+DIfXH+FSGJm+dUEYHLbTyPwrQLl7EO584oQCxXkcdT60AeRa/4YmsFaa0YzwDll/jj+o7j3Fc3Xvh8m8TE8SMez42tj6iuJ8VeCS/mXOkrmUfM8Hr9Pf8AT6dwDzminOrIxVwVYHBBGCDTaACiiigAooooAKKKKAPpia5V5CuY4Vk4jmhUZT61VgeS3k2airTPkbXb5t49VP0pkQdVxIVYNlmUYCgfXqDVx8xW8fk5ZVOQrY+QH0oAuxlLFXKPHcOBwpAG0ntWbes05YqdrynG0fwkeppzM7zNE7Jhx8r9MYprLmQRQAN3Yqck8UATeX/oUqRwgydWKknB/wA96tRTPHbmJl2c5VlboaaokitgNzF5MgMeO1WooolYm5keKNQCSMfOfQA0AYk91idPmeRRgK7c5NXYpJ7lJFmndfMICFegI57e+BWxZ6ZaSXZcyIYJFyijrz2AqWTTkjkUFfKjQEFW5yOuAaAKMN5KLVyJGjukYHGSN575qvFqjSeYWAWY45JIz6n3rUnSCWHbFA4uCRuOMmq76QTuMqqNrbQD8hx26/rQBkK1xKreUyqh5bLgH9ajiur2zV1LSNEefKzx9QOn5VeuLBY5FaTaNv8AdcE4NVi4Eq+UVIH3VPUj2Pb6UAUFjh1KfE7R28rHhwNpP1x1qe90q7D/ALpEuCh+/Ew3/wDAl6/1q5bw20QkAId3+Z15Pl/T196l062mt5Xm8zy8KSjpgbz6Y9DQBlyFljENxDvYryhGCMd8HmuS8UeDrXWwZrFjDqGdp3j759CR1+vX6138U631rJJqCeZdx5PJxle4BHfv/jVS5RnRG2LJH0A6MPYN6/WgD531fTLvSL6S01CExTp2PII9QehHuKpV9A694esPEdkEnZhIOAxGHRv7wz+GR0P1xXifiPQ7zQNSe0vkwRykg+7IvqP8O1AGVRRRQAUUUUAe2eAY3fwTpeYYfLxKA7dSfNY89q2bqLyXUHcE25+Q8H05H41gfD+dYvCOnCcF1O8Rpu6/vGzgfnXSvcOWjjskZEiHEUgyjc9j+NAGZM9vOD5BiTPBADE/j7j1qIW8bXJGcYGCwO7t39/pWldFozuUrbsM71CYB/8ArVk3svmQsqxYkY7iwOdvFADjaWplCLeyyBc9U6r1xV250yTTLRLq3kilix82xDlQfUdazrK4jiR/JIRimDux19q7TT7OLTNIt7m6mglmdC22R+3+NAHDNbZnjhZooS5H7yQED8e9X9Oke3M8UT75VwpwPl6+9Z+u3Mk9600XAZyxXjke1b2majY/2dcJPFIjvzG5AdWx+vpQBDbyQo8cstr58vKsSD8vHQ+oqukjxIyKiRr5gXPQHOf0+ta6rcXt1CVgTA+bzi+A3TK8nH4VBf2ohuoraQzfZ3PmB1G3y2PQEd+goA1LHSbK0sZbm+SRyVDKLdh+6z39/wD61Z8kbJAzwOZ4XOFJGG/PsevFRx3i6deuk7PcW8q4YEYDjtjn8qvnXLOA+bFYmOFiFAibPPXPPGfyoA8+8W+EhqFu13ZptuV74wW9nH8m/P28tmjeGVo5UZJFOGVhgg19JqI78TfZpvMD/MmDhkb6Ht2xXAeOvDX9oI00cPk6lECDxgTD0PoaAPKKKc6sjFXBVgcEEYINNoAKKKKACiiigD6HWVI3CuibCSQ7Lnr2pfPzCwt5hHtPzblzkf56VFbyKxwI8qrZBb/GlW2zu3KFKjeQTkY7DNAEi3ZG2IRh4gfm9VNW4ApLq0rRkDKYHBqpDJHIxd4wVc9Pf6ilEiwzBHRwWOdrdOaANaSdreRGl+YckANwBxVi5ZrizWaQIrINu/Gd3sKzrEiKaRroq1ucZBXmtMmCSYww7hGMbQewoA1/Dgglto3kgQeUWjweuCM5H41v3i2VqiPEY7mVoQR8xGw+pFc8ZEijaBGZRIRyB1wP8ahu2lgaKSJsSMMszd/UUAPS7kVGknZGj3E5ViNo9fzqzqkMl7bRCFmKbQxl3Zzn+dZEtw5MhhZV6FQRnI7gUW2pSDPlb/L6NgY/H6UAM1PSbiK0E8CyMqryF+9/9eq0UQtoo381DO4PDjp7f/Xrct9YnjuTmVxEVwYycgjvUd3FBJNH5kI+cYjZAQB/vDpQBg26tBIXJBjPIHYH2FT3F4Ht0MZb5sqGPbHUACrsljC7uGuYxsGFjAzz7+lZV1bGG8RGG9MHlDwv40AV5nkgnil2JgkgjrkfSkurZosSWvMJbcGGR8vbNWGgEkILMXXPbip4ZVS1kiVXwnHJ6g//AF8/nQBBBJ5g/egGTGQ4HJ+vrVDxToFvrelmC8OImGYpgNxhbsw9V7Edx7gVbgJhdgxLI3Kt3UjoRWtp7JMJLaQqqygkMR91u+B6HuPxoA+YdY0250jUp7G9QLPCcHByGHUMD3BGCD6VSr2X4l+GJL7TpLmKM/bLBSQByXh6lR67eWHtn2rxqgAooooA9w+H1rcP4K0tjEsts6S5BXkYlfODWxeOlqjRKC0W8EHpsGOn1/wrn/Al68PgjTYg2VLSEoeRzI2fpW1O6u7i5QxwH5iwbKk9jj1oAmt5UulZXySDtRtwAPvzXY6dY2dzohC28UgdQD5ahBuA7964G6h+xW5kj3MJD8q46e5rS0zXWnnlhuZYRDcKEkilG04x2IOKAJL7SdNtb62hubbylYhyyMXKj154q7r+l2El4GsL2CeEJsW2mkCM2PStW+NpFZLshaWRocKcZVR6ViS+HYprITXUA24yEiOMP2OfSgCK28KQ3zquJRuJ3IWwAD0w3NVLfTNO0xZ7O7im+0FSIwr8RtWlp+rXNpJFbpHAkqJuEXUufXr+hrJ1HXhfXsceoq9vOjnDMo+Yep4xQBJoUt5Y6jFeRW8t8jMC7onyqPdf6Vta3qVpqivcaMitcTrta3iG7a2cHGfun2q7pOqJHII9PggkV1KywAn5j/eVu9Xrny7vSntNKt30+5YEhwgYs2OVI/qKAOBUJbgWet2biInLYU5UHuMEcZ61P/ZyW9q0kSWskLFdyLIVbb2bJ/rW1b2082lj+0hcCW3kKtOCSEP+1n196nvkg02Yj7SS8zK0aKODgdAeh9zQBj3GnbZIr6zZjGuGlxyQO2cevTNJdEX1wE1BmjlkG4O2SMH9cV0FpZz3NhqObAW8cZO6aF/m3dVLLjkE/lXOyB78OFR0khPnRTdQQfvIcdMHn86APNviL4ZlgzqEaDeOJdvIcf3vw7155X0TZwS6nZ3drcREhQXCOOoHDY9+leK+L9BfRNQIQMbWQ5jYjp/smgDAooooAKKKKAPoqOVXkVtgMSjcVFOdTdIIypUI/wB5OmfXHpU9xJbwgsF2vJww9fQewqKFwWWOWMsGOVCYxQBFJaC1cjLOxPRSOPWpbUxyI8ztIqJ8oVxgg0iGPzCiEhwMlByTTpYpAfnUEnoh+9QA8yuqEtHuUnAHp71NZSyxzgNMDkfICOp9Kit4plTA3AnnDCrkaRugxGryxj+E4JPsKAOl0XZfOiB8BAdyMMjdnpmrd9bwyxCSDcPL4AUfKfqD71haQstpcAsGSKVsyEj7tbIeVdSVjGothwrZ6ex/woAxkgjExeS324GSwPA/CrP2e2giWYmUSPwRtC7M9/rxXSLbWZUFFDAks4YjCke1Yl9PC85JC5ckFB0OBxQBXNrDHZhoUkZRk78AnmjeWtCCj7lwVJORjuahinaQBBhHHy7Me/vTZ5Ni8SOqKcNhRz/9agDOlkMd2CgKuDy3+IpLgLHHvXJB+VmGev0q7PtcfaCFKAbQNvIqNGEWVniDFhgqCQMH2oAzrc7YiXOI25OB/L3oYkKuGIQpgHPUdjinTuI12jy9hb5wB0xTVdxCYnwmH3RsR1HcUANDeYggkRRIASjA9ahhWRMSAExg4cZ+6ajYyJcHcNm045HIPqPatCeRW8qWBDjrImAdwGO3egDRh26hbRFhhoyCvGcMOx9jz+dfPXxK8OHw14omt40K2dwoubXnP7tu2f8AZIK/hXvEd1H9uQRlYxJhCo/lXMfErRl1nwpfoMvqGjObmA/34DgSr+Hyt+B9aAPBKKKKAPb/AIfBpPA2nxxNIkuJcMoBz+8fp3rShEmSt5BNPlOGj3Dp3YGsn4f3zL4L0y2LGOP95l+wPmtxxz+dapmvI/OjWUBGyHfB/KgBLeOc5M1ysLKMfvUIHfj3zUUr2kULNNGsjxYwYyVD59RimztHcwg3MkxckhCRkdO4rLuUeVkRT5z5AwSeOwFAHZeENbngguQqKEmUIkY6SYPTA+YHJ61v6Zb63qM0j7Y4opFK7EOePUDP4Vm6dpN7o1hb6nL9mmWJhGFA+ZG9ccf/AF6rNLdzR3NzIYooj/qnml2lmHbA6CgDc1nQYViMltqNstxtyx3BXJHVQexrn4NOl1GKWxs0tLi9b5w0xXcvTjcTyfpWSLmW/uU+1rEwOFG0k49f/wBdb+k+Era6aR1llk8wfJB5bcf8CHNADdQ8Kavo8cF1Y3IkxES8XmD93+dWLLWNXt7K3vtStGWSJto2klnVu+AOK1dW07ZZ4u7u4SZYxFHarkFiDkZqukFxusII5kEgTMonjJUjdnbuJ+tAESx3q6pL9gnD/aod2zcNrA9sEYP0rO1KOazsbu9ureWZIpkCxFQ3l92Ix61uajqt9phiVbCBrOQ/MynccZwMAc8e1Vr3WLzT7JlmtoZI5QWRlXO5cZB65B7fjQBnWfjCaW9CX9uPLKhJET5dyMOCD3x7/nS2iLotxdGeJzabN8UgQtxjgZ79elVG26lYxTzTeTdq/wA6xpwnPTPY+x9at313cNby2F15NxGg2KVY4lB5XHpQBHLf74ZozIhnlXKSKmFKEjgjsen5Vz2t6QmuaVcafcBfOiyY3z8y8ZH5elai6laxaXMlyh2+WUUD5SADgkHsais4lsrqKWSVZ4rg4ikUHOR1B9DgjigD58u7eS0uZbedSssTFGHoRUNd98UtIEN4mowoQHPlzHH8XY/iBj8BXA0AFFFFAH0TbylHaC6MjGTgjHQ9vwqRW2CVXiU4YEBjtJHtUyfZjKY9ztbEAoTwVJ68/wBKmcQ7xJK58oAqF/iA9jQBmbPKJ8snLPuD53Y9Oauy4keNnZ5G2jgcE+2PSp5YovJkRHKkNgluoGOKht4sNtUtLgfKAMNn1JPagAiupmEisXAY8cVcsyzysqMBLs6gcE/j0qojOgVGLBDkfKeR9TV22iMrNDCXwep9KALUd2Vk8u9jCsMkuD+laH2sOcRnbt+ZWzu/HmsUyRPqEqkgxglQHXnjvmrapK7kqoKgDbhcZHagDR89476N3aORCeeece9aFwqWs8sn2dGDjG0HGDislUCeUIkUYO5mZsY9qsX+JJnDOrSMmQyvkKfXHcUAEUcYncBQ8mMhgwwv1rOvHJbbuUg53Ajp9KeLeRUVVx8zZJ5qzLBI8RAtpWA5y3Ix60AZlkUSXYvKED5ST19etS3kokeDaCrgZJznj8aa9oEKEPiTOCNw4qbUooQ26OQSzIuOeMe4oAqajmMBl4THPGfxquQkkIaX5+OmScYrRjiF1amKR4y7Dk7uaylQ27sEG8LnOONv1oAcYPLuBDMS0JPyhhkqT6GuitNFAt28klmQZIYc/UetYsurzW+UmkwoA8tAB/8ArqgPEEsWVkZtpPPJ456j0oAdfpFa3JMwKEfKQB6d6sSndq8M8JRw+5HGQVORhgfqDVW4M17GbvcpmjkXnblXUnqR2OetQ2EN0L3UrkQxuMFiXxsGWwD1oA8I8W6UNF8Q3tkmTCj7omPeNuV/Qj8ax69K+LWlSKkF/jcsUhty4HVWG5M/+P15rQB7r8P7Qn4e6Xcx7lKmQNyAH/evjmtRLhXhfyUZhuw8ZBYrn+IEf55qD4aO/wDwrzSQu8qDKGRVJ3gyv/nitWOZUkeFLaOFVUqHTIOfTB6igCJdPsZYX+1XO2X7yj+Ij2x1+tU7DRJNS1kWllmOJRuMrRklhnHBHf8Awrq9E8IR3rLNeySvG2NgjbGR3HPNbZtYfDlpdHSElkuI41yztj2yR6980AY8Wl6loEUdnqNy1zY3H75kbJJ/2uehGOlYGmeD7vVdRe4S4WaKFzIyQnIUD+8DW6l3JqhszeedJclz5gkJAAx1UnqKoX0baAWmsb0tOrbvKjiKJtJzhsd/50Aa2p2k1jYSGx0yAbP3jSbCPMHoBWfpGuBbcSRLLYXEhJMQyykjAzntRe+Jry/Fs9xLGmz92IUYKrD1z/8Arqld3n9qDzrQQ23lZVXbBYseOPWgC/rPi/T7a5WLUUmu5MArcIPvMf0P1q1FeT6vp0k6Fo5X+SOOUrhh2+Xr+Vc3ItzqGhPbXgf7TbZkil8gAOw7ZyBiq2ia5u327wtC1qQx425PfJ6Dr29KANHXbC+n2SRTM7REKNzKm09OlVv7Mlvbp7W+ubi3uUXCIjCQzL1+Udj+NaVpNHPIl1Hbs0kRDyzl8hj1xkmq7+ItIg1lbme3lkRzh4AMNnsy+metACaJ4f1Y3s8kkDN58JJD8Lg8ZwOjCsbVvKsnk0e4uDHKGBE7D5Qw6j8R+VehQeJ7GBpJliuELDarM3TPHPrXJaro8+qyzh5YbhkzM2776L2B46dP0oAzm057zS5lt4RNOh3vnIYkdx7EY4q7ZQ28egm6STzFWQedG/JToUP1ySPcGsvRteVbQx2rNBdI3lA7vllXPyk+mD+lbV5dNYD+1IIA0d2WiubVl6MQM8dxnkfWgDE8RWMd5p91bSlZIZl5bqRnoR7g814RcwPbXEsEoxJExRh7g4NfSl3Hb3lvF9jgKp5JQoOSGHPPt1wa8R+Ith9l1tZ1HyXKBs+rDg/yFAHKUUUUAfRsTIkrRl2YbvlZuMY6cVILiFWQPFkbsMwYj2qrdGQzSGSQOS5AIy369qnsoVuE+dAW4boQOPegC3ODHcfKU3tymRyV+neoCDMu5JyGY4A2nitiL/SrZfOVU8rBR9uRjPTPtVOdjA24HeoYsQOp+ntQBBCE8zLrgIMdMhs1ahkVJo/mO1SX+VOmOfWkg+Zj5EbbTyxDYA+pq9/olvbsYmEjvkF1XAA9v8aAKSlwC8hwck5ZQc+1TQM0hjxzjOHHc+gomk/0bKBGUnnJ60toxG7P7sL1U84GKANN7d3hjlVSARk7u2fao0tf7QiKQl4pV/jfPbtU/mfZtMDPGVaZsqW6hQO350lkVaEvDI25M7xu/wA9aAKsl0kPmWzyO4H9zgj6mo11CQzqEEu0jo/Ofzps1py+X2qxPAqxYaeqR5eYOVBxuOcelAFS5mklc5ChmHO0YwKie3RgGVyDt+ZcdR9aneRRMV2SOVIHIHP41YknjhSVoo0a4bGWwMJ6j60AV7KOdmICLEhOzLgDj8eTUsaRNKscbR/fxvz1PvjoP1qldtKt5EYsupKnew6fjSXN4LaceWqsVbdntQA6TTAspZiqM2QAx/rRcaZE9sC0QOCMyKfT17VE10boBVzv7g9Pr9apRvPBdS8sMg46jj2oA2/B0mnQar9mvkltYZDhXxvXOR+QNO+I1po1ppVrNppk+1G4ZZlOQqnsw9vy61jST3M5iYyAQrKvDAMQc+h5/Gnags1zdCOYLHHHKdwkjyq84H4YoAyv7LGt/DzxJZyurTRKlwgJ5Uof8DXz3X0Do9wbDVdRtSNy3VpOpIPGAhP9BXz9QB738Ows3gDR1kughj810UnGP3z8e2c5rUuJrqZ/NmWG8tRypV9rH6e/1rP+HEtsPh1pq3sSMgSbbuHVvNc54pJr22t724jhnVmZQsY2naT1OP1oA7bwzpWuGI3d8iwWCR+ZDhgdvXHIPPHBrm7yfxJaazNqFrfOLaQhMg8MOMgr+FbvgvVtRTTbsvIh3jEccmCHA6gA9qrHWrixlhsXsAI2PmMRhgp9SfT0oA7ZGc6LFFePFLKowvnR/Mp/DmsePV7e18+xvLG2YTPtL7y5bI6AZ44xXJt4h1C8815pIHjViCrnDJzwc9OlYOom4udTaaPyvlwAU5O4fSgC/rqmG4klh04xW5GI2kQsFz6HsfwrCbULyMbtsXmI2SXBII+grZm+0XiZurkvESEVRN9wj2Pb603+zbOwg3287XKEHCnawyTyPzoAih1BJYEmMoe22/PGS0isT1GDV+21ewuNOGmSwRpcSHAlOUKjPfsRWXY27xttncgMc7I4zwOnNTXENms0vlS5ZBgeYR0PUZHpn1oAsX9rPp0SEXVz5EZ/eBDuCH0x0wR/WsewkhlulkYIcS7cquCAT1x/9at3SWgW0jVAs0G7a+ZSxP8AtY64pmpWGny7jo0sVrOSMCU4Bxn5l79v0oAguLe4vNTSygiWS1iBInyCXHfI7nviugv9PkN5BqukhpLmFR5luCQZEA4A/wA/hWD4ZupoRdtK6TOASEZtjP8A7uOtOW8voSnkzRC2SX5yWXcnsSDzQBK+ifa799QsbWS3uI9wmtpVwWY9AfTPr9KjvNSuHsTLOu6N8Iy4K+VKoOOPcYH4V0FzrN3pMwhmlMtjeIWWIrvePOQCCOozjmrniOys7y2gjhYA3CLJIdozuUc8ev5UAU9JtrNdOtLyKbyrm4t2zCxI2k9v89M15X8TbRptMWYLhoX3YA4weP616hYS2y2we62xWqxhoGHZ8FT/AEP41zPiGz+1W0tpKV2SI+2Q/Q5FAHglFP8AKk/55v8AkaKAPo1JA6yhCSw+fsRgenr9afvV0ZXBd9wzk4GKh097eOVWDKxGQYW47dj6U8C38tmy24vnYTj9aAJ4VKAor5XqQTgMPYetW2tUjtommBaRm3KgPJ9yewpmlqlvGZpozjOY4ivb/a9B/Opgsk2btAJCW6nkH/P9KAIJ2nllaNUdNpw0K8LUTptbGybIPQqeKfd7VMcYlI53fLwx9yaabhpVbzMjB+Vi/WgCa3Pzu0g8rgAFlzj0NX7BkS/C3JLA5IYd/c+tVY5EjhDuJD8vIzn+daLJLcWcc6u8CM212yMD0yf8KAL+oPFeaZG0292jYhA3GB/WqEF7Fa2vkJGTKTuPGPpmrPnCW3ZXQMqsMN29icVWPlrgyhtxOFZADj6igCvcb4trvI0gPIUcAUsN7jKlUyFyQ3b6VLLCMGRZcl8ALjbioolJYeYBySAR/jQAQb5w3ljY3TeeT9BSzxm3twrbN27kEcimTId6tI3lYJAJY/5/Grg3TRyHIfGCuf4h9KAM+8k3RRDbjA5PfFVljilAIUNhsbjU9wEKnJAfpw2QKiMUsivhgEPO4c4A+lAFd5GUllwg9xgsaiguGdliOQScqe+fQn0p1x5WVRSfLXgdzUcMWblPlCqh3ZPOaAJIopWO9DjGATxjkjircySWslwBPueUscuCcjtVmdVDQ7EALMASegwev16VRvG+0zRsxZ3D4yOjDqfpQBkPHEt5cXuCBFZ3Em3OQP3R7+nWvnmvobxOv2fw14gu1G2MWckWSO7YTH/j1fPNAHvPgCGzk+HWkNcy+VIDKFYtwp818E+3arV74bgiSKc3EchkYGKSH5hn0I9T2xUfw3R5Ph3pe5BsAmAcqMAea+Rmur0NF02zMsM6PbKxcpPgD/gHU+nNAGNbXzxT+RcfaYMHKLs3BRj7vrn+VW7nTYpLiUWskolIHMhIxxnnPU9q6SO5iE7SGBGZk8xVVdzc9xnvTddiiaP7XPA6KzDzInP3gOnfigDiDpc6XUYKl5i5O+FgyspHCsD16VbtdM1iwuLxNNt4JVVC7JJtB+vP0q3pepSrdS2YsXWAyF0ldgdox2I6GrGpSb9MeYOgulcIJpCBkZ6Z7jnpQBgWMkl+yQvawiPZt2qw3N9T35rVtdRsIF+y3MTpMgBW3VOOOMH1+tJuvPsI/s6KFlBHzbVbYe4UcZz+dMksbiexkmktmGwfMY32OD3yD0H40AavhrTzfRzSSwhccAuP4SOAT0P4VzF34LvdPuJHu7eV4m3Fo1ZeR6+wrc0nxWNGtUs5nBQ56Zyo7Enue1bNjr6agoF20VwWYxhC+OCep5yMf1oA8xW8eKdI9LtjbR8EFhgnB/vHqPauk1F7K9htpZFgk1AttkVXPOO4x0P6VF4hsbWC+8uJljBBYxsS2B7GsqzsoJ7WXUgfOaPBCBwCR3B4xQBFHp6vqE0aYijUlo2kOVA6ck+tNk055LhvsMkcsykhk6Bj/X/69b8DS6hZwPJZKihSQqJ8zduR3qbQb3T/ADdkKQyT5KsgXDO3XBzx+P0oAepkfSLNDCY5rQ71BbJK+gz15wcVBcXEtvqEF7OxL5wAGO18joR2x1qXxD4ijh2WstpHLAyHySHKP1wVz1yOcEd/apbC+mfTbdrgILMEGOeVd5KnIOSe/WgBwttLv7KzTTZ2trR9/wBqSRs+SzEfd9s8VU1nTm0+2hkV3ksxvBLLym7gH3HP51LpMdsmqkXtusFoGEDhTtDHOVf6fd/Oui1uIarompG2mCxxyNDNC/GwoODj0JwaAPL/AOwdN/ufzoo+2S/8+/60UAa11bpBcuQ2FYAAIM59BWh56RWap5QnmQA/vMbU/HuRVXUg0YRFhK4BKt1/Cn21rcXMqKrgx7eUZl6d8CgC1Y3Mrq8hkAYg7nbv9auQztBGkcI2RfxY4JOP5VCIYIiIka3LR4HzSdT68Vbnjto5EWecGd1BYqCOf89qAIZ3hOxSm8kFt7jPHp7U+Czhm8uRjtXkgKCcino9pGjCOOZj0ywAUH6dqb5qqqpGJiMbgMYX6ZoAsSvHbkR2sIfGDuf+E+wqeeWaUfvCWjcZPfb6ED86ypWwRujkUdsdjT4p3ibzHjMKjJO4daANJBIU8pmbyz91lOGx706WBnhXHmOc7cA4xU1sVuZInndXBXrgKa6BLCO0sw9xwrHcpBOW9iKAMmOwhaINcP5Spyx3cj3qrcBfMzbuxjT7uB94jvV6bU7SeP7P9ncfMcHPU/SqCyyRxARRFwARz2/IUAVWSdlVpIS745Y9vwp+nxstwWuHI+X5Vb17HNIl5M8jjfhTlcD6etQAyBXKPt2jILnNAFm609I1MzEskvJRCDhvr2qtdZhtAYfMMb8cccelMtWl+wGOUB1eTcMnqfr6Uj4SNFkuMqMnapwBQBT3KjiQ7MgcKwJAq1AYvMRZRugQhmOMb/pVmGPzZMzSGOJl4K8tx61BcvceZgMGRccMAQfTt0oAUSG43zu42RMWYL24OP51HDbPEgaXMMWQzMeGx6D9Kt2DbLOaWOOMlxhioyMgg49PSqd1OTu3sXZvmds9D/gKAOa+LF/s+H9wcBFu7mK2jUdwuZGP/jqV4LXpvxo1YSHRNFibK2cLXEuP+ekpHB+iqv515lQB7p4EFqfhvpv2yd1XMmFVjwfNfkAc/lWnd6na6h5SQWrTv0VmkKome3tzXPeDLi0PgPSbe4BSTdNh153Au3H1/wAKtWsEMTLJHF5rhifKVzz68fzoA6vw/rN9YFpRBKygCMxs2QvuP0q/p0kV8bxtWluIriUgIJZQUbPT8K5afWdRa2jaBSqBiMk4HrjHQVCNfZ3WO9jNzICCjcZB9B6CgDuILJY3SKeP7LZElllRsj6MPX8arX722oR3MG1TawEDzXbC9ewxn9e9Zd9e6jDFD9pScRnMgjZCwAHfGSKuaB4htri2ltNQtnuYxJuWWFShXI69OfTBoAvWOlTrG8djZ2wfaGgEZ/eE+vJPX1rK1m81awmMOrWTYjZSQQRuP1xjNX7HVAbn7VNeXNjFbbjieIBip7EDkj6+tZ174kn1SSS403zZ7fkMtw+7cfbqR9DQByWqO15cySjMSq23Zs+77HsDVnR441m8vYGkIyrDrkdj65rTtI724WVEeC2YjDGXAUj0z/jWfeRSWdxbi4iil2kHcjgKQP8Aa7igDeXRIteSL7RdyxXG3ZgNvWqZ8NGxkjEl3HPIpAjt0BAYj1re8Myz6pFbmO7tYEiBQpGgy3ckD+Z9auXtzFpu6YIJJT825wM8dcGgDn9GuL6S9mfUfIj8tyrxs5XjoMDpWNcWtrLc3QsgkUB6lWOAeuR+tR6ze2oYM0U4k3Z2Jzn25rWsbnQpYbWe9huYY2O1kdwF3elAFEWkesadErTjzrZz+828nI6+/StTwxryraLp97bpfaYQV2svcggY75yCaZrD6TaawYbaCSKYRZY2z45z05HpWv4Vn0qUSPFbxyx2jKYgUIj3g/NgnqeeaAMrT9IkvtG1K7M4nniudkMbHIAUH5c9sgnr6VteFp5mt7i5uo22NYSpcIQGV3UAIG75HIH0rMiv9Kle9NiJYGjvhJLFHn5jzk4zjB6fStvVPtGgaeksFuYxdMqz2xAPyknDfjgYoA87za/8/Ft/31/9aitT/hCR6f8Ajq0UAZ98iG4jlnkQHH8I5z7exqa0O4iRnTYrZUc5H+FVNTu2W8KeSGHO3vkem6n2kTAlgAyN6Hge9AGzF5Y8mbiQkgEgHIPrVuRPMvH2ZcluvUDPNQWcYitlm84bSCpVzjJ9ienNTG4miGGhATA3seR04wOhoAmuY3ijU+Wo3NtYoeuOmaI7i5mbEO1hgqdr42ke1E1wW3Ewb0GDgHbjiptPhhjY7Y2CAht+7B/GgCe3W6SIgjBYZDMoJA7/AIVPaQRMP9IdXT+/tyMfjxTr95rmMujLEIyMlTkle1U5V+0wtCZitoOWAB60Aa6arbwvHDDBGGjPEhO5sdzjtUuoam1ykfllRJuOTuK7/wD69YcSR2wYtBhezEZ3US3yNGu6N9wJO4dQaANqykgaNDLAu9jk7XJAHrmrF1FFAEWGGMkkgkMTnP41iQi4ZEljA2k8vI/APuKlkldo5BFIuRzketADbhxbqwNrFHIM/MTvwfxpyzTGAeWEdTgNsjAqtdxlhubc5PXaOKbF9oCDblAvRm4wKAGyXVwXCsgcZzlsACh4Vty8t3ujQ4KxEjc3+Apv9oW0k/7r5JmGBcYyAfoe1Ubobjm5dnfuW5yaALsU5mJZWUL0VQDwKv48uKO3iwZn+Uc/dz/TPaqFnF5e2Z8gAZ2+tXrdFR/NmRhuGRjqPT8/WgCzdCWCEoXWWSU7d5AA4ABOOnJH6Vh6kqW1pLNcSrHDBGZJWyDkD+nBrVh+WR5rhsQEcJ3x6j/GvLvjPrxtLePQLZ9rzhZ7hVPKR9Y0PueGOf8AZoA8u13UZNW1i7v5eGnkLAH+Feij8BgfhVCiigD2bwe7p8P9MEiLJGRMVXgkfvWGR6HNalpYRXVv50DNbup3hZJABjvgjnrWF4Qkgj8G6Ws43b0lIC/eB818H2rp/CclnBctLcS+Wqjb+8ySc9cY4z0oAvtDLFBHHqNms1o2HM3JJxz8uOtYVzbwXczyFpprOR9yR2+c+wI7CvWNT/suXSIfszm4VgDuc7fz5BH1FcYdIK3JGnb4nlyFdJVZR7bhQBDa3UNwkdqss9vL5ZGGchkwO1ZCW7WysX1OZrVX5miBXafcYFdLF4Hu7u0+1SpLCzHa8sLbwD9eTzV+XwjFDZbIZp3v7hdrBvu4PqB1NAHJWrtEpgklkn3OHEjITkf7xHI+tMubuGGSZ44BGwIDIUIyfp0H1Fb2naTqVjp13bX0iT2qHMcTAocex9qof2dbW9y63KTS3D8R/vNxIxwcj+tAEUmt3F5AUS2QnbuYE9h9ar2t5FJLH5/lByCBuACj39KqHSb3zWA2RYOFEj7cDsc0650G/eLzrhBHAgIPXkDv9PpQB0k9hdNHDc6XBFKCoJl3bMAnkACq9laRC+MGo2l7byuCwkEodG/HGMfrXMR38lqJIjdzhMjIDMEx7j/Cuu02Ce7to5NOvWtpScHbjLDjqfwNAFDUrHT57J3umvJHD7I4oNqEHPXvke9R3mizzwRoNIaWReIZDPtH0/r9a6LVNMeS2ZNRSWedc7Js53+mQo6Vn2WiOs8EgthJCAYzbySbQ3HbP4HrQBcbQ3fQ47W5uYkadx5jPgyIWwOGH061e8P6XHZRWEG9jp8ZJlUcncDjjOBz+NcVfahfabqzvbwJay2hy0LSB1XnHQZz9a0tH1caxaTWKJcfbJ512spwqsxHI9F7enFAG5dabbz69fXMNr5ccUvnuDhUBX7n1PUk/wD1qdres/2nY2onl3fZmDPKwALCMFsDHq3H0ra1+DGuRaA7tPf3D+ZNKcKgRUH3j2z/ACqhrGlvJcRQBIwj/ucqoGQmNzD0zz+VAHkf/CU6t7/maK6nz9K/55xfkKKAMS8neTTo2AVnSQglznIbp7ZzVqyneBZFkQCKPksgHXpgDueTz0p8AigS7juIW2PE0u2QfN8p9un41Wt9USeAK4jhD4UMBncB079OaANATyytE8zZjwRGCnAA6UqXZllZ8b4y2SjN1/z6VSjfyioDiV/ujHJ6jj6VrRvJAfNjWMyDBBcYCD0A9evNAGqVWKygfCpPIGUgE4X0PvR/Z0bIElV0MY3LjJBHp7VUujJJcWYhXe6QAuD0wTmpYp47XaS7OzLuwpOP8KAJpYmjmDsfLGAWwScYHpUkEIZVWKR2QtkHIA68n6VUmuJrp0dUjcSEZBXORVkxmaYw2iuvlLyApxn/APXQBYv33b2jl5QBcKOOKy5djqplDuW+baD+vNaEOmX0itNJhU6j5wM//WqpcMUchpHypGVPQ/40AXLfabPyoQA7DLc9PpVaBWSUbtzqR8x7n2Ap9uZvtBdkWNSPvdsYqGXzFhMkJfD9GxgD6UAXdNZlJFzIFj7AnkfQUkt6boeSYlaJjyzMSx/HGKyo5QI9s6iQEk5U8/QGrYmidAmPJJ4GDkn2oAmt4LQFmQZCjIDDP4fhUMiLKBJLKCwyNxHb6f1qUQRQNtZy+VwEQHc1WYbU7w1wgHGcN91R7+tAD7aOJ7f7S6u6DAjjb+M+uPSmtJIX3S/vJTyB2X3P+FXbvUIig2KCq/KC38X09BWNqmrWuk6fJeanIsIUbmHcegx6nsP5DmgCh4k12Dw9ps2qagRMVO23t2P/AB8Tdgf9hep9uO4r521K+udT1C4vb6Vprq4cySSN1Zia1fGfiW58T6u11P8Au7eMbLeAdIk/xPUnufbArAoAKKKKAPXPC0/leCdI371A80qVwf8Alq/4iltLmea7G1SMH5S2CSKXwrAzeCdHkjOXxKu3OD/rX6etWLON2MUyxuIyTuYjII/woA1Y9VuZbRYbiQb1cDaV2ZBHPTj86s2n/EvupLloTcRsA3lngKR0O3+RpJocCISCFos/uwr8ge3rxUcyfvG+xzSZZeI25BHpk/yoA9D0rx1cWpjWC3cOSvmKoAOMY5Heptb8TRXNtDJmS3lkcxtIp8sY9SMEZrl9CsvJukFn5ttKyDJB8xRkcjjqM8H+dV7/AEe8FxOt/NFcxSn5niYrtz6ZwARQBux6xeiSSC7aUw4VUmUBx14OT1zWFfyXcUj/ANpQQTRg7Yri2OO/G5SeKyHlutDijhSC4kgkYlQHBGRxkjP6Uy01G/WxuZpI5DEsnEyRkcY6MOhHrQB11/qV/ZWksU8rbpACn7oZH4+nvWJdJrE07TTmSCRFHllCAkgHTpxTtH8U2dvsWSN1L8b0XzEb2II6+4zXT3WsyppNtLbonl7xvBGQF+vYUAcKYbZlaS4huY2J+d8hlB+nXH50211qz027cFXEJICsSGHTuorV1rXLG8sp4o7aJM/MZFbB/wB0Ej61xy3cqOv2e3jVAwJmkTJwPegD0e38Wwxww3CvIzxnIG0qM/SqOr+Mrg3sfnTIGLszgIMsD2FYMuore27LNvWMDbhV2jHqBx+tYFjp9zqkEjoDcFGwgDcsOnFAHoN54k0eSAQDTYI5L1doYAFsZ/ix79q0vCUGj6DYy6pcvL9qcLBG7HdsJ4G0emTXNeGvDzWmmfatTs2jMbbVJ4YfLnAz0645qvq5kGkpcqc/vGWFpEONw/jC+vpn60AdXfy3bWGr6nfTJtt2WLcr5eRAMgfQ4x9DVE+KZGtNa1bUNsf2K0kMaMfmVpDxx9MfiaZoduun+ELGXU5FlgvJzGkTNlmfH3fxJGT6V5r8XNatI4G0jTnLTTzma9k7Ejoo9s5P4UAedf2te/8APdvzoqhRQB7vrUX9mpcq7fNJlTu5JU9fz9axrSYtIuyGNUQffKkgDsCTxXWeIyUsb6Z548R8NsTcB6Vwen3cV2Nss8rRt/COACP60AdLGm1i0SIjNksyvkjA7A1YzIY0XYhU42Fu/wDWstEhxGIQMOS2d3bGOv51uaNbrc3SF5VljtV8xmU9Mdj9eOlAFm+uMXsnKgqojOwYJwBx61c06zjmTH2xlijH7zenAz681nQi4vrmaWQtBE772YJjj8aSa7d4JIIDsgY7lA5yfUnvQBtreW8U4W1kjLggbj93HbGO/vUhuRDMREAjMd2Hffu+pzWDahfk89OoGSOATU/20x74oRERvPLct+FAG+Gu5bR42jURnrkBQPpWc8MkKEl26ZUr1X8agW8RoBh2cqQrIzZz9Kks0uN5mIMcI4BZcFT7A0ASkTxwKm4zzMwb92fmxVl7OaO13ySgZXiLPzA+mPWn3BkeQGC+itlwM5c5I/CqyXFqsp33E07DgEHaPw70APhtvMX5YmDxgqVxk5+lMjgjjCm7aOMqOFT53z9OgPuamSeeS38rBtrY9z8pb8ByfxqJYUtn3AHaBwrcZ/z7UAWoLuKAHyYZNvYtjL+3emxI92z3F5N5FsmSef0FMYGRwzcAD7zDCj8O9ct438WWeiwIhkWW5x8kIPzfXHRR9fwzQBp654isNJtpLmWUoqD5GI+b6KPU14d4u8TXXiO93y5itUP7qEHIH+0T3Y+tVNf1u81y7M94wCj7kS/dQe3+NZVABRRRQAUUUUAereHJJ4fB2iyW0+xgJQCR9w+c36Hiuo0jULhEkeGCIXBHKqN271welcJ4eLv4e00CIgIHHmKT/wA9H6j9M102mTPauirGfk+ZW3A/U0Aa8V4LvaWlWObO05QMM46AUkcbuzIJMqcsozjaPb1/yKVpbe5nXO1JuuQu1H9x71djRJ08uSGZplbAfA2n8c96AIbTVLzSbnyrCE+Y4DBhxtOOCPSt8alc3CWsmrSptKMHQgcN3YHv+NYnlsBHLOsaxqckSsQQAfQc/rVlrlYgh0+4tZUfndgLtbtjJ460AWrDUbO2nyzRSwJ13w7lYemelWdQ8TR3NqBa29rPbx/OIrZcBl6EEjisVXa2neW9tJ7l2X5FDh0b07/pV22+zswuk0ua0OcDy2AQH3Q84oAbdz6PMLaeO0kt2DHELHKr68getWWubCdWnvpR9miIykKAHjkdDU0WkS3NxNcG9tUtnjKmFgqrn6k/zrmr7Tlsn2xeRIzHKpHtkAx9D0oA3ZrDw7qtrvsriVpGO4oV5PtzwDWbquiaUpWGPU1+1ADELLs2/UgEVT0G6u7Wfz41tgd2GZkONo6jb1rp7jUNNKPO9hBLcsAMzR/ID9P89aAKjwQxx2tnmRm2ZaOMK2PYk80s0FhBd2cVtpc4kDfukEhCSH+8e/X+VU2k0fTL1mitUt9Rm+ZvtAZypx0AH6VBFbXLLcXlnqJMkvyPMMYg7n6E4oA6jXLu+ntodNa1KRR4kZt5VZG7j8+lWrzR7HUtRW1u0EU9rGgdIhkbsZVTjjI/SuYtLS/tJbPUL2a6njUny3OWaQ/3gvYV0ehCDTNGa81OG4jtlma6mDtg3EhOQmeuOBk+goAwvE8Gn6RrYTVblre1s4FaDJyVxyxVexI7/wD1q+ctcv8A+09Wu7zbsWWQsqZ+6ueB+Arrvil4oudd1id55AZJm3PtGAF7Ljt249AK4KgAooooA+kfirHZaT4FV5VWOW/udke2XnavU4I/X3rz/QtPsGtokje8hVcuzFQ+c9hnFX/jj4mtPFHxKay0VgdH0dfsdqQMoWU/vJBzzluAfRQahtPs6WAeEASx8vvjzkE/eBz+hoA2dPtNLjWa6nlvJREAu0IqBj6A5zj6VdbUj9l8m1mltYzklY0VAffrk1g+c1zB+8lZlXJChAq4/DpSI0YOHLIqgAhgSDQBqwys8rCeaaQcZBxjb9KuR3lsgwlp8qnj96FwPXGKyrZx8w/cZ29XYj/Jq2bRjjyijbuMowz+VAGuL63mCLNGsbbgFeMFsfUd6inuwszMpjRGPEkcQ5HvVGGHyZnQOHlxwqnIQ+vXrSwRNHuJckL0BTrQBf8A7TuIyBC8Z7liBuX6cYFSrqs+1RduLhAeCcEEenPQ1WjtZJI2mcCKEjh3XA/+vVy3mtIlU22mxSsw/wBfOpYcei5wKALzO86RvZWm+NePNljUYH1pgWWQ7XlYZ/hjbAH4gZNQ31/5FsZNQl+zInO5goVR7ZwB+dc5qHxE0WzWRXvbi7kX7qW65z9WyF/LNAHUCJllAJ2/7Tnn9ar3+p2Ohwm51C5QBujytwfp3b6AGvKtZ+J+pXUbxabbQ2SH/lo372XH1Pyj8Fz71wt5d3F7O095PLPM3V5GLE/iaAPQvFnxLnvA0GiI0K9DcyAbiPRV6KPc5P0rzmWWSaVpJnaSRjlmY5JPuaZRQAUUUUAFFFFABRRRQB6X4S3nw5ZBY2xh/mHf526mt+yljiYJKrTY6AH7v4kcVR8ANLH4astnl7W3npkj52rQubV4HLoTG7jOc/KPTBoAmBiYq6gtGGIcAZCgdDirFtcbvNCXXk7R8m0MN2Oxx1qnDKJoQnkwrNn/AFnmZL59fpUpAjvMXkLFQOsRGM+vpigCS7WOdg1xcSRy5+Zhkjp1/wDr5qC0uYtOnVpnu7ku2ELY8sehI6kVdZBJYjMAk5xlWBYDp061DPAllbwoS01vuIYsOg/pQAsutaqwaCKVkjZSoxjA+men4VVgl1PfG08+BGCPMxy2amdLX7SGiJVV55kBb65/wpIbdG3SxstwGY4+cZX3PrQBUvNevJ5/IuZJZQvIVvlGPwNJeaxp94gN5Bi7DYxGwUfXirS2sNxtt2Di6zhSAGD+3HSrEnhPTYbkHVP3YA6o5GWxwOfX6UAMl8i91LT4NNUm4RNxczcAehPsPauos7uwkha2uYbmS5ikViySlkGPRhxUP9k+FrK3Q2zNZzuPKZ3UvId3B46evrXR6Zpum6JFbw2YS6Rzuc3C+VxjoS2N3FAGDczvf3kSxBo7eY7FdWXzXycHk9hWynw8vrDT4k8OSJfxeaJJn2H5Wx1JPHFbWta9DZW62+kWWl25VQU+yoGH0BPC+5965m+1S6kuHbWr6aOF/u6faEqp/wB5u/8AnpQB1VnHbJEpu7t7hbV/3r/wStj7gPfBrzL4x+NYILJYo/Le6mXbFAn3I1B5Y/X9cY9ayvGvjKa300CViluW2Q26cbgO30968W1C8mv7p7i5bc7duyjsB7UAQyyNLI8kjFnYlmJ6kmmUUUAFFFFAHoOg6BPGivNCFJ/iPAH9a6mGwWKB1RcSSjDPMdox1OB1/Guev/iJaA4sdMnmx0e7uOf++VH9aw7jx9rL58gWdtkYzFApOPq2aAPQVsYlKhZHYDORFEScdxmrsdgUhPmWk8hKbgz4TP59a8dufFGu3AAl1a925ztWUqPyGKy5p5p2LTyySMe7sSf1oA9yLWlu6b7nTbZsglprlMgnscmqlx4k0+1R/N16wbPBRFMoYf8AAVrxOigD2Gbxn4Ujiw/2t3ON32NSM+4MmCKik+J+iWsmdP0C4uSv3WvbgZ+uACK8jooA9D1L4o3907tBptlEWx80m6Qge3IA/KsK/wDHHiK9TY+pSQxjotuqxY/FQD+tczRQBLcXE1zKZLmWSaQ9XkYsT+JqKiigAooooAKKKKACiiigAooooAKKKKAPVvBrFvCVlEYGaP5yXRu+9uo7VppbahESkSFrZxxHKMEeuCODXO+CpJBo1t5e87S/MfJX5ieQOcV1lncEqR5YkBO4tGen19KAK5sW2LIilMMW2rxjA6f/AKqVAREE85pIX5A2ng/WrzRxkqxZlbGUcgAg+2OtKbRth+zF5VUbtp4I7Hj0oAqW7SxSgxyTKxH8WMEfjwatJeGKDy7qNZA/zMgIwf8APrTTZTLtGNj/AHghyQR7Gle0lRN5QBOhZB69+e9AA1vp93i6t8xgkK7EYVD6Ef1FNEEXlSLKQWzkMF2qf+Bc06IXMCMsUTSDuCvJ/Gp7dGnd96C2Y8DcNwY+4oATwrcafp2pCWdfMcIQgZ2IX3GB1rakigviZRA1zKrEqqvJ+ZYkAVnWlnFZxnzY7WVwc74tyt9PStUQQFo5bfKvs5Rjwp/PJFAF691iwtXgEVhpceovHgFpGmYe/AwD+NRR3MZs98ipcyocyeY+4t6ADt7VFHZaXEPtBMhn6sSuQfZRnj8RUt1rNvZWJuZYm8uIZMkzDCe2BhRQBJc6hMlmEVY4pWBJEacqfUseWPb0FcH4k8RW+iWYa5IluG5S3Y/M/wD8Svv+Wax/F3xOkJkt9DkMhIx9odAAn+4O/wBTXl1zPLczvNcSvLK5yzu2ST7mgCzrOqXOr373d4wLt0VRhUHYKOwqjRRQAUUUUAFFFFABRRRQAUUU5FLuqqMsxwB70ANoq5/Zt3/zy/8AHh/jR/Zt3/zy/wDHh/jQBToq5/Zt3/zy/wDHh/jR/Zt3/wA8v/Hh/jQBToq5/Zt3/wA8v/Hh/jR/Zl3/AM8v/Hh/jQBToq5/Zt3/AM8v/Hh/jS/2Zd/88f8Ax4f40AUqKu/2Zd/88v8Ax4f40f2Zd/8APH/x4f40AUqKu/2Zd/8APH/x4f40f2Zd/wDPH/x4f40AUqKu/wBmXf8Azy/8eH+NJ/Zl3/zy/wDHh/jQBToq7/Zl3/zy/wDHh/jR/Zl3/wA8v/Hh/jQBSoq7/Zl3/wA8v/Hh/jUU9nPboHlTapOM5B5oAjgnlt5RJbyvFIOjIxUj8RXRWXjbWLcATSQXijp9oiDN/wB9DDfrXPx20siBkXKn3FO+yT/3P1FAHoOnfEmBWxqOkM6n7xguCMntwwP862LXx14ZlUIW1GzHTEkQkUc56hsn8q8m+yT/ANz9RR9kn/ufqKAPZ4tf0G8zJFrdsjE4AkLwlQPYrj9aui9thEkaaxp9xuznybtD+eTXhf2Sf+5+oo+yT/3P1FAHvy3KhGJaMOhwxSVW47YINWxeWkUyi5urZeMgPcxr+eWr52+yT/3P1FH2Sf8AufqKAPoF/EGgrCwudY02A/7Ewkxz32ZJrIvvHfhWxLPBdz30/wB3dDbNjH/Ayn9a8V+yT/3P1FH2Sf8AufqKAPQdY+J8krn+y9NSPjAkuXMh/BRgD9a4fV9Z1DWJvM1G6kmOchTwq/RRwPwFVvsc/wDc/UUfY5/7n6igCvRVj7HP/c/UUfY5/wC5+ooAr0VY+xz/ANz9RR9jn/ufqKAK9FWPsc/9z9RR9jn/ALn6igCvRVj7HP8A3P1FFAFeiiigAqaz/wCPuD/fX+dQ1r+ELW0vfFmiWmpeb9hnvYIrjyjh/LaRQ20+uCcUAbANLXpviT4YaVG8j+FvEBkQciC/TB/77Xj9K4HUtE1XTATeWb+WP+WsfzofxFAFCimqwPQinUAFFFFABS0lKDQAUUUUAFFFFABRRRQAUUV6T8PLOzs/AXinxKNLtNW1Swkghihu4vOit43J3StH0bpgZ4GKAPNTWbr3/Hon/XQfyNdV4qvpNS1GO7m0m10p5YVbyrWAwROOfnVOgz7celcrr3/Hon/XQfyNAEWnxyNaJsjdhgn5VJ7mpXBRtrAg+h7VreHi66NEIRjeTv55PzH8qvjT/uMyDDjeeeW9hQBzZUgAsCAenFJ3rV1lJHaKNYSCvHUYz6Up0V0gDSFjK3RRwB9aAMwQyNGZAh2DqaZWlcabNG6qGBj6kk1F9nUyFRCxVP4lbigClRT5I2Uk7GCE8ZpnegAoooFAC0UUUAFFFFABRRXU/C2zttR+I3huzvoI7i1nv4o5YpFyrqWGQR3FAHLUV7h4j0zTta8O+Ppbzwzp+i/2BcY0/ULKBoBMfOKeU4J2uSMHIwQcV4fQAZooooAwKKKKACtPwwpfxLpKqgkY3cICE4DHeOM9qzKtaW6x6naPISEWZGYqcHG4dKAPYdafVNPT/SdF2QknbPFOX2+3GR+FUrPxIRNtga5DEclfmH0I4qpZ6rNa2/n6NFqkIcnMyyFgfbBHNUxfajdHfPawXka8kzw4/AkYoA3b2zs9RDNLDbvcEbi0TiFx+GMGsG70GeIn7K/ncZ8thtf8OzfgaJrHz4muRpotol+81rPvC/VSSRTIlmjYmKdvLPIWbgH8cUAZhyrFWBVh1UjBFFdB58V9+71aA7QuFuIvmZfTkdR7Gsq+06S0USo6XFq33ZozkD2I7GgCpRSCloAXNFJRmgBaKBRQAUUUZoAK0tA1/VfD16bvQ9QubG4K7WeByu4eh9R7GszNFAF7W9X1DXdQe+1i9nvLt8AyzOWOB0HsPauf17/j0T/fH8jWlWbr3/Hon/XQfyNAGv4Ut57iwRYpgke1i3HT5q0P7OefUmVJXKKoQBT+dP8AAkMM2jrCXCzTKwAHB+8e/wCFdjYaOwXyrOIRFjjd/e/rQBkw6FNLJGxJCxjOAM/hUXiW2uk8v7QxEX3vl4z7V6fYaVJDZiMOHfGWyOntVW70kXMSoSpC56jvQB41co9zNiSQIgwQCetZlwkkIIjjYKx5x0r28eDLM4NxAjbv41GMVz+v+EJIkMsDq0C8bAvIoA81WZvI5jw49eageCVwGePj+9jpXXtpZVSXi+bsTVaawfO7k+vGcCgDkJFCHAbP4Ypordu7LnLRgA9OcVlXkUcc2IsqMZwTn9aAIKKKKACiiigAqewvLnT72C8sZ5Le6gcSRSxttZGHQg9jUFFAG3r/AIs8QeIYo4tc1rUNQijO5I7i4Z1U+oBOM+9YlFFABRRRQBgUUUUAFa/hGGG48WaLDcgmCS9gSQDupkUH9KyK1/CPmf8ACV6L5Kb5ftsO1f7x8xcCgD6fsfCvh5miL6JDNAo/du0rK35dDU2o+AtPn06ZGaeCB23BUIG38q5GO9uwjyam+oCWNsC2JGwEcgg9K1rjxgYrWBytzFGR+8EpAAHf3FAHO6h4FtdEtEls9QmLYybiWP5MHsT1/nUWk+EjqlkzO6eeOVmjbarD/gJ5/ED8a6eOa515VbQ723FuPmRWYHnuOOlYNzf2VvO9vfQTRarE2fOtzsDf989fpQBxuv6bd+HLwxTl2L/MrBflZfrVO21GJQ4mXyHzyUXcreoYdPetnV7yTWgXeWe6iTK7RhjCenXgj6GsS80nVLIGZrU3EC/Nv8vdx6nHIFAEd3ZwTHzLBlBxkxg/Kfdc8j6GszuQeCKkiu42/wCWMXPPyZU/oasoIruPazhJh90scZHoTQBTop80TwvtkXB6j0PuKZQAUUUUAFFFFABRRRQAVm69/wAeif74/ka0qzdeP+iJ/vj+RoA0/Du6Kz0+dTtKuQD9XNeu+BjLPc+WThPWvOPC2kyvo2m3UrILV4pGHrlZGH9K9P8ABzRveqkDbs8lO/50Ad9GDBCMgHcNo96UWqH/AFaLuHPHamyEeWiqQF6Y67fxqaKIkExMwU8fWgCFgS2zAIH5k0x4oPKbdznqCM1bW2YliQcgY681CkC8rLuoA5LUbK2VWkhtt5z/AALwK53WdMWC3NzCmw4zsJr097T5SAeMelYGsaQ1xjBICjkUAeEeIoLm5kyEY7BkgNmueIKsVbII7GvZ9R0NEY5G0r3ArltW8OpPDK8gO5QSrr2oA4EUtDo0blHGGFJQAtFFFABRRRQAUUUUAFFFFAGBRRRQAVteC3aPxjoLpt3rfwEbumfMXrWLWl4bJXxFpbKxVhdRENjOPnHNAH01rc+p6nCLS5hit2GGa4RB82fpwelcldaJ/aWmtp1vqRlYlvmlAQk59e4rtNGa6RoftfkiMrvOOGYdifr6V02n6Hp2t6bfEFLSRhvhHB+ox25oA+e7iC68IXcamESRkDcyEgH6/wCFULrULKW5kuM3UcztkLHgKnPP1HtXoXiDw7I2pzhlN1JCCgBPGPWuIu7K7QSRERP5h2LHNHsI+hoA2bKTR7yBZ7OcW2sZxv37Vnz/AAMDxz610fha+ubIwS2CwCUyFXsbiTDH12Oen0NeS3MFxZyNDcwSR88jGQfxrVsb5dOvUi1ImSFcEPk5XuKAO31210zxBLqEFhp0FnrVtIWurSRfLZwRnKEd+M+9efXunNbuWiYlc8A9R/jXr/iLQLbxbolrrVjM8V/HFtjkBwxK9DkdRXlt7ZSxJLlWMyvmWMD7rf3lPofSgDPwyRbbiNngPKlW+77j0qvJG0e0nJRuUbHDCnB0kQNkhhzkd/wp2ZIoykg3QsfwB9R6GgCCinSIUbGQQRkEdxTaACiiigAooooAKzNe/wCPVP8AfH8jWnWZr3/Hsn++P5GgD0zw3EX+G/h9jhVDTMT6jzXzXZfD/Dy3M42qjYX3P41xuhMZfhLpcMS7pl81gBz/AMtnrU8Lx3f9hNPbsUl8wEBu+DQB6/bRRiMNKRtzUjXsca7I84B/GqNnIjWce4FWwGJz3x/KqU83lzk4BIGR3oA6NbpQmXCgn86rySwMRsHzse9Y4vht3MMDuanhkWQkqcsDmgDSbfwuO3JqvcOqkoGBP06U8TlkLOSCD1qjKwjkZ2YfN0zQBl6tarIpLKMHqRXJahCkb8ZCtwcV191cLOjc8g8+1YV4m4NgAkfrQB5N4o0eb7QZrZRJGvp/KuclikRmLoV9jXpepRlWkWPI3dQa5y7sPtTGJ2WOVskE/wBaAOToq1qWnXGmyKLhcxv92RehqrQAUUUUAFFFFABRSUUAYNFFFABV/QCy67pzIAWFzGQD67hVCp7JmS8gZDhlkUj65oA+udM0i51fRrVrK4jjcxcu52gL1xitvStLutNgWXVI99uDhJYmwAPXPauA+Eniye60KSzv98jRttjZRwBXW6trKS2DafqU0v2bydwJY9B6UAZ2tXuhR3k1xDM11MMr8sudo9wK47xLBas1pIkkCsZPvbuPYc1oLo2nR6XJqGnwuRIdm1OSp/vDv+dZnivSBqFiJFMonUAkspUvjv19KAO20fQ9E1PR4or8+ZLtDxyhgzIfqOo9jWNr3hLTdTjZPIlSZflR9hAIH8/rXFeFZUV1RL4xTR4fy2PBAP3ea9WTU0CxKHLqWOc9B7UAeW2Vj4q8IXRgs2aXSGfeFlHBHfg9PwrU8RaLqEUUfinw9F9pIAF3aqQ+31Zf7wru59SWez86GcTxp/rFJyy8/wCFbfhy4tdOtZZbaMvZyYZoyclPXHpQB4xYeD7DxPp11caZOLfVWUSrbSDahbuFPQZ9K4e6sr/S5ZYrqKSKRDtlQjgH+RHvX0dq2i22nOdT00qsNyfMGBhWGeePUVynxHt7bUdK+0hpLa/VRvKfMkwHfpz9KAPGoHinRonBViMrtGQSP61WYYJB59xUlwjRzHgA5yCvAPuKmKvKvlup84DKN/eHpQBVopBS0AFFFFABWZr3/Hqn++P5GtOszXv+PVP98fyNAHrvwZiWXwxFFMit5iSMmT23sCB+P86lsL6WyvkszD5So3IPcZ61U+G80cPg7RyX2yDzWHbP71wV/Ln8KvacwudRvhNGZIY2OD14J4oA7a4lICIsnylQc5xVqLyxbZK5I6Y/zxXIwXaSyoZWGwHaMniumsZI44HCKzEn5hnIH0oAVbZXkyXC4NaVnHGjnB3A/lVBoWVsgo3pmrNrA3lvucZ7AUATyyhnMaHDZ9asyW8clruDFjjkkViC2nF0Qh2N2HXmtCzhu2BV2Ozoc96AMzEMTkDkk4qpdqmNxHIPSug+wCWLaRjHORVebSwsbOxOenXrQBwGt2+7MioQzc81yl9bkypIGO78q9N1i1wCW+dv9muXvbVSWGzGD0NAGCsSXVk1neRrJbP09VPqDXB6lYy6bevbTduVb+8vY16EU8uV1ZiFXn8awdVVdWhbzQFmiUmNj1PtQBydFJ0JB6g4NLQAUUUUAFFFFAGBRRRQAVNZgtdwAckuoH51DViwcx31s6nBWRWB9ORQB6H4W1e+8O6pDLD5gt2I8xcZUjv/AEr3mb/T5YZ2aOaJ0AVkwSvHINeI+HreXXjGsq7p0OwPjqoHQ17zpRs9JhiinjaSFuWIT72AMZwccnFAGPqFkzaeLTSAoaPL5YhTkVygh1Wa2uYr+cKQDhm5P16V6Le6hZ2bvLBbow6Eg+v/ANauf16O7vPNuUiWPdzneB8mOPxoA4PTrWG5uo7RkE1yEyshjBB/yKv6fLN4cu3ikVr1Lj5Y+eAPUE/5FU9Sjlsbi3uWDqkv3ii8jnHPv0qPRdTuLLVPMuI5Jbc4MO0DDc8k/wCe1AHWXvhu9ngOrWUMlu5GJIlfG0cZIHcU+FNR0mGG9t5xLEn+sQc5TuMH2rTXxjBNKzpBtnjX5o3QjcOnH4V0/hqbStSgcC2iMa8vGDtYjGOPX60AY1xqcEtjHGkjNplzhkfOPKbsMj1NTf8ACOw6rYfYdScm1nbCyAYZG7dPetyLwtBcr5WlyKIs52y4HB7enBrHujcaOGjvFkRAT87ZxjpQB86+JtKudA8R32iXuS0EhCOR95TyCKzmaUIpJYKhwpHY9a911jSbLxVCzXzCV0kykxI3oPTP+c1yes+CPspnS1iaSALuAAOQR/SgDzec+YfNwAx++AOM+v41HUlzE9pcvC+QQOh7g1Gw2tjrQAUUUUAJWbrv/Hqn++P5GtKs3Xf+PRP98fyNAHfeD0T/AIV2k4ZhLGzqMngfMT+FaXg7WAnhGed2Mly1zsY455B6+1cNpeuvaeF4dPRPkkWQsfcscGtfwpFP/wAInqqKpGZkZB3zjOfpQB100q4BQnLjIHbn2rsdAWR7dBJkgfLz/I155ayjy4vOUu/GT6V2OiayIblERso/DA0AdqYvNCIpAc8cf41LBaNCG3MMe3NJbTJPtPy8jII4NWt2DgNuBPpQBEkDB94PzdBmrMQdR83QdwOtSqV2gspH0qwqhxgEH6UAV3cKnTB64qncM7DcuMEc56VPeR5UnnI55qrGd6kucHFAGLq0LKcqMsBuHNcleIsrMx4x+hrsb2Ebmbkjvg9K56+tgVmCcDGfl5xQBwWp3azLMg4HTI7kVhoSFVicMTt571uXWmPFdGJ2O3cax5liREDEblG3APegDD1q3W3vP3fKsM5HQ1RroL21jmtmJOJQeAKwGG1iM5HY0AJRRRQAUUUUAYFFFFABU1p/x9Q/74/nUNT2Ize2427syLxnGeaAPUvCmvWulW8Ukz+U7PtLf3SO/wBMGvZdN8UabqMNu1u8c8jjYYIyMnHUj8K8Hd9OGn2ml3VtJ5qM0zTQ4LqW6If7wxW14MsZDqbadbzQSi4AETFsEHtjoQaAPWLx0ELsiybY+REF3DB6DnnsarzadeajGksIUITlo0fJx6YI4NautaXq2lW0JIaV3iRN6OGXcBz17Hrml02zvHjV5LgIAB1+XHFAHJ+I4WSwMMUckb4B5IwW7HGOuMiuSkcjVYp3gbckZYqeF2g9R6V6xq+lw3MKXN7qUSLb/wDLV8HA9B6+lYOqQeH7+IWlpqwW7ZdwSf7rgnPHpQBw7anJDqUEYUNvOAMYPt1rqtOvLkrGsClWyMZO3nmuciiWy1FEkQSTeYUideUdfXP5V2VgzxyYvY9sy/6sqACy+h7H60AdZ4O1ZoNStpZmMEmNskbHAJ6fka9OvLO31PTJIJI42SQcccBvUV5DBFFqdxGBHxHwGJwc+jD616Bpd7PDbKHGJUwCM54oA5O78KS6Y0xWMGNsFu2AP89agtpzYokpPHRTnORXpUd1balbFLgKG7cdPpXIeLPDv+ipHHh7WbKq442N2B/WgDyT4teHrPVrNNV0gRrfQg740IHnKeenr1OPrXkAQ+VuyNw6r3Ar2+HwqtzHf2V68sRZGUFvUdD+fcV4gpktrqRZBmSN2Rw3fqDmgBlFOkUK52nKHlSe4ptABWbrv/Hon++P5GtKs3Xf+PRP+ug/kaALlpZNLoNpPvUIoYFRy2N7c11nhq8hGmbIizBGIHy5OPU1zfhK3uXS2kU7bZAzOT0OCePrW/oepwrf77NNp5aVAuBIcnNAG4dxs5LmABuRuVh39qrR3U0UnHBHIJHSrL3cMnlvboBExLM2e/0q66ebguqKeOQOooA6nRNVYIjSDAIHTmumtL2KQLg/KOR3rzmDzIUITOB0x1rY0mV/OQlsIRjn1oA9CEm4bsnA7+1TRyAkFmx/u1lQSnyVIJJA6U+ScbflBDY6DigDXllTYcjJA5NYt62clc5/u0xZX35LyYHbrin3GxyDnaw5zQBj37hUZsuCwxisto98aJcSGMyckKMnArrLazWdmMrHaBWVrdtBFGHiBcrwM8H6UAc7q629zaeUi7MfcY8/nXAanozw3Eh8t/KGWyK712JUyOmDjGwjoKr30qNE4AKsVHP1oA8x2t5RAU7jwpPasq6hk2bzGEC8EjvXoz21vI4RlDjGB7Gs/XtGgFgBA21nf5lIzxQB58KWtG/0e4tVEiYkQ9geRWcKACiiigDAooooAKs6eQt/bEqrASqcMcA8jqarVb0jyzqtl5wBi89N4PpuGaAOkndJZ3kjQRhjnYDkL7D2qzb3UsmyM4eZSDE+35x7ZH0p81pp5DtBdzhR0Ah3j88itnwr4csL+4W41DxALCBSPL2QM0rn2BOAPc0Aeq/DX4i3un6LqEXiC1WXTcBUM3dh1x6nFbd5rWlaiI7nRYYlicDzFZj1x1OeleW6t4ktNTuk05LGa3gtwYlX6H7zHux7mqemX8dje7NNSYSqc8cHJ9PX6UAd34gu7y9/cxRBLRMg/Jkcdcf41jXdrpt5fwXNwj2dzDGEEiRgqxxkA1p20WoXlo13GBMjfL5gHKN23L3FSi11WUCSExLIFy68MrDp0zkUAc5pWqR6fM0DQC6tZMiSBgVIbP3oz2Yev4GugimmXUIreSRmkCh7dnIzIP0zx+NY9zpLXckzsoS6UFgik9R6Go2mnSCxttV097iC2y4m8wq6rnoT1/H6UAdrFqP2O7Au7d4ST8w7AdiD/Q10mn+IIm2NFKrP0CH+Id8Gua8K6ppGsXrWYvZHjBK7Jjl1HbnHI960NV0eLSvmjgTbuO59wzj8+frQB12l3oaR8/KuehrdhvkL+XOA9pIBuDDpz/jXCWUzJZq0Pyhv+WbAgH6GtiC+EcYDx8H7yHqvuKANDxboyXSyeQVSVEwrg4yCOhxXyh4u8N3+hX0j3YLLIxZj6V9YXF8slkrx5kVcK2OeO2a4TxRZ2usolve2/mI7HnP3fTNAHzZ/ABkEdeO1JW14v8O3PhvV5LefDQMcxuPQ8gVi0AFZuu/8eif9dB/I1pVm67/x6J/10H8jQBLpM866cqGVlhwcAfU10/hyFbpx5QAkWPI5wzDvxXL6ZIg0+BJd2wluQOnJrb8PahDbXZjCEq5BVm6/h6UAdbDbi3UAqcYyVI4NX2la1ljCI0iP055wazkecuATvRzleeQPT/61XrC4SBiLpN8RBKZP3SMUAdDZQR3DqmxwcZLZrZiso41KxIPmHHFY+k3asykFRzXW2d1vOGUKo4zjBoAksrZlQKeg5B6HFWTErcBskdzV6MK0XP1z7U7YuByp/CgDPjt9u47tuRxiq0kLlhliPcdDW3NAhjI3bRmqyRDbgMNvUk0ANsnURqgYYI+prK1Ib1JAHHStKBMysflKg4GPWq95CCWPTjg0AchcpISzttAU8DFZOrXERt0JXLkYHHFdHe58sqDk/WqlqIJY3jkRcqc/MORQBzyWcryRuEVcr2H8qyNVimUsHO5OnAwQa9AFk3lI0ZA4JBPWuZ163kg3Ex7iTvLeooA851WaaFVhjG5c53fyrGugFm4zyMnIxzXTajG8sEJVTuB3Y9qxruAu7y4IZhwPSgDOzRTM0UAYdFFFABWp4XtheeJdItmkjiE13DGZJGCquXAySeABnqay6u6NCtxq9jC5AWSdEJI7FgKAPUPFPh6+02Robu3vVuoTmNoUDQlPVWQkVz8UV61x5QLiYc4IAyvqM9/amLe3NozWqXM8XksVDROVIHTBHcVBOzvtWSXzccq+496ANy2GYjF9vRL1CPkli27x3wfp2rpNB0RJZVuNP1ILOpwwkQ4bP8q4GG5YFY5t0sJG0oTk8+hr2b4V6Pb3cGfMSZxgoCpXjPfng0AereCfDyy6ZE15GEQDgpja3c//AK8U7XpdC0+4f7Jaxzzngh1+TPt6mptY1SG1ihsn3xBOEOc8Y/UV5Z4uvre489be6IbGGUP3B4NADfEvi230xsG1U5z8p4C+orkD45gvb54zbIsRBIBb7wPXB9eO9ZniQ+fZH5vMOAZFZCcH27fjWJpFiv2qAXEIbZ83lOMbl6nkdaAPQPCC22oXt3LZxNHN5Z+63zOecY7E+9drZahLc2RV0IOMeXJ/EucEEdiKzfBM2h2xk/sh445XHm4kGMew9+1bMs1tJftGItk7HJI+6x+vrQB2Xh57S+097WSCNbkLmOMj5Xx6djXOQvPHc3NvdQ5VnPlHoUHp+FTXDRwRq65iYcqR/CRWjZ6jHfQOup7RN1E64yw9GHf69aAJtMVvsEpUorg564JNU5YRuidoBHuJYk9Pep7CQw3ElspDDJYBumcdvao5HMckkeGMbAsUz0PY0AcX8QvC7eI7JWt2C3MOThujrjp9a8EurV7ZEMgwSSp9j6V9PO8iAMPu8Z+ma8X+JOinTNPhkb/WS3DynA6KTxQBwNZuu/8AHon/AF0H8jWkKzdd/wCPRP8AroP5GgC1pk0KaIivErEhsnODncavadLFCdvksRt3c859MGszT43m0qCNIySSct7ZNdHbRxvbRQFkXb/EBgj60ABvJo5ASrBl5C55zWnow+2eZFPcFCwJXPQH61nXNrcxKsb4YnmOVT1GeAav2mmlNhlj8ucnlicgUAbEMeo2gVYFM+eNysCK6zRr9yiPeF0f3HT61xP2m4spSm8KfUda2LK+mijXfI0nOVzz+tAHptvqSsmEYEAdasrLC21mLYPBwc81x9ncrPGgdWEjclQKvxyTGUsqnbjHfmgDqDdRIu0tkDnrk0ebHKhIcZ7ZrnvNnBVzsHPIbqK0bdxIC2BlvWgC9bqAEKAHLdRSanJ5VoysoLNyPpUAZvMXbwAO3Sq95K087byQv3RQBlyuRh2GEHU0iRQywyZX5iBhgaddE7MKRt7jHWmRkxRybBkHHFAEltbyM0cZPAbnPcVU122iMcu1dz42g+laFpOVlRcDcy5BqnO4luJY8H5+QDQB5ffwNBK8n8J5HHQVk3ysnKY+YHGa9E1nQmSCNyVwWYcGuRvIQ1xIhUDyx3oA4T7LP/cNFb2x/wC6lFAHn1FFFABV3RplttXsZ5E8xIp0dk/vAMDiqVWdNUPqNqpIAMqDJ7cigD0nxulvM+n6hYAvBdR/6wJgM4PIP+0OM1zQOa3ItV2Wj6fNdK2nb/MMYTJDf3lPY8n61qXHg2aSz0vUbWX7XYznE8i4VlGcAkf1FAHMaXa3N7fJHY27zun7xlUZwo6k+1eseE9YuLZHsVhaGSQjZMVwpP1H1rB+zv4cgmjtTc21zGvKYG5uchtw7UxNWhv3jNzHPaXLLvcxNmORsdcA/LQB1eqa7qMdwkF7IguFyjqPnIPTIHfPWuM8RJOI3813YPyuFI4NdXDYjUNKhlaNvt1v/cI810zwCp6j8c1py+GNY1SCCC28oRY2sLgFHjH1wc/hQB5LZTygRr5riSJ8cngj0IrstF0d9TjhdEYSZ2rJuACc8gH3rVk+H40mWNtQYTSlsbc7QD2Oep7VqeIdOvtO0aFdHi3SbsLEmOG759R1oA0tO8IWlpZY3MZIzukMgGeTnGRTWhW0HnW6uqIwOwjIAPfNaHhbW4WsHg1WGVZSgXdGmcP7it3+y5rqBvIhdV+5kptBBHGQaAMC/vJbvSi0TKDyAB0Y9+aTQbiO9tFjDneDhsgfLjsRV+x0lLW3n+2oEhgXPk7f4s/yzXMog+1yeTmKUnd8i/ez7UAdXNA6qwBVmY/KVP8AStrwzYSavZ3LTFku7dAo4++Of8P1rj45bmBo5GHmpkAqTyR6/Wun0HWLqx1pbWERBrrC5PUUAU47GS61B4gwCAkE9sV518cE2WaL1C8Cuy17Xv8AhHLbVHmiDMu5IyDzuPevEtY13VNdsZ21aUykjfGSACB+FAHKDpWbrv8Ax6J/vj+RrRHQVna7/wAeif8AXQfyNAG34alS20eBxtMjBiMj/aIq5HZzEGRckEcqOxrL8KwzT2W5CSqDaBj3J/rXpGg+HZ5YN0kZyQDuJoAzPDdhNqGIgHAX5jkdCKu62YLRyLhTg84Zeh6Zrv8AR9KazEeSm48bv6VleLNOtL258ud0WXb8jqOnt9KAOOW6tr1QsqDH8Eg4q8tpISi286spHHUVinQbu0nZ3XKoflOcgj1rVtGcojMCG7beT7/WgDttFsYYUR2nLuwwfm6H6Gt2SFoY1MQZifTmuKsI5mlQtc5bqqMMZHvXTW1zJuRN7K68kZ4oASeCZzvKtkHkN3pbN3SY8E44xn9adqV+0aZMgYsOy8VkxatcsGxEFyODntQB0i30cCliN5YdFrNluQSZNpbf0ArHa7lXfvPyng1XN9IIyB0x1oAvXd7tYDBGR0AqAXm22DSOQWbIycGqaSGRSXyqtznHJrPlk866AQ/KOgOaAOns3kJWZGDZ9eopJUk3NPAwLYHBrPsLr7PGFJyueDTZb82kx3hjFISymgC7e3XnWD7xjYwJz2rzzVZUjllPJLDBPTNdJr+qmKyaKMfPJhmPtXI6nPAyRcZwQxPpQBU/ef8APJqKk+3xf3T+VFAHmNFFFABVrS136laJu27pkG70+Yc1Vq1pkRm1K0iHV5kXrjqQKAO0S0IhjElt5iK5/eQtksff/CvVvAd5aR+DQyXCrNbOXaOcY+XP3SB29DXn17YxaLbKlhOLi5V9szISOCMg479e1UbC+m0++u1lmE4niKPg4BPVc/Q0Ab3jWTURqrajBeOUlOXEYwgXt9c1FF4kt9NmR5rG1vWuESTzh8skWOqkAYJqt4d1mJtVW31ZZJLGX92SBuMP09QPSuo1/wCFbLebtKvmnhkTeqsuCCe3J6UAXrfVrC8cSaklpJA3+peNiG9QG/TrVHXtXvrbUWS11C5hSM74gh+VWwOPc+1VNC0SfTIZLHVdPljbBUScNz6gfyIqiuiXAN1G5m+9vVX/AIscflyKAOs0/wAc20yI+t3ZmmC4Mix4/FR29T6VuWXiWxjtGb7Odj4AnY5yw9vrXPeD/CGm6hDZNcRu0YYo8iMAA3r+FdvqNpY+HEe1jsoHgTlZWbLHp6980AaegNDd6dLLC0UcxyTK64INUm8YQaaGtL+5ieRSWMpfHy/T/CsTUrzVZ9OaZWiihZDhYkAA6Y3CvLdZn1V7fa0YuI03DdtztU9j7ZBoA9ZPxB0by3SVLhju2gs2Q3uPbpT/AA1cp4kmkvIEijhhO0luHyMjI/KvMvBegLcskkyr54YHyy5y3PH4da62xi1DQ7x4BG4spMHcF5BLdKAPSLrTo2sU8+TLkFgVGOPX61gaQt5ca8srqRa2cZfecAsQT+mMV29tp1vFoUVzrBUKYyVhJ3HtgfSuT8aX0t/pG21tI7eCIgJHHlQ47E45b8aAOC8c38+rXskAUqC3Cnr75rmdfhhtNLuUXG+PamfbH+NekaEmny3Ml1qJjeaFQCM7mLn2FeffFIR2kj28a7XeQbh7YzQB58vSs7Xf+PRP98fyNaQrN17/AI9U/wB/+hoA7r4e6Fc3ui2FwgCQlnO/1w5HNenaZHPEzQztuMbZx0GO1YXwpkSD4f6S0wLK7ygY7fvX5roZlkn1Ugqq5GA45zQBtJcxiPIXOMEH0rO1O4hCvJcRBlHVe9XIbfYAsoY56P2rK1SyuldsYKnkD1FADLe7sGhVigRcZCNz+lZl1bmJgYATbNz8i8Y/pVz+zFmt9+0BwvygHAFUpPNj8tJZXhZRgAdqAJbeBySyJyo+X8e9UnzAQ090w+b5doyalm1nyIyoTz5OhOME1WtLiG6I3wuzKeQOStAGnFqdm4Ee6Vnxz8pFXLVYHX5Z2WPuTGTzVNF2wmTYnPfv9Klhucqo6KORzx+NAEs+lmZSUuSUJBzt5PtzUE0UVrAflPndPnxwaml1yC0t2EZSWYdMnoa5W4vJNQkcySYbrg+lAFm8uhEufNDOwx8tY0Vy5kbexT3HXFO82LzAqAkqcEtU6tE20TYyec4oAu2M5MaDaxycZx0HpTrvN5KUiOMMQe+BV3TJI9hIAZOuD61oQCz+xy3KIoaNSSFPpQBwGpzmS/mRBmNPl49qo+WVgxIv7wnkVpThhcyyKVHmklR6nvWXq07xxSsBgryKAK/lj+6PzorK+3v/AHZPyooA46iiigAqeyJF3AVJDeYuCOxzUFT2QzeW4HeRf50AekWzya1f20NpsWdYVVRIeGcDGM+5FZl9aXUdxLLdIqSKw3gHofpVPA+8DtdTxjP+RWs066nbW6SMPtcIKgBSWlXtz69uaALfh6e1aRJNkf2uNsuJWJ3r6r2yK2/Es+q6bKz2utFpUwV2BiSD29OhrDsNPTTDDqWpxumwjyrZmG5/c47V3virXbPXNA0650rT1029gXcTLzG6jP8AF0z7UAcdp/jrUYikt7Gt+FK7km6YzyAe1dtpGqS+I4TeDTktLSI8SxyMzAZzhun868rnuY72ck2xeUnrGSAfwxn8ak0mPUInna2V/LyFdGBIJ7ZFAHol7qUelXUgtzbrHLIrgK7COQ4x1rUvFvdamjW+h8qFTvLRyZzx35+lYmh6fqOr2dxawRxSBx9xJVbafUqemBXQxzXWmaM9vZx2N1qaJhYBdrvcAfeAxwfb2oA5DxJ4qk0VksNLgiljJLM8oYgc9AOmKyU1S+VVu9eVTZynakceBuAPAwOwrQ1DTprqFzra29i7YZ9g3SLn+6Dxj2rjpoII79oU3zxr0Lv1HrxQB6ZY+LhqEsUWgadHFOmC5xlWA9eKu6h4s1Wwi36nBZyzxjfaxHBLkgHc3Xp2zXDyX0ujaYUsEkihl6yA4ZSf7pPNY2n/AG3VL2NJJ5XCnczsclVz1LUAe/eB9Vu7+wB1q7R3nbcUxkxr7VH8ZPEA0DTYhpsJ+03i/IWGQg46D6YrE0Q2emXDrFLHczEboreN89v4j749as3ujyaxHc654ivDDYRwtvhK4VAOcA/l9aAPNLTWL+3lW6SWOWZf3giReA3TJ9TntWZ4z1SbV9WE8+d5G4jGMVvaVrujNPPFb2kSeZ8kcpByi8lm+pFcVezfaLyaUDCliFHoO1AENZuu/wDHqn++P5GtKs3Xv+PVP98fyNAHo/gZr1PBulyQziOAeYpXGSf3rdK9F0bVdL8oR/aFMkYBYOfmryXwf9tHhqzbZI9qA5XA4Hztk/nmjVI55F3wLJIxHYY4oA9e/wCE30cTm2EhlPTHY1etNb0/UR5QKhhwAzAEV89NHPFNi4jKk8oB1+tdNo0ZMfnXE3k44Mh+/wDlQB6xqQS3QGHLKG6Cs1rmKZ8tGWGP7v8AjWBpviOZF+zbvMVBxO3TH0rUWXzhvEpYt93BoASXS4rlDJBtglxwWH+cVn2cc8DSRvJAkw9D1Fak8+IvKLklSMgf1NIwtzaNHgO55bJyR9DQByuoalOspjVx15YH+VI9xIY13vhSeoPFaF3o9s4UliFznk8imxWkUagI6sB2z3oAywF3jaxy3pVq2jji8yXy9zlcdea0Y4CFytspAOQepHtxVaaObz34yMckHH4UAUb07wrrGFORwp7U9hCxj3sCw9OhqOezkSfdJnbjlMdqNMWCa+VFYuO6LkgUAdFp1m1xHmM7YQCST1+lT3Ntb22n3ZGQzKAc1ci2QoIZpBHjnAHOB2rD8YS+dafZ7QYaQ/M2cE4oA5FblDICwysTEDnrWZeXq3MrtJ3bbgd6vXECWxRJF3OQBnPAxWDq1xFv8i2GRyXb3oAX7SPVaKycUUAYNFFFABV/Qo/N1zT4wM77iNcZxnLDvVCtHw9Mlvr+mTSY2R3UTtnpgOCc0AdfqVhDYXbLLLvU8hE6/Tnt71Fa6lPZ7WtVihcHIdU+b862PHGq6XrN7Hdacn7wjDELsA7424x3rA3x+WqomDjksMnPt7UAXrPW7u08112S3UmQZ5Rubaeq81EdQu8ZS6dI1OVQfdz34qjUhaMFTHG2Ryd5zn8KAGb2yTuIY8kg4NaVvqT2lo4ttyzSYBdwCcdwKWzOltHNFdx3UayfNG6lTgjtz2rQ1bR7Wzhspbie5McqZQKoO49+e1AFbTdVuoLdmtokEoBUsjlevqo4qnJc3iOLwSLHNv8AvxnnI/wq5Z6lDooSS1t4ppHb94s2WIAPTIxjIq34tit76GDVtJUJayhUlgVQPKft09f6UAYlxdz3sLtezySOgATnk89/arWnZW2Y2/lvLH8wDMAVxWcsR81kkJTHUkcD60trJ5Fwrld6jqvrQBo388usMWAw9sh3IASQPU0eFYJbnV4YwH8rq4xxj3Heuqbx9FLYQxQ+Hra1jiVUaeI4YgDBJbHJx2NUb/Wra6uon0K1+yxxj5pcZLHvx0GfpQB2ElraeD9Gi1a5KvPNLlVi+VpF7Ak9hmvOvFfirVfEc3l3cxisYyfLtYzhB7kdzV/xHfT6zqkKX0bwpbxiFI8kqmDzn3yayJtOaa/lt7aMKwY7Tn5QoHLGgDLUbeRxjikAqSbYJCsR3IvAb+970ygArM17/j1T/fH8jWnWbr3/AB6J/vj+RoA9J8H6lFa+BNFjvJY47f8AenryT5z9e9ai/wBmTxPIZm8vOQqkCvOfDkyx6Xa7kLjDHkcfeNaSozt5sBwoGVBOM0Aas10NOvZBDGJ4ScqzgHg+lSm/tWtw0cQznDButZDGcqrBiVJ5yOlRzPJtKKqxnPBx1oA6F5gY1bnYQARitvSDDPExgkzs4xn+VctpdzckIuwSDuRyP1rauLSOREmtJPJ/vxj1oA1Lm4SJwm/POSCetUru7SNHZSQcduRVeC0uLkby249CGH8qoXqTrviWIOo4JBxQBCuqs0r7mLjvnIxV1riGKMSM5GfSsqGC5SQyPHtQDnvV4TCQBWRCegbA4oA1bO7IwA4KnsT+tWWv0tpFDHJxkBSDj6msOK0d94lKBB14p1vptqZC77iDwCpPNAGhf63p6ASOQHbhwxz0qjHqcEcwuYwnkv8AwJ8ufxq1daTpUKRyN989c8/pWLqEYX5k2rF6gc49qAOgXxBcXCskEaoSfvnqKxbucwuGDNJcdBk81DZ28hjMrSYDLwvQgVUuDHbsHEY3vwTQBLePIHhedQVwWZR2NcjdsTO3G3nOK1NY1V3kaKNNjrwXzzWKSSxLEknqaACiiigDAooooAKtaYyJqVo0i7kWVCy+o3DIqrU9lj7ZBnp5i/zoA7FbMys5sm82NQTg/KQPpTbK1lu5jHCm4gc/MBj0p+lQPcXsaxPsOeTtLYHqQO1empp2gaLDatr13b3d6saztbQLg84xvIxke1AHC3vhrVdP0mO51OKCxgc/L5z4eX6DqawzgNgNuHrjFdn8RPEF14s1SFp1gLRLiMRttGPp9K5aZEg8vaoLg/NnJGP60AV2VvLAY4XqAf8ACpnuLoQCOSaUxMMAMTj8KUSWy3QMiPNCCMn7rMP6Ul3cGYIgQJGg+UBiaAIBGzIzBSVXqfSur+H32Zrua1vGKpMuTk/LjIwSPr3rlM/Lt9+tWVmS0U/ZW3TNwZcY2j0A/rQB6xqPg3TJtOlluLyCWFCTmEguTjgkg15deaPdQ6kLGC3lL/wlj94eue1UIZp4ZTLDPKkhOSwY8n3q0l7di7U213KszAHIY/KR6UASyW96Hm0qBjtUhpV6AsB3+ldJDF/Zuj2kM1rH5kamdwh+Zx1BJ+vOKYFeLSLS5v4nS4gkJMRGDOTzl/QY/GliN3dJJf304MkpJIxgEdsegxQBQVPtlwZJldEb96zAfjyfrUviG8isNIhsbYAXl2gkuHzkpF1VPYnqa1WRdD0Y6hqR8xhJstbd+fNYDPP+yCea4OaWS4uJJ523zSMWZj3NADAMCloooAKzde/49E/3x/I1pVm69/x6J/vj+RoA0fDzzx6fCznZAAdhxnd8x/rWu8M+pWrNA0cZhGd0ZG08+lZGmYbQLVX2k5YKGPGNxq5psF1ZuJYHXy252jv+dAFe3u7qxmMdwA6McZzxmupFs8rISQqkZKvwBn0NZt1pweaJopSIyvzRntnrVzTLlLGNrW6mLRDlcDdigDRigaDAjOFB7cU+TVdkrI82HHZsc1ka1Az7XiuJAp5BC7QK5vUba6KeYJjNF3weRQB20Gozl3CSCI4yTnOea0ri1k/s83Rfdu5OD1rzHTLeaZg8bsEB6AnmuztLySK1KSzuqk8cZx+FAEV1dSND5W0op5yT1ohg87c5nwrDk4wK0I42u0yTvReScCnkw/Z2wyKqHBJHT2oAw5LhTN9mt2ZABwQev51q2kMkSrK/mOCOTWXLEkl0Zd5WMdAByf6Vagu2mVl83AU4yO1AF651SyhjEcgDznkIOQPrWegnlma5nUgDpgDilhjtlkdtyM3XJI4NFzqICFI/LJUclTuAoAqalPukQt5sg7KOM1k6rfEIkaSK79TjnZ7fWoLzUnmhKIpG7gyHuPas0DFAC+55PrRRRQAUUUUAYFFFFABViwCG+thISqeYu4gZIGar1PZ/8fkHX/WL0Ge9AHaQXMkCy/YZfs6kbS+cOw+v+FRSeZNcxjzGd5FUZZs549a1Y9BZ9IW78wqGk2N5ibdn680zUktoYYoRJui2jDBBv3D+QoAyHjeGRkcFXHBwaGZmADMSB0BPSkwOi5Jp6ozjKRtx3xxQA3rwB0oLZUA9qkjheSURQjzHbGAPWrMWk6hcGUpbSBo8l93HA7+9AFGnRoWySyqoHJY1YWFXuFiZ2eVzghVJx78VcFitrNsumw5XcsbRgMw9/T6UAU7S0e9m8u13c8EtwB7k9hWpayHToSkCBrndsaSMZA9Tn/PWq9hbRxzyK5n2yIcFDtAHv1z9K6vw9pllYyxzySO6sCQApJHTAx0755oAo6TZTXIAuM7BnaxGQSe35eldfc2em6bbHVdQ/c6daqqqjAhp27Kq9yT+VWoYrHSdE/trUJBa2KkqpIJknO77sYz+vr6YryrxX4iu/E+p/abkeVbR5FvbKfliX+pPc0AV/EOs3Gv6rLfXIEakkRQr92Jeyj/GqFFFABRRRQAVm69/x6J/10H8jWlWbr3/AB5p/wBdB/I0Abvgy4s5bCO21CIrsyYpUHJ5Jwa2dTkjtvLkijZ1Y4JYcH6Vw+nRkWEc2Ts3EHaeRzXZaHI11Btl/fIRgqwIzQBUuNUt7iUCIZdexHI/xqBbtJ5mJTIz6cVt3+jz2zJK1tEYpDx3P59qhm8P3V02IoUjyMeYDtP49jQBTgttzMILhWUnBR25H0rc0zTYbJna6mjCEZCsM5rF/wCESmTHlXKu5GSFB4NMh0vUPO8t53jbnIK/1NAG3erYqWTTvLSUjlkUd/0rFe2axGbxZmizkEHOSalk0u9Rtk8hC8NxgZqnqGorbXAijZpto5UnODQBZ+1ajdgfZFRLYA/KT8xqe1muI1aORA8p6jpipdEnlupFY2jxx9AxGPxq1fX8dq7PGVDA4K7qAMe6sdVlkWa3XK99q9fwqc28vlAXEwhcc4AxUcmttPFIsU0cTN0BB4rEklfzt1xcyOFOPlXr+NAFwXce5kVXMadWzkuf8Kzrm5kmU7B5cGcbRxk+/rTri5icExpJvbqWbNVSSxyTzQA+eZ5iN2AFGAAMAVHRRQAUUUUAFFFFAGBRRRQAVpeHIUuPEOlwyEBJLqJGJ6AFwDWbVzSE8zVrJCrsGnRdqDLHLDge9AHuXi/X/wCzbFdH0OKC8tTH+8mkQblPcL36d68xIGScbcn7tdXaWWnavttXlJuIUKguCjZzxz3+nB+tYEukanG8iPp12Cmd37s4/A0AVUyCGVgrDpzzWpb2lvJp29tSjWRmCNDhuT256VSg07ULkHyLGdgB8x8sgD3J7Vt2OjW8c6JqF7aBWX5hA29vw25FAGDC8ttKZkQq8TDJ/untXbaL4qmkuLkX9gLpZELKNu3aT9O3vWHeaakRG0XksJO1GZQDgdyDTLeS7itWSCJlj3DcQN2R6EUAX7nWrpxHBpkX9lwpyXtRzn0z1NU41u70Y8t5pXJ2zSn5z6gjvVqxjvZ4WKQGKIE+W7YjGB161pWFrfahDLJ8kEUSf6wSAKvP8TZwBQBDpOj3KXEavuGW2sjEDaB1JH9a6WWXSfB0BudVJmndR5Ngp/eSHOct/dXp164rlL/xPaabbyWnh+ISTsNr3rjOPXaD1+prkJnkuJ3nuZHmnkOWkc5JP1oA0PEWu6h4jvxdalINiZWCBOI4F/uqP61nDgUUUAFFGKUUAIKXFFFABWbr3/Hmn/XQfyNaVZuvf8eaf9dB/I0AGkXHl2iJJu8s5HGPU1biu57GYmynPlnkD/EVn6bE8lopRS2M5x9TUzqyffUjNAG5B4q1FIykz+Yp45A6flUiasSoeK6Ik67X6A/SufRtpyAD7EZBqRDA2fM3oT0KjIFAHQ/b9VOJSICTzlRgms2fWtRWXMk0gwcjJNV4rZic295FkdAzbf51aguJI5fLvYoZ0zz84496AJbjVdXvkRt68LjOQS351Xs0uppHYmIzf7Qz/KrFy1n5qvD5MRz0DdKjn1Zo4RHalWb+KTaB+AoA3rdNUigYEqwb7uG244rAurVrcuXuljyclWOSay5pZZiTNK757E8UzAoAuzXakoFLEDqfX6VJJqKm3MUUPzH+JjnH0FZ9FACDpS0UUAFFFFABRRRQAUUUUAYFFFFABW54Gge58a+H4IneOSXULdFdBllJkUAj3rDrR8PahPpWv6ZqNmVFzaXUVxFuGRvRwwz+IFAH0b4g0zxNFL8tytxN/wA9hEEYAerYOfxFcjfW3jC6G1tVnXC7SHYLx6fLz+NaSfHfxWzZvILK4GNpynb8qim+MNzPzL4d09j3P+RQBysmm66DuaVXKjbh2RiQahfT9TKIm24VACEKnAP0x0Fbtx8RIZ0+fwxYFjwSWPNQp8R7638w6bpGm2jSJ5bMqkkrnODQBFDY3s4is4lup8n55NuSvbbkduO9aUWgXFtA8t9iwjjbG65lC7h0z61z13418RXMQiGoG3hHRLdBH+orAnaS4kMlzLJM5/ikYsf1oA7HUtZ0SyMiW2/V7llAMhykQPtnk1zWp6re6mAtzIFt1+7BENkY/AdfqaogY6CloAQDHSlooxQAUY4paKACiiigAoooNABWbr//AB5p/wBdB/I1pVm6/wD8eaf9dB/I0AQ6c7pbRtGzKwzyDjua0U1GcDEgSZe4dev41mWH/Hon4/zqxQBbaaylOXt5IT/0ybI/I00QWz/cvAvoJEI/lmq1FAFk2LH/AFdxayfSUD+eKjNpMP4AfowP9ahwPSjA9KAFK4OMciiiigAooooAKKKKACiiigAooooAKKKKAEopaKAMCiiigAqaz/4+4P8Arov86hqaz/4+4P8Arov86AOppaSl70AFFFFABRR2ooAKKKO9ABilooNABRRRQAUUUUAFFFFABWbr/wDx5J/10H8jWkazdf8A+PNP+ug/kaAK9h/x6J+P86sVXsP+PRPx/nVjvQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFHejvQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mammographic breast density results from varying proportions of fat, connective tissue, ductal and lobular elements. The mammogram report should mention the density pattern using the standard BIRADS classification into predominantly fatty (Panel A), scattered fibroglandular (Panel B), heterogenous (Panel C) or dense (Panel D) breast tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30580=[""].join("\n");
var outline_f29_55_30580=null;
var title_f29_55_30581="Osteomyelitis femur";
var content_f29_55_30581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis of the femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 485px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the pelvis demonstrates destructive lesion of the metaphysis of the proximal left femur (A). Magnetic resonance imaging demonstrates high signal in this area, indicative of osteomyelitis (B,C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30581=[""].join("\n");
var outline_f29_55_30581=null;
var title_f29_55_30582="Hypertension in autosomal dominant polycystic kidney disease";
var content_f29_55_30582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypertension in autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Arlene B Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Frederic F Rahbari-Oskoui, MD, MSCR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30582/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/55/30582/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is common in most chronic progressive kidney diseases. However, the pathogenesis is somewhat different in autosomal dominant polycystic kidney disease (ADPKD).",
"   </p>",
"   <p>",
"    Hypertension is a common early finding in ADPKD, occurring in 50 to 70 percent of cases before any significant reduction in glomerular filtration rate within an average age onset of 30 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, the tendency to develop hypertension and its complications begins even earlier (eg, left ventricular hypertrophy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/4\">",
"     4",
"    </a>",
"    ]. Affected young adults have a higher ambulatory blood pressure and left ventricular mass index than age-matched controls, even though the values remain within the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This raises the possibility that treatment of normotensive ADPKD patients may be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased activity of the renin-angiotensin system (RAS) and extracellular volume expansion are often present early in ADPKD (ie, prior to elevation in the serum creatinine) and may play an important role in the rise in blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/7\">",
"     7",
"    </a>",
"    ]. It has been suggested that cyst expansion, leading to focal areas of renal ischemia and enhanced renin release, is largely responsible for at least the initial rise in blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Two observations are compatible with this hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renin-containing cells are present in the attenuated arteries in the walls of the cysts and in cells in the connective tissue surrounding cysts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Renin can also be produced by the epithelial cells lining the cysts and active renin is often present within the cyst fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/9\">",
"       9",
"      </a>",
"      ]. Renin may directly promote epithelial cell hyperplasia and cyst growth, since angiotensin II is a growth factor.",
"     </li>",
"     <li>",
"      The degree of early hypertension varies with the degree of structural change, as patients with normal serum creatinine with an elevated blood pressure tend to have a higher total cyst volume than those who are normotensive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of sodium retention and vasoactive hormones in the genesis of hypertension are less clear. Although aldosterone and vasopressin levels may be elevated in hypertensive ADPKD patients, and patients with ADPKD may be slightly volume expanded, their plasma volume is similar to normotensive patients with ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/1,7,11\">",
"     1,7,11",
"    </a>",
"    ]. The circulating levels of prostaglandins and norepinephrine are not different between hypertensive and normotensive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/1\">",
"     1",
"    </a>",
"    ]. Importantly, measurement of renal blood flow utilizing PAH clearance techniques or breath held MR angiography demonstrate a relative decline in total renal blood flow that correlates with cyst burden (kidney volume) that responds to inhibition of the renin angiotensin system. Renal blood flow, similar to hypertension, is a risk factor for progressive renal disease in ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p>",
"    The large number of widely available antihypertensive agents and increased physician awareness of the importance of blood pressure control have resulted in a dramatic increase in the use of antihypertensive medications (particularly RAS inhibitors) over the last 30 years. Data from the University of Colorado ADPKD center (a tertiary subspecialized referral center) comparing the two periods of 1985 to 1989 and 1995 to 1999 showed an increase in the use of RAS inhibitors from 19 to 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, registry data from Denmark demonstrates a four to five year delay to end stage renal failure in those individuals receiving RAS inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a comprehensive review of the electronic patient records of 1877 adults with ADPKD from the UK General Practice Database between 1991 and 2008 showed a dramatic increase (from 32 to 62 percent) in the use of antihypertensive therapy in patients with ADPKD. The use of RAS inhibitors increased from 7 to 46 percent. The management of hypertension resulted in a drop in average blood pressure from",
"    <span class=\"nowrap\">",
"     142/85",
"    </span>",
"    mm Hg in 1991 to",
"    <span class=\"nowrap\">",
"     133/80",
"    </span>",
"    in 2008. More interestingly, mortality rates decreased significantly during the same time period most likely due to a better control of blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3984957\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypertension and ADPKD generally respond well to an angiotensin (ACE) converting enzyme inhibitor (and probably angiotensin receptor antagonists [ARBs]) since, as described above, focal ischemia induced by the cysts stimulates the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. A separate issue is whether ACE inhibitors or ARBs might protect against secondary glomerular injury as it does in a variety of other chronic renal diseases, in part by reducing the intraglomerular pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glomerular hypertrophy. Secondary glomerular injury appears to be less important in ADPKD, since glomerulosclerosis is not a feature of progressive renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that ADPKD patients who have proteinuria might have a slower rate of progression of kidney disease with ACE inhibitors. A meta-analysis of eight randomized trials of progression of nondiabetic chronic kidney provided some evidence in support of this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/18\">",
"     18",
"    </a>",
"    ]. There were 142 patients with a diagnosis of ADPKD; mean protein excretion was 920",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    which, in a larger study of patients with ADPKD, was present in less than 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/19\">",
"     19",
"    </a>",
"    ]. This suggests possible selection bias for ADPKD patients with proteinuria or proteinuric patients who might have secondary glomerular injury or other factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=see_link&amp;anchor=H4#H4\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\", section on 'Proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At a mean follow-up of 2.3 years, urinary protein excretion significantly decreased in the ACE inhibitor group compared to the control group (-0.33",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    versus +0.19",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    This benefit was greater in those with higher levels of baseline urine protein excretion. There was also a nonsignificant trend for a decreased incidence of progression of renal dysfunction with ACE inhibitor therapy (29 versus 41 percent, P = 0.17).",
"   </p>",
"   <p>",
"    A study that was not included in the previous meta-analysis found that effective blood pressure control with an ACE inhibitor (or a calcium channel blocker) appeared to delay the onset of renal failure. In this prospective study, 24 patients with ADPKD, hypertension, and creatinine clearances greater than 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (a calcium channel blocker) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/20\">",
"     20",
"    </a>",
"    ]. At five years, there was a similar degree of blood pressure control and preservation of renal function, with a mean yearly decline in creatinine clearance of approximately 3.4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. These findings compare favorably with the rate of progression in patients with ADPKD but uncontrolled hypertension (declines of 5.8 and 5.3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 in MDRD studies A and B, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, enalapril, but not amlodipine, had a consistent antiproteinuric effect, but the ability to lower proteinuria did not correlate with the preservation of kidney function in these patients.",
"   </p>",
"   <p>",
"    A non-randomized trial comparing the renal outcomes of 14 patients on a diuretic and 19 patients on an ACE inhibitor showed similar blood pressure control with both agents over a mean follow up period of 5.2 years, but the annual decrease in creatinine clearance was significantly higher in the diuretic group (5.3 versus 2.7",
"    <span class=\"nowrap\">",
"     ml/min/1.73",
"    </span>",
"    m2). Additionally, urinary protein excretion was significantly increased in the diuretic group but not in the ACE inhibitor group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/22\">",
"     22",
"    </a>",
"    ]. This small study suggested that diuretics may not be an optimal first line choice for treatment of hypertension in ADPKD.",
"   </p>",
"   <p>",
"    There are limited data on the use of angiotensin receptor blockers in ADPKD. A randomized trial of 49 hypertensive patients with ADPKD compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/23\">",
"     23",
"    </a>",
"    ]. The blood pressure was equally well controlled in both groups. At mean follow-up of 36 months, creatinine clearance had declined significantly less in the candesartan group (-5 versus -21",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in the amlodipine group).",
"   </p>",
"   <p>",
"    A potential complication of angiotensin inhibition in patients with ADPKD is a reversible acute decline in glomerular filtration rate (GFR), with the serum creatinine usually rising by less than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/24\">",
"     24",
"    </a>",
"    ]. This complication occurs in less than 5 percent of cases and is seen primarily in patients with underlying renal insufficiency and massive cystic disease. Concurrent diuretic use and hemorrhage into a cyst (which can lead to enhanced vascular compression) are additional risk factors.",
"   </p>",
"   <p>",
"    The fall in GFR related to angiotensin inhibition probably results from interference with autoregulation via a mechanism similar to that seen in bilateral renal artery stenosis. In ADPKD, however, the vascular disease is intrarenal due primarily to vascular sclerosis of uncertain etiology that appears to be associated with progressive ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/17\">",
"     17",
"    </a>",
"    ]. It is not clear if the vascular lesions are the result or in part the cause of the hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important consideration in selecting an antihypertensive agent is that hypertensive women with ADPKD are frequently of child-bearing age. Since exposure to ACE inhibitors and ARBs may be associated with serious adverse fetal effects, women in child-bearing years should be counseled about the potential risks of ACE inhibitors and ARBs, and if possible, should switch to alternate antihypertensive drugs prior to planned pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In sum, if there are no contraindications, an ACE inhibitor should be the initial antihypertensive agent. Careful monitoring is indicated in high-risk patients after institution of an ACE inhibitor or following an episode of volume depletion or cyst hemorrhage in someone already being treated with one of these agents. An ARB could be considered in patients who are intolerant of ACE inhibitors. Patients who develop an acute clinically significant elevation in the plasma creatinine concentration may be more safely treated with another agent, such as a calcium channel blocker; however, some experts prefer to use a beta-blocker as a second agent given the potentially detrimental effects of calcium blockers on cyst formation. Diuretics may be considered for patients who do not have adequate blood pressure control on an ACE inhibitor alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Blood pressure goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unresolved issue in ADPKD is the optimal blood pressure among those with hypertension. In an attempt to address this issue, 75 patients with ADPKD, hypertension, and left ventricular hypertrophy were randomly assigned to rigorous (less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg) or standard blood pressure control (135 to",
"    <span class=\"nowrap\">",
"     140/85",
"    </span>",
"    to 90 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/25\">",
"     25",
"    </a>",
"    ]. Left ventricular mass index was measured at zero, one, and seven years, and renal function was assessed every six months for three years, and annually for another four years.",
"   </p>",
"   <p>",
"    Although patients were also randomly assigned to initial treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , this aspect of the study was stopped after two years because of funding issues, with subsequent antihypertensive therapy largely based upon enalapril. If required to attain blood pressure goals,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , or a combination of agents was added.",
"   </p>",
"   <p>",
"    At seven years, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Substantial blood pressure separation was obtained, with the mean blood pressure being 90 and 101 mmHg for the rigorous and standard blood pressure groups, respectively (approximately",
"      <span class=\"nowrap\">",
"       116/77",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       133/87",
"      </span>",
"      mmHg in the two groups) .",
"     </li>",
"     <li>",
"      Renal function was similar in both groups at study end.",
"     </li>",
"     <li>",
"      A significantly greater reduction in left ventricular mass index with rigorous blood pressure control (161 to 104",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      versus 156 to 123",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      for the standard group). Subgroup analysis found that this benefit was more likely with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To determine whether rigorous blood pressure control to less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg improves mortality outcome, the HALT PKD study, a 4-7 year randomized placebo control interventional trial, is being conducted among 1044 ADPKD hypertensive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the recommendations of the JNC 7 and the KDOQI Clinical Practice guidelines on hypertension that goal blood pressure should be to less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Evidence does not support more rigorous blood pressure goals. However it is possible that a blood pressure goal of less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg may provide cardiovascular benefit among ADPKD patients with hypertension and left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30582/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is when to initiate antihypertensive therapy, a decision that is complicated by the observation that left ventricular mass often begins to increase in children and young adults prior to the onset of overt hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/24/38277?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3984669\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension is a common early finding in autosomal dominant polycystic kidney disease (ADPKD), occurring in 50 to 70 percent of cases before any significant reduction in glomerular filtration rate within an average age onset of 30 years of age. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased activity of the renin-angiotensin system, possibly caused by focal ischemia due to cyst expansion, and extracellular volume expansion may play an important role in the rise in blood pressure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there are no contraindications, an ACE inhibitor should be the initial antihypertensive agent. Careful monitoring is indicated in high-risk patients after institution of an ACE inhibitor or following an episode of volume depletion or cyst hemorrhage in someone already being treated with one of these agents. An ARB could be considered in patients who are intolerant of ACE inhibitors. (See",
"      <a class=\"local\" href=\"#H3984957\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop a clinically significant elevation in the plasma creatinine concentration may be more safely treated with another agent, such as a calcium channel blocker; some experts prefer to use a beta-blocker as a second agent given the potentially detrimental effects of calcium blockers on cyst formation. Use of diuretics should be considered after using an RAS inhibitor. (See",
"      <a class=\"local\" href=\"#H3984957\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Goal blood pressure should be to less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. Evidence does not support more rigorous blood pressure goals. However it is possible that a blood pressure goal of less than",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg may provide cardiovascular benefit among ADPKD patients with hypertension and left ventricular hypertrophy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Blood pressure goal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/1\">",
"      Bell PE, Hossack KF, Gabow PA, et al. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1988; 34:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/2\">",
"      Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/3\">",
"      Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/4\">",
"      Oflaz H, Alisir S, Buyukaydin B, et al. Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/5\">",
"      Zeier M, Geberth S, Schmidt KG, et al. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/6\">",
"      Almeida EA, Oliveira EI, Lopes JA, et al. Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2006; 47:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/7\">",
"      Barrett BJ, Foley R, Morgan J, et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994; 46:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/8\">",
"      Graham PC, Lindop GB. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 1988; 33:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/9\">",
"      Torres VE, Donovan KA, Scicli G, et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 42:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/10\">",
"      Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990; 38:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/11\">",
"      Danielsen H, Pedersen EB, Nielsen AH, et al. Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 1986; 219:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/12\">",
"      Torres VE, King BF, Chapman AB, et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/13\">",
"      Ecder T, Edelstein CL, Fick-Brosnahan GM, et al. Progress in blood pressure control in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 36:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/14\">",
"      Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S. Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int 2012; 81:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/15\">",
"      Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011; 57:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/16\">",
"      Ecder T, Edelstein CL, Chapman AB, et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999; 14:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/17\">",
"      Zeier M, Fehrenbach P, Geberth S, et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/18\">",
"      Jafar TH, Stark PC, Schmid CH, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/19\">",
"      Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/20\">",
"      Ecder T, Chapman AB, Brosnahan GM, et al. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/21\">",
"      Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 1995; 5:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/22\">",
"      Ecder T, Edelstein CL, Fick-Brosnahan GM, et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/23\">",
"      Nutahara K, Higashihara E, Horie S, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005; 99:c18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/24\">",
"      Chapman AB, Gabow PA, Schrier RW. Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 1991; 115:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/25\">",
"      Schrier R, McFann K, Johnson A, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/26\">",
"      Chapman AB, Torres VE, Perrone RD, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010; 5:102.",
"     </a>",
"    </li>",
"    <li>",
"     K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43:5(Suppl 1):S1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30582/abstract/28\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1675 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3E383B0E56-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30582=[""].join("\n");
var outline_f29_55_30582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3984669\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3984957\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Blood pressure goal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3984669\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_55_30583="Lund and browder";
var content_f29_55_30583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Lund and Browder chart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 688px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30583=[""].join("\n");
var outline_f29_55_30583=null;
var title_f29_55_30584="Evaluation of microscopic hematuria in children";
var content_f29_55_30584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of microscopic hematuria in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Marie France Gagnadoux, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30584/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/55/30584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic hematuria is a common finding in children. As illustrated in two large population-based studies, 3 to 4 percent of unselected school-age children between 6 to 15 years of age had a positive dipstick for blood in a single urine sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a long list of causes of microscopic hematuria, most of which are benign, especially in children with isolated asymptomatic microscopic hematuria. The dilemma that faces the clinician is to identify the child in whom hematuria caused by significant underlying disease.",
"   </p>",
"   <p>",
"    The etiology and evaluation of microscopic hematuria in children will be reviewed here. The evaluation of children with gross hematuria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1127?source=see_link\">",
"     \"Evaluation of gross hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria is defined by the presence of an increased number of red blood cells (RBCs) in the urine. Hematuria can either be visible to the naked eye (gross) or apparent only upon urinalysis (microscopic). Microscopic hematuria may be discovered as an incidental finding on an urinalysis prompted by urinary or other symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urinary dipstick",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common screening test for hematuria is the urinary dipstick test for blood. The reagent strip that detects blood utilizes",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , which catalyzes a chemical reaction between hemoglobin (or myoglobin) and the chromogen tetramethylbenzidine. Different shades of blue-green are produced according to the concentration of hemoglobin in the urine sample. These strips can detect 5 to 10 intact",
"    <span class=\"nowrap\">",
"     RBCs/&micro;L,",
"    </span>",
"    which roughly corresponds to a finding on microscopic examination of two to five RBCs per high-power field from the sediment of a centrifuged 10 to 15 mL urine sample.",
"   </p>",
"   <p>",
"    False-negative results can occur in the presence of formalin or high urinary concentration of ascorbic acid. False-positive results may occur with alkaline urine (ie, pH greater than 9) or contamination with oxidizing agents used to clean the perineum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Microscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive dipstick for hematuria is confirmed by a microscopic examination of the sediment of 10 to 15 mL of centrifuged fresh urine. Microscopic hematuria is defined as the presence of more than five RBCs per high-power field (40x magnification) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microscopic examination is the gold standard for the detection of microscopic hematuria. Dipsticks for hemoglobin are as sensitive as the urine sediment examination, but result in more false-positive tests. In comparison, false-negative dipstick tests are unusual; as a result, a negative dipstick reliably excludes abnormal hematuria.",
"   </p>",
"   <p>",
"    The procedures for obtaining and processing urine samples in children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42886?source=see_link\">",
"     \"Urine collection techniques in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Glomerular versus nonglomerular bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis including microscopic examination may identify a potential site of bleeding (glomerular versus nonglomerular) and aid in determining the underlying cause. The identification of the glomeruli as the source of blood is important both prognostically and to optimize the subsequent diagnostic evaluation.",
"   </p>",
"   <p>",
"    Signs of glomerular bleeding in children with microscopic hematuria include the following (",
"    <a class=\"graphic graphic_table graphicRef65786 \" href=\"mobipreview.htm?6/26/6571\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red cell casts (pathognomonic for glomerular disease) (",
"      <a class=\"graphic graphic_picture graphicRef55778 \" href=\"mobipreview.htm?34/38/35424\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Protein excretion greater than 100",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      at a time when there is no gross bleeding. The optimal method is obtaining a first morning sample to determine the protein to creatinine ratio because it excludes orthostatic proteinuria, a normal variant. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of proteinuria in children\", section on 'Measurement of urinary protein'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Red blood cells (RBCs) having a dysmorphic appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although helpful if present, the absence of these findings does not exclude glomerular disease.",
"   </p>",
"   <p>",
"    Morphologic study of urinary RBCs, particularly with a phase-contrast microscope, may be helpful in distinguishing glomerular from nonglomerular bleeding. The presence of more than 30 percent dysmorphic RBCs or of more than 5 percent of a specific form named an \"acanthocyte\" is highly suggestive of glomerular hematuria (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"mobipreview.htm?40/13/41170\">",
"     picture 2A-B",
"    </a>",
"    ). However, confident identification of such cells requires expertise in urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In nonglomerular hematuria, microscopic examination demonstrates urinary RBCs with a uniform normal size and shape (",
"    <a class=\"graphic graphic_picture graphicRef80282 \" href=\"mobipreview.htm?43/46/44768\">",
"     picture 3",
"    </a>",
"    ). However, hypercalciuria, a nonglomerular cause of hematuria, can be associated with dysmorphic red blood cells but not red cell casts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several population-based studies of unselected school-age children have shown that the prevalence rate for microscopic hematuria detected in a single urine sample is 3 to 4 percent, which falls to 1 percent or less for two or more positive samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. Among the 1 percent of children with two or more positive urines for hematuria, only one-third have persistent hematuria, defined as a positive repeat test after six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of hematuria and proteinuria is less common with a prevalence rate of less than 0.7 percent in unselected school-age children in a single urine sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173801352\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both benign and serious conditions can cause microscopic hematuria in children. The most common causes of persistent microscopic hematuria include glomerulopathies, hypercalciuria, and nutcracker syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=see_link\">",
"     \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hematuria in these disorders persists for variable periods. The causes of transient hematuria are different. (See",
"    <a class=\"local\" href=\"#H43199854\">",
"     'Transient hematuria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199775\">",
"    <span class=\"h2\">",
"     IgA nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgA nephropathy is diagnosed by renal biopsy with mesangial IgA deposits on immunofluorescence study (",
"    <a class=\"graphic graphic_picture graphicRef58102 \" href=\"mobipreview.htm?12/0/12297\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69895 \" href=\"mobipreview.htm?23/2/23599\">",
"     picture 5",
"    </a>",
"    ). There is often a history of gross hematuria preceded by an upper respiratory tract or gastrointestinal illness and usually a negative family history of renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=see_link\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199790\">",
"    <span class=\"h2\">",
"     Alport syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic Alport syndrome (hereditary nephritis) is a recessive X-linked disorder that is typically seen in males and is often accompanied by high-frequency sensorineural hearing loss, ocular abnormalities including anterior lenticonus, and, over time, progressive renal failure (",
"    <a class=\"graphic graphic_picture graphicRef68942 graphicRef79434 \" href=\"mobipreview.htm?36/44/37577\">",
"     picture 6A-B",
"    </a>",
"    ). Heterozygous carrier-females also can have hematuria, but do not have progressive renal disease. The genetic abnormality in these patients involves the gene for the alpha-5 chain of type IV collagen (COL4A5). In addition, there are autosomal recessive and dominant forms of Alport syndrome with mutations in the COL4A3 and COL4A4 genes (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36377?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199797\">",
"    <span class=\"h2\">",
"     Thin basement membrane disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thin basement membrane disease (TBM), also called benign familial hematuria, is an autosomal dominant condition. Kidney biopsy reveals an isolated thinning of the glomerular basement membrane on electron microscopy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55486 \" href=\"mobipreview.htm?34/50/35624\">",
"     image 1",
"    </a>",
"    ). In many cases, TBM disease is the heterozygous form of autosomal recessive Alport syndrome involving the COL4A3 or COL4A4 genes; two abnormal genes are required for the Alport phenotype. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199804\">",
"    <span class=\"h2\">",
"     Poststreptococcal glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with poststreptococcal glomerulonephritis, hematuria generally resolves within three to six months after the presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199821\">",
"    <span class=\"h2\">",
"     Hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalciuria, defined in children as a urine",
"    <span class=\"nowrap\">",
"     calcium/creatinine",
"    </span>",
"    ratio &gt;0.2",
"    <span class=\"nowrap\">",
"     (mg/mg)",
"    </span>",
"    in children older than six years of age, has been associated with asymptomatic microscopic hematuria. In studies performed in the United States, the prevalence has ranged from as low as 11 percent in the Northeast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/7\">",
"     7",
"    </a>",
"    ] to as high as 35 percent in the South [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Thus, the association between hypercalciuria and hematuria may be more common in areas where there is a higher prevalence of nephrolithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199828\">",
"    <span class=\"h2\">",
"     Nutcracker syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left renal vein compression between the aorta and proximal superior mesenteric artery, referred to as \"nutcracker syndrome,\" has been suggested as a cause of hematuria in children that is usually asymptomatic but may be associated with left flank pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Nutcracker syndrome is detected by Doppler ultrasonographic assessment of left renal vein diameter and peak velocity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Nutcracker syndrome can also cause orthostatic proteinuria in children, (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17655?source=see_link&amp;anchor=H274766758#H274766758\">",
"     \"Orthostatic (postural) proteinuria\", section on 'Left renal vein entrapment'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The frequency of nutcracker syndrome as a cause of hematuria in children appears to be highest in Asia as illustrated by the following case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Japanese case series of 85 children with hematuria without nephritis, nephrolithiasis, or a tumor, Doppler ultrasonographic findings were consistent with nutcracker syndrome in 21 of 23 with gross hematuria and 17 of 52 with microscopic hematuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were seen in a Korean case series of 216 children with isolated hematuria; 176 microscopic and 40 gross hematuria cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/12\">",
"       12",
"      </a>",
"      ]. Doppler ultrasonographic results were consistent with nutcracker syndrome in 33 percent of patients with hematuria. There was no evidence of nutcracker syndrome in 32 healthy normal children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43199854\">",
"    <span class=\"h2\">",
"     Transient hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of causes of transient hematuria is much larger and includes urinary tract infection (which is typically accompanied by dysuria and pyuria), trauma, fever, and exercise. The supporting data are presented separately in the adult section. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Transient or persistent hematuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=see_link\">",
"     \"Exercise-induced hematuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173801409\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation depends upon the clinical presentation, which falls into the following three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic isolated microscopic hematuria",
"     </li>",
"     <li>",
"      Asymptomatic microscopic hematuria with proteinuria",
"     </li>",
"     <li>",
"      Symptomatic microscopic hematuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Asymptomatic isolated microscopic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, asymptomatic isolated microscopic hematuria (ie, no proteinuria) is present in 3 to 4 percent of unselected school-age children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. However, significant clinical disease is rarely detected. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This was illustrated in a 1979 study of an unselected population of 8954 children who were screened for hematuria. Among the 28 patients (0.3 percent) with two or more urine samples that tested positive for blood, extensive evaluation was performed including renal biopsy and intravenous pyelogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/2\">",
"     2",
"    </a>",
"    ]. A cause was found in only five: two with IgA nephropathy, one with thin basement membrane disease, and two with uretero-pelvic stenosis.",
"   </p>",
"   <p>",
"    In retrospective reviews of patients who were referred to a single center for evaluation of asymptomatic isolated microscopic hematuria, standard laboratory and imaging evaluations were unnecessary, as they typically failed to detect any abnormality. This was illustrated by the following two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 325 children with asymptomatic isolated microscopic hematuria, serum creatinine and electrolyte concentrations were normal in all 254 patients who were tested [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/7\">",
"       7",
"      </a>",
"      ]. No clinically significant findings were detected in the 283 patients who underwent ultrasonography. Hypercalciuria was present in 11 percent of the 263 patients whose urine was tested for urinary",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio. (See",
"      <a class=\"local\" href=\"#H173801352\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In another series of 342 children with asymptomatic microscopic hematuria, evaluation included complete blood count, urinalysis, serum creatinine, C3, and ultrasonography or intravenous pyelography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/13\">",
"       13",
"      </a>",
"      ]. No diagnosis was made in 80 percent of patients. Among those with positive findings, the most common was hypercalciuria in the absence of stone disease in 16 percent of the total group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings have led to recommendations for observation of children with asymptomatic microscopic hematuria with normal physical examinations. Extensive diagnostic evaluation including laboratory testing is reserved only in children with proteinuria, hypertension, or gross hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/7,13,14\">",
"     7,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is our recommended approach to children with asymptomatic isolated microscopic hematuria based upon the available literature (",
"    <a class=\"graphic graphic_algorithm graphicRef56645 \" href=\"mobipreview.htm?34/43/35504\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1-4,7,15\">",
"     1-4,7,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation including blood pressure measurement and a urinalysis should be performed weekly for two weeks. One should ensure that there is no exercise prior to obtaining the urine sample, since vigorous exercise can induce hematuria. A thorough evaluation should be undertaken only if the patient becomes symptomatic or develops hypertension, gross hematuria, or proteinuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=see_link\">",
"       \"Exercise-induced hematuria\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic microscopic hematuria'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H10\">",
"       'Asymptomatic microscopic hematuria and proteinuria'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1127?source=see_link\">",
"       \"Evaluation of gross hematuria in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If isolated hematuria persists, obtain a urine culture. If the culture is positive, treat with appropriate antibiotics.",
"     </li>",
"     <li>",
"      If the patient remains asymptomatic and the urine culture is negative, continue to observe the patient every three to six months including physical examination with blood pressure measurement and urinalysis.",
"     </li>",
"     <li>",
"      If the asymptomatic isolated hematuria persists for one year, the following subsequent evaluation should be performed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Measure urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio for hypercalciuria. Hypercalciuria, defined as a urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio &gt;0.2",
"      <span class=\"nowrap\">",
"       (mg/mg),",
"      </span>",
"      has been associated with asymptomatic microscopic hematuria. (See",
"      <a class=\"local\" href=\"#H173801352\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is disagreement as to whether children with hypercalciuria have an increased likelihood of a family history of nephrolithiasis and whether hypercalciuria leads to renal stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Although lowering urinary calcium excretion with a thiazide diuretic can lead to resolution of the hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/9\">",
"     9",
"    </a>",
"    ], there is at present no consensus on the further evaluation or treatment of children with isolated microscopic hematuria who have hypercalciuria.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Test parents and siblings for hematuria to detect possible thin basement membrane disease (autosomal dominant) or hereditary nephritis (mostly X-linked recessive). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=see_link\">",
"       \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consider hemoglobin electrophoresis if there is a clinical suspicion for sickle cell trait. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link&amp;anchor=H7#H7\">",
"       \"Renal manifestations of sickle cell disease\", section on 'Hematuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perform Doppler ultrasonography for the \"nutcracker syndrome\". This study should only be performed by clinicians with expertise in detecting this abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Asymptomatic microscopic hematuria and proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of hematuria and proteinuria is significantly less common than either isolated proteinuria or hematuria. Although asymptomatic hematuria with proteinuria has a prevalence rate of less than 0.7 percent in unselected school-age children, it is associated with a higher risk for significant renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1,2,4,16\">",
"     1,2,4,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of these patients starts with measurement of serum creatinine and quantification of proteinuria either by a 24-hour urine collection or determination of the urine protein-to-creatinine ratio on a first morning urine sample (",
"    <a class=\"graphic graphic_algorithm graphicRef65331 \" href=\"mobipreview.htm?38/9/39071\">",
"     algorithm 2",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If protein excretion is &gt;4",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per hour or if in a first morning urine specimen, the urine protein-to-creatinine ratio is &gt;0.2 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine in children older than 2 years of age and &gt;0.5 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine in younger children, the patient should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease) since it is likely that there is significant renal disease.",
"     </li>",
"     <li>",
"      If protein excretion is less than the above values, the patient should be reevaluated in two to three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the hematuria and proteinuria have resolved, no further evaluation is needed.",
"     </li>",
"     <li>",
"      If there is only asymptomatic microscopic hematuria, the patient is monitored in the same fashion as those described above with asymptomatic isolated microscopic hematuria.",
"     </li>",
"     <li>",
"      If proteinuria is persistent the patient should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease) for further evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with significant proteinuria or an elevated serum creatinine at baseline, or persistent proteinuria at follow-up should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease) because they are likely to have renal disease. Further assessment should include microscopic examination of the urine by an experienced clinician, serum creatinine, C3, C4, albumin, and complete blood count. Depending upon the findings, other tests that may be considered include ASO titer, streptozyme testing, antinuclear antibody testing, imaging, and renal biopsy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Indications for renal biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptomatic microscopic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of symptomatic microscopic hematuria is directed by the patient's symptoms and clinical findings (",
"    <a class=\"graphic graphic_algorithm graphicRef68294 \" href=\"mobipreview.htm?3/59/4017\">",
"     algorithm 3",
"    </a>",
"    ). This category is the most challenging because it encompasses a wide range of diseases with varying clinical presentations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. The clinical manifestations may be nonspecific (eg, fever, malaise, weight loss), extrarenal (eg, rash, purpura, arthritis), or related to kidney disease (eg, edema, hypertension, dysuria, oliguria).",
"   </p>",
"   <p>",
"    The presence of nonspecific or extrarenal manifestations suggests a systemic process such as lupus nephritis or Henoch-Sch&ouml;nlein purpura (IgA vasculitis). Renal causes of symptomatic microscopic hematuria include glomerular or interstitial diseases of the kidney, lower urinary tract disease, nephrolithiasis, tumors, and vascular disease.",
"   </p>",
"   <p>",
"    The diagnosis may be evident and straightforward from the history and physical examination. The urinalysis can be helpful in differentiating between glomerular and nonglomerular causes of bleeding. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are often clues from the history that point towards a specific diagnosis. (See",
"    <a class=\"local\" href=\"#H173801352\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent trauma.",
"     </li>",
"     <li>",
"      A history of new onset of incontinence, dysuria, frequency, or urgency, suggests urinary tract infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of unilateral flank pain that radiates to the groin suggests obstruction caused by a calculus or blood clot. In comparison, flank pain without radiation but with fever, dysuria, and frequency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urgency is suggestive of acute pyelonephritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of pharyngitis or impetigo (two or three weeks prior to onset of hematuria) suggests poststreptococcal glomerulonephritis, although a recent upper respiratory (one or two days prior to onset of hematuria) infection can be associated with IgA nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of predisposing or preexisting clinical conditions such as sickle cell disease or trait, a coagulopathy such as severe hemophilia, or deafness (Alport syndrome).",
"     </li>",
"     <li>",
"      A family history of hematuria, kidney disease (eg, Alport syndrome or thin basement membrane nephropathy), or kidney stones. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=see_link\">",
"       \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exposure to medications that can cause interstitial nephritis, although hematuria is not typically the central manifestation in such patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include measurement of blood pressure, assessment for edema and recent weight gain, close skin examination (eg, purpura), direct visualization of the genitals (looking for penile urethral meatal erosion or female introitus pathology), and evaluation for abdominal discomfort or masses (eg, Wilms' tumor).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the urine may suggest an underlying etiology and potential site of bleeding (glomerular versus extraglomerular). Glomerular causes of symptomatic hematuria include IgA nephropathy, Alport syndrome, and postinfectious glomerulonephritis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H173801352\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the history, physical examination, and urinalysis, a preliminary diagnosis will be made in the majority of cases and will guide further evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intervention (",
"    <a class=\"graphic graphic_algorithm graphicRef68294 \" href=\"mobipreview.htm?3/59/4017\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma history &mdash; Obtain a CT scan of the abdomen and pelvis to determine the source of blood.",
"     </li>",
"     <li>",
"      Signs or symptoms of UTI &mdash; Additional findings on urinalysis suggestive of a UTI include positive dipstick tests for leukocyte esterase",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nitrite, more than five white blood cells per high-power field (spun urine), and the presence of bacteria on a Gram stain of unspun urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An appropriately collected urine culture is obtained. If the culture is positive, treat appropriately and repeat urinalysis after the infection has cleared.",
"   </p>",
"   <p>",
"    Adenovirus should be considered as a potential etiology if urinary symptoms and urinalysis are suggestive of infection but the culture is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs or symptoms of",
"      <span class=\"nowrap\">",
"       perineal/meatal",
"      </span>",
"      irritation &mdash; Supportive care and reassurance.",
"     </li>",
"     <li>",
"      Signs or symptoms of nephrolithiasis &mdash; The evaluation begins with imaging. Renal ultrasonography is the preferred modality in children. Abdominal plain films may be useful in identification of radiopaque stones but will miss radiolucent uric acid stones, small stones or stones overlying bony structures, and will not detect obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Spiral CT scan is the most sensitive imaging modality. However, because of concerns related to radiation exposure, it is not typically the initial test in young children as it is in adolescents and adults. Consultation with radiology may be warranted in younger children to determine the risk-to-benefit ratio of the test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs or symptoms suggestive of glomerular disease &mdash; Manifestations such as proteinuria, red blood cell casts, edema, and hypertension suggest a glomerular source for the hematuria. The evaluation includes serum creatinine, complete blood count, C3, C4, and serum albumin. Other tests to consider based upon the history and the physical examination include ASO titer, streptozyme testing, and antinuclear antibody testing. Such patients should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications for renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy is not usually performed for isolated microscopic hematuria. However, biopsy should be considered if there is evidence of substantial or progressive disease as manifested by an elevation in the creatinine concentration, significant proteinuria, or an otherwise unexplained rise in blood pressure even when the values remain within the normal range. Biopsy also may be considered in the child with persistent glomerular hematuria, in whom the parents are worried about the diagnosis and prognosis. In addition, a kidney biopsy may be considered in a child with microscopic hematuria and a family history of kidney failure in early adulthood in a first order relative.",
"   </p>",
"   <p>",
"    Patients with clear evidence of poststreptococcal glomerulonephritis represent an exception to these general recommendations, since gradual spontaneous recovery is the rule, although proteinuria may gradually return to normal over many years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of renal biopsy with different hematuria presentations was evaluated in a report of Korean children with an abnormal urinalysis detected by school screening: 289 patients with persistent isolated microscopic hematuria (&ge;6 RBCs per high-power field in a centrifuged sample for more than six months) and 163 patients with microscopic hematuria and proteinuria underwent renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30584/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with isolated microscopic hematuria, biopsy results demonstrated normal biopsy, thin basement membrane disease, and IgA nephropathy in 47, 34, and 16 percent of cases, respectively.",
"     </li>",
"     <li>",
"      In children with microscopic hematuria and proteinuria, biopsy results demonstrated normal findings, thin basement membrane disease, and IgA nephropathy in 25, 18, and 46 percent of the cases, respectively. Other findings included mesangial proliferative glomerulonephritis (3 percent), poststreptococcal glomerulonephritis (3 percent), Alport syndrome (2 percent), and focal segmental glomerulosclerosis (2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results demonstrate that renal biopsy findings in most cases of isolated microscopic hematuria are normal or are consistent with thin basement membrane disease, a benign condition. Although a significant number of patients with isolated microscopic hematuria had IgA nephropathy, these patients have a minimal risk of disease progression as long as they do not develop proteinuria. In contrast, patients with persistent hematuria and proteinuria are more likely to have significant renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystoscopy is rarely indicated for hematuria in children. It should be reserved for the rare child with a bladder mass noted on ultrasound and those with urethral abnormalities due to trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/51/17202?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/9/1169?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic hematuria is a common finding in children with 3 to 4 percent of normal school-age children having a positive dipstick for blood. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common screening test for hematuria is urinary dipstick test for blood. Hematuria is confirmed by microscopic examination. Hematuria is defined as 5 to 10 intact",
"      <span class=\"nowrap\">",
"       RBCs/&micro;L,",
"      </span>",
"      which corresponds to a finding on microscopic examination of two to five RBCs per high-power field of the sediment of a 10 to 15 mL centrifuged urine sample.(See",
"      <a class=\"local\" href=\"#H2\">",
"       'Detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of red cell casts, proteinuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysmorphic red blood cells (by an experienced observer) indicates a glomerular source of bleeding. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Glomerular versus nonglomerular bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both benign and serious conditions can cause microscopic hematuria in children. The most common causes of persistent microscopic hematuria beyond six months are IgA nephropathy and thin basement membrane disease. Less frequent causes of microscopic hematuria include hereditary nephritis (Alport syndrome), hypercalciuria, urinary tract infection, and nutcracker syndrome. (See",
"      <a class=\"local\" href=\"#H173801352\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation depends upon the clinical presentation, which falls into three categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asymptomatic isolated microscopic hematuria",
"     </li>",
"     <li>",
"      Asymptomatic microscopic hematuria with proteinuria",
"     </li>",
"     <li>",
"      Symptomatic microscopic hematuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic isolated microscopic hematuria is the most common presentation of microscopic hematuria. It is usually transient and is generally not associated with significant clinical disease. As a result, our approach starts with initial observation with repeated examination and urinalyses (",
"      <a class=\"graphic graphic_algorithm graphicRef56645 \" href=\"mobipreview.htm?34/43/35504\">",
"       algorithm 1",
"      </a>",
"      ). If hematuria persists, subsequent evaluation includes a urine culture, measurement of urine",
"      <span class=\"nowrap\">",
"       calcium/creatinine",
"      </span>",
"      ratio, and testing of parents and siblings for hematuria. More extensive evaluation is warranted if, during the period of observation, symptoms, hypertension, proteinuria, or gross hematuria develops. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Asymptomatic isolated microscopic hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with asymptomatic microscopic hematuria and urinary protein excretion greater than 4",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per hour or a urine protein-to-creatinine ratio &gt;0.2 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine in children older than 2 years of age and &gt;0.5 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine in younger children should be referred to a pediatric nephrologist (or a clinician with expertise in the care of children with renal disease) since it is likely that there is significant renal disease. If protein excretion is less than the above values, the patient should be reevaluated in two to three weeks (",
"      <a class=\"graphic graphic_algorithm graphicRef65331 \" href=\"mobipreview.htm?38/9/39071\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Asymptomatic microscopic hematuria and proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of patients with symptomatic microscopic hematuria encompasses a wide range of diseases with varying clinical presentations. Assessment is directed by patient's symptoms, clinical findings, and urinalysis (",
"      <a class=\"graphic graphic_algorithm graphicRef68294 \" href=\"mobipreview.htm?3/59/4017\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic microscopic hematuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/1\">",
"      Dodge WF, West EF, Smith EH. Proteinuria and hematuria in schoolchildren: epidemiology and early natural history. J Pediatr 1976; 88:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/2\">",
"      Vehaskari VM, Rapola J, Koskimies O, et al. Microscopic hematuria in school children: epidemiology and clinicopathologic evaluation. J Pediatr 1979; 95:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/3\">",
"      Feld LG, Waz WR, P&eacute;rez LM, Joseph DB. Hematuria. An integrated medical and surgical approach. Pediatr Clin North Am 1997; 44:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/4\">",
"      Diven SC, Travis LB. A practical primary care approach to hematuria in children. Pediatr Nephrol 2000; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/5\">",
"      Fogazzi GB, Edefonti A, Garigali G, et al. Urine erythrocyte morphology in patients with microscopic haematuria caused by a glomerulopathy. Pediatr Nephrol 2008; 23:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/6\">",
"      Iitaka K, Igarashi S, Sakai T. Hypocomplementaemia and membranoproliferative glomerulonephritis in school urinary screening in Japan. Pediatr Nephrol 1994; 8:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/7\">",
"      Feld LG, Meyers KE, Kaplan BS, Stapleton FB. Limited evaluation of microscopic hematuria in pediatrics. Pediatrics 1998; 102:E42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/8\">",
"      Stapleton FB. Idiopathic hypercalciuria: association with isolated hematuria and risk for urolithiasis in children. The Southwest Pediatric Nephrology Study Group. Kidney Int 1990; 37:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/9\">",
"      Stapleton FB, Roy S 3rd, Noe HN, Jerkins G. Hypercalciuria in children with hematuria. N Engl J Med 1984; 310:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/10\">",
"      Okada M, Tsuzuki K, Ito S. Diagnosis of the nutcracker phenomenon using two-dimensional ultrasonography. Clin Nephrol 1998; 49:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/11\">",
"      Kim SH, Cho SW, Kim HD, et al. Nutcracker syndrome: diagnosis with Doppler US. Radiology 1996; 198:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/12\">",
"      Shin JI, Park JM, Lee JS, Kim MJ. Effect of renal Doppler ultrasound on the detection of nutcracker syndrome in children with hematuria. Eur J Pediatr 2007; 166:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/13\">",
"      Bergstein J, Leiser J, Andreoli S. The clinical significance of asymptomatic gross and microscopic hematuria in children. Arch Pediatr Adolesc Med 2005; 159:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/14\">",
"      Stapleton FB. Asymptomatic microscopic hematuria: time to look the other way? Arch Pediatr Adolesc Med 2005; 159:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/15\">",
"      Patel HP, Bissler JJ. Hematuria in children. Pediatr Clin North Am 2001; 48:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30584/abstract/16\">",
"      Lee YM, Baek SY, Kim JH, et al. Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening. Acta Paediatr 2006; 95:849.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6089 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30584=[""].join("\n");
var outline_f29_55_30584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urinary dipstick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Microscopic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Glomerular versus nonglomerular bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173801352\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199775\">",
"      IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199790\">",
"      Alport syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199797\">",
"      Thin basement membrane disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199804\">",
"      Poststreptococcal glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199821\">",
"      Hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199828\">",
"      Nutcracker syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43199854\">",
"      Transient hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H173801409\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Asymptomatic isolated microscopic hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Asymptomatic microscopic hematuria and proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptomatic microscopic hematuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Historical clues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications for renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cystoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6089\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6089|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/43/35504\" title=\"algorithm 1\">",
"      Asymptomatic microhematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?38/9/39071\" title=\"algorithm 2\">",
"      Asympt hematuria proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?3/59/4017\" title=\"algorithm 3\">",
"      Gross hematuria algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6089|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/50/35624\" title=\"diagnostic image 1\">",
"      Thin basement membrane EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6089|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/38/35424\" title=\"picture 1\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/0/24591\" title=\"picture 2A\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/47/14079\" title=\"picture 2B\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/46/44768\" title=\"picture 3\">",
"      Phase contrast micrograph showing monomorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/0/12297\" title=\"picture 4\">",
"      IgA nephropathy EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/2/23599\" title=\"picture 5\">",
"      IgA nephropathy IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/46/34536\" title=\"picture 6A\">",
"      Hereditary nephritis EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/46/24303\" title=\"picture 6B\">",
"      Hereditary nephritis IF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6089|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/26/6571\" title=\"table 1\">",
"      Glomerular v extraglom in child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/18/16673?source=related_link\" title=\"calculator 1\">",
"      Calculator: Urinary protein excretion estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36377?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1127?source=related_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27973?source=related_link\">",
"      Exercise-induced hematuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/2/17445?source=related_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17655?source=related_link\">",
"      Orthostatic (postural) proteinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/9/1169?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/51/17202?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42886?source=related_link\">",
"      Urine collection techniques in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_55_30585="Candidal intertrigo groin";
var content_f29_55_30585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72073%7EPC%2F78179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72073%7EPC%2F78179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE6AbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCnpusmyiRZ96ox8uOUY3W7evPUD/PFbkN/5dxJFNLmdW5cqFWXjk4HCn1H4ivJ4NQFi7216zGLJDGYbtpH17deKv8A9ptaWuEklntAcI4fLR+xz6V5qqdT20tbM9nYII8sCqnGQD8yHtj1rDvNPiS9jkWGNTPvaRQpKknHz56dwcVy2ieNbeSNLW7k44CTDnd9D2NdxZ3cVxHMiKChUyRsD2OAR9Dj/OK1upE2cWYd7ZteP5ckZ8jIwxX5NwHbHsO/FYN5oszal5eV2Md+BwVA75HQ+uK7ucqE/dMMYDAgY9Dkdu4/Gm/Z4mheRiynJXzDwcMexolBS3NY1OXQ871HR3tpoYY7UPJMm1Zgx+QZ9e1cbrvhaX7W76dPiXOJEL7VY+5HevX9dSO0tBBE48+4O2In+4vUjPf3rmodHzeYijdPMYbUb0/vfzqHGz0NPijdnE2MV5FbRJetKBjaUQb9p7HI6/T2rM1/SFumXy7ZmySCVHzj3AFehzacWG6Da0AJDTxncHPsfTvnrVNtPMFvLLAxjdcDfGxHJz/hUJNO6M5UVJHj0fmabfLHLIdo+5IBwefT+ld5o17ui3GQMpPXtgjpUOtabudZwkMkkbrIy3K71Yj+8O4PQ/WvQ/C/gvwj450Zrzw5Zz6DqkQ2XltDesfs83UEJLkMjYyORxxnIraFN4jWPxI5/rLwbtPbuYdtdeYHWbBXA255wcYOPWuhs7sRIwZI5gME7iRn1wRjmsy6+G3iuzMrWNxpGqxocHbcfZ5SOcZR8DP+6TUbaT4o0yHzL3w9qiwsdvmRKJlz/vKT6Uezq0/iiehRxtCttJG5PepIuxWkwWyPNbfj0A9vasW/VJpGYxqCMjGPqMY/E1nvrMG4pMWilHJjnQoQfxFV2v45FG2RGVem0iodS+jOxqFtCxpd7c6BrdrrenO8d9ZOJFIJAZM5eNh3RhkEfiORmvsiUBJXA+UAYUL6dcn+lfGug2cmva9YaPDky6hMtuox0B5c49FQMxPoK+zIyGYvGDsLELt/iGcD8MAYrtw7fIfL5go+190bs2ufMbbxk8ZOTzn60wKu0blKNjJJ7e319qcnykndtwcjPr65ppdQuUYMc5Yt+hPpmtzzxwPXByxO4ZxjPuajblN2VK5HJ6+wFNZ+AkhjGBlVA6n1J9BVd5lypYsFPKkrjPvn0qkiXIsglmCgqFH8ZIAX159aRHjU9Nw6kA5Le5JqqJpHYLEFny3DZxu9sdBTGnY/L5SbgTubPBPoPQCnYXMWCykk7gW6AHkge1DMqRSy3MiLFGhd5ZH2hVAyWZugx61ieKPFGl+FdJfUvEl8lrGf9Uq4aW5bHCRR9z29OckgV83fEHxx4k+JcxsLW3l0zw0wDxaer4kuxyVeZh16Z2D5QQOpGayqVY01qbUaMqr0Op+KnxzaQT6P8Ppiyt+5n1vBByeq24Pft5h9yvZq8UtrR52PlWouJnfc80kuXkOTkuWPdj1/lWsFk05IrWWBfMkYIHGG2j1B6Dtgj6VUWOKRILU3KxXRyCpGxWAJw27uTnocdK8urXlVPZo4aNIiUF5il1CxglPKyqzDzMfMUCkDJJJC+wyTzUul6c8106RTSiWPcITLCCzoQAo2DBXkY9sZ6VZ0OWWzmhSa3jkeN8oVkxgLkYHpgE89jUURT7LLaQNNMcGQYKkR88deox7jpWXMbqNtiTWdF1aC3EckNoy2/Doo2lPdhnPfHaqFtp88jSOsYNvbMgnfaeWBxuDg++Per9o32m7ia9HnQ20qmUXROCrdyB94fnWxcC3sHmQ2MyxypvQROoDvu5Kr2H+zngUbgzjL+Eokb799s2eCCpTDYBJ7AY7VZtJGlZ3aVTIAA0e4bWUcDIHHX9apSgvdxxO58hZUEjMpJOM54PXpiurtLVby1gjhtlt5lkUK6FTuWTGBg9QeMntzQ02rE21LtjOZtNli1K3jmjIUrOcltykK205znBGD71Dr+lTQwTyWaMFVmZf7jkH1xg9QM+1S+FtIurqUq11brgtGqyEoCp/1jDsAMKPWtzTtCtzaxq8yxCBsF7l2ZVcHJKEcBT1xjnNUoOaWhN7M5vT9LkvraKPVLhVsVIZ40ZkDkDoTyM+2K6DSfD7Wt3HHfWMEkd0pZf7yqB/yzGcDt1GT19q6Z78OqtdWUl40fy/b7Vt8SL6ZH8jWZPa3uoXaKJJ7O0V3VZNm1wTzhRnIUhc/U10RppW6mMm2U4NDmjF/OtwILG3JBjZS7leqnAIGcnj9az00x3eK2LwpDIBIBcEhHHXjHJPtWtNZTrDLbW10RCMOhYEBmBwRu7n1rXOlwuzQ6hJJLIU/dyHopUcgZ44rRU01sYSbuc/YWF/JdyOkVq7KoRmV/nQc7cq3BY+tX5LVLadVltJwFxKyMwO5gNo7nGSeTxnHSppJHhtwWaXcyFjKo4CgcHPXtyD61YsHjlaa/maORdiBW3/fZR/9cZq1BLYlPuWMeRa/aVcSrEh7ZOfT8KoxK1w0fnOS0qbgyEZ9x/s/1qzMRKdszGKEqX+R8M3YYA68/nUcdwJogxiJlLbFLLjp0wO3qarrYl6Crp0NtemUACWRSGyB82Ohx61PIzK3RiNpIduAPRT6dKhLKQkdyHeXd8jFtxU9c7u49jT5fMO0C1Viv8Jdhkd2HbgmqWmhHNfcSby2cpIdoXBCoe5zwRVe6iPlgtLMoAI4+UNgfz+lPaVTckWkgWYLh1DfeyemD6VPp0ZmZ0e4ZpsnAYjCHPIx/WgdjF3SyHy3T9xGQUbBwx+h60+Hc/yTFgRngqFXAx2HT+tbE1hOZ1ljmibozB85PXoR/Ks7UrOaWA+dDKkO8FjuDhl9MDkD61Oq1E4pkZ08eURGPLz1lTIY/wCeKrwWj/vIY4SdvO8E5Pu3rg1o5gMQZvtEjH7qAH/OO1LBDIPNlkS5iUqAkeTgKPU0aEOJkTWUfzLgs5YsQx5PrwOaxrjTvKUvOqtvGEAGcdsAV2TJ5kTFURAefugn681Vlgj3OJCWl65Tqx/pSa7CsjI1fTZJJWRH89XjDLBKoJOewI7+n1rA8iW2uHia2ERbBKueG+g7V3E+jTRWkQkd3nZOBnBPHJ568VzK2d1eQuk87y7CeZDg4Ho3XNcVSOux76SaON17S5YUkuLAuYvvTWyHkY5LJ9Ku+HPGNzpEMJlnNzp7nIbPzo2RncP698Vfj861WKFoo/IT52mzhvxB6EeoPNZHiHwsftS3WlTQwSz8NGx2xyHjBB6DOeh7+lOm09GY1Yyp6rU9l0bX7PUVE8DIUYblIPyq2Rkc9B0rfEwlhVVXy+sZDnkYPA+vavmPQtc1LTpHkjhkLKSsydQ56HK9QeO3XFet+E/GVtqsKhpsSsowhOcsDwfr2Na3towhJT1idhqyebc27zEFEiZFkP3lIcFvxwazFhFxLLuGMPjyw/bJ4B9cVrXNx9ptE8mMSTsSkfGeSOMe5qvavDDe4dDNDL8zYOA245J56EHK49qh7nQr20I7LTHjV/LACE+XhGxg8EkjGACOM+2KoahbCOG7bcS0jKhIHynuzfoB+NdNAFWwjLMNuAxVflHHQn0HPesvXBlF+8CBvxgDLew/pTkkkaw3PP76EeXMQy4jVUQYyzlv4vy4rP0HULnwl4lt9Vtrf7Ssa+XdWjA4uYG+8mf738SnswFdTqFpJCm6RenDIRyPb/PSueSEXU02zd8nJ46HHA/Lms4NwmpR3OfF0lVi09j6n0q103W9GstR0qeO6sLiESwSbQA6N0BHXPYg8gg55pw0KCM5it3jVsb40lbbIe5z615h+zv4iay1O68L3r7ra5D31gHP+rlHM0S+gYHzABxkSGvewqvwCCOmS2ce2K9eFZySkup81OhyNxZx11okMoMVxC01uONkiiRlB/u7gcVzmpfDbw1qCqj6DaTS8hZEjMbMOwOzAOPWvU2t1IAYEk8hieMVE9orrjYFPXJOc/hTclL4lclQlH4XY8t8N/D/AEnwpqkuq+GrRbK7lj8lxJK0zomeRGGztB4JPtiupOpa/GYxJ9hlTbhWRtpOPUdu1dOYGJyCc9D8oz+FcR458f8AhTwYZI9c1OI32M/2dajzrh24IyinC5B4LkCqU4pWshOE5Pdl/wDtnUSTHNaOzjqsRDFvVu2R9KgfWgAvnQujDnDNgY9h1rw/xZ8dtXZpovD/AIRhsoohkz6qzysUb7reWm1Rwf8AaH1rz2f4meM7y4Wa11HT7LgyOYbC1iCnHJJwSfQZ5qfrFJFfVKr3PrL+1Isbdu/OCuxtwNTRXU0o+QXJJAwyqWH0PH6V8bXnxH8fymNz4p1DaOU+zuqgYyOiYA7/AM+etUb3W/F2qeY83iHW70lFbIuJQCp55BwPb0znGaHiadhLB1D7N17XLDQ7M3PiTU7XSYiMK0rqvmY6jYCWJ74AzXj/AIu/aEtUBtPBFiLufLKNR1NdkQ9PLiByfUbse4r58ax2SNLc20/mhC8gulYuQekmCBmtDR7KK8PlzTwiRCpTJG1kPPOP5frXNUxWnuo7KOBV/eZZ1LUdQ8QatJqniC7utT1MfMJbluDGOygcKuT0HTmtzQ9VXTrpobgmRWixACQ3kyAllz/eByRgHr09KrroM9zYxPBdxmMrJuHm/cIPK7cfKflBz0I6ZzVeGwuoGElrKk3khAGaIblLAkKff0Oa8+U23dnrwpKCtHY6CS2k1DTpJAsUSqQgib5SSTnp/eGTVMaZcJdzGNZvKgi3SmOFSq46ZU/w5Iyc81Joltf3UpBia4iZkkEYIKkH+LaCOeM4zXWaLpP9oTXVpL9onEMoaSOaVkTA6jyjgk4xgf4ioUbs1vZanCYvVuVuEummnmDRk7V2uG6gemRjrzVrw5KsTNucylo1PlSRhcMGLEAnhhgcH6Ct7XdDCXCusAFq7uqrDGRnA6jPQ9eucHjmqUelTTSxQESPMcrJCRghFxg4xx3H4VPvJjaTRk34YTTo+0S+Zgxp8hUEZz/9bPFLGjSq1wISUZijIoJAfI+76N7dx6Vv23h4XIW2tLs+S6J5cvIDlsjaSehB7H88VLFo2UK3kewFncpv2hm245HY8Erk4OCM5pqD3Juji20OVIUuYgt0CwRQpAw+c7QD7Z579K2NC0a8u7ZAIxLcqoZYYG2ygDkN6ZGScHtW1p2j3lxHK1i08+/BljjZQJFzhlzk7WLdDjjGe9d3pVhKumxm8s/tME4yLiNv3hyMBSnykMPunk8AnHFawp8+5MqllY5PQdKhht5C8/maomcwJC3HcHB7n9a6mygh8/zLlfMtGK/aGIwBxgLtHT5uuKkvLGwieNIIfJ3RpE853DbjoCx4UHoGJPp3qK4t4cMLpopJY8hoJFyXQ8HAXKnHXk/jW8Icpg5cxr6rItq1ztEiRqVysa4EzspwOOo4x9cVnXywR3QQbYiWEjnJ+8qkBefdhg96RrmV0We2ntXdF8u3hy3Q4zleV7DBqO1mkuprlrqG4ubm4IcxMiwoAPuLknO0HPOOSM1qnfQzaIJtOuZb2ATvmzAAkWY5Ik6jGPu88kdeRTNUt7qXULOKziw4Zg5kkyFbHYe4/KtZllhh/wBMEaE/cSMgncT97Hr7/hTrq3aNAUKrK+NirhjG2eGPPfnNXYzZTttIuY4tz3Ie4xgMFwB6/hWJYtZqLlL+PdfQSvHsUDy1C46Y4xnP510UkkiSfY7gyRELllH7wO3XGR0A4/Oohpdqlqp2iItIxL7uCT2JPf8ATJocddDJ9xUsrZXR7a1bzFwCQdpORnr6VQumlM85Rgz2s24IMBjHjr7nk0XGn6jaSTRwXXl2IIK7EMpjyP4cnjnnHOM02W0sgjRfbFlMIJzK+G3noRgZ/OlYi/cTVLgy2ha0hWYbuDDgHcOSGz9044x70Wc93PBgRxI6MEmgYnzAOh5+h7daSW2a7Mts1u3meX5gZVEXI+7uOct9TjrVd4U8oGd1vjjmG4mbIx0OcjGcdD+dPYlK5qLqEI8qLMcz5IaPG1olHTjv7/nRceVayxySi1jmkZtvzHLJxwf8TWdZzwy3SJb2UloScERZYn02MuM+4NWZYoIpX2QOZHAzvLF2HoFboPXFHS5RNJPJNcbYZ4xbkgx7QOeeST9OlPRnjlWKVoJJHO3DNj8Qex9vypNPmm89YWtHjaMMwhhK4UHqfTH54pZxcSI0pliimPCBRvIwfp6UBYpWNvHNPdSNFLAG2NGd2VwQcAe2Bn8atNaSFQxhaVACV3MeB7juKdYfZ0aZPMKrv25GQGI64J/zxU1rHPENhjmkMRO12lBJHq2M44oSEykYJsqUitxtz86szEenTgDPaoJY8Fop7iUb8h0jQB23D8/xqSa2bzneL7RJ2Krc4Vj2Ug9fwpqb1lRm0+OzYNtL5MhPJ6bRx+NIVirLpwku3ZGufIjyfL8wk7j1Oc57c+vFXhG9xBIkFtHNIrZZ2woQj7rDHfr9a17ewNlpxjJWa724iXdt3cnKk9dw559MVDpumyQiJrhczKM742Ayx4G0emPWudR8j3nNSXoctqOlK1w7TQ7luMEOD90j+EgVUk02SO3MaYZB1Q4yF7DFdMkMsbXEN+qxQEZQIuUDDnHrk9afPh/9TNJ5SrksSCwGOM+/FR7NEO+3Q801vQPLmF7BEYp3XE0ZOVcY7+hrnb7SpY7iWa0D2eooFkMTt/rQRkMPY9mHBr1vUYHQRtIpaRh83zFucc/yqDQE0m5u7Xw94s+0LodzN/xL79Tsl0m6fj5W7QyH7yHKBsEgdQ4x1sYVFyrmSOY8HeNC8Qt74MkyfeBOMN26c16jYTw6nCHHmR3ByTJEVPmHHcMMHPHvXlfxE+H+peCNYEWvqFt5W22urQKVhnPUA/3Hx1RvQkEip9BvdQ0uSOO4zJFwBIOmKzbcHaSOmi1VV4vU9htogYy0RskcKAXeLbIoAzvIy38qglg2XjPCPOujnMjYxF6kZ6euev0qHS7uK8sVZoUlYA4EzEqD06d/xrSkmiuNtsGMoU4EUY8tFGPQVsrNFNNHIajbPORa2kgIAyzs2UUHrkkZ69uv4VizwQWcCbCywlsFv4mcnrx3P5Cuzu9M2mZmkzE7ZS3iGFQe59T361Ul023mQLcxxeYWDIV4CKDxjHf1pcpEmjkc3Oj6la39gy/brOZbmHDYBYHO047EZU+oJr6q0jWLTVdKs9TtH/0W8hWWMnAwCPukdiDkH3FfN2pWqBppFQAsQpIPt0+ldF8JPH1j4ZtdW0fX7h4LJM3tnsjMhfcf3kKqMkndhwB/ebsK2w81G8GeZi6V/fR9BqTnr8p5BI7965/xh4x0XwlBD/aszSXkx222n2w8y5uG9ETPT/aOFHcivJ/EXxQ13V7lLTw9byaDYTR7xdOqT3suRwBHkrD3ySGI44FcN5sdlBPcxwi7nu1P2mQlmuH3YOWnYbn57E9OlXOtGJFHByqbmx49+JHjXX71NPsw3hTTJAwXyn8y5nA5OZlHyHAPypg5DDceK4S28OfYEkYWpRPkd28sNg4AZGJUsWZWORyeeR3rZ1G0tdRR57UL++yUCy7cbcMAvJx09q1DdXUOwao87WcyiVr10Z9ilcKu/qDgAE46jriuOc3J+8z1KWGjTWi/zPP2hkgvvM0x/LjhZ/Kt7keZJCT91WTHzZHOcBc+hrE+wLNBKbxzcuM5RYt5GOSQeMDAJBAPTmvQtcgeWKzIVlnt1EAeYYwM8IxwM9cg1z95O91Y23kzTx3iKbeaMttDfNlSD+Zz/SsbtaFypo4m4tVDDzhBHB5RA3cYYgAHgEjnGc9MH3qvMl1OqpBLby8AgDduOzjAGcZGM446g11lxcWTWs0EXkwTI53SGEMCzjJAXGMDkgD0FZsNnbXivbwRzzSSMgW4yFVGbIxyeMjjnFaRm0c8qUWZl5c3L6Zb+fdxzzk5MrRZbbjCrvJIP1xkdzTNPjeHULdtmxd4YGR9gKgHIz05J9+ldBDbfZop4LNkJaUESFTxkHcu05HUZH/1qp2rvHMkiW6eeJFwmc7yp4Y5GB1xnuc0nU3Qo0kjUhASOR7SZEBc/Kh+T7gbcMAA4IOSQO31G0HurZIkkkV7e5jV1AXpJ13D+Jm5K7sHHY4rPgeO6VruyS1DTOGYPIwZOQT06KCpB4NbtlYTWXkahftKYIcLEAi7Qo6hMfdPJPb1PWs0mdF7olsreK31COGB3i+YPtQ5Ke2VJJTHG4VqeHdXtUt54muBM8QZxDPLvVXH3cg8AYPUenSuhW3GuQWsWy2nWDLBNxRsjg7H6qQMfL3rL1LQrK51KORFMN1OUidXUbiQcBldemf8a3UHHWJPMpbj7awuZIZntpGEEM4kXym81CfvbwrNk/MFPGM/SqOtTSad4stbtQIpEQywhVLxsH5Clcbipbdgds/jXVS2iaZCu9zCGQCOdXDIMEKQVIBIycn6e1cv4stli1awljTymRn8x1BYrjA+dRySGyQ2emO9VJcq0BS5nqV9k1xO8lhHHDqLDzTbudqkcEE5bGwc84zzzS3txLeaTc4hNuPkiYwgOYuSd2/PTceoXocc1oPpdxKok066gu5Vx51vKnVTjIBPPbBHX1rQljjhk+0NC9pASj5x5sYjIwRx2DY+lJR6Ck7GNothJDeRzadctbM+BcQeaXRXDhVAJ6ZC57HAx6V1FvpWpLKBBeQGAtysMeOSTwyucYB9MHn0NW7u2Ine+BQXks3lukb7Bcx4+UD0K4GG9hmmQRW99MZHEpnDM7LLFxjG3DcfXBHJxmtVFLQ53Jy1NWRX+zyI8Y3MQuXYsFLdeTx7DArPk0427yfKscCbWGzOT7emfqKsyQSxRl1ilmwoV2SUkqoOeNx4xWdNqV7JZl4oRJO7AEEEKq9dxz1xx0rTTqZO/Qkkdbu6aG3ubVVjOx5RES/uBk7c/QGnLpNhaklZrkSPgbixdj7DOc8e2Kt6ftldogk1t5bZdpcbmz3yOOSetWJRJ9saK2Adlj2u+/7u7k49TgD6ZqtAb6IzfssFtcx5uoFlZCNrN+8b0JAPTig200sflS+R9kcZKSREZ9wM5rXnhiht42cRRSB1XzPK5UE8AHr7URGGWeRIohCgGCX5LepHcj3qrIzbOZs4rK0LFlR4SykFDgqPVVHU59Pzq5coDFIJNzERnHmAYA9SemfpVye0t/tJKQbXXnzUAX5QOdwHbsPc1T0+W0MKmRIt6Mys82WyobgjPUf1peRDZmQG2v444llDW0u5ZJA+0St2Gc8A44wPx5qxHBHCjWqD5QxVdrHaBjjnuakmt45Zt9pZwywiQgu0YG5cD7oA5wecn86fI1wisqzie4zuRJGAK8dyOPx9aI+ZLM2azlIjluUl3LlV8oj5l/4Fg57+vFVpWjRwY0aERYjYyqrSOMdFAzjr1561ote2kCEXGmah5sowxVDN7bgwPHXtistdStYkaS2nmacDYqSW+GUemQMkjP59KV13GiK4ht9V2R2rNNECshmjRgWHX72QDjHIxV6KadIw728piUjzFLjkY6g55P8A9esK0u7mOzhtQYkgAOPKbG9R1K5Pc87fUn1q/aavbO8sMTCOYOSUIBdVUYUkdSxz070RaEy2scE75e3hllVFwJcgjLHbyf5inMtzJeJGjl7a3OXA5Kvg4VT3A6n/APXVW1W4RpkS68qUhVYSD54gRkAL2POc9BVmeeC3kNnG4uLkRhiq4UqrZwSvUf3snOfamgZeubZFhUOREgxy4zgelVFtLfmNGuJlBG4YbZu64OMflVC3vokji+eEXCMoaJwSzkD05wOuCPpUv9vRWrSCSOTypGeSMuCOT6n0B/PNDaJ1NCJo/NIVkQLFjEKnI659x2pGvLgwt5MM8e1AC8i7vb1yT7cYrLuLizvlSOO6uXu5uGy4VT8ueAfyFW9Iu4490E4jikjOV2IX+Xtz3PrihMDpr22WeQGaQeby0Yx90kdM+44qe6MVu0qAFJ2iUBlGQg/x7CorW6jeBJlJkUDdhedxHT9Car3ER3t5iNJLuMkgDcAnqPpgDFYp2PWhvqZd9BdTFUt1C27ttfJ+bHr9atLpqQx7pADMRiMR4zuz1YemKu2CTM58sDbk4Vz69z7CtCS3WKFmtwrvGThm6O3cj/CptfU6eboYs9iS6fI8g3KSqHG4cDOPQcVyXiK1tniuY3VJ7dtykZzlD6/TkfWuyv7lYIwh8xZB8qbfvP8AjXHeIEXzZfMdWeQbmK87VA5x6jPX1NZydkZum92elfBDxdF4w8OX/hHxOI7+/sIgpFyA4vrMnCuwPVl4Vj67Tkk15z8T/Ac/w9vrS40JZLrw3fytFFaTsTJaSYyIQ5PzAgMUzzxgknBPFaTrV14a8Uabr2lozzWEhk8pflEsRGJIT7sufo2K+vb220Xxr4UWGbF5oesW6yIy5BKsAyMvdWB5B6grW1KSxFPXdHlu+Gqc0dj578J6vHIrLBLtdeJIpBhlPoa761ihmuYbp8+aoK8n+gry3VdGuND8S3ek6hOq6nZsFS9Hy+emMxuR/tKOevIIru/DeqTSRbLlCzrnJUdxWMNHys9aT548y6m9ewARZLBsDuB+grFlsVEQjiJCxv1bnJ68n0rpIsOvyOZCAC2AMiqWoWzGVvu5yCpU5zzxmtrGafQ4jWIGkeXzGBt8AgH5WznOc/54rgfFMMkMZnhBM0Tb092HIr1TXLLEJyVYsCCvoP6fWuA8SRRvFJjHyg/y61z1UVGHMQaTe6bJaWcbIkxdRILnLCRcjlUJxjBGCQc4FWYYba+uotL02dlugFXzw3mNMGbhiOzqMDaOvGOprzTStO+36lNZGW5VWIljjil2BD/E2DkHj0r0TRbG50Rrgm3M0ZCorGThQwyJBKON4HOO3FTJrSxVK6vc6eLT30VlENxGZYn3b7yA7jztyFHBUndu9PpUo1i1Tw/bA2sogiGySI5w0ZJGY36bCMdelZN34lAjuLdruKOaWIxPcXmVYR/d2pjPzFSRjp15pLnxCIpokSGOWExfY3tArIjAY+8Mc898gACqulszTlb3KGuJLqTX/wBluhBBEnmoN+5BIFyDk8gY4rntR1WOeyVBp7Rai6ZkfzdyuRghgvXHH6+lXp5JItQv47ATtslYOIMMjLgYxnv1/Cs6exe7sIJo7iMTxMY4mi3hm+UnjjHQ/jg1lKXYJRGWxguQbUNamXaDE/3HBLfMPQ4yfxFUFjFvcyw222YShGf0+UnYgI4YdDU8UTzgRTQtb+UwbzPLDbS3RiOuHA4Izg8d66K0sbPyIQwlnmWbY2wglC2cA9QDkLjGQe1K19COW2pzkYNvbypOLW6kEg8mZyVAJ4G7HGR6VZ8OaTLeavDDcPaxMDuPmElGOcLyOq9sj1q9LZyBSI7MOzSssm4Z3P8A3Ao7g07TprpLiFbmBovsi7UmiztJPOAAM/LnketTG19SJRfQs21pcRGGeCFUd2kjCk7oyMHoe4JH6V0en6hFJBaOE+RYTHzwYnYDKt1DAgkAnsKWwax+yWkNofLZI2Zdrth8NuYODyDhm/POeoqK7tv7O1a4t7iEi2mC3Mao3mBlA+7xyeOfpWqTjsK19yfRLVJ4p7S3vZoLuNjKLaSMYYZ5YNxkgenat2AQ31u9scW18rCWCZMhXkUDcqZ6txux+VZIjuInkhjtfNlj3ABcSBF27ty9CSeh+mO1VbS2upJ5JLefas4EqmM5ThQ25D95GBzkdQc8EVpF20sZt3e52+lXVvfWMkxeMJLgAON6YKjK5+uTXKXmmXV3BqVxawRNIp81LaOUlTCeCm498ZOexxV2z1QW8Iu5lMEshYmPZmO5Uj5gMfdcddpxyOO9a2jXkVxJBcJGi/aUKrsYMpXaD1HBwQQcdDxVv3xax1M1DcW6p5vmRywELDdJGoaVcgpIw/vEYB7HvT7EXd1fql01ykcSMJ4EQFUydwBx045xWjqkKR6bL5quUjUOMrwMNkj9cgVVsId2oXBun83zSY1dnwsoTBz7MOMVXWxHQ2LWJY3WaKUGFl+VJsZGe4PvVuwhSKFV+0L5p+UyKfmI6D8AKhE8YZhMAZhjOSCjevsDUInBtZAqxoqnqQFAB6A5/pWqItc0Jsqpja+kAVcu4xyPeuSt9MmnlcW9w5s45WCzHByR1yOmB0571qapIkWmXpjkEixoQJEJwZD3z2A6DGck0ulzXSFEubWOS1kCnCrsdOOuOh/HBNBDuticWVw0aqlzGo3Kw2puO7Iw2emT6dK2YoIrRRHHlmY/M8nJz7mpDGThwCcDOVxnFRGUmTbFsJ5Lb2+4R9P88VeiI33IY3W48z943khtplKEZPfH0PAqm1tPdCSOdIfLRyGDEq3qD7VYmVomMDyytIT5kQViq564I9O+DVG8iUzozMYpm43RHL47jg/5zSF1IZ4XtllmgSUomPlmAKbu3zZzgZz+dRSTRvZsm+GSSMbTtHyhuvf8eaqXOk3VzOxjMrzuwUR3J3K5xgA47bRkg9eKpJFPdXksX9owSSJE0bLZrxGd33MnII7fSp5mTJFqSe1inhaLzmt84kRMoI89MZP3e5GabLqWn+S66dJZx7GwJZHPLf7AHJ+tUYNKgiMianKt7lyS82ZGbgAjbnHGAAwAq3LFO0MYtLWEA7WWSAKC23sd2MHA5ppszLMuooipic+bIAzNKQqKCOoPQcjis69vHtZ2bZLLdXTMArLy/wAoxwfugE5JPbHrUV7qF19id5LJZLDzhsiixhuoIbueT7dK5yIGdruSC/vIggAVQzgKOBnPJYZxz3/KiUuwkamqTwC3L3CogVRDDbqiguOM4IGSTj8APeo47M3V2k17HFaIEIVIl2hR/dBHJPuetQ6Zsm1NGklW4lVPMKTtuIj3YLKTg5Awce3pW5FBDHM6QTsynB3unmfUH045oWuom+hTe1iKstlemBjxuZmUc9cn3qtJNFbXDNBGFumcCSdVDtKQMLlgB0BwAe1GpzuZGaCFJLMSDMm/bsf1CfxDinaXfXa2kUUkl2HTCFFsiGLA8gcnPt096Lq4m2OilADS+XdTXYTcZYsksQeCOw/pTxJdzzTMYtqxYUIxVmUkZJI6Y571nyS392jJJaSxwyLvijaT5pNvJ46n1wOPrTo9XigkZPOGN7NM8S+WqMf73fpRcTZLe2guZpE2NE6gBgsYK+o+b39qfArkokUcTIF6MAoRh3B/vYyKrm/kIM0Ec87nBCRSAhsfy4pwvJriRmurO32r0KzbhxyTnA9RTshXIfhd4vF/afZbk+VdQEh0PT3x/P8ASu/VdsgmjkyzKHY9DwCP8K8++JHwj1PwBef29odzLfaGP9ZO6hZrXngTBeGU5H7wAY53ADmtTwv4oW/tEhkO2ZOHXgbT3I7A8VzyTi+Vnr0ZqpG6O7sJISqh5ojOeVXbtO3/AHf61cSN5MRxIGLHCYHJ9+wx7/WsW2mskumlPllgABIVywHbHrk1cudX+UlDgMAGYkcjsB3Pemn3N49kUtVcQzuzyK8xUo0m7Crz0U8Y9zXCa05M7x28kMuDgMq5DD+v+TXQalI18qllGwjkucY9+OciuXv55UdoWCK+7jjcZGHUjPGB/n0qJM2ZzsUAnvJxFsZoWG5FO4q2M5z/AD969q/Z08TsgvfB15KP9GH2zTt3Uwsf3kY4/gcgjvh/Ra800/SVt7dhEDuuNzPJ13sR29qwdVm1Dw9Jbaxplx5Gp2chlinhxuUkFWxuBHIJGMVNJ+xafQ461H2kGup7j+0lbaVZaPp2tXF9Ba6vbN5EULY33sBI3gL1+TIfd0HzA/erzzw3riS+Vlvn4U85zg4rh/HOpC/sI9RF3dXV5OoEtxdyiadgwOMNxgAnAAwoBIArD8ManHFdGzaRREr7becMSDgA7M4BOM4zjn8quq+Z88RYZ+ytTm99j6i0m7WWJWVlJI65rSjjWc7Q+E4DN2OOe3X6V5n4X1fYVS5cOCPm612yXkSxh3KBF6ITx9SB/IU4zudEqbRR1yTETRQqRCuRvYYUnnn35rzHWCVkljjbjJUg84Pr/wDWrvdVuvNMrSbi20sF+6zDqCfTjkD0rzzXJVAlwAQfvY/h+mP51nNnRShbc821e2LXkax5G+Qx5K56ciu10r7Q/wBktJktZ7edvM/0qcqkRHdSucd+Spx1rjNeIaCJlXCCXI7Y7dTn+VXdN+yf62axm2yLhhGwdXfnB+8B07gVnH4UzJv940d3BrM9rZTWkU1ncWwkZwoPEJ6HEu3k+g5HOeM1QgvLqO4kgZYEsnkdRF5gLK7oMEZGB2HrjnNV9CuImjhjMMVrtAG6QDLMDzjAyuMYJye3GK6axubh9bmt7q1strL5agReaAMY47kkE8n+lF27am3KGl2NnaWUiXcQd4shmkUmJccBOhJBx1znpg1qpt1OCCS1e0RnjcZhukWVWUckggkKOijkcnpmn2V8dH8uK2S6MO92SWKQO3ljHyOmATtPO709Ku3Uulx6pdTvdx2LmyNxvCqwkZnw4dGBBOMcjBGetapaWRDXVnD3l60t9YzS28TC3AWRUHlgxu/KrySc7uCOeRxxWUn2S1vFeaKRo+dyMmSuGwDw3zjbjPcZ6d6s3kEc+p3MkcZubOGVGiRD5aNuyhdV78kYORjBPetfVNIFlpcd3CJ1MTblt5pTIpYKCMN/eKndjrwME1ja6uO1tBLIRzpBDZyRK0UW5phKGWQ7idx/iJXjpyBzzWz4fSD+z73Trv7Nbxl2kjudhcSv1JR8/K3Gcfyqho9l9vgubSzjWIFPOtJm/wBameXTd/EVJ5BHQ1u2ekme3hs7x4ILiEJG0SoGi3dsKWBBI7pg855rSK6kStazINM1ESTTWV/8xu2juIMOBtYEbZAUzsYYGVI5+hNYPjG1uZL1zD+6DOGDbRsO7gMpUfIpIPB5Bx65O6uhTaZdyRxn7KLkFVXy1dWO/nDlsjjJ9RzUWtXy3MNxMnmvNIqKqoygBlY5BA79SR6YoavG0i6dnUXLsQWF9qFjemS8mnW9VmZbjkLMi/eDlsoSPXj1q7c6rZzraPEt3Esl5GzzSARRhjknDLwGPXP3fauf02O4YXNjrMr20CAzoFYEbxgBiOxwRyDg49abr2hPNfFIomKAoxMoEO7JwpZc8cjqM9RS5mldB9Ui5tN2Oyu72FbFb8XMRmCGVZJU2iTL42ttOwHGPTn865XT9Wn0+9d5R5Fq8oYqYWKbmGC4y3GCMH8DiodV1WQRRpHOGLxiNld2Ytg/MOCOQQQc57cCsiG4fTL4TSRFVc4AISUAbeOGGC/oSM8DnilOdnodVHCWg+ZHoun+I7O9CRTTxo7KXCMcKwJxuUnHBwfx7ViXXiGGLzBFIDG7lnVxwGJ+8AOhOOcda5JtVMvks7eVAxJJc+Y7OcgsoHb689asSWiQwAyIqkNgKV2A56MWIxk8jb1HWk6ja0KjgqcX7xv6f4yUwxxtZqjNkDb03dBz1B6/h61o2uui9vQXhc3E0Rjjj28KR0YHoeSOuMnuK5Wws4LqXfb28m6I5aNRkuQD8uR3xXS6JbSW1tHLNcESbNsiFt4BPIIOBtXoMc5xnNEJze4V8PQUXyqzO0tYFmt7OAmRXMQlKudzbG4BJxg85OfWugmhC2ksSqWQqcx5w7j0rzC316LTdYkJu7gWkYIwkJ3q6BjjceAoBbj39K7XT9c+16f5sSytJtDEPGQcHkM2OmQema7ISTR41TCThq0U9SXWGiiFtqMcSO0aBwhIfJ5w2eW2gnp/LFbcYaBEWTyxGRg9AvsPXP8AWsmS9j0+P7HcoHYOXgDDjac54A+XGTx71k6neyLYTJYhLyb7/wA0wMm5fmwT0BwO3tRzJGcoyaUUbuozK0LStNHbxoQ+9TuZm6AE+vsM+lUftrtPJHGotkkAkDSqckjjBxjB9jVWC6N/Cbq3tYiHQkSSDaF/2eTkH1x+FN1L+0HtZDbu0t4xCjLGKNBnkgA9PY9e9Ny7Gfsruwl4DeXLpFOs2SqiKQkBiP7jIfl7565AHvSKrWzmACJJpcZji3EhRz1OMLj25qvpdtqTQvDrF15q7typbxiIlR03Efdx7H6VfhsnjDfYJImYnczTFt7Z+9ubkntjPShPqZzhyu1wjhFuGjQR+fKASwUKox0HoMdcfjWVNcXkM8gija5fKkL5oUKpPVgR1P16VfvXnYxRNDwx3SnaAsYzwc5OWJ4H0zR9mK5yLhtxLCPzNxPGMgnv79KbfYxcbHNeIbXUbyeOHPnRylTMlvGoIy2Mh+Sxwe5Arc0/TIomVbaB4I4/mMLE4XA+8Tj7344FXbOwWKB90BVoyWYl1ZsZxkkn5j9fTik8wTyGF0dxGTiJFJdvTgdunLHBOe2KSstWS77GffWVrc25hbEE1ufNjdCd8TdmQYJYkEjnIOapwWEZt2hjSAyMoBC2xSRPqCQCD6/UYrZvIHklhnuDG80bZS3XB2jlSxJ6seRnOB2x1qtK8tw8cdxHJArIQSJBlCeQvHTNVoHLoZhE8DvHFuheJtzxC4RoQ2M5GeB7gcc4yajubebyXb93bRvlhNJMpLO2cnABOOe2Oaul7aOZY47qDzI4xG0O0kHnI+pPp61n+H4Z7t/tt1HE0TBsM0m0tycMFJ4GMDGfepv0FyvcqQ2yeXGl1fGGV4/niigMAHyjBLZLMoJ+nXiqFiFskWH7H5jxAujWwBZucZAx8wzzuHWt69uZ3sxHbSqsU2VP7x2VcckgED6cfX3rOgeRJI1060uoZ7ZcMXQuhVuckjtnOOoo0FysniEksmEtLgySAOXml2c444/OsuVCzTyXl95k/A2piRTtzxk8DHY9PWt1DDcRr8txFJ2LzbnBJPDMAAVz0wO9At72e3liwHJH7y6O/wAvbnoEb72CPp65qrXJse/eAvFFl448NreJahCwa21Cxlw4hkA+aM54KkHIPdSOOor5y+JvhCb4beLkksFdvDl8S9o5ORH3aFie69VJ6rxklTWpBear4P1k654dYuwAW6tmP7u9iBPyN6MMna3UZ7gkV7DfrpHxd+G1zHpsm9LlS0DSKPMs7pRkK6/wsp4I7g8Eg5pXVeHmjsnTlhKl18L/AKseT6Hq/wBriDs+HGMEdDjvVueYMdkUjEKfukjGR0OMdea8g0i/vbN/KcPA+WRomBBilU7XQ55BB7V6Ho0skjJK2WZhtLEnn9OvesIu7sz0Y2kuZGlcPNJbusaoXODktk/iOv5+lZMNjI/m3bDz1jJbn7q85xnv/uiujtrG2iJlW3V3fPzMThgOeR3Gc1etrJZdzvcNJtGQiAAL7egrTluHNYxJ4Q0CBQd8mDvYEMSeowPuiuX8U2yFZYydykfMQPbn+VdZrWr21oXSNg83R1QHjnoCfyFYWvWzGEsSACmMDkgHt/n3rCrsaxVlqeMPHcFXs57gRWAPCdWcnO1f93dxntmqd5pclq9xMAWe2ZCQpJ4IzuJODjHsK7rV7T7HNa3UVulxPbOLlI2XcrBOSCPQj+QrN8S3n9qq2rSAyzXT/vnI2MQwzl++Twc9KKdW8fM46lC0tfkdF4PvWkt4yJXbjoWr0iyu9kSOsqxuBuXcuTn2Oa8L8GXrQ7ojJlo2wwU5xjvj0r0mLUXSFELlkwSQOO1Slyto9KD9pFOJsandqIm/0kvgY2xjbjv1J6Vwmu3LT/uLRfMlk42AYPuc/wBa13mOoTm3tiJG6uxHyx/U9/pUw0+CwibY/mzyKBJMRjPsPQU1Bz9C5Pl93qcFeR+fotxHKDF5DqWG0Flwe3fv0q9puno0LvZMJI5o280k48vBxyD0yO3XiotZQy6kLaMbZLtAQwydqpy2AOpwM1vaZsazuH+020pDDczlQ5UDp0weuf61nFNKxnGnzT9ClpWpvpl6XeVUuTnDn5o39cqfYc9+nWunl1+7Z7a6Yw2l3/yxmMmUPOeR0+b0PSsZ9P0q5igfzi8e4wzLs24Vh94EccHH/fQPan2+l2SSSR+RPc5Xb03BgCCQ5PQgDI9+tCulob+ztujpLbXf7Qtx5UkaXcEobdKm1kzwSCeoPv7ViXV/fWtr9nuWBKZxEV8xpQc5bJzggHHHbpUifYrmMwvbmUCPiOSPymAHUc8kDtgmmDSoWubf+zp4rWWWXC+a5aMvtyqsDyrEg4yfTFDbZpGMVujFuNQcyCI3DQCERpH5bcJt4HI6g4Gfzq1/aLuu4ETDZ8pGd6EnqCT0GCM9qhvLeYuZHiE0EjbZmRcFZF6lR34bPuCPSs7csl6kaHahyEiVMEqFwFOehx17Gs22DjFHWWNw8diJ1uFXftYSOxUMc/fUjo+Rz6itTTfEk9pqsZcR3IdfKAlAwpPIYvgEkkceg471zkOnqsibdViknkUsIduGjZeqn329yMHBFaN8zfYdlwlsbtmEkVyPkHyjgbQODnHWtFKS8ifYxkdF4g12TUdNjk2GFo3VTIDuXBcKwwDwME9fYVnpc2CvdGV1WWMlFR12iJyMOoH4AVg6xLP4gt1B0/ypJJSjTxqVUhQpKheASWw34A8Vl3sGoSFWmnBleRlDtH5YkYNg5PfoOfWnKo277mtGhFHRXF7cXMDrpsETLC4BkkQSM2DjCk84/Q46UJFd3V3bpcbYQNofI3BlJwWH14rDtDOoOyRlj2g70XBDY7r6deRV3RrnUPtS2ieUskzFYpwSSXxjYvODyQSKhSu9TpqwSV4LUtDTYUVU85YZIQfMZhlicnt/eOP1rKu5/t0k8UiRybSGAH4DB98kVqSFJ4IJ51hfzlyUVsFCGxhh1BOMjrwajHlwSKsaNs37JFIyDzyfXgj8jTkiqKfKnLUrfY5bQR21yD5bqPLWUZMfoD6ZqzC7uzArCWRGRmPz5XpkA8E4z9KtTWTCLKs7sxC5PbGMH8eg+lU7ndIloI4iYFU28oPAc84A7jjqarlsKWtrHRaL9nsbBkCbGiGJOMM754wOuenWkm1qXU45ore0uAkwDvKVIULjd06AkDgHvms97ia4W4VXuhvjWJypHzIu3b1GSoC5Hc9e1MZEgSSUTXQkiQkDcPLfJz5o9uRleT374GnpsRHDxvzPdm1DbW8duksttczxtOsiSJcAlSQcF0IPz88ED7vFOttQ1GzDwXFzIsLMHMKkMxQHHyE+2eT0Fc4xd7wCC2MLmMv5gOQFIzwD0471R1K6uI5JbVbhnR0UbWxuIGeCRyB/OlKfLqglg+fS51x8VWF1eTxJcmHCbVkboDkgFmPOR3xUNt4ltLgXu6aNyI3LpbRiFUYDBCjHTpzXIG0tPs0jTQpkIZOAcA44/Dpx3pNP3C5hhHlyDDOI5SqO6bzjgZKtkd+ox61CqS6nJUwdON0j0S0it42SaBQrtGXZfO+7JjJBPcE9sZGKtNqKgt50sruqDISQAjHsR+dcXp+rhGnaUyF/MUARoH8uQjse/c/qamutUuEmm/4luHQDr85zt/1pGa1VSNtDieEblZnYLqMjbWsYjIhwPNBwpyeBz1Na1vLMLfkBpHxl8cKD0/HqcfnXF+GHutRBS8DKsWGMIXAb+7g/n16V3qKtpB5kqhVXqP7oz1P5j9a2i7q5xYml7N8oz7KkUYeJiJJD/rSSNxxjccdcVXgtpUZp1uX82UZkYwbtxHAAPYe1JdX3lTllt4biWMgtGZCBznjP/AVNO0yC5ntpGvGEZcktEjELH3AB9P69adzldNpXZX+xyqqfbHmnaWTeEVcAEgcOOuPepYUEMbGEmQu5MmU2byeM7ux7c+1XAmBLDDllZlRpGOSMjJ5HPH9afdTnzFt8NGfLLFujY3YwPb1PXkUC5ehlTB7lH+YwsqbYothBBx1LdD16dKgcnVPPht2V40KrIM4ZGYdCMZ7VvOiuvlrlRswSZM4Pr9az7+0+33xdlMaGNdzIwXevbcRyeOnehsVlsYusRrPa/ZGLPcuPMjSJg6A8gM2MMQD17Cmtp89xCYG063MMFsQDLcKUQgfJgcnAPIzzjg10g0+MKvkSsgQEI8a/OD657g8UpgZOP3kqAs0pZQMZ4GMdc54pCsZEOmvNKst2YFmVF3eVHuaPIBO3cMDJyfXFWDZr52y2VNifLcT5+ZSOhA7n9O1aMm9H+zvlouuVyXU9gc/Tp1ougwtX8qF7foqyOD8o6A7e/XNWiHE5q/1CcPFa28TX7QymLdJKqqZPVhxjH88+1WvMndFOZJnJ2swGzDEg/Ljvg8Hp+db0OmpaW4ihSNjCojZiqjzTnO5vU9fep5sGHa/l+Wx2Yz1yeh9R1p69RNRtZIq6jpiTJIrRqMnBAPTmuI0q91PwD4mbW9FjeWI8XlkpIS7iHt/z0XJKn8OhIr1G4VZI5fkKjcSwB5HNczqunjlip+bOPc1g04PmietpOLjPZmT8YfC+n6tZRfEHwoRNo98qz6h5I+4TwLjb2Kn5ZR1H3iODXBaPeyWrmCYyGVTxtI69q7vwb4hj8C6vd2+pxrP4T1MkXsbpvFq7DDShf4o2HEi+wYdCKwPiJ4HfwleJf6U8d34UvXV9Ouopd6xCQZSJm7r12PyCMAnPW5pTXtI/M56bdCfs57dDe0OZlhTzGLN1Iz8x+men9K3Y5y0OyTZGMfcU8H1PvXn3h68Z3IkUOVwOmAOetdvYlLrZIW3uuGLjhRSjLTQ6ZPW7INTsrWYebeRB1VhsXO0IQOMfX3rAvz5snmSxgL/yyhBzu4+97Ctu/vImyseWViFViS24+yjlz+lImnyRjzJ4WMj8pb7g0jn/AKanoP8AdFZ1FcuLfU5a10trnVpXdt+2IDB6AnoPyya5KXTl0i9e0uEzbyn/AEbeoKqSxPlt6AnkHsfrXsFpZLb2aiI7nIZjvwNzH739FFYXj3RVu7CTcWVFiBGByMDg59cj9Kw5XHVFq0pWZ434htzbXFpq1kP3aHy5ikW1ovQy+nXGcYIrpYbhZdOysg5G455Bp8E0N9YvHeJBa3iJ5fmRgKzZ/wBgDDBv7pGDzWbbabd2QItFUwA7hFLlcYPVCecZ7Hkccmqqaq6NsPTlB3todn4WhU6NBMpQlk34QZyff+VVtbu4osjlEBxnqBjtn+lYlje3VnYR28djew3JJAdo2aJ85I2lMjOOtMjsdR1mXbPDLBAGK53FWJ9FAGQc9+vpVOcmlFFQTu2ldmdYSteao0+CBATwiFxzxsOPbkkdOldwkKyWjSq9lMPLxhvkK84yOvHIHOOKyraw/s9I4ldUeNdgi3tj3yw7+9XEs47vZIY1ypDlgfnTnquTzweMnnipSeyOqlQlBXluT29y4SQNcrE8qGMny/MHt0ByAR6fyqGHV5EucPGiSSkFAihPM5wSMjvjpwc1CqiN0hluFEudyo+FBBPOSOmMfN3WtGSYwrPZfZrW42YM7+ak8ecjk9ABjjGc0e89TocVui3dxR3c4dkhhjd1AilZsk45bOCOD3BPSse7gubAndPbykJuMRdmLDBPLY4xx1BHOQalsbFEhjltdQvLfzHeJobQjcFP8KYJIGMjnA7ZNS3VhdQXkctvM9/MjruSQiWZiATs4JTIA6Ecfjw5K+tjlk7aGELfUYDJaXAyY9qukM6scZ4lUhtpA4GQT1x709ltb61cXUFnNPGNztJM8LSIcgc4A+8Mg8nPFWpJbKNo2XzmR5sW7QqFkXHDBSOF+bnBOCexFVL2a2urZ7iXUbdFBJhS5geV34BCCRVKGQZGSR2zxWdmPnTVjMHmQultPIEnTbIsskmCiZ4YuucE+hFTT2kjzyTzx/a/MlO2cyFwVHXaTjOfUY9KPKjkvUVI1gnKkFShjwy9fmZvvYPIxj61PeaSlrpcU5jgilLiEjy3dOpxuY8A5wwxwR2yKnlshwab1KsF1fPO8LkwmSY+RAznarcKTgcIeBknOenatG1h1K2klN7FY3TLtdm5RwRyNr845GcY2/SodMv7NJp4baRN4k+4qDYcjbncPp9O+K0HuUhLEkSwSgxs20ttfHyggdMZI3DrinHQ1cdNWShrK9t/s2nLBCpUubedvnXuQpGcg9j39qgntfkUxRFA77tmegxjIPY1SEsUju8TyLIIg0UoAUB8AHjOQe2Dwa04LqzlgVvO8zd0zIGbOcbenQGqspHRB2RTtpFitlaUkkuE2sMklRgHHUcVKkizliIDFtUKAzld+7noecfjVuS1SONZViVwgXackkc8n1PQD3puFiJWdsRx55dc/r+NVGHcHrqiKKbyDHG6vcEEb1KlEBBB45zk9N3pjFXLHzDcJthby2QuC3zNuD8rjOc8YweT15qO5hMcsghtBKsBDTiQcOhChe/JBJ6ZwK1LPTLC1vpJb242Wc6Sguhy6OU+QiIkFwG4xnJ+laRTuczrRb1GXEMSweeZp7WRZCZW2kqsTYCMSMlSS6qBgAkDoSaZ4iu57WZ1MepRXKwR+cNS8uKQMy8sVHA4POTnHWrujXF7qOmzzwvPYxkSWhEYGLkysu63DNtxnYxw7fxYB4Fc3qNtbzwq8Vts8wkiNeFiBbIVR7Lwc9uvNObsrxN6F5VGn0KBe4vZEAjebcxQYXr2IAGd3Tt2qWSWFvMfCxohz5MKBFJxxjHOKrySZidJlDSIAM9c/UDpx6fzp48t4neNRvBwjAZx7fgBXG2d3InuRHM83mSRuiAAEgHJ56f/AF6pwySR6iZ4o/MkXcgUMA23HfPX1OammCMXBlYx9Qu3GD6j8j7n0q5Y2KyyqUKrFnaN/XHUZx3JJJ/Kkk27IipCNhsUtwqJFb2qLdSZTfhTtzxsHPTpz7fhV3SbiKS1Mt3eW7KsnlJHFIZp2kUgMdo6KBzliOnHeqc9klvc25lQbFmUyOgAV3XlflI+7kHnp25qydL8hpLlUR8MRiEELz1wMYKnPbA9q1jocE6alLli7HdeH53snlF0i282RnziWGOMEbcjODk5OK6dTDd2a/uXnRxvJOUGSOnPTAPb1NcHpQuZLu1triJksEceYEQCQfKdu0HjAJGVPGM816Ha2ZIiiSRZzsBJf5SxI6jk7u+R/Ku1O6PFxlFU5avUihtYoVXcSqchnLKN5Ixn2IGOtR2MJttPjt/tMr/Zw0WXPmSDDcDPfqOTWnHC6q6mMSRgbQ+7H5qenrSKMzyRvtKZG/gHt+XpSOB66EFtbyxoY3IjGcAJjcQTy2fXPNSfZhln275u8hJ+mSaVSROu394o4xjbtHXGe/OKvxIN7KzbmfA4b7x46egHApmdmihItwFKIsQYg7WwVA9eO1VrZTFFIoIYvgSvEuGjb6fTj2FaTfuZnmxsViqgsThuORgd++aSW1U3Bk2q0jL8/lvtYjsQR1x3BosBn3EcEkUqPh0lU/InO+PvuI7cHmrUcQhSOQIgaQj92ueFwAAM9hjqfWoJdOiuAYBBtjkdWZ1IXcAfUfN+JrXMOxi6KpfJyzdAMdBQU4qwy3V4oOV2OD0XnGe2T1I9ahSAG4HlEsoO6TA3kk8AbjwPfAp88aG3kUxlSW2SRgtn3GQe4J+tWbYoflRT5fIRBxtB9Kq5k49SpeQRtCqTsCnmgMzHjgE4HfFCxzTNHtmUFTuBEQwAeOB/ngk1LcQSylY5FjijV8gM29mVec84xzirK26FCSxfPOSu0/TA78/rTuLlSIsuQGIzz19B7epqvcWyyofMK4/vk8fhWfqsk7WzLaKTMciPYcAHpk+n1pLOS68pIryTz7sjDlAAPw9B7mk97HoqLepzniSy83e23+LqRgj3/Ssrwh4is/Dlje+GPFVoNQ8C6iSk0RH/ACDy5yzqBz5ZbDEKQUPzLXTNJ9rd7SKNshsLIT1bv+AFcz4g09EmcMN0bnC98jtWN3B8yN6lCNWHJMq+K/B174L1a2SW4fUNEuBnTtSGD546iKUjjzQDww4kUZHIIDrSee8kjheJ1g4ADcIT7/8A161fAHie2s7J/BfjkC48KXqiK1nuGKmxfPyxs3VY842t1jIA6YKweIvC2o+E9aSx1uS5uNMmfy7PUVAUTjH3JB1WUAHjowGR3FOauueOxy0ZOnL2VTf8y5ELO0uImtRJd6l1Hl87PQL/AHR/Otqzj1Fws05jteSwB+Ygn+Jj3NV9GS3tbcfZWRh1Zs8/iwFWpro2ys74BHzfL8zY/GnFO2p1ay0QsyC2ZUy7nGZGYcuTj06DNc54ku1EcqSsVlcjMajOD2GOwA61pCe7uLtoNNQS3LcKDyiLx8zN6jPT6U99DgsLcsXa4vJPlklY4z68dh2FXGm5bFpKm/e3POzpTT2rXNgdtzHwQp++mckf4Gk0u5iubEnzpI5ycBJRtYMOvUdT09CDW5PLLo10vBn04Hc6AZaHPBZPVfVfyrE8SWI029s9StXLWt5lQUIId16Ee5HGfpXNZwdjqpTcZa9SUSlZR5yKWCsgjKgpzx8u5srnuORkcVWhmRYwLmCZ+BhUmBx/u44A9+tVpXV7iV5I2W5UBtshwwBAzwPXd/OpbTfbP5cLyqCMCBVLeXz1B9/60r2Z6kEnqjXEunpDtKSSuFV3jWMkBicdT1I9RS2MDSrM1ta5DMCsIGcY6A9y2fSsi1uGgv3gRbxBw8isBsxnkA98d6tQz3UTq6yb03CQCMMCcHHysPusOmenIpqV9WEtE7FnULW0W3Jk+0CTaW8oxEk5HLAnqeOT05IFV7SBnmeaC2hmaN9yQs4VATzuePqwIzwMfXipZbu/uN8ksd7vYlZImdSUyDlT7EE4I4PPeq1wHu3VnEnyZAk3BTK4HzIep2BSBgYOSfSm7Xujmm3ZFme9ijTbJcSFwWDvbR48onOI0VP4OcDk9TxSR30g+Wzkmtsu7OCP3m/AzgKBtPYA98EYosEtbOaGdLSeO5kY+TbWfzAHnoT0xjOTnIqW9udR1Jro6hOI14SWNCiyIFO4YYc7wQc5GMcUb7mPMloYUOm3cmqxxx2bnz0MhMQ8wLCisHPllgfNwM4DDocA8VcjZLS1lSOO6i0+eRpctN5qIxwcYwODkckZ4FWysrRSi6gtgwHnStN+7mYl+HygJLrlRkDP5mlvLu4tme0mjVJCFzPK4lL7gvylVBZAMH5gN2G6CpskKSbYktyiW6QkrM0q4YTjcqtjnEqDaynAIUjKketZssiXAhaaN2gjBTctwWBYHO4A/wB0YGPc4xmrt1Y2qSCbTL1PKGGEsSbfNbAJ+U8MVPeqV9BaxSNcCEuE2N5qR7ZPMJO7KtwSeB0wRUyv1HCKKUsM11etNsR18x1DwlMucF+AOScAgDr0FZWpnF7G9oxuYFJQRyks8acjJ6YPPNXll+zXLXFtbtYXBdlE8casY14GEJ6ZA6n3HeopEigle8aaW4t5nJedflZeSxB/H+VRp0KindqWw2ym3xRiIWgcrhkZMse5J+hBxSMIbW5ibzCJFKyFWXgc5PI7UtxNAZY5bS1aBifnmQlYySepHeoobmPfJ5q3bOw6mEFc55GepBHPrSt2OhS6HS2EwntgUEqlhkgZJB6Dj9fSrKStcoApuFUHcXBAxyCBnsCTgn3rDtZWEkJg3ywqW2csu0HOMH1BHIq0mo3v2gOtos6GNvM2sQy44yR+A6VtCdtCJyetzZv5JDb3zGAW0sjPZiM4Pl/KrblBPUjPP071naSYQ8cwuEhkUkl5HzIT/eXPU557VXu5GuJp3jLySzPuaQcjOMkAnoM8Y68Vf0aSC2k3Pc2qXGQymWMsMdiQOMBsDBzmqi7yFRjyxbJ3M06XskdxNJMwdncHazxZ43gNhiQM45ByeoBxQvvMaQ7seeo+c8k5U4/HjvWjrVzvlBEcq4QMYmlDZIYknOBj7w47HPrWRJIUXyiu3DBumTnG3G7rtOTntkA1NV9D0KKsrla4jPyoF3bhlQ56AYwM/TmqwZJclRvVBubAICjOOvcn0HWpJHfLGQd8gHpjpzjpx0pTFHIWkkkKdCHX5SO3H+Nc3U6HsRSWs6ziCdGSaPKLG45Ujsc/Wt/Ro7Xe6yRb3Vtqq3OPU/h7elc/KJ55GbzXmfGGZk6DoMn1J/PFW7aIhXEs0gVzsURrtOccDjpwRmqg+WWxz1o80LXJ9SIkklkhWOER48pg2BIfuscHgL2yK1NIsW88LBGh2lJGTHyqcc4GeevGPrWTLLFeOqwxqq4WOIytvwoyMMfUklmxwMitzR57lYJlgjSF0jCsjyA7Bu5Ue2R1HtWtOzdzitKK2OggnaEiE7o3Y5GD97nGQa3rPzHBxkYONhblRkZH8jXn8BlW4hje4ZrmZyRHnmFRwCT6nngdBiu5jjMdnG3J3D5go7+/euiDUkefiqCjbXc1W1Irb+XbxgAcSb3yCwGCQPfrUMmqfYFbzIVmiAPTOTkckEdD+lUlGGkOBtQcDHWq97O9qz3NqWd4U3BAScfh3p+ZwRoJytY1NHa8FtGL1ohNKoYq33lVjkBueuO3UZrbgZhMcOrLzuGOBjA4Pb6elcxo13dX8Q+0RCPaw81lQjcc58wDtngHHce9ad5cXVvry20siptJDIFwMHngdjxj6047Cq0Xz2NtIt7lmcFkG3btBU8enc89frS3KNFb3DwxL9pVCwyo+Yj7uBUtjKsyB4i20HJPQKevHv0yKnjCjZuQksexzjH9PaqOJ6PUzNGmuLq1S4vbRoZRkbWO3Hpke/rV6GPCAqy4clmfqM+lWHJXcHbcSAT3wM0w7WBiicrGpCnj9M0ldFSak20rEQtlluDI+Q2zdjoRz1I/E0iCP7OVmdoFbkgEqT15GOfepJgwkWRHLJyjZIGSTx83YjBxT7x44oWXc4aQhNxBL/hnvTJsVo3kVUZ7gvJMNkOevAzk/wAzVqJWU4YruYhs5yxPqR2HFRyC4AilWMB1O1V3gAL3HuTUixi/TBA2I3+qXqfYnqRmgiSOTe6CFo45NsecE++e/qBSQ3KupS1+dWPLc5dvb6+vQYqk+1VZbiJmZeNiHAPOeT3qK23tnzsbTyI1H6H0o5j2HSVrovmBII3IY+cxxkHH4D2/nSzWcSxYLIx6sV5LN2/z/jUPnGMgKiqM8IeR+NDKFQecAoHQAcZz1wOtOyE1Jrc5XxBZRXKGNkHlsCGDLnNY8dvc6x5ekap4m1a2XzEl0me7ufOsYZ0BCRzKw3KrAlQ6txnoa63UoZri1kdBwM4Yrwe34n3rHNrauGt7wRMZBjYV4bIwV568dqlaarYVSjGpHle6/A6DT7LVdOa2sNe099L1V0ZhbPKkq3Cr954mU4bHGVOCM5x3qlrO+3LNjPIXJ55Pr/ntXS+CNQtNVEHgbxlEb20P73Rr13KyqyciIyAgrIq/dYEZUEHkc6viHwZqVpFIkBfVbXG1JlZRdRjH8anAfHqvJ9O9O2l4mNHFOhPkq7/mZ+itZ6XpaQw5kJXLkDBkPqTVXUrrzpC/y8jgA8KPSufsNReQTI5YTQv5csZypVh6jqOCDyO4qz5+w/KBg8EV088eVJHbToqT5mJe20bPGhKuXGTj+EnsfeuI8aKNO0a6tzzAjoyLjOBvXIX0OcfrXaRXIUyXM4zFGvpneewFcd46lWPSFVyzXt+2IY+CFG4F5CR/CuAB6sfY1w1veeg6k+WSiZ8C71V4o5zlOXZN/wBB6dhWgqyQM6vkx5DbWOOv64/wrN0+6P2U/a2dXLcknj8KmjuLSRA8URuCXw77t2Dn9PesT1IXa1LTEW8TBAY/M5VpEyPzzzWeixShmlnkB4UvCd3APA3DOOfpTReGQ7ZISCz4V8bv0z/Kp1a4Qr5Dxee7Bt7xFVRO3YZ7c/XrTVpDleKuWHGU855pIYyC26QH92F6dBxnGB25pkLSQSJDdSxskz+ZGYJo3dJCucNg5GSM8471UuNRla1WMwgsWCyzbizZzyNn90dat2nl3NxcFmjttwOTBabnlIzlW5AxjufTrT0exyu7Lck1pbIovYZEuEJcSB1kYoBnocEDPvWX58O8zTJY28uxpvOm8xSpYHCNtJ+XHYjk9aluLS2eC5YQtdSTbWMzxuqQqDn5dp2nIx94EfSte0v7sW9tpwuoba3kUhkkQyOEzkhiQSOefy7U9ZENXRm2shdJHnbUJ4Fjff8AZ4VAUHCoWK/UEgnnj3NGnG0s5LiSBNL3Q/fZEMhlLKc/Lu3DlcbcjggjOa0rcNEI57S5lvJpCAkbQsyKzfIvIKtnAb8BnBzVG6tJhdQ3xs7GZtzKN9tI0eACfKxJuXG3J2jLDBxjHBa2pk+w+7020tT5dqbZ97CNZEJhLkgEN5bfd+npWZfTzxWw/cfaRAwLTwzgIWyQQQfukD8OKjufPv2KqbKxIRW/0WMrCD0HDfdPrzjnrzWbmaFpXZzNBIdzomUZvUnDdPx5rKTS2Li5O1y9f3r6m8r3JnLTMSVlCx7Txu5A565wMc81h36Xc8D4aB1lDNuHyOwPdgexHPHP4VYu3tCV8m4Uqu6Ro95WVR32tnGOvGeO1Ja2cV2zrYPdbEKiSRlXdGD6qeTx/Oo1vc1SUtCtNco9qlvcWzwzpIuAXAjCj0OcAVsWvn3KiWR0eIj5JHZlXHUYCg8juTnvWQbOOCWQNtmUZST5SrxccH0BP0qzp0BkiWOO4mREJZolOxj/ALRBGCT044p7mkbo2rVC1x5sUohk+6xPK7gf4h/XrVtI1llDNcPBJEu8PE2MHrwR1/GqMUUCJNIhyoUYRcbcY4zzwR0p1pOHlWJ1UpklpANgcHqB69/1rWPZkVe5JqcYhulguImt90SMyh94WRwHQgg8Z3c9+oqfS9RD2KmKRBH5isytIVjLjGDkjBPHTnryDSa75a3Mt5IGRoUjkbzxnehACgk9OvC9vanaBqEUelvFJcXJDlXCpKFVOu0sn8WOoYDI56046OxFCV0osdcSxrIf3B3fMyxlNoRTu4ByMflWdK29VE7eQzqRmQkkj0OOg9+ffFasdxA/SeKaRSVbrhxjv+ROTjP4VTuZ43QqHgdt+dyyBjnIwCQeBWc9T1YO2hRkd1UsXWcEAtwQF6gDOeR3/EVA4OGTcNwXghCpHqDUjusLiN45NjAyLuOChAOOencn0zUJkgIjGJRmLbJ8wYM3txlR65596xfmaRfREhCoiLESgDHcS24ggcD36nHpUd3cZLRyYMTMCis2c4PRsdcg9unepY2WLa0aDbjBVjwBjjn9amFvLEj3DTHcEUbY2CgHPOfbGfrS3CaurFrTtzbV+YovCqq4HB6Z711em6c6mGRYYoNwCyMRjYo6n3JzzXIWLK0iv5LMmFyrOSkmME5PocZrrI9RllVrdI4gzYZQpJRR1+9k49q6aLVjnxUJtWibn9nrATJGIhcO4C4jyEA6nH071aaXLhWdwAOcDgkDOR+tc7BcXiamkEaG44DKzLnt65//AF111nYOYcycsy+ZuPZ8+g7V0R12PHxEXTtzu5Sfz1tEht3xcsMIzDOG6jP+NX9ASaPTka+EZui5kYbcDHYUbVhuoj96XBBGPbr/AIVNmVvuAttxkf3vUU+tzklK8eU1I5o1lTzMfdCtg9UzwPTI7H0yKq61BJtW4s0Wa6YCNWbGGJzhiT0PU/j7VYhswyI14p5DNiJ8AKR3Pf6VYtbdHyVBUKu2PbknGMZPqc8/hRqc3MoO6JNMgljtohcNH5qnJ2DKnOMjOOeR/OrsPLEk4BY7Wx2+npUMR8wyAkB0PIx/n3/lUsKqgMIDZVsjPoeao5pvmbbFRy8gYcHcExnon9ef50+TbCSScR9drYxkDnB/pTEItldSdo3kjnOc9sVHPIsdo7zqjJGwYgrxjPT6ikJDllCxt5kfyFslZG+Zl9APw6U218uZkuPLdVfIj3Zyo7k+hOOntU6LiUJtG84JP8+v50y2aN2lkXODK/046nHpnvQUSHk4HynjJZeeemKRYo5WUuMlScHGD+fpSb8w7pOFDbcBsjH9amijwyg7TgYLDinclopeKPBkunF59DhluLLOWslPzxc8+V6r/sfl6Vx8dxZ3FuWhcFAcYGcg/Q9Dx0r3q+hM9u6qSr7Tgjse1eS+NPCs+oZ1bQUVNXiIW7tmO1L1ccNntIOx79DWjp9UPC4zTlmzmzMqgrxg8g45Bq1plpJqMjSXRJt0/hzwc+tc3ayi5US7WIWTYwA2kMpwyN/dIPBB6VqaRfyXVvGxZwRlCmduwg8qR+FKmlJ2Z7D2906DUwhURRbcDkjgA+w+lc5daak0MiSAbGyR22+hHofetnIcDoT19/WkKiQc8MTjPHStp2loKEeVaHH3UdzDZTS7W87TZluYJ0y0iSoQ6F1P8JAIyPXkV9MrKZY1kSLKuocH6jPSvEvsAvLSSBAWm1CZbOI+uThsj0CgmvbyBbRIi5JAwCeuAKypRtc8jMpqUl5XOU8UeDdI8QyNczW722pbAhu4flkIB4DDo6j0bp2xXkXjWz1TwfG0t3pRvbAEg6hZqzRx45/ep96PPryOetfQjoCvzOcjjg9aryByxbG9hjJUYbHf61pKClsclLF1Ka5U9D49l8avcW/n3sBQlv8ARrOEeY0g9cDt7msWwjuNQvpdQ1DebyQDCdEjjHCqPpz+Jr6G8a/CHTtWvZNS8LvHpOqSKIyFixbzHJwXVeVY5xuHHtXik0bm8kt74xLNZytDII2BWN0JU8j731rjnTcXqe1gKlOrq3qhZbcpG0bHGQRkrgY6ZpVSRYkGAkR4yqAD34FXfs0sgL7jINqjc75AGCePXnNRBcxBcpE0QwxHy57H271k4nu06isVEleKUDyDKmMH95sKkfxD/AVI7pFlsu5cEsGXp/nrUjzwK8UchycfMqkZP4/4VSMs11cxxQpGloxdWDsHIXHOPTJpGntUSiKURtLEfLlUYWQwhOMdyOuexPNSmRRLCsgvJFkZTKjAMqvjG5exGBgcZqO2nuwxhtZpVj6hQ28g4IAK4+YYouSVHkTjGFLgLCQ20DAb0IOO1Nd0Q1zbF+0Fm08qJCJinyxFWBCuGyS3OVx7ipftkcsm57VJPNjCC2Ro+MNnG4DcB1O4EE9KyTq32O1EKraOjqFVYrfDn2DE8jpmkN7cyQJGWkST5f8AVxDKgZBGB/COvFWpGSg73Z0bHUo9MeCFZokkAeJzOHCnd0JOflI+XOfrnpUN28UFmJbewiinY+U3DBo2GRg8nLfePbp6cVjGSLzglw0bJLtiR5CQMb+SRxz06e3pWpb3NtZvDNZSNG8jkM/lMxmwDhjg9eSMdOCe9aXRMqdjLVV/s6LE032i3UgeYwUN6pz/AC/SqdtpkcgDrlYx8vySspEnUjA6HkcVZluvtrSTIyTM7FZWUkMTwflVumBgZPXGao6hI5SNrdobifbuYRPsI54OR1IzjNcr3uUtrCraJeQyubSGdZGQB0OGXBwevQ9vx6cVnX2nPHJcfJ5TIAEkVjuHOSMjtz3qWUxyjzNUa6F3KDIZlfIkPXGV689M85FMla8COqKqwAlSCcSSD2B6dOpqWgj2YxGkgWJYwyXC5LKqA+59Mj35qR7hZZFjWJ4XDhg2eFUjlBjrkgnB/Cq1lOJJYv3xVyChimHCgDJ5+vcVZmkimEghZQdgDpj+HH3lHfHXNKzN009V0LJeSSa4SIos/wAqjA6kjJYj6cVdtbu0sp4Hk01SyuoLC9YQ44IQxsp446hh1rEcySM3lB4nVV3qWGSSBzn071Bd3MHlOLiWf51bd8oIDK3yrjuuAOevWqWhjXtKOp0F3cS3rwG/eEvFIXkimznk4DDjkuOcDoMVMkBt7qZbeOSFDEZjHEPLCMvcr6fj3IqCK4ntNSDTCLzdhmWRiWYSdBIMdDxgZ4GKLqW6uI/3bs80jgyTvcBtnJyPock+9U7b9THDw5kXJCwZfLYLvBkxGCoOB0PfI5JPpmmL4uu7GxutFZDNZ3MT2gSSFRsDdCrDGSOvOc4+lSRoiqrq5lkXOH2kKyE43e4PT86rysZImdUG0ZDAL0APb0OOn0qX7p6fsY1oJSVyrIsclvlnRwXLcDgHvikRSAAUwC2TkdPb/wCtQ0WWxIJPNKbyzDGdwDA49SMVKrySRxwpIJUlOVRxhQe5xWVu50p6XRZnEQhbaQSzAIU6Nj19e/0pTGzRARIoC7jtGTtB657kVVmaNGEe0o44AOcDtkntzVy0m8lGYr5gVzjd930BJ79f0qkk2Z3a1Q0QSQz7Crj5lHJGQOpGOh4rptDt764uXitEcIP3iPJGgUAeoJ568Vk2/kSMgAJZSp3FCWB9T78/jXcaFZkWscxQNInDJ6AdD+Hb61tSp9Tnxdfkh5lrS7NLO2glQmRlwZGz27n8MVq28okMq2e2Rj3I+UfU+vPSs9ZkeQxMiiMoZGA4JUYyn0J5/OtK1iVY1KfczleNuc/5710nztZtu8iq6SSTbZQNoO0ybcEdPm/nxRJJsYkjy2/5ZL/C4/vE9h3ptyzYOA5cseGfO4dgPfNMiDrcFHRstHuPGcD+gHNQCV0bZk5UO8ZLsBmNjjGATt9vr61oqGDIkagICAc8YyPSqlu37xJSNrFstlNowRgf0q55wDeSxOThiMZ79famjkluO2bZomJydx3FT0Hp+NSMVB8wdTwQO4HrUfCAKGB5+Y4zjjk475qRZeMHB28n3qjJoifa8ojGGjY8o3U/j/SnMuCN7ERL8wUnOf8AOajJ/deaoVAnByMk/wCR/KpN7ktvC4HqMDHbmjcYyG1K+ZmeURbseVkYBxjg9e+evGKZf3EWm6ZPK4Hlwrv4H3R3NSqweMsCSpdgCwxzmpgglRvMCsPuFSMg8c0hqyd5bEWlXMd3ZJPblZIJDuVwMq/uD3FaMePmUYABBH0qrZxQwJGlriONeERPugew7D6VMqhwS2SCc8jOTTuTUabdtjsNAcpbPZO7NLZN5JL9WTGUbPfK459Qaq6lYxwXwnUbUmIR+eM9sirGq7rGSPUYowVUCO5HfysnDD3UnP03e1aMyLcQEA8MOGXng113s7nl3szh/Evw6sdQmub3SJhper3jo1xc+X5qSheDui3BSxH8XXjnNc1efDrT7e4u3t9X1M37oEWVyggDDpmNQN/GQSTwDxXocupeU81kk1ub2NV3orhpFVs4cqOQDg4yOSDWU6hI9u3OOACvBHv70lTT1Z0QxdWmrRZ5Jfag2j3stnq0b293CA7KPmWVT0eMj7y9vUHg4pY9QlvreOWCCeCCYhY3eJmeU55CRAFnP6epFd1ruj2WrfZv7Tt2mS3kMkTq7RyKT97DKc4PQjocCug0i002xiMulW8cDMMNJvJdsdixyT9Kl0pd9Du/tO8VpqUfA3h6azMGo6pE0VwiNHaWsrBmgU/eeQjgyNx04UcDvXZgEHcY9xIIPPvWUl4E5M0i9zv4FXob2CXaHkww6f45q1Gy0PMqVHN3ZaAAGcbTn0yKiuUPOUDuOQwOMGpEcdVZ37DJxzS4U8IxXHJ4yDQZGXeXa6fBc3jYEUELzPuYKoCKW+Y9hx1r450xru1sLZpISXkV5XaU7iWdtxwQOevvX078atT/ALO+G+tiJ42urtVsINmN26ZgpBP03H8K8EgdbVgC7SRQgZ3KCVHTGOtYVnd2Payqk2nMxor6Rm2KfmGMqvAbJ45/z+FWZGJVxIgXb/ExzuJ7AcE/U1el0qwu4z5HlrKQEChiOc8Eeh9jxz2rIljvLOXy7iOWB1bn5s7cDsD0HcHmuVpo9qMraFme2TBYOJA3z+WqAsuB1B79OnAqpFF5xDWyJG0g+ZkXCgD3HTPoeKsfbbhoTJctFshZW82RVAPoCM8t6YH6VXRklimkimI37mJijSJcdWBAUdvX9al6Gqd9ivdO813JcRSy2x2702xY+YqMnrjkfgariITxu9uWmaMD5U+8DnngdMc5rSEUcXmxw72dRgAgbmA4/wCA4z3wOM1CJ5psTRSyq6/ISi9QeWyc5xnsfrxSavudNJvZEWyGC2Q39ijh8oMyATKpGc46fQ8jr0NW7WVrRVaOKBisfM6NudATghh2PfHoM1RhsLmWSBbeFkaXIQFN5kbcT8ueufQenSnTW/ktE/mebEybwiFACw6nDDGcZ46+hpxdtUjXlbWpq/Pc3KrsL3DykQpBIqhnxyAhHfHGO/r0qOaRItRjjaNo2jjkEkgCoXUkEggHA5ypI4wOBzTbKXy7fzmaLBUSFW2urDaeoHfgjjkdOKn1IPJdwLcwrHlz+7mJ/dIeGOMk4AwMbiRgZrZK6uc1SVnYLr/SdQg+2Oq2RjaGGS5UIkRC/wAPBGOgBP6Vj7jGkfkgNuJ8yJsBSeMkHsc44PHerTII4/3IKRRMyrG0YDYBwR2DjB5PJxjr2guHS1Ki1l8xWBTHcIACMDnPX9OnFYz3uEIpqyIZVt7mPiMxOXy0eMHbnIIUd+O2R71BBdtDtSQRhQSyuQXyB9O/Xg4pRapebFRVck7v3bFvvEYBX+FeCePXnpVmHTJPmWRpREzMpjEzAH0z69x6VmvI0cWtDOgtJpreGNyJIXzI6OgGTnk+uPT6VGs0XmJDKEDKNsUqZAcg4+Y9mI71tyDyJYmG9/MGwsF4Xj5Rjtg8enFYcscRklDsxRJdrSLnqehyO4P1p2sTttuSwFEeFR5MrSBYzE0hXawIO1uwGMjOeKz2jia6hZwzqHRZA43Y5GfTqSfzqe485wYpDJIx3E/LkyYzypAwcdz1quxkWS3a+geZlmA3EjYIwufLAAPJyD+XqaErmNWpZHR6BbwyzyMZLckzyGTdGVkD7zgc/eBUghR05rXmW2tGjkEUAmmAddhyOCQDsHBOKw9H3XNo32R2toyTG8+CU3k5Cs3qRklsHoK1HkEVysplSRAdrwSIsabcHhfLA25AySOtW31NMNHlVmipK4Risi+Zbu2MqfmQZxkDqT9PypRNFLFGRctvy6ypINvl4AZGHruGePUe9JGkbJ5owVCERnORgc8Y6UNCPs+8RMMkKQGBxnOM+o+VsfSsXdnpRjy7MNiRW6FY1SNgWj+bIAPbnkH2p8M0cfI2FCOCW9OKiuBHFIY1B3AbiGGMe4Xv+Oao3MUqxxzOx8splk4yuehqG2WtFY0ZQXO44AIJAI+8R3pUspHBliUxxOApC9G5JAx36g/nUKSzMoYorphevUn0/wA4rY0WaWZgrO7AqScjAVcnt7dfenBKTsxu/Lcu6HBJb3KyTRO3zBcYxn0Irq31uOzkeCWIxTOGfcik7s8dawtAVJtReCRmEmAfL5G0dxn+VdQ+nW72jvGA8+MeYSMDJwM9z9BzXZT0joeVjJw517REenQXTeW93KLhgpwyrtIUe/fGR+tdHIpkG+Mo2QOfbrzWDBpZsYoraK8KZYpJMfmwMEgAe/T+dbtlEbexiRnDp94bzudQBjaW4yPzwK0PKrtN8yZXv1zcQvuCLn5kXru7VJpcciC5cEv5jdAchlX+Ec5GCc80iSOOX5RTtVeCuP8ADHNWoIXSfgESMu75cA4HQ/UUjmlKysaSESRlUyM5CkLkfjn8qdBmJ5hISwBHz/njPrj1quWMkkYOCVXdwcck9T7etOMcpc7SSr4XJOfmwSPX8D6mqOdjklnGHjxICfukYJ9/5VLB+9QyAhom5GQCT6/4VDbtuhQs/mOqgkquc/X36irsCGOJFwWbngds5/yKBMj2FQFVfMRs4Vmxjjj9aI0VDnZ8uOFPUcdvxqdVQbht4C45Ocn3qIyfdKhgAcNnqAO/+Ptmk0JK4sD+cZVKMMNzuAyM46U/zBDGQvLgdGbk/jTQrbHdmXaDnIzyB1H58fhUkYDsVYINw4Ud1I4pDdhUJKoiNkHJOOCPoaeQfJO5yNw+UdPwpiDIRsMcDgE559aI+SWH3t2BjnpTE0ek5yNp5B4wR1qnp0f2MtZAYhQZg9An93/gPT6Yq2pxwTjH61U1RxHbLJGR5gbCH68H9M11I8kxtRkWa+ndQi4+QEKMsB6kckZzVB1PIK4Y9MVadUUYCsV4x6t71Ey7GPOB1w3atUrGbZnSryGAzzg87vx9qZbzPASyPtJOSFOD+HtVySMOcNkHrt3YB/xqpLblyGWRVkHAPTI9KsSlY0I7otg9OPvDml/1nLgMCfvMcfpWdE0kIPmJKuRgbOV9/rVqKRcKxlK54w0fQn196ViuYmU7eWhYgcFlYcD/ADmrMWwqFMswJ4VW5yfzquFIXKuQwyAy81wvxW8df8IlpqWGmun/AAkmqp5dsgXi2Qnabk+mP4fU/Q1EpKKuzSnCVSSjFas5b4ma2uv+Lv7IhkD6ZoEhUsM4nu2Hz88j92DtHoSa5G5ZZZZHG5CpGdxDEn34wQKfpennTbSKOBzLHH8wkPVyfvEk9STk1cSOMbAYtokyQSeGH+z68158pOT1PssLQjQgo9inJEBdebAZYkJJXzCGbAGSTtGOf61dSa0u2EdwElJOU3EkoOwHfHPTmo5ImYMRDM/zbEDcKzdefwH6VDNEtqg/eK7kA5QHgdh+tC0NJxUl5mJf6c9lJI+9kjBzGEAG4Hltuc89OOMDpRcvBMlvJdKS3RlB7dmwOh9D7dxXXRT21zZPHJHIJl6iUZz9PSsLWNHRLZ5LZA8X+rkMakfKR39MdqlwRkm4sr2yN9pxdBX2gRhmwGjOeenPHQ09rUXMm64Vzn593qQOmep/DmobiIW985up2md3DvLGoBXPJOO/Yn8a2LcSTweWCWmt8sxXGCcdR6HpRa+h30paXMq5jligjQlAy5dTEcMD3A9M/qaz5YS204ljLKGJBDB89BkdR068g+vFXtQDylljRjnncMEj3P51EIY4dPEcMguGcMzxiPBB+6pjkz6nlTjoKzau7HatEQRW8AkmEtxLDJHuVnRlKu/y/KpXp1J3HAxkcGobyfyrRra3jDI4LyI4MnXgkH7wIPfPf8KvSwlI8pHNNcbCjTwKr8425yeQSM5BGeOvSs+CHYjSLGs4DFA8rkeYpOFJXs3Oev8AOqemhjKnzbjb+8HnRBGWSOELGy4JcjJ5JzwR7UthP5uwibE6sYuoBwWIzjP61DfxnzZhNNvMY8vdIMhBwe3UZ6ntTYVlCEokZMUmSCNwYMOhPcZFZttvUiVK2xYyoKtGzOwbcx25yTx+OOK0mJMaxjadwGc8YGPaseyJUPGIWjfcCrYwrccZPQdP/HjWg7vK6PE/ES7io5UMRj9O1C0Whm3rqVb+JZ3hIXNsJPnYHAOOwHp2zis7VyI7VX3FISAjYABPPT6YrU80m5wiHa4KBTg8e38zWVqshgV5gw82Xci78bWjX7pA7/NkUO1iehk3blp8gNho1wxYlhng9frz+PpTYCH3W6xIboTYWYEnqpXYG7H5mYHOMgU7UG2pFINypJmVCV5ICdj6ZJFT6RFNPbRiaZGw7iKMLudNuze3YZJCKM+hqo6HFVak0l1Ow0y2hFhGqxxmOQAFgSGib+AdcHgHBwar3ySh4XtmRZEYkrnIVMdWX+769+taTTLFZmKdWTzGAIEYPlvkEuoPcDPAPNZF55Mck7W539ZE5wWH4cZwKJ2SR61GF1Z6FfcqmCORBlU8lbqJgVkCkbDt45Gce4A709TGquHZEmj+XK88dCAf89acxRpWCowhBY7WOSATyD71BIjaZKs0YVkXjD4KsSMHAPsf1rCXc2iuXZjxtaZA6KgiIOFXJY8AZxx2J/n1q7KLeSCRnZvm52sfl/L8KzredVi27yRnqvVQenH9anlIkUJhlABQgcnn37VFy0uw5VItw4O8sMpI5K5Bxjp6VpaYrmOQSsEwQN/U+ox61mpdFFI2hIyChYjOBjB4P+R1rQ0u3fKrmVpNgClzkZ/+uO1VC3MaO9tTptCgkuLsOqtGxP7xSvzOg756/lXWrKlrlFChgB8zDqx5x6dqx7OKS3shJDF50wIMp3ZOPX6g1K+j/atQd/tMkbTICVSTapw3pXfblVkeHW5ak25uyLKajbyzq9o5ZGXJ2jPzdCpHr6Vs6BZviVbtriJpPMfEisMH5QoYN0GOOORgmpjpsNpEZlhCzxjCvEmGB6EDHOcZrG06+kOoSCTduD53yAneOOSfbp71S31OSyqpqmdTcRJHGrDbtXgZAAzjgZ96r6JJ9rt4zg4wSBnkc/d781Z2s9pJ5cZIK7QMeo7D0q7DBHbWwRMIVAZfQYH8qbVjgk0otPcpGJFvmZkK4Ugv1BI56D2PIqWZz96Nd2So647j9Rj8qRHWSEGUmJ2If15z09xingAl2CiIqcKhP54P4flUpGL8yYD95kAKOSQ2Ofwp6hRhWjwijBBNEWSpZflYjPToD2pXj4xJlix6f4im9BDJCQyAAswJbGOAelQq5W6JC87DleAGfpx+lWRCPkCFhGTjbngnvUTQiZdyja45U5+5nr+Y4zSYKwtvCywqsBKx4zl8t9dvcfTpT2Bto5ZdzsSMZxwPQY/Gpo9qERJ/CgFAJRgqgn0xz/8AqpCI4GjNpG8akwBQRuUj9OtRpdQtO1sSPNChivTAPvVkygFdx+ZzhRnPzCkIQBySAAcDd246U0S2d5C5AyoAA7DO361R1ZzJPEnyjYN3Xue9XioUZZflzwQef/r1lMzzSSyjGGOB7V1rc8hshIC5J3E57feJ9qY8WAV2KoPPX+Zq3tIGWbAx1z+tQylUVVOSzcqoHJ9zV3M2UmUkkFSw7HNRqi4xwrfzrRW3AT94A2Rz7VBLAVbgnnIGapMkrYOCjAbf9kUGJWI3AZA5K+1T4wQDjnABYYOfeqOv6jp/h3R7rV9cuFtNOtV3TSL35wFA7sTwBRcaM/xf4l03wV4budd1V90CYjijQ/PcSnlYgOxPOT2GTXzhpV7feKvEep+JtdAN5eYDLGvyQoAAkaj0AAHv161zfjPxdqPxQ8Wxzzj7PYx5hsbXPEMeep/vSHjJ69OwFeh+GIE06C3MKKqSpuJ3AF8g5BB6qMfrXFWqc8uVbI+nynBKMfay36D7lp490OAVjwxK8kHjCj3IrRuImWJV4aRPkUsvKjrwT71BPHHMkc+ALeaQkEnn5erY9PStC6c3TRyLC0yqDJkfeHP8RHGeP0rLzPfcErFWJR5DQhI0c9dhPbOSc/Sqkr77hSr+XHEAQi/MxI6sfwrWuo/kKxI+wRfMHI5zwefU5qk8cflfKijaNo2jHfH/AAI0WIUluZcd809yEtzKsrglmYfKozwas2V2HumW5SUoyFGOcbj36dRjp6EU57TM7mJRA4XDHAJI+vasu5UR3UOHZYUOfvFcMen8quF+pnW5ZfAT3mmNHhkZZI+qt1GBzjjuc4rPiuJUCOMiE/u1k2kA46DI4PHrXVRSYRUct5Mo8t1RccH9PQj6VR1C0SOJ4OVX59in7oYc7iOnPc+1Jx6kRqygY7uk8c7MjAsNwwcc9OD2HeqcMUrOxi/eMkKtEjrgO2dmOOO/fsDWsbaWGTyokVZiQIlzwc9ME9RVSSbZcMASsisEMe5SVcHJBI4H4ZrKS1PSpVeaJSFoVkcQMQ7ruZ2ygkB6uQOmOw7Y57VJdP510rMZJZps+Ykjj95wM4IGCuNpGRkEU4oTcMWhuFWUu7lGxnuG3AcAdCCMYB6UxcNHuj2GWQDfGIysRbHDAHJ56jHBPtU7I6NCvHF5ZEbzKrxjLsykLCpH3sYOecDNUDDy7SxNGyBdzK2epypJHA7/AIVoS25uA6xGSSNB9+Tcdx6lPbJ7HvUN6PIMQiXbbhTsKp8pYZxjPJwQQTk9OPSs2tNRyXQpLbzTI5y3mxEOGY/Mobjdjv2/Onw3Bt0ZWQtGq5Z14wMDqPrkU5yqyskYILIVO1uRkdfTqM4+mabeRvNmVUDCEbyCOmSAo+gPX60XOOpHoJBdtK/lvu8nkKwjZxjs2Bg4/wD11m3s6XCokKxyKqvFuWUl8Z9D7dAK0knkn8wBir7C7SAgqiN1JPcdsg8dK5/WFaLzm2L+6zkBBtXJxvAHGOMHpihe87HDOaim2U57tnmB8p2RS22NgRtUAttHp/exWp4aPkXlurEozRGQgrwFxk59c4J/KsSMC9a3tokSMF1UPI+3LN6n7vrgnGBxmunihlS4t7hh5cW7ayAH5FYDI56noT6Y/CtJaIywy9pO/Y0Li6eW5hhjmuGZXBjSDBXj2PJPTGKjkuRKjQySjC/u0ES7QvOfnGMnqec5pNUiBmIkRCWGNwJyT1DZx3quYRlo1R4HEYztbbuA/mfr1rBs9tRs9NhWlmt1dlw+SVG8EcnjAP4GrtqtvJbBw5eRjkLICChyRgexqjB+8jQtIJWZcsP+eYz06dT6ioZlkigM8UvlRISNr87DkEj1Geo/+vUoTbWpdRDFMAi7VzgM/f1H8qsWNxuPliNpj5hjJcYUen41UkdJJ1jO4OF+dScAdMEdyM5yMelXbESW7zzq8bNIwEaOn3iF6g+o9KS0GpdSd0BRAqEEsOT2POTn9K0dJmMl0zSSpuDBkPqdwGPYkZOT6YrKiWaeYyfK2cA/Ngk/7IPHWtfQbKb+0TDDGUe3cPIBHuIAbknPA64yfXFOmnzJnRKyg7nQWTXOnTzm2gadly5V8gD2z6V6JpEYe2iYvauyHImRCA3HUbuQPb2plgqu6xyJEWVRtKJgAdDjuemPWtR45Yo/kkKMRsDRjqD7evtXelY+XxmJ9r0syBHw6zMZCCpMY3YKg9z6k9f0qW2hjdQ6x4Qk9TkjGPy7VM8CSbGWOOEKuCi/dU9D9M1W05QFLLISVYkt0GferPPU2ldGmsYMflhQqgYKnng9/wBagkcmzfkqyqQQRuwcY/8Ar1IHKvhRllAy3OD+NRagDhwibvMII9N3GRSepknqDx+VbIrnGxV6dyPT2okAOxXAKswXy275/kcU2W4iuFkYEloyEyUOQ2cGpbhiSXZCCCVRO5bp+fOKL3Kv3ESNd2XB3DJA6nd0JP61P8xAIOwd/X61VtYGhaV5JGlEp+QN/DU7yKiZlKoByXPQH0/+tS3E99BXcxqVAPfPPX8PxqS2kKjnagAycc4FUE3vHI06u+9DsUZHU5GSOD9KtQlQC0m1MY+Xd0PXn/PajcTsWw27LN9QB2FRNkvtIKsc89fzpkUrO2ApKk5Zuxz2FPPzKSMhwAQfbvTRL0E4EgXbwMsG9/8AGiQegLKxy+VNPXlw5PB5VgKWTeXHPGM8DmkZpts7C8YfZ3wGLn5RkdD9aqRDIAXLsMgEDgVJqUwXYJCoQckg8n/PNUJpZZW27zBFj7o+8fau2K0PKlKw4ytK+23w+MgnoPepYIxGWcgBj6nOaRYY1iUfu2DEnYg5H1qTBUc/MPZcU2QKXMg5AA65FBUbSCfk755/GiPLDOTj0HNSKoByR+RpAiCKHzHCjqeM+gr46/aH8fv418RDRNDkLeHtNkKRbD8t1P0aX0IHKr7ZPevXP2mvHw0PSR4T0acjV9RQG8dDzb25/hz2Z+n0z6ivFPAfhIzRNPLBubZuCFc4x0/PH51jVq8ukdzvwuG5/elsZfhGyFnuFys8RT7zKpJ7K5BUHIHykZwOp9RXpZ81YhGXlZIv+WpOHPXjHYd8j1rQ8U6FDp2n27Wrxny5wY5toOUZckSL7r+ZwfWsdJpILWMMWZN8fXnzI2UFSD3yOR37VyPrc+sy6S5VBdC/NdPPPZrCUAVmUxowJ6ZPzHjOKsadN9rtG88EKqYZdoORu69elZ0MMbzfaYmAfLKFAzn2z2+tWrbENy8EBAzHhnZMY92P1zj3px8z06jSjoXbhZIbUSmNlWRlVI88KBjdkd+OlR2ykytI+wFTuQBcMBnvnvz6VauzLtiGCFRQq7o8kkkdTnmkWZ3u4FucB2UBmjXgdsYyQKtHKoykiW5cW0IhGA+CQ3Xtk5/xrlLeN77UQSkkMAYmIbOGJHOTXQa2ZxEzQy8kiKYP97BOOM+gx0q/aWsNvavDC8itCgjZ5uWwAfmPvg09yGlTjd9TPy1rMrMuwMMYkP3lxnA9/T14q1iKZR5mCAu5Ny4VW9PQ5FNucJKFtRIQ4CISAflC4x+eeelV4k+1SKWQIUxudWPPr16H+dNLUykrxuRSWm62uIstI0RV4vnCiJeSwwe3I+lc7tlF1Os9oiqzKm0LjLZ+/wCinjHvXU3UCxlhbFHXnAA5KnsR3pk+w4nW3jkVl8ogcfL275P+IqZIKM3HYwIrWO5mtreVlMDKA8pU8IW5PvyOATjNVLxlFzIhV440ZjG2CCq574/h6e47da6aS22hkPDGMEHqPyHb2qBrbzZZfmYp97IyMAgcD1/Gs3C+h3Uq63Zg3QdCI0lEJ2iQukpCSZ6HqMjPXIyKogNbSyT+ZCtwrFQMGTYe7hRxxnjJ61uz6QZo1RI0Rid/yrtJ9yfQelQahai3x9lh8pGiMaCTmM+rfie9RKD3N/axloc9D5RjieOaRpondfnQgcnIYHJ565NQz5kjSQzPJtDEBGHfr1IIz1OPY8mrqW0Ss2YlljZWQh0KtgDOQexz6duKoXUKuWC2Vx50MhG0zfMQCTjbj36fl3rK2hz1ppbmejOLRAj/ACyR/MDtGADg8Z5yOvrxVC4nAmkvIlmGR8u1trOuNqhhzwSOc5z0rV1qN38tBELdAflhPGzAO7cBwBk557VzlzdQpM1vbqZGEgcS5J3BRwNo9f0zVxWuh5FaaS1NPTohdTNcwq3yAxzCMDazsCTt4zjtjnHbIPHQ3uoGWGF453VIVTYEjJK4OQckZAz+XNS+GoEa1Vj5QTyxNIVb5Q+cMoGAFGRkH3p2pRKmnx2kKKJTIwBjO0SBj3zzxjj1zzTmelgoONO73ZkQ3cjwndLMWUnpwpGfYdvfP1qW1mlZywdwy5ZXChiCR75pibI1TeSUPBZRhgD6g9eabOkgZTuiMm5VCBe/riudts7+XlVieNt37xGdzHyVDbW2Zz8oA65OfY1ZngM1kXMpbact5hDAgd+cc/4moLe3nw3yHarM5JcdB1/E9sdanFs9osnmRtEsZ2vBMRncASV9R649aQ7K1iKwRUkDSxmVw/lspH+sTnbtbJ24Hb2rRiZLsRxqxWPJOR8u0DoRnjOawBdyQqTCx6LnuVbHGPYCuj0A2Nz4euzdsElt7guyjcZtrJtXbgEAFupJGAM00rmPtI07aPU0fD0s9sPNWOF0MbMm6MTSq5IB2ZIK5+bJH59K6nTtDSWWC4tzGiwuVlkjlcbwHJPynvjoRxwD71S0Rvt1xZxvb7PKQEfMFUFlywVfvBR0CnsM9629Mt7q01NYbj54n3NiJcgxgYBwPc10wSsrnPUqys3szrbc3Iw6ncBnbuADHt06H6+tTtcDzbeKSInkq3mMCzHgZAOOfcZqOPaJBLJcjjIbAznI4Bx1PpU0dut1FKL1CytwFbkpxkY9GFbng1GmakDB1Vg/y8lecYx0+ufWoZIVt5GkiYeW+NyFeM4xu/LAplurWpkRzvg3b1cckDurZ9+c+/PSpQrlCUJijIwfMAbHGD+Q9aDle5MGdfNUxltrYYL17YGM/wBapXdyHuFt0ZI52ILHgtGo53f7Pt70hs5nhtQtwYwFCygKAZBgfeJ71cVVafd82AuF/iJx6k9fWkNJLUjVo8oCNixkAOo2hsdB+fXt6U+ABwrnftAGCepwecClxujCOWxj5iO+e31pDbqXMghjYMd23dtwR0PoegphoNZhGPMlGTLkBc5Jz90Z9P5VDtywF2Y/Pb5m+UlR6bM8VMyPIIwoVhGQfmGBkf5P6VM42t82Svdh0Oe2KLD0QqsHf7xYgZwFzzTQoeQM8fygZVW6D3+tSIrCL7pIxyFPf0/KlXkuQFAXueKZm2IBx5fJcgnYuPX9KfGUBU4BOO/GPYUkYKpvJILce59zT1B4XIJ6YHPHvQRuNthsRGPyg8g+nNG8/aY3IZl5UZ9Tznntx1/Cpc5iVcliTt+h6VGxWEhJSpGQAc8nPGKVwjqzZ8lrh/MnLSS59Aqr7Cpi+04j2KvXGMn86Am5guNo/i3Pnn3pyhAVxtLDoFHT3rvPEFT7u5zz1JAxS8k7myM0F+c8sx5zngU6NPlLbQxx37UhjkAJzyR9cVi+O/FVh4I8K3euajhxENsEOfmnlP3UH9fQAmuggjMh+6MeuelfHvx78Zf8Jx8QFsdNYnSNKLWsBDfLLLn55f0wPp71lUnyK5vRpe0lY5HS4tQ8YeKbrU9TZri6u5jPM5GQWJ6D2A4Ar6U8G6CmnaSBEFVmjbk4OPT6gVw/wv8ACeyCNyhQgblYdc+tevGCNStux2iQfxcc+ma5op/E92eyrJKKOflignSS3dWkV0YAFMq6r/NlYkfTFeRXm3TtTOjyAJCrvHalx96JmLrGfTaWO09RyD2r2PxGzfYPMj2xXKNtO0YX0O70GO/vXmHjOG18RkG0k8sPlAECuBdBhhcg/N93gjghutRLyPQoNw/eIhf90ETBDHK7m4cZ9cevTNN02RZRNPDhl8wJsZTjgAgD+8BzzWbo980liLmW2jkSOTaWHySW8g+UxuO3TvWzZy+fvMMrKSxkBLqB6gkjjPJoR71KalG6LUrzxQulypYKhbrlgcZB46dam0svJAxmiiUPGrLg42jGTz7VFdzl0jwH37Q+R64+8COeOuTUmnrJItvG74/d/dVDz3JI7g1S3sXpyEd3ZmZHa2XzEjO8vwdvbcD/AEqfRQ1zcsZpCqs+1wX+QkcZ/L+dVr6No3XyMZlGxgvB+XuR6jOKqW0psnkijJlg8xjuUYZccEDNNStozKpSc1obDGBV2uhEZzgxnrg5B9QOelQ6cym8aOEtv3feY53A9P1z+VSo9vNDthiZslSFICEnv39uhrOsditcSh8gy7YwkZ6kZOT0/ChuxhyXTRqzxieRpYpkQuWWMAcgDoQf6fWs5JzJHOJI/LZJkLjGAGwclfY8Zq1LOsX7l0Uv2Ut8qYPqOhxT73yoLiKQNlXU89ACB8pI/P64NUtdDmmuXUiLRGGHDrHHkFdzYB/2ffOapsZHs4Vw22Vj5a5+5gZ/If4VPAglSMSxnywrHYV6EgYbH1Gar2dv+884szKqrsVSBggYIyeM/wCIqdUzONVRepYFz0YIFkYhUA5AB4J9D3rPurV5HmkmDNJ91Vc/dHTgdq0y0EEkkgVjDgBFLDP4HtzVd5zDDDgp5jk8Bgx+p9P8aHruUq3LrExpIA8/lu37qIgu7tjCnP4DHT8aztUtbfy0RA6zjDszcCRv72T37H6VvXOpLB5ckbAy43sMDryMAHgZODk8Vx2u64IbLUA7+dPsZEaJsrBIE/hPQnLIrL7+tRKKeiMKuLXxS6GFrWqwS+Ra2JVnmGwOF/h3Z8wg8Hceg7Ac9az7G2mkuXkkCrKyBkS3UtgZGckdBnk+5FUIre7u1a4u5XkVX8v94332PLBfx444GM13Ph7TGRo4RC6Y6rnOAccMB1wR1796iVoqyIwlKWIqc09EWbS2kQxwvGQoYlg5xwfmGfU8/hxT9e2Q28SxPJIqr87kEHHoffNbhtra1aJ5EDbH/eF+FbcMk55J5AFYN9JJcqrszu7Aj5zn+Ln65NYztFWPomnokUraVpLiIRKWbOCxGSKbLAzl5JJFIX5lH6YFSkmO1lKMxR8iRFYjlTx9ecHnv9KJ3kliCSgkKPlYjrkdvXmsXojVK7uJG72txHcxgSSI4bBXKng9c9uahuJp7q4drn5pHO5sEZZicn+efxq/HaPPZGZiI5SdoD8DaeDn0OegxUM9o8dvbxxQD7SdzO+/O/HQY7cA8UtbWK929+pmP5W9mVCxLYcAH5T0z79OPxrqvCl1N/Zl5pxu7dLa4uBP5bKWkeXBxgoOuB0bjk96y7O0WeSa31G4kSDyzPAYhlVGcMjAcge46H616BpFhGZ4po41hg8ryA8Ax5kecjzMD5m56iuijF3vc8+rKNndbDrG2ls7xZ8eSHXzHFzHll3AZ+buo4IHau0haKKNWkmHzuPnyMKcdCewxmmRWqJHt2qsLrtjByM8ds/Q1csREgWNoAXXkMi5JBGeldSieTXrOY/TGjSRnjaR0xzI/fPoD2471ctXU3qBFZoyhkkl38B8gAYHfv7VnW0CW1pvhLqgY5UHdu5PB9O+BW1psMUURCKFC9AR/k0I5aiWrJpWbckbEdRnjgjPNAiRAcLgqRyOeee340GRwxBXI43sc+nA/KpImXBkU5GdxPP+f/1UzmlohyEiMs5VcZJAH+eelNJbcmGIySw2nGfrSKyM78Kx6fTH/wCupJlAkiDLu3ZQjHqKCURWzCTfnoCwbB6nORz9KmfgFnbhB0zgD6/lUEUgeFpFykZBPTAIqeJMN0Yx4/j7D/PFK5bQ0KeTuOTzjP5cUNtkm8tlAVQJCCevpREpW3g8s5MYA3HuOnP6VHJJFHOqnGZDgZ7EepNK4rXLEkmxWzuXAySTnFNXeGEjH5iMD29vr605kd03cZxwMcGkVllVwFBY4DjOdo7cVRmx6KGcFz0GRzjinIG5diMAYAHr7mmsMglnyD36mnsrAcbQcYC44zQSlYiLeXIyyYKk5z/dPvTV/eXQPVUQjkd+P8/jU6vtjHIx0Ykg59ar2mxZXij2gcsABwOe1BaXU6EpsblFBx9al3HawDDB6kCkdlzhE2nOSSakjG7lgfyruPCGopyMg+/PapRjOFBxmlJCDJJBNRXV7aaTpl3qeov5VpaRNNJIf4QBk0mxpHmn7RPjxvCHhEaTpspTXdXVo0KnDQQ9Gk+vYe59q+efAPhmS4mil2/MzLgEc4zyah17V7v4iePLvWb1WAncCCJj/qoQcKv9T7k17h8PvDT2lmCyq47ktgj0rhnL2kvJHsYen7KF3uzsfDumx2FqBHmMnhARwK0bpUwTIMZxnvn2x37/AJ1WS7MCAXIC/wAO5yevvxU8eZFVywaRXJYZxjj0q79jVXTuylqUYktCDHlid7KnQ+oPTPHBrzLUtKSGK9aW382ylJUGFihiJO6MZ7lON31GM16ldxi5j2GRwpbDAsdo+vvnnisi9KrA/nIzwyDDA9VAyOh5PAFRONztoVnGPL3Pn6+t5dG1+CcnMN8+x5cEMJjnIfrkNj8xXSae8a2yAEAkMuEXGOc4/A9j61seMNGUyxQX0rXdndW5UNGAstvhuG6ndg4IPBB4wRXnWn393Zzta3z7bpGw+/KiQ9BJn0Yd/wDCstIHfhMRaXI9nsehR3kccWxlZmKDaSwAj6t/j+VSxyKlurxoxUIAVHAj4ycd8EnPHrWHFcwuq7iwcLkEHGSOcY9citC3uVjDY3OWGWAGcZPUD/PWtL3PXtpdFx0WKCKaW5L4BLEhd5X1z3545qjGjwok7BpGckuTyDx0znntmq948lxGUURyeYMfIQdwxxgdQfqKkkuXubEQxxr5Magb5F+ZT79+opcy6FRT6iQzOM7W27vl44wcjOD+Q/GmQXkkUEdsSTCspdm5wW7OB6nnnriq8kGyT5t3LbmYEfzH/wCurG95ZcsqoxyMIMqTjrjuBUpsKnL2LtywuBHG7HcF3hiMZHYkjpUkcolt0jOSTyxBJGBx09u1UIJQzH5QExtUMQAoHcVbEju7orKzN8m8DHbgn9MitotPU8vEJ3sieW4Kb3YSKVU5C9DjI79umaSYKtrCAnLtyVYdh/U4OfrUd3IVso3ZwJ5VchUGWUDjH45qtNNm3jWQKXHz9cKvAB/EDk0N6nnvQo3LyPcSj5SkX3mPG3HQY55+lYmq68tpECBhnbA43s/HRU6k9OavXM7RJNM8xESK8pnxkjIx1HOewPbOa8+l1Ga9kedYJ4bTe6JbqRu2kDqTg46nJOO/rWbb6GFabTsai6pcXd1cXV5OVeJWKpE2ZPN2EFic4UqHX6McDGDWBAv2l3W5C+WFSa2eCMZCr/yx27gEGCGOeehOSc1ctYJjut9OjcXMYZf3eMqvmIVHAwD8rEkZOAOea1NH08TSIszyIgZWAcbtz5OSSB9/8PqazdTlM6dJ1ZK5HaWBme0FyY4UP7yMHlAzHovfaoAH1JPeu609DZsJo7ZhGVEgLPhhnsOnBPPSmaJpduzGO3HnSk/vJowB5ZP3SQeQDjgds1tXdpctLPczPHI1uELfLhxhc8dx6/yrNX3PoKE4UVyopRWN1cXO9bZVijjTeskqhkZslCMcjJ7e3NZXiiymtYrVWEkeFLMcY2tnHpkGvY7XR7W3kL26IjOFLyIgHmem9up+hP0rmPH2mh7FVCt5yS7gM5QLjlfqD+YPrVzp+6xQzBTqKNtDzTRdJj1OZojcwRASZHnSiNMYzwx747GujbS7YWqTgg3AA8uRE5C9AMZxkHHWudS0kiQxRKJfOcIqyD5d2erD+705rsVt50aF0t1jSRhkHLlRgA8nnGc9uKyppPdG+Im1LRmPpdvcQ3D7whUkSRSqSNp/ulckn7vJ9/pXRw6PGyQearSs6ld4GdxGSDyMHPr3zjpTJtHYzwlGZpIQWwzcqQ2RsHoK2UlJ+yRNsc/cYr2/Hpg5/nW0I2VmclbEuVnFmJe6NBbPCwWWEo2UmgJV4zjGeOeQe2a37DSZFsIY7SR4h1MrQISeOnYA++BVG4tbqXVkgkVTaoDjBGS2eo5+nWungO2NVGC4TkEEAf41pFGFao+Va3ZDp2lm0WTBUlzuY424PqB/P1/GtYRMfmVgNoyoQYB55Hp6/wCRRGBHbkbjtTop5PqAPf8Axq5Bb4GZNsZzyudwHHr3/wDr1astDz51NdSrAM3CKYArBRwRk/j2/Gr24BPkwxCll3dzSi12sZFkHPXLH/H9KXbuXd5i47KB8o+me3tRczck9hqxtl5t68jc8m3JOOvUk0Kdyhy5JGT8y9B6fl7VZibaM8jccDPI/D+VMJ2kEhvm4CrznigybuSswVTsYogyeR1x61XuUFxH5JfaOGYjr644/X2qUDYP3vCk5yBnio49ycoytxj5hnHNJgtB6szJDuRFO4jA6A4PAqSdztcquSEJyexwadKimLazYBYNuHYjvx0pGdiuBhm+6WY4GM9aBXJuBCMqN33Ao747D3qMjcN7IeuQVHIqOOMoP3iiRhuLN9aejhlLTjyyeVBP3R2/GgVyZW+b5ssCeMDmooolV1k4LNyT1De//wBamy7ycL82fvHoKkVAijarFhznHBpkrceNqHeVGX4DdST/AEqQgYV+NucH09uPWmPHG7iQp84GAN3A59KkdWIKuy88qc4FK4yGZA6SLg/MNpC8ZHtiqttaLay4VnYgHBJ5Hr+NXw2zluAB0HahgCSTyufXkfQ07lc7SsbMKYHy4PuamwM9T+fWhgo+8x6duhpB12oOD0IruPBHopml5LEduK+eP2pPHDS3cPgnR5sxR7Z9SdTncx5SI/8AoR/CvZPid4wtvAPgm61eQiS7I8q0hP8Ay0mboPoOp9hXx34YtbrXtdlv9QkeW4uJTNNKwJ3OxySa5q1Sy5VuztwtLmfMzuPhd4fDMktwhOPmYbc/hX0JZWqW0KptACqCD2x71zfgrSFtrBEkTGIzn/8AXXXkjYGJbk9M8H61lGPKrI7m+ZleZiGjC/eZgrHttpkixxPsYBVxw23OD6VZKIWOQAduCT/hUbnzEwQeTxu6HFBaZRuLtbUssx8ohv3eOFJPYH8c1j3czT35tYifJyJPMYZC5H3Vb35PcYzWtqaymzdYgm4ENlxxgHkY9cVTPkyRIFXAQ43A42em39eKo2hZK5j+JLNLyJrd4kDsu+I4+9jjHHPtXkfjHRprq8LrbpC4IyXXPlYA2tkfdBOenqcg17RqiTCFgSZGQZExOGBHI4HX0NcjeCQtOXikSS4DSEhflQKoOM9xjNZyQ73R5Lp+t/aVaCeO4j2MEeNgC0T9wG44zkjNb1nepNZQqxkFyh2E9M8nnnkVT8beHpL66F9pimC9kUEH7qSrw22T8+v0rntH1VrtZLGaJ4tQtmIeA8ylO+3+8VIzjrgnGazcX0PTw2P5bQqPX8ztbk7IVWAxSN5mSjgqAfXJ7jrxUKlbiRVmhQovyJvwpHOS24dyemaqLqRER/ex3lnMQyTdfmHU+ob2NW7bUIWuPnhikzyBjYxXuAR7dqFZvU9WNfTQlluI5Zo9qFNp24zkBQM8j19/arE1ykKKnlsQnGS2C4xzjsKzjcR4MezYpJVFZMBM8Akjk84oW6iSzdnJDlh+7OGwoPLDPbI/U0r6mnMma9kQLnT2vGZbTI4bqUz97HcZqYzp80kBZMzbNrYyAO5A7dKwGk+0zMG/dhUAKH5gg6jBPfNTAsbl3jCpEJiilecu38I9cYJrRM4MRbqzY1GaOC4gYvtb5sbDlgc8e3Y/l71mXd7ujAuN/wAoEW0e/LE+vrmoLmaP7XJMWWONN2QGBC/XnrxXOa74jtLC6+yyMn2r5QnmrlLcH+KRRnJwT8o9Rn0p6t6HmVqsKUbyGeLtV2aiLVWRbpY1/cO+QOPkBA4IOdxHfjNVrMX0sEcLwWs8QxuaeNQvIwHDLhjgdjke1ZNlAsyxwLI1yJmMizR2+3fk8+YW+Y/pXepZraxR+WI4iNpBQZZD6r6HFZzk1ojhpxdX3mY0UYnnXyY1idQZTJFuwz552qec4HXPfFddpPnQvK32mFrgqT5J+VFQAAEHrnnoapaez7ZUjTZNLlRK/PUjAx/Dzx+frSPalVjgYTIxk8sITuJG7n6nj8RXNe2p3QVjo7KzLiOTJmnLq08YG3C/dwa6W3sUGuwRQFpY3kxPt5BCDIAPcZx+VcrqEdzDFEcMbd3Ej7JME5HQHqB34zXc+DtOmls47i9DxzKMRAZDJnqfxH6VtBXdjeaap87Zt6f8tiojwVzsUleoDEA1i+JoZQIo0Ebjcwfn5mwf4QeCcHp7Vsfbbb7QLAyItww+VAeSO3FVtcQyDb+7Hz5O4dD0Xr0rpaurHE7wkmzgbHw4Pt8k4K7kKlZBk7MHgMvc89fatnxBpsLi2ilVhLCwmjkDZJI6g4Pvz+FacqN9p3RF1cptLNn5++D6GoXkaWaIyQATKvlFcfcyeo9c1kopKyN5Yic2nfYrwK7DKyFtnC4zvXjPX+LrTrORI33SjZbo3Egxg4POfUdR+FSW0D6cv2SViYpXYAO3IU9VyOn+NS2UIUeQiriN3VYy3VTkjB7/AI1Zlz7k5jiubh47RljuIG37G569PpkVrW4Zom+40fByFIZfYjv9KqWSoJHJTbKFADvj5lH3QfzxU00QWVC0jNMrE4DE5OOc44Ao2M5Svoi3buwv4lCnYsbEZ9c4Ax2wM1oKwI475HK5wfWqHmh2QMjQyBhgtjIPJyfqPwNWYydqoxjDMMAsefrimZPXUkifgPIMlwwBJ4+o9zU0YU4Ixkf3qqWkJEjKeRCAi57dyatlwNuOXZvuj07n6UEy8gG4tjdg8kr1GfWnjzTj7hUcYxg/nRswAd4H97ucfSnDe235SFzwuOTx1NBNxLgKYWLKPmHQ9AD60yCLcof+IDAyP5U93JCRgkM5OeM4UdT9abCGRirS7cHAbOSfcj+tAXdibb8uBwxHI68UwQsMZbp+OevBpYVIVUAULzxk8H1pdrHgMwHTNAhjlnt2VQq8Z56e31p0aBXOCHZ8bywyW9yachLEqQFKHBbt9B71JGuF4OSOAM9KB7EQ2qRnG7k9fvfhSoQDh24z16frUh4PygkE9QOBSbF27V5XuOpI96CCRss3Hbv1/MVH8jOw3ZVRg8Y5oEhGcqdoHYYpkYCou7JbHYEZ5zQUidVVmJyAR2ND4VtrMvI9eO1Iclty5HB9+aaiELgkMBzjGaPQRv5yeB2zU0O2GN55nEcSjczscBRUcSGV128DuBXh/wC1J47/ALN0yPwhpdyVu7tN96yHmOL+79W/lXbJ8quzxacHN2R5d8ZfHDfEbxukenM50fT90VqOgkb+KUj36D2FdX8M/DAOJQHQ7gAR0P51wPw80A3NyruuCRwB1Ar6Q8IacLW3VZVG5gM/7WBXFH33zs9aK5I8qNy1svLt1WSQOBg4UBcn3qyZAibQGckhAMdf8PrUmcthVJOO3bPt9Ka7BlDLySBkmqLj5kLM4nwzZDj5QeD+dNYqGdScZB3Ajpj0qS4jaWIoACezDoD6ioFbMTA4BxnH4UFkbrxsfop4b6elZTQrHM4UbA4/g5wT3I+vX0rTlba4U4J3ZB9eKzb+ZY3bc+0Om35gRgjnn3PagpNkEjiZEZl2ttKS4GcY46d65jU7U3Vp9nkn2xuy/IUXjPH3hzxz9c4rUe7WNfst9IbdpjmJm6SA8lfQMMdD65qpNMLnVYEhA+X5pcEHZ8uFUD8CefQUnqW7o5u6jkvIlUq3nKZIzGMkIwwM/RhyPX6iuK8ReF4dVklvrHFtqtu++OeMkfMp6H8RXoOqxQvHE0qsYgSyOCQccDqvIwfX1rLuIJoJVk/1bTgQlVIHygcNjoGyD+BqNUU0pqzPGbzU7mwk+13UTrJJKYnzH/rT1Yn+FuTjIOcYzV61121dlQvG25QcF8B8nnKt0Ndx4g0e3ubV1Cp9mhRlwy4ALMDlTyc5rgPEHgia02SWieeoVTJExw3TjnvmpsnubwnVpq8Xf1NhdSUuuyRV42rvbJyeO3Xj8iPSra3A8xs7wMbftKQ7lxnnIJBIz0wR7jvXnSyalpVy0cUlxa3OCHXG1ucj8DjNEes30E0Ikmmmjx03bT6Da2DjH0pqn5jlmMorVWPSP7Qs0jaO3F7csR8rALbRlx/ES+52xjhRtxxkmm211IsM/kLi4TH7xn3rEWHPJOC5PGeAOea45NXjcpLDa3/mJHlne+2gnoT8sanuOpqR7tryzjjGnwWwcqIba1kdIdyH5pHVstIxPGS3Xd24oasYSxsqj0J9d8SraOdO0kkTwZRrl058wHlkU/cx0BOSME8Z45KytZL85ieRpWf96Cudw67vc9SR1789rN6JL+6MIupJSoJb7zl3xzz3HYc9K7XwL4fsSgeXzw7uqskpCMDn7wX8+c1bmoRstzi5ZVql5O6RseEfD8tvl4rrzLjhmaQHZxxjJ5Bx07fSu8XTWh0tbyRAWa5AZeu44I/T6jNULmwuLZbVbRWeSPcm+MdR9fpXV2iSMCjsDDJEGfeu3HGMr6j9axWp6UYcqTWxiaRZeQXuILZLiKY4lMq/KzdeAeQcnGB6VNa6ebm/tFu5PlWZ3CkZ2k5ZgPU8DPb0rYFrFdxYRzACgkdlBBwOM+5NdDptpHJhWUCXgBGPOQDk+w7ge9JQvoKUrajNKsbaO4jZYV2yqFiEi+nPyntn0PpW3GY9p3n5uSp3YIHpnvVOcebPCQVMjDceSeB/FV6ELNIQrK6oASAehP8AKtomTlfVmYNPtp9RjvzGDdhdsbDqBzTpkMrZlOWdMMNnb1zWpGq53cAKeOO1Z2oxMEke3Ajn/gKnBU4wSM8e9XYJyct+hSkiVo4sHO1tzZOOfQHse9ZbW162rSgbUtXGQTgKSOMMPfrkVoRZhjj3ys427TvX5hnv9Kb9px5ixJGzIDnJI3fT1qWOEnEq3wiu08mVVaVUBcM2CmCNzA//AF6fGjLOqmR3kDZ3g4VlPQjtkA8jmmYa/ZmEreYYyI9pGARxj3FSRStIscTOHlU5R3A7HHzD86SJbsWGfABZuWICMqcrk4OQM1bVP3kKx8cHYBxzgfzHeqrqERzvVGUEZU8Z7fjxn3FU79op0iTcfN+WUgE8MTz+H0oeglqzZdocFJdgi6A7s7T2XI5HfFWo0nwiMEdsFiT3Pf8AGsmM2yRhhGnmrIEQkbpEfqF9wcd+2a0YgZn82VVS4QgDAyVHf65poTdiw8jwSeYnyFwAVzu3EdP502zcxvKnlMMHc43fxHr16VBfGUyrEGASRWUkfMenQDtmpFSK28oQYEDYiGSfl9Mn8xmgm+heXZJEWQqxPzAqQcjPrU6cgfK2CM+vf/8AXVYrG3yxEqrcsoG3gdRjsD3qYHap2KvHOB0HvTsSyVlG9SB8y/XGDSBwyMGXnBzg4yPrTUmcAFyu3k/d5H1/xFOxlsbiCew/+vQJDljAAIzknoTUf32KkgpjpkgkU+QttJYY3dSMHPv71GvzMH24dgC2OOMdf/1UFIkZQqLtwpXgYGP0qOKZZFZQ21v4iQRg/wCNSgszMu3cVIByevtSDYkhfPBfGSOnt70hp6ajgAMsGEbAY3YyPbjvSKWeH5vmbuVH505WOOhGDx82B+QqvBctLJNG8ZQRttyR97jqD6HP86aIs2MvLVby0dA7oWwquhwynsf61NZwSQRhJZfOZQFLE434HJA7euKJXK7QFLPnCqo6j3PapIhsUkoMueT6k/4Urai5naw9clxw3T1/zxTGkUuu9DkDg4471InYdAMgcYI/z601ioBJZVODnJ7+3tTAv+L/ABJZ+DPC17rOpPiKBCVQdXY9FHvnFfEc0994x8WXmq6hukubyUySDOdo/hQfQYFej/tKeNl8TeK49A0yQnTtLciUg8SXHQ/UL0+pNQ/Djw1h4nZQGJ3EkZBPfn29KqtJzlyI5cLT5VzM7TwJoQggiIXOV3EYyVFerQQoFVFIwU3DB71V0Kz8i3VgApXgfLj8a0EVY2YdFPHPansrHRe4p+YROu335/DFV7iZYPKcIxVmCHAzg+p9qsLuGSNp5yAOlIVLbgp+YZB+tIpWW5WmuI4z8nzFeir1xUZAS2wWGVHIyBknk1IDkA3ChOBuQ8gH3NQTxR7mJjADAY4zt5oLVitcHzyCiMCOQ5GDjvj1/rVO5kW4HlsxLOjKVPRyOqn04OamvZS4QKwJaTI7KVBJ6/Ss18TzN97zJv3mc43YGMnHqKTKt1My7mU21wkyeYsbjduwzcEDofboRUENrHY280agrLw7MARuwx5z2GOKlmkT7VLPDkxqd4yOGiI2/jio7kNFPtVlkITaise3GV9xgH9KXmNvSxBeYJAYFo5W2/Keo6n6fKf0rJuIJZ2WAY2+XhXJ6OOn/wBer7EeXEh3MoQPEw7IOvPXjIx9aoTy7JNqBWK7W+U5JXOQR6n+dJhF2MrMN7a3KyAQF2yzuDlH6Oqj696x9ajDXVwsm7EFqnlgH/WMWLEntkDgenFdDdiK7ARIm2wyGSSVhs7fKoB/GsvVbSR3EiEvLMNgV8Yzt549qyaOunNR3Ocl0mHUTuvY1mkZmdifl6HPB+uP1rhjpMt40sttEXtZ33rFyF752+hHb2616DcXSr4fUISkYQquFyS2dvB9cE/rVnSW3QR28MO4byCqpjJx7/hn3qU7bHPWSmcJa+F7gqJp0YQsuwHHqOOPUVcutP8AsiJIqB5tu2I7vljA7t6AYJ//AF13s0kTPsEGGUZCSEhsjgfSuG12R7lglomY3m8t5FfIKpk7Qe+TyfwFKS8yLKOxU8K6IjypMUKh2DR5JyFGAOPU8k16pa6RCNNWVUHmOu4Bucnrn29MVzehWTpHBC7qwZQQw6/7pPY8kZrs9NsZp7REkmlzGzIBtwQMYHPfINNLm1ZrFKK0I7dZJtkc086FXVFlJwq8ZGR3z2NdTp7bV8mSSN1AyytwHAPb0rEsrfyL+VZRLuZdi7OcjHGAehFbOmB4rhHfaXYAKjDgY67ffvVxQ2+xbSHZDE0kWSD+7YMRjJzyOvbrV1pUnnRIo/OJXOw8Nj03enP6U2NokifYHYk79uRnnsf8KugJtGYtroePMbk+oHtVcpLkN0xLkXNxJdeUS5ATjBjUdueuK2o9zZOQhxhsc5rPWbfEo2yY75IOMelTwSsoPmKCp4yD2/oatIiTb1JgWwNwU8EDNVLlVVlO5ccbiw454xVoSDIXd/hiqkjRuq71yn8QIxn/ACapDRkygxyOoPKjMY9+49wapmKOCGUOzshbLRAk4U9x7gmr8pmBmMoaRVBwqr82MdvWotvmyidNvkSIFfPBbnjntUtDRSkgYx+aWUneqn+FgSQAQfXsaS+sp0VgsxkknyokJ2kAgAj8Dg5702eKWLKQ5k8p9y55JA9D6gHINaEscl3aqhZjIRghgAz4A49jjHNKwpKxT024+bZdR+RcQMokUAkPjoy/4VJe3KWM8nzBlmXCrjO1xzx7Hj8aqWjuwYwme5dDsZTyfUcn2/PFMuJxOJYJ4pUcKTuj4ZCM+vcZ7VN9BW1Llokwvm+3BDE0ytG6vljlSMkf3ga3PlSSOM/PFId25T36jpyKyYLndBukw8qoA/mAhm6Z698e/WrYJt3imAZ0xtJkGCgPv6dDVImcuY1HiRomUsXjHJyckZ7/AFqOHpJbysrnhllHU+hpkVyQqCJS3oXyCaglnKyxz5KxnIUEZYj0/HFMzRdQbJY9wxICRkDoDj+uPzq5yiuRkNnqOwPbHesqaS5aKPCRARkYYsccnn6VctpXlf5mMu3+EHkE5/pQU9SVpCRnaVJH3Su7p6U5bqQkb0CsSDg9PqPrTC6ld0e0qedoOAaczo75GTtXdtXkgn/PWmK1ieRmlXC5UkEbvT3pWO1CAMEKMbj09jUETBR94MxUH2x6fWldzG24BR146ZHfHr2osNalhvuZySehJ5xTA+XVcMSCWO08GmqQshILHPQY7U52XerAsCOMqeKQD96FwFbOcHB4NNMuyMNhGCgnA6/n61EDl5XeJFcNgEEkkdifQ+1PGGBDNgHsB2Hf60yXYYXh5YSKDy2Vbrz+lLC5Ziu4sg5BIxnHp7UyZVYByybQeG9eP1pJAhjBbzMkcAEdB3NAKzLZnPyBlOSfug5FRtLgHEeC3Qt61VE43gFlUvyuefx4qa3jKxs7OCzMfmY5yPT2+lFhaI+SfBGkSahemZ0LkuTk9Sc5JJr6Q8GaQsFpG0a7V4JUgqfxB5FeWfDqNPJjOxcgLzj3Fe96TxBgccf0pU1ZXIv0LsZWOJSCMngc9DT+GwuTgAZBGfwohAyxxzijGZmzzhc8/SrKImwiBl4AAHT3ofaIN6cbm3HaO56k/lTgf9Ldf4dpOO1VZeHYDjPXH0pDWo9uc7iAFAJ7En61Vu4kMKs2ZNo3YHGef1qeM5OD0qK74spCOoC4P40WKWhSlggkI35KDJXnI/AelZTW5USKWO1wVZOhGDkEH1rVnJ8285PDx49sjmqc3MrE9dq/zqWUmcxPM1vuaZAqwIyyISADG33nA7pnGR2qkt4s6h7ZopSsp8sBsAxYxyeoHv8AT3rfu0WR5VkUMpABDDIwSc1zjKI5tVEYCBLqHaFGNuYjnHpmp2din3FlulVGWFdskYeQqPvIoOMY9DuUf/qrPnuPKll8xlEVvP8AZyA2QSw3DA7c8fhiotbZo1SSMlJDJOpZTg4EcmBn2wPyrTMUZ0+IlFyjEKcfd+UHj8TU3GtCkw87dNMobYSAWBIds8sf5DOKxtZZ5JXaJS6xSbN+ACCQMnOMYHPqa2JyVnsmUkM0LhiOpAHGawvvDa3IAJAPbrSZVzCu4RdahZWHzxw7vMkREOI+wAJPJ6nmun05lhiMiW8jBFMSjGE3E5IJPU8dK5jQCf7bvjk52Hn8RXV37uDcgMwAiDAZ6E4yfrSgtLkSkzlPF2r/AGS3lt7REWaQZZ3YgKxOBjPfrx0FYeiRJJNChLyLj595+9k8/TPqKxPiVLINSgQO4XbuwDxnjn61v+HfntYWb5iY8knnJpSjomZRnebXY7rRgHmYyh1AO0qF6DPH9a6nTViuJJJo7jy5kwCu4qeOmBjB/Q9K5DRmJuICSTkHPvxWpZSP9rc72yGABzWiN73R099PE8VrGz4uMkqB1A9TjrVjTLgouCjKWHJGCWP8/wAhWWoA1ViAMm2Of++6041VY5GUAN1yBznNNdxvsX7gkRRmELuDZO9tufb1/D6UsFw0nywKXlBxK3mdPpn8ao2nBLfxbM5755rWCIVRSq7RIABjpwKESnrYlDzJI3mP8nG1mIAPbGOtNtb6NpxEVy4BxwTx9anWNCkGUX8qW6jTbO2xdw6HHPQVVyk7llX3R45yp2nnkHFMmdSWC57EgE9e3HYVXdiJlAJwW59/lqOPm13HqTgn2yaoRE52MjfMrDOSDjJIxxVQSiJiq7vKk4yeFB7fj7VozAfKMDGDWZ1huc84Uke3FJ7XBEhV0UzEbpA3Ix1Oev49qsfN5Y8phjA2nPUdCp759PSodPObK5z2C4/76qxCAVcHpvAx7Ec0gbuVCiW13cPHj5zvKbThw3XjpwRSyuJCqIwWSMcbzgj1GOvI44z70+5+aKLdzyw5/wB2qGmAT6ZGswEirtID84OSO/tU7EbluwmS8RooWUTqzRsi/MxH16dO1WoIXjHlsA6AZAYkBR6Af/WplvDFG8aRxoqF3+VVAHap4wJLTShIAwbO7dznB4z9Ka2E9GSW8zQxqrphOFHzbgSOh55HvUsEuJnV4syYyFLbcj0Gev4VXKqlrI6gK42ncBg5yKiRmIkyxOJOMnpVeRBfPmRDML7V/iR+SoP1ot5S8jfMiTAKDIoAzjPUfj+tSSKFulUABdpOBUF0B/o5wMtEc+/zChlx1LTzMoLZXhS29Bk++R+XFLFcrJ+8UDk8DgHNRIdyw7ueh5/Gp/8Anr/v/wBBQJokikdGVV3EFyATg4/IVIh+UHbvbqpVge/b2pBwtz7Sf+yipQASwI4607E3IJJvJJXa7LxztwV756+9MkvIXkCEybh/FsZVI+p75q0igtACARux+lUoAHjIcBgQc5570WGtS3ubI+ZcnB5bk9uSKcEfcw3YIPpx6dais0QxEFVILMCCOtNuFVYF2gDgdBQybEhKxlUG48nPzDB/WkXEjBgHJPTIABpkYHlRnHJUE1JCB8/A5TJ96YIb5QTg7d+TjAxj9etIoaUj93vUHcDyN3v/AIVJcDKNnnBUD6YFMjACkY4A/wAKW4Pa5//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque with satellite pustules is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows severe axillary intertrigo. Erythema, skin breakdown, and satellite lesions are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30585=[""].join("\n");
var outline_f29_55_30585=null;
var title_f29_55_30586="Adjuvant chemotherapy for resected stage II colon cancer";
var content_f29_55_30586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant chemotherapy for resected stage II colon cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30586/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30586/contributors\">",
"     Hanna K Sanoff, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30586/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?29/55/30586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?29/55/30586/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?29/55/30586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H589528227\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 102,480 new cases of colon cancer are diagnosed annually in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical resection is the only curative treatment for locoregional disease. Outcome is most closely related to the extent of disease at presentation (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). Five-year survival rates according to tumor stage at diagnosis (using the older 2002 AJCC staging criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/2\">",
"     2",
"    </a>",
"    ]) for 119,363 patients with colon cancer reported to the SEER (Surveillance, Epidemiology and End Results) database between 1991 and 2000 were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I (T1-2 N0) &mdash; 93 percent",
"     </li>",
"     <li>",
"      Stage IIA (T3N0) &mdash; 85 percent",
"     </li>",
"     <li>",
"      Stage IIB (T4N0) &mdash; 72 percent",
"     </li>",
"     <li>",
"      Stage IIIA (T1-2 N1) &mdash; 83 percent",
"     </li>",
"     <li>",
"      Stage IIIB (T3-4 N1) &mdash; 64 percent",
"     </li>",
"     <li>",
"      Stage IIIC (N2 disease) &mdash; 44 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year survival rates using the newer 2010 AJCC staging criteria for colon cancer, derived from a smaller subset of colon cancers reported to the SEER database between 1975 and 2000, are depicted in the table (",
"    <a class=\"graphic graphic_figure graphicRef81414 \" href=\"mobipreview.htm?40/54/41824\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/4\">",
"     4",
"    </a>",
"    ]. The differences between the 2002 and 2010 TNM staging criteria are outlined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'TNM staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have undergone potentially curative resection, disease recurrence is thought to arise from clinically occult micrometastases that are present at the time of surgery. The goal of postoperative (adjuvant) therapy is to eradicate these micrometastases, thereby increasing the cure rate.",
"   </p>",
"   <p>",
"    The benefits of adjuvant chemotherapy have been most clearly demonstrated in stage III (node-positive) disease (an approximately 30 percent relative reduction in the risk of disease recurrence and a 22 to 32 percent relative reduction in mortality), and it has become a standard approach in this setting. The benefits of adjuvant chemotherapy in stage II (node-negative) disease are less certain, and the use of chemotherapy in this group is variable.",
"   </p>",
"   <p>",
"    This topic review will cover adjuvant therapy for patients with resected stage II colon cancer. Trials demonstrating the benefit of adjuvant therapy for patients with stage III (node-positive) colon cancer, optimal timing of adjuvant therapy, use of adjuvant regional liver-directed therapy and adjuvant radiation therapy, colon cancer in elderly patients, surgical management and prognosis of colon cancer, chemotherapy after resection of colorectal cancer liver metastases, and recommendations for posttreatment follow-up are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=see_link\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530323\">",
"    <span class=\"h1\">",
"     BENEFIT OF FLUOROPYRIMIDINE-BASED CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of fluoropyrimidine-based adjuvant systemic therapy have been clearly shown for patients with stage III disease. In contrast, the value of such therapy in resected stage II colon cancer (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) remains unproven, despite multiple trials exploring this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530330\">",
"    <span class=\"h2\">",
"     Trials in combined populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, multiple trials of fluoropyrimidine-based chemotherapy enrolling a mix of patients with stage II and III disease have shown an overall survival and disease-free survival (DFS) benefit in the combined population compared to surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/5-11\">",
"     5-11",
"    </a>",
"    ]. However, in almost all cases, benefits were clinically and statistically significant only for stage III disease.",
"   </p>",
"   <p>",
"    The possibility that there might be some small benefit for adjuvant therapy in stage II disease was suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In subgroup analysis, almost all of the trials conducted in combined populations have shown a trend toward improved overall survival",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significantly better DFS favoring adjuvant chemotherapy in stage II disease.",
"     </li>",
"     <li>",
"      In at least one trial conducted in a combined population, there was a statistically significant overall survival benefit from adjuvant chemotherapy in stage II disease. In this Dutch trial, 1029 patients with resected stage II (n = 468) or III (n = 561) colon or rectal cancer were assigned to one year of",
"      <span class=\"nowrap\">",
"       5-FU/levamisole",
"      </span>",
"      or observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/12\">",
"       12",
"      </a>",
"      ]. Chemotherapy was associated with a significantly better four-year overall survival in both stage III (56 versus 44 percent) and stage II disease (78 versus 70 percent). Interpretation of this study is hampered by the inclusion of patients with rectal cancer (one-half of whom also received radiation therapy [RT]) and its premature closure before reaching accrual.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530337\">",
"    <span class=\"h2\">",
"     Trials in stage II disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three large trials and a pooled analysis of five smaller trials that specifically addressed the benefit of fluoropyrimidine-based chemotherapy in populations consisting either entirely or predominantly of stage II disease have been undertaken, all of which fail to show a clear benefit for adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/7,13-16\">",
"     7,13-16",
"    </a>",
"    ]. The largest two are described in detail:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530344\">",
"    <span class=\"h3\">",
"     Quasar",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QUASAR trial randomly assigned 3238 patients (91 percent node-negative, (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    )) to 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV), with or without levamisole or observation following resection of colon (71 percent) or rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Adjuvant chemotherapy was associated with a significant 22 percent lower risk of disease recurrence and an 18 percent reduction in death, which translated into a 3 to 4 percent absolute benefit in five-year overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/15\">",
"     15",
"    </a>",
"    ]. Among patients with stage II colon cancer (n = 2146), there was only a trend towards better overall survival (hazard ratio [HR] 0.86, 95% CI 0.54 to 1.19).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530361\">",
"    <span class=\"h3\">",
"     IMPACT B2",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an analysis of pooled data from 1016 patients with T3N0 disease enrolled in five similar trials of observation versus",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    there was a nonstatistically significant improvement in event-free survival (EFS) that favored chemotherapy (76 versus 73 percent), but five-year overall survival was similar (82 versus 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of these trials enrolled the estimated 4000 assessable patients with stage II disease that would be required to demonstrate a small survival benefit, if it exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530372\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several meta-analyses have evaluated the benefit of adjuvant fluoropyrimidine-based chemotherapy in patients with resected colon cancer; three of which specifically address benefit in stage II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/17,19-21\">",
"     17,19-21",
"    </a>",
"    ]. The two most influential are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530379\">",
"    <span class=\"h3\">",
"     Intergroup analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Intergroup analysis included pooled individual data from 3302 patients with stage II or III colon cancer who were enrolled in seven randomized trials comparing LV- or levamisole-modulated 5-FU versus surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/19\">",
"     19",
"    </a>",
"    ]. In multivariate analysis adjusted for T-stage, histologic grade, and nodal status, adjuvant chemotherapy was associated with a significant 30 percent relative reduction in the risk of recurrence and a 26 percent relative reduction in the risk of death. Treatment effects were consistent across all subsets, with similar risk reductions for stage II and III disease. For stage II disease, this benefit translated into a statistically significant improvement in five-year DFS favoring chemotherapy (76 versus 72 percent), but the difference in overall survival was not statistically significant (81 versus 76 percent, an absolute benefit of 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530390\">",
"    <span class=\"h3\">",
"     Ontario group&nbsp;analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A literature-based systematic review of adjuvant therapy for stage II colon cancer by Cancer Care Ontario identified 37 trials and 11 meta-analyses that were published after 1987 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/17\">",
"     17",
"    </a>",
"    ]. In an analysis of a subset of 12 trials (4187 patients) with a surgery-alone control arm and at least one 5-FU-containing chemotherapy arm, chemotherapy was associated with a small but significant absolute improvement in DFS that ranged from 5 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22\">",
"     22",
"    </a>",
"    ]. However, this did not translate into a statistically significant difference in overall survival (risk ratio [RR] 0.87, 95% CI 0.75 to 1.10, p = 0.07).",
"   </p>",
"   <p>",
"    Based largely on the Ontario group analysis, an expert panel convened by the American Society of Clinical Oncology (ASCO) concluded that direct evidence from randomized trials does not support the routine use of adjuvant chemotherapy for stage II colon cancer. (See",
"    <a class=\"local\" href=\"#H589530438\">",
"     'Summary and recommendations from expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1055568461\">",
"    <span class=\"h1\">",
"     BENEFIT OF OXALIPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less data is available on the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based adjuvant chemotherapy for patients with stage II disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107170851\">",
"    <span class=\"h2\">",
"     MOSAIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MOSAIC trial compared six months of adjuvant",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    versus FOLFOX (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 2",
"    </a>",
"    )) in patients with resected stage II (40 percent) or III (60 percent) colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    At the final analysis (minimum six years of follow up in all patients), the addition of oxaliplatin resulted in a small but statistically significant increase in six-year overall survival (79 versus 76 percent, HR for death 0.84, p = 0.046). However, the survival benefit was limited to patients with stage III disease (73 versus 69 percent, p=0.023), and there was no benefit in the stage II population (87 percent in both treatment arms).",
"    <br/>",
"    <br/>",
"    In patients with stage II cancer, five-year DFS was slightly but not significantly higher with FOLFOX (84 versus 80 percent, HR for recurrence 0.84, p = 0.26). In an exploratory analysis, there was a suggestion of a greater magnitude of benefit in patients with high-risk stage II disease (see below); however, because of the small number of patients, the 7 percent absolute improvement in DFS and the 2 percent absolute improvement in survival with FOLFOX as compared to",
"    <span class=\"nowrap\">",
"     FU/LV",
"    </span>",
"    in this group were not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107170858\">",
"    <span class=\"h2\">",
"     NSABP C-07",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSABP trial C-07 randomly assigned 2246 patients with stage II (29 percent) or III (71 percent) colon cancer to bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    or weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (FLOX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/24\">",
"     24",
"    </a>",
"    ]. The addition of oxaliplatin resulted in a significant improvement in four-year DFS (73 versus 67 percent, HR for recurrence 0.80, 95% CI 0.69-0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/24\">",
"     24",
"    </a>",
"    ]. In the stage-based subgroup analysis, patients with stage II disease appeared to have a less robust DFS benefit from the addition of oxaliplatin (four-year DFS 84 versus 81 percent), which given the small number of stage II patients, is not likely to be statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107170865\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    for stage II disease remains uncertain. Neither the MOSAIC nor the NSABP C-07 trial was specifically designed to address the question of benefit of oxaliplatin in stage II disease. As has been seen with most subgroup analyses in trials of fluoropyrimidine-based therapy, the number of patients with stage II disease was too small to detect a small benefit from oxaliplatin. (See",
"    <a class=\"local\" href=\"#H589530330\">",
"     'Trials in combined populations'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p>",
"    In both trials, there is a suggestion of a rather small DFS benefit in the stage II population; however, the exactly equivalent six year survival in MOSAIC is discouraging. If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is eventually shown to increase survival in stage II disease, the effect is likely to be exceptionally small in average-risk patients. (See",
"    <a class=\"local\" href=\"#H589530401\">",
"     'Risk stratification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530401\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon these data, the magnitude of benefit from adjuvant therapy seems to be small for the average patient with stage II disease. However, most trials have shown at least a DFS benefit for adjuvant chemotherapy in patients with stage II disease. Furthermore, as indicated by the Intergroup meta-analysis, the relative improvement in outcomes with adjuvant fluoropyrimidine-based chemotherapy (as measured by the hazard or odds ratio) appears to be independent of stage and similar in stage II and III disease; this may not hold true for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H589530379\">",
"     'Intergroup analysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This has prompted efforts to utilize clinicopathologic and molecular prognostic features to select groups of patients with higher-risk stage II disease who have a greater risk of recurrence, and might derive a greater absolute degree of benefit from adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530408\">",
"    <span class=\"h2\">",
"     Clinicopathologic variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicopathologic features that have been associated with a worse prognosis in patients with stage II disease are a T4 primary (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/3,25\">",
"     3,25",
"    </a>",
"    ], poorly differentiated histology (including signet ring and mucinous tumors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/19\">",
"     19",
"    </a>",
"    ], lymphovascular invasion (LVI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/25-28\">",
"     25-28",
"    </a>",
"    ], perineural invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ], bowel obstruction or perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/31-33\">",
"     31-33",
"    </a>",
"    ], close, indeterminate or positive margins, inadequately sampled lymph nodes (less than 13 in the surgical specimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/34\">",
"     34",
"    </a>",
"    ], a high preoperative serum carcinoembryonic antigen (CEA) level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/25,35-38\">",
"     25,35-38",
"    </a>",
"    ], and occult nodal micrometastases, as detected by molecular or immunohistochemical methods . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Serum CEA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Nodal micrometastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of risk conferred by these factors, particularly the independent contribution of obstruction and perforation, is difficult to reliably estimate from the literature. The contribution of clinicopathologic factors to outcomes was addressed in a study of 448 patients from Memorial Sloan Kettering who had undergone curative resection of stage II colon cancer without postoperative chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/25\">",
"     25",
"    </a>",
"    ]. In multivariate analysis, only three factors independently influenced prognosis: T4 primary, preoperative CEA &gt;5",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and LVI or perineural invasion. Five-year disease-specific survival rates for patients with zero, one, or two or more of these poor prognostic factors were 95, 85, and 57 percent, respectively.",
"   </p>",
"   <p>",
"    In its 2000 consensus guidelines, the College of American Pathologists recognized only T4 disease, nodal status, LVI, a high preoperative CEA level, and positive surgical margins to represent category I prognostic factors (ie, factors definitively proven to be of prognostic import based on evidence from multiple statistically robust published trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Category I factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite their adverse influence on prognosis, there is no evidence to indicate that patients with these high-risk features are more likely to benefit from chemotherapy (ie, factors associated with a poorer prognosis are not necessarily predictive of chemotherapy response). Few studies have addressed the benefit of chemotherapy in higher-risk subsets of stage II disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NCCTG trial, described above, was the only one to restrict eligibility for adjuvant 5-FU-based chemotherapy to patients with high-risk stage II disease (such as tumor perforation or adherence",
"      <span class=\"nowrap\">",
"       to/invasion",
"      </span>",
"      of adjacent structures) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/9\">",
"       9",
"      </a>",
"      ]. There was a clear benefit for adjuvant chemotherapy in the combined population, but the results were not stratified according to initial disease stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H5#H5\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Bolus 5-FU plus LV'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the MOSAIC trial (FOLFOX versus",
"      <span class=\"nowrap\">",
"       5-FU/LV),",
"      </span>",
"      there was a trend toward improved DFS with FOLFOX (82 versus 75 percent) in the subgroup of stage II patients with high-risk tumors (clinical T4, poorly differentiated, perforation, obstruction, or &lt;10 nodes in the surgical specimen). Overall survival was essentially the same in both groups (85 versus 83 percent, p = 0.65), but whether these results are better than with surgery alone cannot be ascertained because of the lack of a control group treated with surgery alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the US Intergroup pooled analysis, patients with node-negative high-grade T4 tumors did not have a significantly better outcome if they received postoperative chemotherapy as compared to surgery alone (five-year survival 72 versus 69 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/19\">",
"       19",
"      </a>",
"      ]. The study did not address the impact of obstruction, preoperative CEA level, or total nodal count.",
"     </li>",
"     <li>",
"      A survival benefit for fluoropyrimidine-based adjuvant chemotherapy could not be shown for stage II disease in an analysis from the linked",
"      <span class=\"nowrap\">",
"       SEER/Medicare",
"      </span>",
"      database of 24,847 patients aged 65 and older who underwent colectomy for colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/40\">",
"       40",
"      </a>",
"      ]. In contrast to stage III disease, where adjuvant chemotherapy significantly improved five-year survival (HR for death 0.64, 95% CI 0.60-0.67), no survival benefit was observed for patients with stage II colon cancer without (HR for death 1.02 95% CI 0.84-1.25) or with poor prognostic features (HR for death 1.03, 95% CI 0.94-1.13). The poor prognostic features included in this analysis included obstruction, perforation, emergent admission for surgery, T4 primary, poorly differentiated or undifferentiated histology, and fewer than 12 nodes examined. During the period of observation, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      was unlikely in the study population, and thus, its potential benefit in high-risk patients was not measured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the lack of direct data from randomized controlled trials to support a benefit for adjuvant chemotherapy in patients with any of these high-risk features, consensus guidelines from an expert panel convened by ASCO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22\">",
"     22",
"    </a>",
"    ] suggest that adjuvant therapy be discussed with medically fit patients with high-risk clinicopathologic features (inadequately sampled lymph nodes, T4 lesions, tumor perforation, LVI, poorly differentiated histology, or neural invasion). (See",
"    <a class=\"local\" href=\"#H589530438\">",
"     'Summary and recommendations from expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Updated consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest a discussion about the potential risks versus benefits of adjuvant therapy for all patients with stage II disease, taking into consideration the number of lymph nodes analyzed, presence of high-risk clinicopathologic features, and assessment of other comorbidities and anticipated life expectancy. (See",
"    <a class=\"local\" href=\"#H589530438\">",
"     'Summary and recommendations from expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with stage II colon cancer and a high preoperative CEA level could also be considered at higher than average risk for recurrence, and this might influence the decision to administer adjuvant chemotherapy, particularly if other risk factors (eg, perforation) are present. However, the 2006 ASCO expert panel concluded that the data were insufficient to support using preoperative CEA levels to select patients for adjuvant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Serum CEA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530415\">",
"    <span class=\"h2\">",
"     Molecular prognostic and predictive factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An area of ongoing study is the impact of tumor molecular factors on prognosis and the response to adjuvant chemotherapy. Among the factors that have been studied are 18q deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/41\">",
"     41",
"    </a>",
"    ], thymidylate synthetase (TS) overexpression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], K-ras, BRAF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], and p53 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/47\">",
"     47",
"    </a>",
"    ], microsatellite instability",
"    <span class=\"nowrap\">",
"     (MSI)/deficient",
"    </span>",
"    mismatch repair, hypermethylation (epigenetic inactivation) affecting extracellular matrix pathway genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/48\">",
"     48",
"    </a>",
"    ], gene expression arrays such as a 12-gene recurrence score assay (Oncotype DX Colon Cancer Assay) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/49-54\">",
"     49-54",
"    </a>",
"    ], an 18-gene classifier (ColoPrint) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], or a 13-gene classifier (ColoGuideEx) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/57\">",
"     57",
"    </a>",
"    ] as well as identification of circulating tumor cells by molecular methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite encouraging preliminary data linking molecular findings to prognosis and potentially better prognostic stratification relative to TNM stage alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/49,55,62-71\">",
"     49,55,62-71",
"    </a>",
"    ], no single molecular marker or multiple marker profile or gene expression panel has emerged that has",
"    <strong>",
"     predictive",
"    </strong>",
"    utility (ie, that consistently identifies groups of patients who would be predicted to derive greater benefit from adjuvant chemotherapy). However, there is one exception. The presence of microsatellite instability (MSI, the biologic footprint of DNA mismatch repair deficiency) appears to be associated with a relative resistance to fluoropyrimidines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Prognostic determinants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530422\">",
"    <span class=\"h3\">",
"     MSI and mismatch repair enzyme deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of colorectal cancers have sporadic or inherited (Lynch syndrome) deficiency of a mismatch repair (MMR) protein, most commonly MLH1 or MSH2. High levels of MSI (MSI-H) are the biologic footprint of a DNA mismatch repair [MMR] deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link&amp;anchor=H17#H17\">",
"     \"Molecular genetics of colorectal cancer\", section on 'Mismatch repair genes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMR deficiency is more prevalent in stage II as compared to stage III colon cancer (21 versus 14 percent in one study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/72\">",
"     72",
"    </a>",
"    ]. MMR-deficient tumors are characteristically located proximally and have a mucinous histology with tumor infiltrating lymphocytes; they also have a better prognosis than do microsatellite stable (MSS) tumors,. However, this better prognosis appears to be attenuated in the presence of a BRAF mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/46,73\">",
"     46,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Mismatch repair deficiency and tumor infiltrating lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, MMR testing has been reserved for patients meeting the revised Bethesda Guidelines for Lynch syndrome screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Identification of individuals with Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, beyond the issue of familial cancer risk, increasing amounts of data support the view that MMR deficiency is a prognostic biomarker associated with a lower recurrence risk in patients with stage II colon cancer, but also a predictive biomarker for lack of significant benefit from adjuvant single agent fluoropyrimidine chemotherapy in this population.",
"   </p>",
"   <p>",
"    Most (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]) studies support the view that adjuvant single agent fluoropyrimidine-based chemotherapy is less beneficial, or even potentially harmful, for patients with microsatellite-unstable or MMR-deficient (dMMR) tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/66,67,77-82\">",
"     66,67,77-82",
"    </a>",
"    ]. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early study found that untreated patients with colorectal cancer and dMMR tumors had a modestly better prognosis than those with pMMR tumors, but did not seem to benefit from adjuvant 5-FU-based chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/66\">",
"       66",
"      </a>",
"      ]. There was even a suggestion of harm in terms of overall survival in treated patients with dMMR tumors.",
"      <br/>",
"      <br/>",
"      These findings were confirmed in a later systematic review of 32 studies stratifying survival in patients with colorectal cancer (CRC) by MSI status, patients whose tumors had MSI derived no benefit from adjuvant 5-FU-containing chemotherapy (HR for death = 1.24; 95% CI 0.72 to 2.14) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar conclusions were reached in a pooled reanalysis of MSI status or immunohistochemistry for MMR proteins on 457 specimens from patients with stage II or III colon cancer who were enrolled in randomized adjuvant chemotherapy trials conducted by the NCCTG, GIVIO, and ECOG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/82\">",
"       82",
"      </a>",
"      ]. Adjuvant systemic therapy significantly improved survival among patients with stage III disease whose tumors were proficient at MMR (MSS, pMMR). However, patients with dMMR tumors who received 5-FU derived no benefit in overall or disease-free survival relative to those who were randomized to no treatment (HR for DFS 1.39, 95% CI 0.46-4.15). For added power, data from these patients was pooled with that of 570 patients in the original analysis of MSI status and 5-FU response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/66\">",
"       66",
"      </a>",
"      ]; the conclusions were similar. Deficient MMR status was prognostic for a better outcome only in patients treated with surgery. Adjuvant 5-FU was not associated with a disease-free or overall survival benefit in the dMMR subgroup.",
"      <br/>",
"      <br/>",
"      The authors concluded that MMR status should be assessed and included in the decision-making process for a patient being considered for therapy with 5-FU alone (eg, in the setting of stage II disease).",
"     </li>",
"     <li>",
"      On the other hand, at least two analyses have confirmed the prognostic significance of dMMR, but not its predictive capacity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of 1913 patients treated on the QUASAR study, a randomized comparison of",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      and supportive care in stage II colon cancer, was able to confirm the prognostic significance of dMMR, but not its predictive capacity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/45\">",
"       45",
"      </a>",
"      ]. Patients with dMMR tumors had a recurrence risk that was one-half that of patients with pMMR cancers (risk ratio 0.53, 95% CI 0.40-0.70). Patients with pMMR cancers also clearly benefited from chemotherapy (OR for recurrence 0.59, 95% CI 0.45-0.77). In contrast to the previously mentioned findings, there was a suggestion of a small chemotherapy benefit among patients with dMMR cancers (OR for recurrence 0.81, 0.29-2.22), which translated to an absolute decrease in recurrence at two years of 1.6 percent.",
"      <br/>",
"      <br/>",
"      The relatively small number of patients with dMMR cancers and the very small number of events (total 15) makes it difficult to assess whether there is a true signal of chemotherapy effect in patients with dMMR tumors, and these results are not powerful enough to nullify the previous studies indicating a predictive capacity of dMMR in stage II colon cancer.",
"     </li>",
"     <li>",
"      A lack of benefit for adjuvant 5-FU in dMMR tumors could also not be replicated in a study of 2141 patients with stage II or III colon cancer who were treated in international trials of 5-FU-based adjuvant chemotherapy for colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/83\">",
"       83",
"      </a>",
"      ]. Patients with dMMR tumors had reduced rates of tumor recurrence, delayed time to tumor recurrence, and improved survival rates compared to those with pMMR tumors. Among patients with stage III disease, 5-FU-based treatment was associated with significantly fewer distant recurrences (11 versus 29 percent with no fluoropyrimidine treatment, p = 0.01). A formal analysis of the treatment effect in patients with stage II tumors was not performed. &nbsp;",
"      <br/>",
"      <br/>",
"      In an intriguing subset analysis, the dMMR tumors with suspected germline mutations (ie, from patients with suspected Lynch syndrome) were associated with improved DFS after 5-FU-based treatment, but patients with suspected sporadic tumors did not appear to gain any benefit from adjuvant fluoropyrimidines compared to surgery alone. These results are hypothesis generating, and require prospective validation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resistance to FU is presumably due to incorporation of FU metabolites into DNA rather than inhibition of its effective target, thymidylate synthetase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the prognostic value of MMR deficiency is apparent in both stage II and III disease, its impact on clinical decision making is greater for patients with stage II disease given the modest value of chemotherapy overall, limitations of conventional clinicopathologic risk assessment, and the increased prevalence of MMR deficiency in this group.",
"   </p>",
"   <p>",
"    Information on MMR status in patients with stage II colon cancer can be used in two ways.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given that patients with stage II disease and tumors with MSI (dMMR) have a better prognosis than do those whose tumors are MSS (pMMR), this may impact on the decision to pursue or not pursue adjuvant chemotherapy.",
"     </li>",
"     <li>",
"      Furthermore, if treatment with fluoropyrimidines alone is being considered, the presence of",
"      <span class=\"nowrap\">",
"       MSI/dMMR",
"      </span>",
"      status may identify patients who do not benefit from fluoropyrimidines. Updated guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      recommend MMR testing for all patients being considered for fluoropyrimidine therapy only. (See",
"      <a class=\"local\" href=\"#H589530438\">",
"       'Summary and recommendations from expert groups'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not known whether the lack of benefit from adjuvant FU in patients with dMMR translates into a lack of benefit from an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen such as FOLFOX, which has become the standard regimen for stage III disease. Some studies suggest that MMR status is not prognostic for outcomes from adjuvant FOLFOX in resected colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. However, while one report noted a significant benefit from adding oxaliplatin to FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    in patients with MSI tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/89\">",
"     89",
"    </a>",
"    ], another suggested a lower rate of disease control with FOLFOX in patients with dMMR tumors compared to those with pMMR tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/90\">",
"     90",
"    </a>",
"    ]. None of these studies was prospectively designed (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21941510\">",
"    <span class=\"h4\">",
"     Testing for MMR enzyme deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish between the two major rationales for testing for MMR enzyme deficiency. The first is for purposes of obtaining stage-independent predictors of recurrence risk to help in adjuvant therapy decisions as mentioned above. The second completely separate reason is to screen patients for Lynch syndrome (hereditary non-polyposis colorectal cancer). Patients with Lynch syndrome have germline loss of expression of one of several MMR enzymes, resulting in a predisposition to colorectal cancer. Some experts currently recommend routine screening of",
"    <strong>",
"     all",
"    </strong>",
"    patients with colorectal cancer for Lynch syndrome, while others recommend selective testing focusing on patients who present at a young age (under the age of 50) or whose tumor have clinicopathologic features that suggest HNPCC; this is a controversial area. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the rationale for performing the test, immunohistochemistry (IHC) for the most commonly lost mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2) can be used in place of the more cumbersome MSI testing (a polymerase chain reaction assay that can take up to six weeks), particularly if the results will influence a decision on adjuvant therapy. Absence of one of these proteins on screening IHC confirms the good prognosis dMMR phenotype, but should also prompt consideration of germline testing for Lynch syndrome. A further discussion of MSI testing is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1055568575\">",
"    <span class=\"h3\">",
"     12-gene recurrence score",
"    </span>",
"    &nbsp;&mdash;&nbsp;To develop a &ldquo;recurrence score&rdquo; able to enhance prognostic information about recurrence risk for patients with stage II colon cancer, investigators assessed the association between colon cancer recurrence and expression of multiple genes in paraffin embedded tumor tissue from patients with stage II or III colon cancer treated on four different adjuvant therapy trials that included surgery only and 5-FU arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/53\">",
"     53",
"    </a>",
"    ]. From an initial 761 candidate genes, 12 were selected based on their independent association with recurrence in each of the studies. From this initial study, patients with a recurrence score &lt;30 had a three year recurrence rate of 8 percent, patients with a RS 31-40 had a recurrence risk of 11 percent, and patients with RS &gt;40 a recurrence rate of 25 percent at three years. The ability of this 12 gene assay to predict recurrence rate was independently validated in an analysis of data from the prospective QUASAR trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to note that this RS was created as a prognostic marker; it has the ability to better estimate a patient&rsquo;s risk of recurrence. However, whether such increased risk can be overcome by adjuvant chemotherapy is not clear. The investigators did generate a separate &ldquo;treatment score&rdquo; that appeared to be predictive of 5-FU benefit in stage II disease from the initial four study patient sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/53\">",
"     53",
"    </a>",
"    ]. &nbsp;However, the predictive value of this treatment score could not be validated in the QUASAR sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Oncotype DX Colon Cancer Assay is marketed by Genomic Health. How the recurrence score should be integrated with other known prognostic markers for routine care is uncertain. ASCO guidelines do not address use of this assay.",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines state that there are insufficient data to recommend the use of multi-gene assays such as the Oncotype DX assay to determine adjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530438\">",
"    <span class=\"h2\">",
"     Summary and recommendations from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant therapy for patients with stage II colon cancer remains controversial. Data from randomized trials and meta-analyses indicate that if there is benefit for 5-FU-based chemotherapy therapy in patients with resected stage II disease, that it does not exceed an absolute improvement in five-year survival of 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/17,19,22\">",
"     17,19,22",
"    </a>",
"    ]. Insufficient numbers of patients have been accrued to determine whether there is a statistically significant smaller benefit that is clinically meaningful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22,34\">",
"     22,34",
"    </a>",
"    ]. ASCO and European Society of Medical oncology (ESMO) guidelines recommend against routine administration of adjuvant systemic chemotherapy for unselected patients with resected stage II colon cancer outside of clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22,92\">",
"     22,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of direct evidence to support benefit in this setting, ASCO guidelines suggest that the risks and possible benefits of adjuvant chemotherapy be discussed with medically fit patients who have higher-risk stage II disease (ie, fewer than 13 lymph nodes in the surgical specimen a T4 primary (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ), perforation, lymphovascular or neural invasion, or poorly differentiated histology, including signet ring and mucinous tumors). This recommendation is based upon indirect evidence gained from the experience in stage III disease and the suggestion of benefit in the MOSAIC subgroup. The panel emphasized the importance of patient choice in the treatment decision-making process and recommended that the discussion include an estimate of the relative risk of recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death with and without adjuvant chemotherapy and the expected side effects of treatment.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    considers the following features as indicative of high risk disease:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fewer than 12 nodes in the specimen",
"     </li>",
"     <li>",
"      Grade 3 or 4 histologic differentiation",
"     </li>",
"     <li>",
"      Colonic obstruction",
"     </li>",
"     <li>",
"      Localized perforation",
"     </li>",
"     <li>",
"      Perineural or",
"      <span class=\"nowrap\">",
"       lymphatic/vascular",
"      </span>",
"      invasion",
"     </li>",
"     <li>",
"      Close, indeterminate, or positive margins &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Updated consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest a discussion about the potential risks versus benefits of adjuvant therapy for all patients with stage II disease, taking into consideration the number of lymph nodes analyzed, presence of high-risk clinicopathologic features, and assessment of other comorbidities and anticipated life expectancy.",
"   </p>",
"   <p>",
"    ESMO guidelines consider the following features to reflect high-risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/92\">",
"     92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fewer than 12 nodes in the specimen",
"     </li>",
"     <li>",
"      Poorly differentiated tumor",
"     </li>",
"     <li>",
"      Clinical presentation with colonic obstruction or perforation",
"     </li>",
"     <li>",
"      Perineural or lymphatic or vascular invasion",
"     </li>",
"     <li>",
"      pT4 stage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We discuss the risks and benefits of adjuvant chemotherapy with all patients who have stage II colon cancer. In general, we consider MMR testing to be of greater utility than the Oncotype DX Colon Cancer Assay given its predictive role in determining chemotherapy benefit.",
"   </p>",
"   <p>",
"    For patients without any of the clinical high-risk features identified by either ASCO or the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    , we routinely test their tumors for MMR status to assist in the decision to administer or not administer adjuvant chemotherapy. In the approximately 15 percent of patients with",
"    <span class=\"nowrap\">",
"     MSI-H/dMMR",
"    </span>",
"    tumors, their excellent prognosis and the suggestion of lack of benefit (and perhaps harm) from 5-FU provide ample evidence to recommend against routine adjuvant therapy. However, enrollment of such patients into clinical trials should be considered, if appropriate. For patients who have",
"    <span class=\"nowrap\">",
"     pMMR/MSS",
"    </span>",
"    tumors and otherwise average-risk stage II colon cancer, adjuvant chemotherapy may confer a small benefit, and individual patient choice remains the deciding factor for these patients.",
"   </p>",
"   <p>",
"    The decision to pursue chemotherapy can be particularly difficult in older individuals, in whom there is greater variability in toxicity and prediction of tolerance is challenging. Integration of patient preferences is especially critical in this population, given that older age has been associated with a preference for quality of life over length of life. These issues are all addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\", section on 'Challenges specific to the elderly'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16290395\">",
"    <span class=\"h3\">",
"     Web-based tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two web-based tools are available to assist the clinician in calculating the relative risk of disease recurrence and mortality based upon clinicopathologic features and the relative benefit to be gained by adjuvant chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjuvant! Online [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/93\">",
"       93",
"      </a>",
"      ] was developed using prognostic estimates derived from US SEER tumor registry-reported outcomes for patients with colon cancer in the general population and estimates of adjuvant therapy efficacy derived from proportional risk reductions published in the literature.",
"     </li>",
"     <li>",
"      Numeracy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/94\">",
"       94",
"      </a>",
"      ] was developed at the Mayo Clinic and derived from a pooled individual patient data meta-analysis of seven randomized clinical trials of adjuvant therapy, including 3341 trial participants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both tools are used widely by clinicians, but the validity of the assumptions inherent in the estimates provided by these prognostic tools has not been tested extensively. One independent validation study of both tools that used a population-based dataset from the British Columbia Colorectal Cancer Outcomes unit concluded that the survival outcomes of patients with stage II colon cancer who received adjuvant FU were slightly lower than estimated by either model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these programs can assist in estimating the potential benefit of adjuvant therapy, the decision to pursue treatment requires careful consideration of all aspects of the individual patient by the clinician, including those that are not contained in Adjuvant! Online or Numeracy (eg, perforation). In our opinion, these tools are best used as a rough guide to explain the degree of absolute benefit that may be achieved by receipt of adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589530445\">",
"    <span class=\"h2\">",
"     Choice of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal chemotherapy regimen for patients with stage II disease is controversial. The FOLFOX regimen was superior to short-term infusional 5-FU plus LV in the MOSAIC trial, which was conducted in patients with both stage II and III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/96\">",
"     96",
"    </a>",
"    ]. However, the survival and DFS benefit appeared limited to those with stage III disease. In an exploratory analysis there was an absolute difference in five-year DFS that favored FOLFOX in the subgroup of stage II patients with high-risk tumors, but it was not statistically significant (82 versus 75 percent, HR 0.72) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/23\">",
"     23",
"    </a>",
"    ]. Just as with 5-FU, the benefit offered by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is likely quite small, if any, in patients with average risk colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H14#H14\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In both Europe and the US, the FOLFOX regimen is approved for adjuvant therapy only for stage III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/97\">",
"     97",
"    </a>",
"    ]. Many oncologists routinely use 5-FU plus LV for most patients but discuss FOLFOX with patients who have stage II disease and several high-risk factors. When FOLFOX is chosen, most American oncologists use the modified FOLFOX6 regimen (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there are no data addressing the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in patients with stage II disease (the X-ACT trial was conducted only in stage III disease), guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    support capecitabine alone as a reasonable alternative to either FOLFOX or",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H11#H11\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FOLFOX is also a reasonable alternative to fluoropyrimidine therapy alone for patients with stage II tumors that are",
"    <span class=\"nowrap\">",
"     MSI-H/dMMR.",
"    </span>",
"    However, as noted above, it is not known whether the lack of benefit from adjuvant FU in patients with dMMR translates into a lack of benefit from an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen such as FOLFOX. (See",
"    <a class=\"local\" href=\"#H589530422\">",
"     'MSI and mismatch repair enzyme deficiency'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1055568850\">",
"    <span class=\"h3\">",
"     Toxicity of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relatively good prognosis of stage II disease, a recommendation to administer adjuvant chemotherapy must consider the potential risks associated with treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase III study, severe (grade 3 or worse) side effects developed in 14 percent of patients with stage II disease who were treated with short-term infusional 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (LV); this led to premature treatment discontinuation in 6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/23\">",
"       23",
"      </a>",
"      ]. Higher rates of diarrhea,",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      and myelosuppression are usually seen with bolus",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      regimens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H8#H8\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Infusional versus bolus 5-FU'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      With the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , 19 percent experienced severe side effects, 12 percent of which resulted in treatment discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/23\">",
"       23",
"      </a>",
"      ]. Grade 3 sensory neuropathy developed in 13 percent during therapy, but was still present at 48 months in only 0.7 percent.",
"     </li>",
"     <li>",
"      In most modern trials, rates of treatment-related death range from 0.5 to 1 percent.",
"     </li>",
"     <li>",
"      Long-term side effects are less well defined. In one study, quality of life decreased after adjuvant",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      therapy, requiring up to one year to return to baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/98\">",
"       98",
"      </a>",
"      ]. Neuropathy was still present in 10 percent of patients two years after discontinuation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      in the C-07 trial, despite the use of lower cumulative oxaliplatin dose than in the MOSAIC trial of FOLFOX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the X-ACT study, six months of treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      was associated with hand-foot syndrome in 60 percent (17 percent severe [grade 3 or 4]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/77\">",
"       77",
"      </a>",
"      ]. In addition, 46 percent developed diarrhea of any grade (11 percent severe), 36 percent had nausea or vomiting (3 percent severe), 22 percent had stomatitis (2 percent severe), and 23 percent had fatigue or asthenia (1 percent severe). Six percent of patients developed partial alopecia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H11#H11\">",
"       \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Capecitabine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23557430\">",
"    <span class=\"h3\">",
"     Chemotherapy dosing in obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cancer patients with a large body surface area (BSA), chemotherapy drug doses are often reduced, because of concern for excess toxicity. However, there is no evidence that fully-dosed obese patients experience greater toxicity from chemotherapy for colorectal cancer; furthermore, obese patients who are given reduced doses may have inferior outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/100\">",
"     100",
"    </a>",
"    ]. Although limited, the available data do not support the policy of routine dose reduction (or capping the maximal BSA to 2.0 m",
"    <sup>",
"     2",
"    </sup>",
"    ) for obese patients with colon cancer. Guidelines from ASCO recommend that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589532659\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of adjuvant RT in patients with resected colon cancer remains poorly defined. Nevertheless, current treatment recommendations suggest that adjuvant RT be offered to the following subgroups of patients who have an estimated risk of local recurrence that is 30 percent or higher: ascending or descending colon primary with T4 disease or a positive resection margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H35#H35\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Adjuvant RT'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589532115\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY: DIET, EXERCISE, AND ASPIRIN",
"    </span>",
"   </p>",
"   <p>",
"    Numerous epidemiologic studies indicate an association between lifestyle factors (obesity, physical inactivity, diet) and the risk of colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H13#H13\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies have suggested that these factors might also influence the risk of cancer recurrence and death after primary surgical resection of CRC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous observational studies and randomized trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    against the development of colorectal adenomas and cancer through its actions as an inhibitor of the cyclooxygenase 2 (COX-2) pathway. This pathway is overexpressed in 80 to 85 percent of CRCs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs may also improve survival among patients receiving treatment for early colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H41#H41\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Aspirin and other NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2949238\">",
"    <span class=\"h1\">",
"     ISSUES FOR SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for posttreatment cancer surveillance and an overview of the approach to long-term survivors of colon cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=see_link\">",
"     \"Approach to the long-term survivor of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=see_link\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21941645\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21942280\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following potentially curative resection of colon cancer, the goal of adjuvant chemotherapy is to eradicate micrometastases, thereby reducing the likelihood of disease recurrence and increasing the cure rate. The benefits of adjuvant chemotherapy have been most clearly demonstrated in stage III (node-positive) disease (an approximately 30 percent reduction in the risk of disease recurrence and a 22 to 32 percent reduction in mortality), whereas benefit is less certain for stage II disease. Data from randomized trials and meta-analyses indicate that if there is benefit for 5-FU-based chemotherapy therapy in patients with resected stage II disease, it does not exceed an absolute improvement in five-year survival of 5 percent. (See",
"    <a class=\"local\" href=\"#H589528227\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H589530438\">",
"     'Summary and recommendations from expert groups'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon the available data, adjuvant chemotherapy cannot be considered as a standard of care for all patients with resected stage II disease. In keeping with American Socieety of Clinical Oncology (ASCO) and",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22\">",
"     22",
"    </a>",
"    ], we suggest discussing the risks and estimated benefits of adjuvant chemotherapy with all patients who have resected stage II disease. ASCO guidelines emphasize patient choice in the decision-making process. The oncologist should help the patient to make an informed decision by estimating the relative risk of recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death with and without adjuvant chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef59439 \" href=\"mobipreview.htm?35/16/36107\">",
"     table 4",
"    </a>",
"    ) and discussing the expected side effects of treatment.",
"   </p>",
"   <p>",
"    We take the following issues into consideration when assessing the risk of recurrence and estimated benefit from chemotherapy: the number of lymph nodes analyzed, presence of high-risk clinicopathologic features (fewer than 12 nodes in the surgical specimen; T4 or",
"    <span class=\"nowrap\">",
"     perforated/obstructed",
"    </span>",
"    lesion (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ); poorly differentiated histology (including signet ring and mucinous); lymphovascular or perineural invasion), mismatch repair enzyme (MMR) status, and assessment of other comorbidities and anticipated life expectancy. (See",
"    <a class=\"local\" href=\"#H589530401\">",
"     'Risk stratification'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    A web-based tool is available (Adjuvant! Online) that can aid the clinician in estimating the risk of recurrence and death based on clinicopathologic features and the relative benefits of chemotherapy as an aid to enhancing the decision making process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?29/55/30586/abstract/93\">",
"     93",
"    </a>",
"    ]. Use of this program is not a substitute for clinical judgment and careful consideration of all relevant patient- and tumor-related factors that may impact the decision to pursue adjuvant therapy. (See",
"    <a class=\"local\" href=\"#H589530438\">",
"     'Summary and recommendations from expert groups'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following reflects our general approach to adjuvant chemotherapy in patients with resected stage II disease. The evidence to support all of these recommendations is weak.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We test tumors for deficient MMR (dMMR, either by MSI testing or immunohistochemistry for MMR proteins) in all patients without high-risk features, and for patients with high risk features if chemotherapy with a fluoropyrimidine alone is being considered. (See",
"      <a class=\"local\" href=\"#H21941510\">",
"       'Testing for MMR enzyme deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without high-risk features who have",
"      <span class=\"nowrap\">",
"       MSI-H/dMMR",
"      </span>",
"      tumors have a favorable prognosis and are not likely to benefit from adjuvant fluoropyrimidine-based therapy. We suggest observation alone for most of these patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H589530422\">",
"       'MSI and mismatch repair enzyme deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adjuvant chemotherapy for most patients with high-risk features (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H589530408\">",
"       'Clinicopathologic variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of regimen in patients who decide to pursue chemotherapy is controversial:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a fluoropyrimidine-based regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated FU or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      alone) rather than an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimen for most patients with stage II disease who are average risk, with proficient MMR (pMMR) tumors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We discuss the results of the MOSAIC trial and the potential toxicity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      in patients who have high-risk stage II disease, particularly with multiple risk factors.(See",
"      <a class=\"local\" href=\"#H1055568461\">",
"       'Benefit of oxaliplatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have deficient mismatch repair (dMMR) tumors but other high risk features, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      should be considered more strongly given at the apparent lack of benefit from single agent fluoropyrimidines. Whether oxaliplatin does overcome this resistance is unknown. (See",
"      <a class=\"local\" href=\"#H589530330\">",
"       'Trials in combined populations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589532715\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence is inconclusive as to the benefit of adding RT to chemotherapy for patients at high risk for a local recurrence. We suggest adjuvant RT for patients with T4 tumors and penetration to a fixed structure or a positive margin (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=see_link&amp;anchor=H35#H35\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     Colon and Rectum. In: AJCC (American Joint Committee on Cancer) Staging Manual, 6th, Greene, FL, Page, DL, Fleming, ID (Eds), Springer, New York 2002. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/3\">",
"      O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420.",
"     </a>",
"    </li>",
"    <li>",
"     Colon and Rectum. In: AJCC (American Joint Committee on Cancer) Staging Manual, 7th, Edge, SB, Byrd, DR, Compton, CC (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/5\">",
"      Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/6\">",
"      Zaniboni A, Labianca R, Marsoni S, et al. GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer 1998; 82:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/7\">",
"      Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/8\">",
"      Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/9\">",
"      O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/10\">",
"      Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/11\">",
"      Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. Jpn J Clin Oncol 1995; 25:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/12\">",
"      Taal BG, Van Tinteren H, Zoetmulder FA, NACCP group. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/13\">",
"      Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/14\">",
"      Moore HC, Haller DG. Adjuvant therapy of colon cancer. Semin Oncol 1999; 26:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/15\">",
"      Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/16\">",
"      Schippinger W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007; 97:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/17\">",
"      Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22:3395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/18\">",
"      Buyse M, Piedbois P. Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 2001; 28:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/19\">",
"      Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/20\">",
"      Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/21\">",
"      Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008; :CD005390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/22\">",
"      Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/23\">",
"      Andr&eacute; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/24\">",
"      Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/25\">",
"      Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/26\">",
"      Michelassi F, Ayala JJ, Balestracci T, et al. Verification of a new clinicopathologic staging system for colorectal adenocarcinoma. Ann Surg 1991; 214:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/27\">",
"      Sternberg A, Sibirsky O, Cohen D, et al. Validation of a new classification system for curatively resected colorectal adenocarcinoma. Cancer 1999; 86:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/28\">",
"      Betge J, Pollheimer MJ, Lindtner RA, et al. Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 2012; 118:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/29\">",
"      Liebig C, Ayala G, Wilks J, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009; 27:5131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/30\">",
"      Huh JW, Kim HR, Kim YJ. Prognostic value of perineural invasion in patients with stage II colorectal cancer. Ann Surg Oncol 2010; 17:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/31\">",
"      Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, et al. Colon cancer in France: evidence for improvement in management and survival. Gut 2002; 51:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/32\">",
"      Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/33\">",
"      Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. Surgery 2000; 127:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/34\">",
"      Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/35\">",
"      Takagawa R, Fujii S, Ohta M, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 2008; 15:3433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/36\">",
"      McCall JL, Black RB, Rich CA, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994; 37:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/37\">",
"      Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 2010; 101:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/38\">",
"      Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst 2011; 103:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/39\">",
"      Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/40\">",
"      O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/41\">",
"      Gal R, Sadikov E, Sulkes J, et al. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. Dis Colon Rectum 2004; 47:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/42\">",
"      Dotor E, Cuatrecases M, Mart&iacute;nez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/43\">",
"      Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/44\">",
"      Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/45\">",
"      Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/46\">",
"      French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/47\">",
"      Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005; 23:5635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/48\">",
"      Yi JM, Dhir M, Van Neste L, et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res 2011; 17:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/49\">",
"      Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/50\">",
"      Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/51\">",
"      Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24:4685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/52\">",
"      Lu AT, Salpeter SR, Reeve AE, et al. Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis. Clin Colorectal Cancer 2009; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/53\">",
"      O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28:3937.",
"     </a>",
"    </li>",
"    <li>",
"     O'Connell M, Lee M, Lopatin M, et al. et al. Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in statge II and III colon cancer patients treated with 5FU/LV (FU) +  5FU/LV oxaliplatin (abstract 3512). J Clin Oncol 30, 20121 (suppl; abstr 3512). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=99494 (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/55\">",
"      Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenberg R, Maak M, Simon I, et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients (abstract). Data presented at the 2011 ASCO GI Cancers Symposium, San Francisco, CA, January 20-22, 2011. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=103&amp;abstractID=71277 (Accessed on March 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/57\">",
"      Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012; 61:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/58\">",
"      Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010; 138:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/59\">",
"      Peach G, Kim C, Zacharakis E, et al. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 2010; 102:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/60\">",
"      Vardakis N, Messaritakis I, Papadaki C, et al. Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer. Clin Cancer Res 2011; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/61\">",
"      Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011; 29:1547.",
"     </a>",
"    </li>",
"    <li>",
"     Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study (abstract #4000). J Clin Oncol 2009; 27:169s.",
"    </li>",
"    <li>",
"     Gray RG. Correlation of number of nodes examined and the 12-gene colon cancer recurrence score with recurrence in stage II colon cancer patients from QUASAR (abstract #331). Data presented at the 2010 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 24, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/64\">",
"      Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/65\">",
"      Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/66\">",
"      Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/67\">",
"      Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/68\">",
"      Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/69\">",
"      Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/70\">",
"      Zlobec I, Baker K, Minoo P, et al. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin Cancer Res 2008; 14:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/71\">",
"      Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012; 104:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/72\">",
"      Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 2011; 29:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/73\">",
"      Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/74\">",
"      Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/75\">",
"      Allegra CJ, Kim G, Kirsch IR. Microsatellite instability in colon cancer. N Engl J Med 2003; 349:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/76\">",
"      Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/77\">",
"      Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/78\">",
"      Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/79\">",
"      de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/80\">",
"      Lanza G, Gaf&agrave; R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/81\">",
"      Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/82\">",
"      Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28:3219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/83\">",
"      Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/84\">",
"      Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003; 106:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/85\">",
"      Tajima A, Hess MT, Cabrera BL, et al. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004; 127:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/86\">",
"      Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010; 66:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/87\">",
"      Des Guetz G, Lecaille C, Mariani P, et al. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res 2010; 30:4297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/88\">",
"      Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012; 18:6531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/89\">",
"      Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010; 21:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/90\">",
"      M&uuml;ller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 2008; 23:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/91\">",
"      Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011; 29:4611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/92\">",
"      Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23:2479.",
"     </a>",
"    </li>",
"    <li>",
"     Adjuvant! Online program for colon cancer available online at www.adjuvantonline.com (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     Numeracy web-based model for colon cancer available online at www.mayoclinic.com/calcs (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/95\">",
"      Gill S, Loprinzi C, Kennecke H, et al. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer 2011; 117:4155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/96\">",
"      Andr&eacute; T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/97\">",
"      Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005; 23:3311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/98\">",
"      Chau I, Norman AR, Cunningham D, et al. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. Eur J Cancer 2005; 41:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/99\">",
"      Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/100\">",
"      Chambers P, Daniels SH, Thompson LC, Stephens RJ. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012; 23:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/101\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?29/55/30586/abstract/103\">",
"      Czito BG, Bendell J, Willett CG. Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era? Oncology (Williston Park) 2006; 20:179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15256 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30586=[""].join("\n");
var outline_f29_55_30586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21941645\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589528227\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589530323\">",
"      BENEFIT OF FLUOROPYRIMIDINE-BASED CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530330\">",
"      Trials in combined populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530337\">",
"      Trials in stage II disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589530344\">",
"      - Quasar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589530361\">",
"      - IMPACT B2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530372\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589530379\">",
"      - Intergroup analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589530390\">",
"      - Ontario group&nbsp;analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1055568461\">",
"      BENEFIT OF OXALIPLATIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107170851\">",
"      MOSAIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107170858\">",
"      NSABP C-07",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107170865\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589530401\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530408\">",
"      Clinicopathologic variables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530415\">",
"      Molecular prognostic and predictive factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589530422\">",
"      - MSI and mismatch repair enzyme deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21941510\">",
"      Testing for MMR enzyme deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1055568575\">",
"      - 12-gene recurrence score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530438\">",
"      Summary and recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16290395\">",
"      - Web-based tools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589530445\">",
"      Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1055568850\">",
"      - Toxicity of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23557430\">",
"      - Chemotherapy dosing in obese patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589532659\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589532115\">",
"      ADJUNCTIVE THERAPY: DIET, EXERCISE, AND ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2949238\">",
"      ISSUES FOR SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21941645\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21942280\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589532715\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15256\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15256|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/54/41824\" title=\"figure 1\">",
"      SEER surv adeno colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15256|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 2\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 3\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/16/36107\" title=\"table 4\">",
"      5 year DFS node neg colon CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/51/11066?source=related_link\">",
"      Adjuvant therapy for resected colon cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/34/28202?source=related_link\">",
"      Approach to the long-term survivor of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_55_30587="Ogilvy Carter grading system";
var content_f29_55_30587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ogilvy and Carter grading system to predict outcome for surgical management of intracranial aneurysms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age 50 or less",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age greater than 50",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hunt and Hess grade 0 to 3 (no coma)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hunt and Hess grade 4 and 5 (in coma)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fisher scale score 0 to 2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fisher scale score 3 and 4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aneurysm size 10 mm or less",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aneurysm size greater than 10 mm",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant posterior circulation aneurysm size 25 mm or more",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        The total score ranges from 0 to 5, corresponding to grades 0 to 5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Ogilvy, CS, Carter, BS. A proposed comprehensive grading system to predict outcome for surgical management of intracranial aneurysms. Neurosurgery 1998; 42:959.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30587=[""].join("\n");
var outline_f29_55_30587=null;
var title_f29_55_30588="Heme intermediates";
var content_f29_55_30588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intermediates of the heme biosynthetic pathway, chemical alterations that occur when they accumulate, routes of excretion, and samples collected for their measurement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathway intermediate*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chemically altered forms",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary routes of excretion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Samples for measurement",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &delta;-Aminolevulinic acid",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Urine, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphobilinogen",
"       </td>",
"       <td>",
"        Porphobilin; uroporphyrin",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Urine, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uroporphyrinogen (octacarboxyl porphyrin) I &amp; III",
"       </td>",
"       <td>",
"        Uroporphyrin I &amp; III",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Urine, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heptacarboxyl porphyrinogen I &amp; III",
"       </td>",
"       <td>",
"        Heptacarboxyl porphyrin I &amp; III",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Urine, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hexacarboxyl porphyrinogen I &amp; III",
"       </td>",
"       <td>",
"        Heptacarboxyl porphyrin I &amp; III",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Urine, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentacarboxyl porphyrinogen I &amp; III",
"       </td>",
"       <td>",
"        Pentacarboxyl porphyrin I &amp; III",
"       </td>",
"       <td>",
"        Kidney",
"       </td>",
"       <td>",
"        Urine, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coproporphyrinogen (tetracarboxyl porphyrinogen) I &amp; III",
"       </td>",
"       <td>",
"        Coproporphyrin I &amp; III",
"       </td>",
"       <td>",
"        Kidney and liver",
"       </td>",
"       <td>",
"        Urine, feces, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protoporphyrinogen IX",
"       </td>",
"       <td>",
"        Protoporphyrin IX",
"       </td>",
"       <td>",
"        Liver",
"       </td>",
"       <td>",
"        Feces, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protoporphyrin IX",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Liver",
"       </td>",
"       <td>",
"        Feces, erythrocytes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All intermediates are colorless and nonfluorescent, with the exception of protoporphyrin, which is reddish and fluorescent.",
"     <br>",
"      &bull; The autooxidized porphyrins are reddish and fluorescent; porphobilin is brownish.",
"      <br>",
"       &Delta; Urine and fecal porphyrins are fractionated if the total is increased; plasma porphyrins may be fractionated, but for differential diagnosis it is preferred to determine the fluorescence peak at neutral pH.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Karl Anderson, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30588=[""].join("\n");
var outline_f29_55_30588=null;
var title_f29_55_30589="Rapid influenza diagnostic tests";
var content_f29_55_30589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of rapid influenza diagnostic tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Procedure",
"        </p>",
"        <p>",
"         (manufacturer/distributor)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Influenza virus types detected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approved specimens*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         3M&trade; Rapid Detection Flu A+B Test&bull;&Delta;",
"        </p>",
"        <p>",
"         (3M)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        <p>",
"         NP swab/aspirate",
"        </p>",
"        <p>",
"         Nasal wash/aspirate",
"        </p>",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         BinaxNOW&reg; Influenza A&amp;B&Delta;&sect;",
"        </p>",
"        <p>",
"         (Alere)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        <p>",
"         NP swab",
"        </p>",
"        <p>",
"         Nasal wash/aspirate/swab",
"        </p>",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BioSign&reg; Flu A+B&bull;&Delta;",
"        <br/>",
"        (Princeton BioMedtech)",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        NP swab/aspirate/wash",
"        <br/>",
"        Nasal swab",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Clearview&reg; Exact Influenza A&amp;B&bull;&Delta;",
"        </p>",
"        <p>",
"         (Alere)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        Nasal swab",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Directigen&trade; EZ Flu A+B&bull;&Delta;",
"        </p>",
"        <p>",
"         (Becton-Dickinson)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        <p>",
"         NP wash/aspirate/swab",
"        </p>",
"        <p>",
"         Throat swab",
"        </p>",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         OSOM&reg; Influenza A&amp;B&bull;&Delta;",
"        </p>",
"        <p>",
"         (Genzyme)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        Nasal swab",
"       </td>",
"       <td>",
"        10 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         QuickVue&reg; Influenza Test&loz;&sect;",
"        </p>",
"        <p>",
"         (Quidel)",
"        </p>",
"       </td>",
"       <td>",
"        A or B",
"       </td>",
"       <td>",
"        Nasal wash/aspirate/swab",
"       </td>",
"       <td>",
"        10 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         QuickVue&reg; Influenza A+B Test&Delta;&sect;",
"        </p>",
"        <p>",
"         (Quidel)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        <p>",
"         NP swab",
"        </p>",
"        <p>",
"         Nasal wash/aspirate/swab",
"        </p>",
"       </td>",
"       <td>",
"        10 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         SAS&trade; FluAlert A&amp;B&bull;&Delta;",
"        </p>",
"        <p>",
"         (SA Scientific)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        Nasal wash/aspirate",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         SAS&trade; FluAlert A&loz;&sect;",
"        </p>",
"        <p>",
"         (SA Scientific)",
"        </p>",
"       </td>",
"       <td>",
"        A only",
"       </td>",
"       <td>",
"        Nasal wash/aspirate",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         SAS&trade; FluAlert B&loz;&sect;",
"        </p>",
"        <p>",
"         (SA Scientific)",
"        </p>",
"       </td>",
"       <td>",
"        B only",
"       </td>",
"       <td>",
"        Nasal wash/aspirate",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         TRU FLU&reg;&bull;&Delta;",
"        </p>",
"        <p>",
"         (Meridian Bioscience)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        <p>",
"         NP aspirate/swab",
"        </p>",
"        <p>",
"         Nasal wash",
"        </p>",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         XPECT&trade; Flu A&amp;B&bull;&Delta;",
"        </p>",
"        <p>",
"         (Remel/Thermofisher)",
"        </p>",
"       </td>",
"       <td>",
"        A and B",
"       </td>",
"       <td>",
"        <p>",
"         Nasal wash/swab",
"        </p>",
"        <p>",
"         Throat swab",
"        </p>",
"       </td>",
"       <td>",
"        15 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Disclaimer: Use of trade names or commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the Department of Health and Human Services.",
"    <div class=\"footnotes\">",
"     NP: nasopharyngeal.",
"     <br>",
"      * List may not include all test kits approved by the US Food and Drug Administration. Discontinued tests not included. Approved respiratory specimens according to manufacturer's package insert. Note that test performance may vary if other respiratory specimens are used.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Moderately complex test &mdash; requires specific laboratory certification.",
"       <br>",
"        &Delta; Distinguishes between influenza A and B virus infections.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Does not distinguish between influenza A and B virus infections when used alone.",
"         <br>",
"          &sect; CLIA-waived test. Can be used in any office setting. Requires a certificate of waiver or higher laboratory certification.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     United States Centers for Disease Control and Prevention. Guidance for clinicians on the use of rapid influenza diagnostic tests.&nbsp;",
"     <a href=\"file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm\">",
"      file://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm",
"     </a>",
"     (Accessed on April 6, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30589=[""].join("\n");
var outline_f29_55_30589=null;
var title_f29_55_30590="Oxygenation at different altitudes";
var content_f29_55_30590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oxygenation at different altitudes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increasing altitude results in a decrease in inspired oxygen (PiO",
"    <sub>",
"     2",
"    </sub>",
"    ), arterial oxygen",
"    <sub>",
"     2",
"    </sub>",
"    (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ), and arterial oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ). Note that the difference between PiO",
"    <sub>",
"     2",
"    </sub>",
"    and PaO",
"    <sub>",
"     2",
"    </sub>",
"    narrows at high altitudes because of increased ventilation, and that SaO",
"    <sub>",
"     2",
"    </sub>",
"    is well maintained while awake until over 3000 meters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hackett, PH, Roach, RC. High-Altitude Medicine. In: Wilderness Medicine, 5th ed, Auerbach, PS (Ed), Mosby, Philadelphia 2007. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30590=[""].join("\n");
var outline_f29_55_30590=null;
var title_f29_55_30591="Tumefactive pediatric MS";
var content_f29_55_30591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tumefactive pediatric multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Axial FLAIR MRI demonstrating large tumefactive areas of demyelination. B) Axial T1 with gadolinium contrast demonstrating enhancement of the lesion margins.",
"    <div class=\"footnotes\">",
"     FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_55_30591=[""].join("\n");
var outline_f29_55_30591=null;
